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Abstract
Protein Kinase C (PKC) comprises a family of phospholipid-dependent 
Ser/Thr kinases, implicated in a broad array of cellular processes. PKC 
activity is subject to a complex network of regulatory inputs, including co­
factor binding, phosphorylation and protein-protein interaction. In 
addition, the chronic activation of PKC frequently leads to its down- 
regulation; this process may be intrinsic to the tumour promoting activity 
of the phorbol esters. The aim of this work was to investigate the 
regulation of the novel PKC-e isoform by binding partners and 
phosphorylation, with a particular focus on the process of agonist-induced 
degradation.
A yeast 2-hybrid screen was performed using a PKC-s bait and two novel 
binding partners were identified, both with associations to the 
ubiquitin/proteasome system; VHL Binding Protein 1 (VBP1) and F-box 
WD40 protein 7 (Fbw7). Interactions were verified in mammalian cells 
and mapped to the catalytic domain of PKC-e. Extensive studies 
revealed that neither partner influenced the process of PKC-e down- 
regulation. However, Fbw7a was demonstrated to represent an in vitro 
PKC substrate. The site of phosphorylation was mapped to Ser-18 and, 
using phospho-specific antibodies, was shown to be phosphorylated in 
the cell.
PKC-e activity is required for its agonist-induced degradation. Studies 
were therefore undertaken to investigate autophosphorylation, which may 
be implicated in this process. Serine residues 234, 316 and 368 were 
identified as novel PKC-e autophosphorylation sites. Using phospho- 
specific antibodies, all three sites were shown to be occupied in response 
to PKC-e activation. Phosphorylation at these sites was found not to 
influence agonist-induced PKC-e down-regulation. However, a critical
2
role was established for phosphorylated Ser-368, in the recruitment of the 
PKC-s binding partner, 14-3-3(3.
Together these findings provide insight into the mechanisms controlling 
PKC-s activity and demonstrate a relationship between regulation through 
phosphorylation and protein-protein interaction.
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CHAPTER 1 
Introduction
1.1 Cell Signalling
1.1.1 Cellular Communication
An essential requirement for all cells is the ability to interpret 
environmental cues and respond appropriately. Single-celled organisms 
must be able to sense the availability of nutrients and, in some cases, 
communicate with other cells to facilitate mating. Within metazoans, bi­
directional cellular communication is critical in order to coordinate and 
control the activities of their diverse and specialised constituent cells, 
thereby maintaining the organism as a whole.
Cell signalling is the means by which this transfer of biological information 
is mediated; a complex network of signal transduction pathways operate 
in order to receive, interpret, integrate and respond to extracellular cues. 
At a cellular level, signalling controls decisions regarding proliferation, 
differentiation, migration, senescence and death; in more specialised 
cells it is also central to processes such as the mounting of the immune 
response and the transmission of nerve impulses. At the level of the 
whole organism, signalling contributes to the control of growth and 
development, as well as aspects of metabolism and behaviour (see 
(Downward, 2001) for a general review).
Given the fundamental role of cell signalling in the control of numerous 
physiological processes, it is perhaps not surprising that defects in signal 
transduction pathways underlie a multitude of human diseases. 
Components of these pathways represent promising targets for the 
development of novel therapeutics, and thus further elucidation of the 
mechanisms of cell signalling is an important goal for research.
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1.1.2 General Principles of Cell Signalling
Cell signalling is mediated by a bewildering array of different signal 
transduction pathways. However, despite the obvious diversity, some 
common mechanisms have evolved. The following describes the general 
principles of cell signalling and highlights some of the key features of 
signal transduction pathways (see Figure 1.1).
1.1.2.1 Signal Transduction
The process of signal transduction is initiated with the recognition of a 
bioactive ligand, which serves to deliver information from the extracellular 
milieu. Signalling ligands include soluble growth factors, hormones, nitric 
oxide (Esplugues, 2002) and nutrients (Meijer and Dubbelhuis, 2004), 
which may be produced locally, or distally and delivered via the 
bloodstream, as well as insoluble extracellular matrix components, and 
other cells. Upon binding to their complementary cell surface or 
intracellular receptors, these ligands induce a change in conformation 
and/or activity, which facilitates the transmission of the signal into the cell.
A wide variety of receptors exist in order to detect and respond to these
diverse signals. The largest family comprises the G-protein coupled
receptors, which exhibit tremendous diversity, responding to ions, organic
odorants, amines, peptides, proteins, lipids, nucleotides, and even
photons (see (Fredriksson et al., 2003) for a review). The receptor
tyrosine kinases, which include the receptors for epidermal growth factor
(EGF) and insulin, represent another large family (reviewed by (Blume-
Jensen and Hunter, 2001)); and yet other receptors are associated with
tyrosine kinases, for instance, the cytokine receptors which couple to the
Janus Kinases (JAKs) (see (Ihle and Kerr, 1995)). Another class of
receptors possess Ser/Thr kinase activity, such as those which respond
to the transforming growth factor-p (TGFp) family (see for a (Massague,
1998) review). Additionally, there are a class of intracellular receptors
which recognise soluble signals, for example, the sex hormone receptors
(Mangelsdorf et al., 1995). Others comprise ligand gated ion channels,
for instance, the nicotinic acetylcholine receptor (McGehee, 1999).
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Finally, the integrins (Hynes, 2002) and the cadherins (Buckley et al., 
1998) comprise extracellular matrix and cell adhesion receptors 
respectively.
A series of intracellular mediators may then be involved in relaying the 
signal through the cell. These include second messengers, such as 
cyclic AMP, DAG, IP3 and calcium, small GTP binding proteins, for 
example, Rac1 and Rho, and adaptor proteins, including Grb2. These 
components, working in series or in parallel, often serve to regulate a 
cascade of protein kinases, such as the MAPKs, and/or their antagonistic 
phosphatases (see (Downward, 2001) for a review). Ultimately, these 
pathways culminate in the regulation of enzyme activity and/or gene 
expression, thereby enabling a response to be mounted.
Cells receive inputs from many signalling pathways concurrently, and 
must interpret them within the context of each other, in order to respond 
appropriately. Integration involves the process of cross-talk, whereby one 
pathway influences the activity of another; for example, both PI-3 kinase 
and PAK feed into the MAPK pathway triggered by activated Ras 
(Downward, 2001). The spatial control of signalling is also of importance 
in determining the cellular response, as evidenced by ERK1/2, which act 
at the nucleus to regulate gene expression, but at the cell periphery to 
control HGF-induced cell migration (Kermorgant and Parker, 2005). 
Finally, the regulation of signal amplitude and duration is critical to the 
final outcome of the pathway. For example, transient activation of the 
MAPK pathway by EGF causes PC12 cells to multiply slowly, while 
sustained activation of the same pathway following NGF stimulation leads 
to neurite outgrowth (Marshall, 1995).
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Figure 1.1 Schematic Representation of A Signal Transduction 
Paradigm. A generalised growth factor responsive signal transduction 
pathway is represented schematically, illustrating the general principles of 
signal transduction. 1) Growth factor binding to its complementary cell 
surface receptor induces receptor dimerisation and 2) 
autophosphorylation. 3) This signal may be attenuated by an 
antagonistic phosphatase. 4) A series of adaptor proteins are recruited 
through protein interaction domains, resulting in 5) the activation of the 
small GTPase Ras. 6) Ras activates a kinase cascade, from Raf to MEK 
and MEK to ERK. 7) This cascade is also influenced by information 
received from a parallel PI3-kinase dependent pathway, thereby 
integrating cellular information (cross-talk). 8) Ultimately, enzyme activity 
and/or gene expression is regulated, enabling an appropriate response to 
be mounted.
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1.1.2.2 Protein Phosphorylation
The reversible phosphorylation of proteins plays a pivotal role in the 
regulation of signal transduction, and many other cellular processes; it is 
one of the most ubiquitous and well studied forms of post-translational 
modification. Protein phosphorylation is exquisitely controlled by the 
opposing activities of protein kinases and protein phosphatases. In 
eukaryotic cells, protein kinases typically catalyse the transfer of the y- 
phosphate group from ATP onto the hydroxyl group of either a serine, 
threonine or tyrosine residue; this reaction can be antagonised by a 
corresponding protein phosphatase, which catalyses dephosphorylation.
Protein phosphorylation was first described as the reversible modification 
of phosphorylase kinase (DeLange et al., 1968; Riley et al., 1968). 
Subsequently, it has been estimated that as many as one third of cellular 
proteins are phosphorylated at any one time, with 90% of 
phosphorylations occurring at serine residues, 10% at threonine residues 
and just 0.05% at tyrosine residues (reviewed by (Mann et al., 2002)). 
The near completion of the human genome project has revealed that 
approximately 2% of the genome encodes proteins involved in this 
process, with more than 500 kinases (Manning et al., 2002) and over 100 
phosphatases (Lander et al., 2001; Venter et al., 2001) identified.
The conventional eukaryotic protein kinases comprise one of the largest 
groups of homologous proteins (Hanks and Hunter, 1995). The 
superfamily consists of two main subgroups based on substrate 
specificity, the protein serine/threonine (Ser/Thr) kinases (which include 
the dual specificity kinases) and the protein tyrosine kinases; these can 
be further divided into additional classes (see (Manning et al., 2002) for 
classification system). Although there is a rich diversity with respect to 
structure, mode of regulation and specificity, a common catalytic core, of 
250-300 residues, is conserved among the superfamily. The bi-lobal 
structure formed by this region facilitates the three main roles of the 
kinase, namely the binding and orientation of ATP (complexed with a
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divalent metal ion), the binding and orientation of the substrate, and the 
transfer of phosphate (Hanks and Hunter, 1995).
Eukaryotic cells contain a smaller, but nevertheless extensive, 
complement of antagonistic phosphatases. These too are classified 
according to substrate specificity, the main subgroups comprising the 
protein tyrosine phosphatases, the protein Ser/Thr phosphatases, and the 
dual specificity phosphatases, which can catalyse dephosphorylation of 
both Ser/Thr and Tyr residues. A fine balance exists between the 
numbers of tyrosine kinases and tyrosine phosphatases within the cell, 
facilitating the precise control of tyrosine phosphorylation (Alonso et al., 
2004). In contrast, there are relatively few Ser/Thr phosphatases; 
however, their elegant regulatory mechanisms confer the versatility 
required to antagonise the diverse activities of the Ser/Thr kinases. The 
Ser/Thr phosphatases operate as distinct holoenzymes, comprised of 
various combinations of regulatory and catalytic subunits, such that a 
myriad of substrate specificities and subcellular localisations are achieved 
(see (Wera and Hemmings, 1995) for a review).
The combined activities of the protein kinases and protein phosphatases 
thus serve to control the balance of protein phosphorylation, which in turn 
contributes to the regulation of cell signalling. The covalent attachment of 
a phosphate group to a target protein incorporates a bulky negative 
charge, which can influence the substrate in different ways. In the case 
of certain enzymes, phosphorylation can regulate activity, facilitating 
either activation, as illustrated by the activation loop phosphorylation of 
the AGC kinases (Parker and Parkinson, 2001), or inactivation, as 
exemplified by phosphorylation of Src at Tyr-527 (Kmiecik and Shalloway, 
1987). Phosphorylation can also promote protein-protein interactions, for 
example, tyrosine phosphorylation of numerous receptor tyrosine 
kinases, such as the EGF receptor, creates a docking site for SH2 
containing proteins (Margolis et al., 1990), and there are numerous other 
examples of phospho-specific protein interaction domains (see section
1.2.4). Localisation too can be influenced in this manner, as in the case of
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the Forkhead transcription factors, whose nuclear import is impaired upon 
phosphorylation (Datta et al., 1999). Finally, phosphorylation also plays a 
critical role in targeting certain substrates, such as Sic1, for degradation 
(Skowyra et al., 1997).
1.1.2.3 Other Post-Translational Modifications
In addition to protein phosphorylation, there are more than 200 other 
forms of post-translational modification that have been reported to 
influence signal transduction pathways and other cellular processes (Zhu 
et al., 2003). Together, these modifications provide additional functional 
diversity to the proteome, and it has been speculated that the complexity 
of higher organisms can be attributed in part to such mechanisms 
(Lander et al., 2001; Venter et al., 2001). Examples of some of the most 
common, and functionally important, post-translational modifications are 
given in Table 1.1. The process of ubiquitination is considered in more 
detail in Section 1.3.3.1.
Post-Translational Modification Functional Implications
Phosphorylation activation/inactivation, modulation of 
protein-protein interactions and 
localisation, degradation
Sulphation modulation of protein-protein and 
receptor-ligand interactions
Proline Hydroxylation regulation of protein-protein 
interactions and protein stability
Glycosylation cell-cell recognition and signalling
Acylation/Fatty acid modification membrane tethering and modulation 
of localisation
GPI anchor attachment membrane tethering
Ubiquitination degradation, trafficking
Table 1.1 Post-translational Modifications. A selection of common 
post-translational modifications are summarised with key functional 
effects indicated (Mann and Jensen, 2003).
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1.1.2.4 Proteln-Protein Interactions
A characteristic property of many cell signalling proteins is that they 
contain modular interaction domains, which allow them to assemble into 
specific multi-protein complexes (Pawson and Nash, 2000). The transfer 
of information along a signal transduction pathway frequently involves a 
series of dynamic protein-protein interactions, which recruit and confine 
the constituent species to appropriate subcellular localisations, exposing 
them to particular regulators and targets (Faux and Scott, 1996b).
Interaction domains tend to comprise independently folding modules of 
35-150 amino acids, and typically recognise specific peptide motifs; many 
distinguish particular post-translational modifications (see below). These 
conserved signalling modules tend to occur in multiple proteins, and 
conversely, a number of different interaction domains may be found 
within the same protein. The reiterated and combinatorial use of 
interaction domains provides a common means by which the flow of 
information can be controlled and integrated (Pawson and Nash, 2003). 
Protein interaction domains can be divided into different groups based on 
their ligand binding properties (see (Pawson et al., 2002) for review, and 
table 1.2). Src homology 2 (SH2) and phospho-tyrosine (PTB) domains, 
along with the C2-like fold of PKC-S (Benes et al., 2005), comprise 
interacting modules which recognise phospho-tyrosine containing motifs. 
There are more than 100 known SH2 domains, with varying preferences 
for adjacent residues. A number of other classes of interaction domain 
bind specifically to phospho-serine/threonine residues, these include the 
14-3-3 (see section 1.2.4.1), Forkhead-Associated (FHA) and WD40- 
repeat domains. Additional post-translational modifications can also be 
recognised, notably, acetylated and methylated lysine residues are bound 
by Bromo and Chromo modules respectively. Other groups of interaction 
domain are not dependent upon protein modifications and tend to interact 
more stably with targets, these include the Src homology 3 (SH3) and 
WW domains, which recognise proline-rich motifs, and the PDZ domains, 
which bind to the extreme C-termini of target proteins. Finally, certain
other modules engage specifically in lipid binding, for example Pleckstrin-
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homology (PH) domains bind to phosphoinositides such as PI-4,5 -P2 and 
PI-3,4,5 -P3, FYVE domains recognise PI-3-P and C1 domains typically 
bind to DAG and phorbol esters.
Interaction Domain Recognition Motif
SH2 Phospho-tyrosine
e.g. Phospholipase C-y e.g. /3-PDGF receptor
PTB Phospho-tyrosine
e.g. She e.g. TrkA NGF receptor
14-3-3 Phospho-serine/threonine
e.g. 14-3-3 e.g. cdc25
WD40 repeat Phospho-serine/threonine (and 
certain unphosphorylated motifs)
e.g. G-Protein /3-chain e.g. G-protein a/y-chain
SH3 Proline rich
e.g. Src e.g. PI 3-kinase p85 subunit
PDZ C-termini
e.g. PSD-95 e.g. NMD A receptor B
Table 1.2 Protein Interaction Domains. The recognition motifs of some 
prevalent interaction domains are summarised, with examples of 
interacting pairs provided in italics (Pawson, 2002).
Related to the capacity of signalling proteins to participate in defined 
protein-protein interactions is the formation of kinase/phosphatase 
signalling complexes that modulate the phosphorylation of particular 
target substrates (Smith and Scott, 2002). The building of these 
complexes is co-ordinated by multivalent scaffolding proteins, which 
serve as platforms for assembly. This phenomenon is exemplified by the 
A-kinase anchoring proteins (AKAPs), which direct Protein Kinase A 
(PKA) activity (see (Faux and Scott, 1996a) for review). Numerous 
AKAPs have been identified, facilitating diverse PKA functions, for 
instance mAKAP juxtaposes cyclic AMP responsive PKA and 
antagonistic cAMP-specific phosphodiesterase, PDE4D3, to maintain a
hormonally regulated negative feedback loop (Dodge et al., 2001).
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Advances in proteomics have facilitated the detailed analyses of signal 
transduction pathways. Recently, the dynamic interactions of the 
transforming growth factor-p (TGFp) pathway were characterised, 
providing insights into the mechanism of TGFp-dependent tight junction 
dissolution during the epithelial-to-mesenchymal transition (Barrios- 
Rodiles et al., 2005). Additionally, the large scale mapping of protein- 
protein interaction networks has been undertaken in yeast (Ito et al.,
2001) and Caernorhabditis (Li et al., 2004), and a probabilistic model of 
the human interactome has been developed (Rhodes et al., 2005). 
Corresponding advances in bioinformatics and computer modelling will be 
required in the future to fully integrate and interpret the data gathered 
(Legrain et al., 2001).
1.1.2.4.1 14-3-3 Proteins
The protein-protein interactions of the 14-3-3 proteins are pertinent to 
work presented in this thesis, as such, their key features are considered 
in more detail here.
The 14-3-3 proteins are small (~30kDa), acidic proteins which bind to 
phospho-serine and phospho-threonine containing motifs, and also to 
some non-phosphorylated targets (see (Bridges and Moorhead, 2005) for 
recent review). 14-3-3 proteins are found in all eukaryotes and are highly 
conserved both across and within species, in mammalian cells there are 
seven isotypes (p, y, e, r\, a, x, £). The importance of their function is 
evidenced by the lethal phenotype derived from simultaneous knock out 
of both yeast isoforms (Gelperin et al., 1995).
14-3-3 proteins exist primarily as homo- or hetero-dimers in the cell. 
Crystallographic studies have revealed that 14-3-3 dimers assume a 
highly helical, cup-shaped conformation. Each subunit of the dimer can 
bind to one discrete phospho-serine or phospho-threonine containing 
motif, with the ligands in extended, antiparallel orientations and the 
phosphate groups 34A apart (Obsil et al., 2001). Examinations of 14-3-3
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interacting partners, and the use of an orientated peptide library, have 
defined two major consensus motifs for binding: Mode I, RSXpS/TXP and 
Mode II RXXXpS/TXP (X denotes any amino acid) (Yaffe et al., 1997). 
Several 14-3-3 binding partners bear more than one 14-3-3 binding site, 
and the affinity of a protein with two appropriately spaced sites is more 
than thirty times that of a protein with only one (Yaffe et al., 1997). For 
most targets it seems that there is a single dominant site, known as the 
'gatekeeper1, and a second, lower affinity site; once the gatekeeper site is 
phosphorylated and bound to one 14-3-3 monomer, the secondary site is 
able to interact with the other subunit by virtue of its close proximity, 
thereby stabilising the complex (Yaffe, 2002). The presence of one 
suboptimal site may facilitate a certain degree of dissociation, and 
thereby confer reversibility to the interaction.
14-3-3 binding typically mediates one of three effects on target proteins: 
conformational change, steric hindrance or scaffolding (see Figure 1.2). 
The propensity of 14-3-3 proteins to mediate conformational change is 
thought to relate to the rigidity of its own structure; it acts as a 'molecular 
anvil', deforming its ligands while undergoing only minimal adjustment 
itself (Yaffe, 2002). The anvil effect is illustrated by serotonin-N- 
acetyltransferase, which is held in an active conformation upon 14-3-3 
binding (Obsil et al., 2001). The steric effects of 14-3-3 dimers involve 
the occlusion of functionally significant sites on the target protein. For 
instance, 14-3-3 mediated masking of the Cdc25 nuclear localisation 
signal causes accumulation of Cdc25 in the cytoplasm and thereby allows 
mitotic entry (Yang et al., 1999). Alternatively, where a 14-3-3 dimer 
binds to phospho-motifs on two separate proteins, it can facilitate 
dimerisation; one example of 14-3-3 scaffolding involves glycogen 
synthase kinase 3p and tau (Agarwal-Mawal et al., 2003).
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Figure 1.2 14-3-3 Proteins: Structural Features & Modes of Action.
a) Structural representation of a 14-3-3^ dimer (red/blue ribbons), bound 
to two ARSHpSYA phospho-peptide ligands (green, peptide; yellow, 
phosphate group), b) The three major effects elicited by 14-3-3 binding 
1) conformational change; 2) steric hindrance; 3) scaffolding. (Figures 
reproduced from (Bridges and Moorhead, 2005)).
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1.1.2.5 Down-regulation of Cell Signalling
The dynamic regulation of signal transduction is critical to the 
maintenance of cellular homeostasis. A delicate balance exists between 
mechanisms that activate and inactivate cell signalling, such that signal 
amplitude and duration can be precisely controlled.
Signal down-regulation can be achieved through a number of different 
mechanisms. Commonly, pathways are negatively regulated by catalytic 
inhibition of a key component, for instance, through dephosphorylation of 
a kinase activation loop (Dikic and Giordano, 2003). Other signalling 
proteins are subject to inhibition through steric hindrance, for example, 
binding of Sprouty 1/2 to Grb2 blocks the interaction of the Grb2-SOS 
complex with adapter molecules such as FRS2 and Shc2 (Hanafusa et 
al., 2002). Compartmentalisation also plays an important role in signal 
attenuation, as exemplified by the inactivating dephosphorylation of 
EGFR/PDGFR by PTP1B, which occurs specifically at the endoplasmic 
reticulum (Haj et al., 2002).
Longer term 'negative signalling' can be achieved by protein degradation; 
this serves not only to extinguish the signal, but also to impose a 
refractory period before which it can be transmitted again (Dikic and 
Giordano, 2003). A major deactivation pathway involves the ligand 
induced endocytosis of receptor tyrosine kinases, such as 
EGFR/PDGFR, followed by their lysosomal degradation; in certain cases 
this process is directed by Cbl catalysed mono-ubiquitination of the 
receptor (Levkowitz et al., 1998). However, it is important to note that 
prior to degradation, important signalling functions persist within this 
endosomal compartment (Clague and Urbe, 2001).
1.1.3 Aberrant Cell Signalling and Disease
1.1.3.1 Cell Signalling and Cancer
Cancer is a disease of signalling malfunction, which is driven by 
microevolutionary processes. Tumour development is typically initiated
via one of two mutational routes, the hyperactivation of an oncogene,
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which stimulates cell division, or the inactivation of a tumour suppressor 
gene, which would normally inhibit proliferation. More than one hundred 
proto-oncogenes and tumour suppressor genes have been identified, and 
of these, the vast majority encode components of the signal transduction 
pathways (Sherr, 1996). Neoplastic cells subsequently tend to undergo 
further changes, which, by affecting DNA replication, repair and 
recombination, confer a high mutability rate. Thus a heterogeneous 
tumour population is formed capable of evolving further properties 
associated with greater malignancy, characterised by more rapid growth, 
invasiveness, metastasis and angiogenesis.
A multitude of signalling defects have been associated with different 
cancers (see (Adjei and Hidalgo, 2005) for a recent review). Key 
mediators of carcinogenesis include the Ser/Thr kinases Raf (Wellbrock 
et al., 2004), and Akt (Luo et al., 2003), the small GTPase Ras (Bos,
1989) and numerous tyrosine kinases, including EGFR and HER-2 
(Kolibaba and Druker, 1997); given the relatively low level of tyrosine 
phosphorylation under normal conditions, protein tyrosine kinases play a 
disproportionate role in tumour progression, contributing to a significant 
fraction of human cancers (Blume-Jensen and Hunter, 2001).
Since the components of these abnormal signalling pathways are specific 
to neoplastic cells, they represent highly selective targets for potential 
anticancer therapies. Typically, only one key component of a given 
pathway is mutated, such that its inhibition will cause a significant 
perturbation to the malignant cell, ultimately leading to cell death 
(Baselga and Arribas, 2004). Where specific mutations can be identified 
through biomarkers, the response to a given therapy can be predicted; 
those tumours in which the targeted pathway is critical will be most 
susceptible to its inhibitory agents. This type of directed therapy is 
exemplified by the development of Herceptin, a monoclonal antibody 
specific for HER-2/nety, for the treatment of patients with breast cancers 
that overexpress this receptor (Slamon et al., 2001).
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Successful therapeutic interventions have been developed which are 
directed at various points of the signalling cascade. The initial event, the 
binding of a ligand to its receptor, can be inhibited, as exemplified by the 
neutralisation of the vascular endothelial growth factor (VEGF) by 
bevacizumab (Ferrara et al., 2005). Alternatively, the receptor itself can 
be blocked as described for HER-2 above. Additionally, the downstream 
kinases responsible for signal transduction represent key targets which 
can be suppressed using small molecule inhibitors; Gleevec, an inhibitor 
of the aberrant bcr-abl tyrosine kinase (and c-kit/PDGFR), has 
revolutionised the treatment of certain leukaemias and represents a 
paradigm of this type of rationally designed treatment (Druker, 2004). 
Detailed analyses of the pathways of cell signalling will be critical to the 
development of further therapeutics of this kind.
1.1.3.2 Cell Signalling and other diseases
It is important to note that defective cell signalling is implicated in the 
onset of many other non-infectious diseases in addition to cancer, such 
that therapeutic developments may also be made outside the field of 
oncology through the further elucidation of signal transduction pathways. 
Diabetes, for example, results from the malfunction of the insulin 
signalling pathway, which normally regulates blood sugar levels (Withers 
and White, 2000). Similarly, the developmental disorder achondroplasia 
(genetic, short-limbed dwarfism) is caused by mutation of the fibroblast 
growth factor (Aviezer et al., 2003). Also, the immunological disease 
agammaglobulinaemia, which is characterised by a lack of 
immunoglobulin antibodies in the blood, is in many cases attributed to 
Bruton tyrosine kinase (Btk) mutation (Vihinen et al., 2000).
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1.2 Protein Kinase C
1.2.1 Protein Kinase C
Protein Kinase C (PKC) comprises a family of phospholipid-dependent 
Ser/Thr kinases with a broad array of cellular substrates and a central 
role in signal transduction. PKC has been implicated in the regulation of 
diverse physiological processes from proliferation (Soh and Weinstein,
2003), differentiation (Kashiwagi et al., 2002), migration (Ivaska et al.,
2003) and apoptosis (DeVries et al., 2002; Mandil et al., 2001) at the cell 
autonomous level, to development (Otte et al., 1991) and memory 
(Birnbaum et al., 2004) at the level of the organism.
PKC was originally discovered, by Nishizuka and colleagues, as a histone 
kinase activity from rat brain which could be activated by limited 
proteolysis (Inoue et al., 1977). It was subsequently shown that (c)PKC 
responds to the second messengers phosphatidylserine (PS) and 
diacylglycerol (DAG) in a calcium (Ca2+)-dependent manner, and may 
thus act to integrate agonist responses (Takai et al., 1979). Significantly, 
it was also demonstrated that the tumour-promoting phorbol esters, such 
as 12-0-tetradecanoylphorbol-13-acetate (TPA), could also directly 
activate PKC by substituting for DAG, directly implicating PKC in 
carcinogenesis (Castagna et al., 1982).
1.2.2 The PKC Superfamily
PKC is conserved among eukaryotes, demonstrating both the early 
origins and fundamental importance of this protein kinase activity. A 
single PKC isoform, Pkclp, exists in Saccharomyces cerevisiae, with a 
key role in the maintenance of cell integrity (Perez and Calonge, 2002), 
while an entire superfamily of PKC isoforms has evolved in mammalian 
cells to perform more specialised functions (see (Mellor and Parker,
1998) for a review). The first PKC isoforms to be identified were a, p and 
y, which were isolated and cloned from bovine brain cDNA libraries
(Coussens et al., 1986; Parker et al., 1986). This tissue proved to be a
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rich source of PKC isotypes and subsequent low stringency screening 
with probes derived from thes sequences yielded three additional PKCs: 
6, e and £ (Ono et al., 1987). A similar approach has also led to the 
identification of PKC-q (Osada et al., 1990), PKC-0 (Osada et al., 1992), 
PKC-iA. (Selbie et al., 1993) and most recently, the related PKNs: 1, 2 
and 3 (Mukai and Ono, 1994; Palmer et al., 1995). Protein Kinase D 
(PKD/PKCn) was also originally considered to be a member of the PKC 
superfamily, however, it has subsequently been shown to possess 
distinct regulatory and enzymatic properties (Rozengurt et al., 1997); 
nevertheless, functional links exist between PKD and the PKCs 
(Matthews et al., 2000; Rey et al., 2001; Yuan et al., 2002; Zugaza et al.,
1996).
The mammalian PKC superfamily is divided into subgroups based upon 
structural differences and related cofactor requirements (see Figure 1.3 
and section 1.2.3). The classical PKC isoforms (a, pi, Pn, and y respond 
both to Ca2+ and DAG, the novel isoforms (6, e , 0, r\) require only DAG 
and the atypical PKCs (UX, £) are responsive to neither co-factor, they 
may be activated through protein-protein interactions (Ohno, 2001). The 
PKNs are subject to regulation by small GTPases (Amano et al., 1996; 
Watanabe et al., 1996).
Each of the PKC isoforms represents a distinct gene product, with the 
exception that Pi and pn, are alternatively spliced variants of the same 
gene (Coussens et al., 1986). Splice variants have also been identified 
for PKC-S, which differ in caspase cleavage properties (Sakurai et al., 
2001), and PKC-£, which vary with respect to kinase activity (Parkinson et 
al., 2004). Additionally, the PKC-£ gene bears an internal promoter from 
which its isolated catalytic domain can be generated, PKM£ (Hernandez 
et al., 2003).
The different PKC isoforms bear broadly overlapping substrate 
specificities, and a degree of functional redundancy exists among the
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superfamily (Mellor and Parker, 1998). However, there is also substantial 
evidence for isoform specific functions. Divergence among the PKC 
superfamily is implied by the marked differences in tissue distribution 
detected among the isoforms; PKC-a/S/t; are widespread, while PKC- 
y/r|/0 are more restricted to one or a few tissues (Dekker and Parker,
1994). Differential responses to agonists are also indicative of isoform 
specific properties, for example, PKC-s is selectively down-regulated in 
response to chronic TRH treatment in GH4C1 pituitary cells (Kiley et al., 
1991), while PKN1 uniquely is translocated to a vesicular compartment 
following osmotic stress (Torbett et al., 2003). Consistent with these 
observations, numerous studies using constitutively active or dominant 
negative constructs, isoform specific inhibitors, or RNAi knockdowns have 
demonstrated requirements for particular isoforms in particular 
processes. For instance, recent work from our laboratory has implicated 
specific PKC isoforms in the control of distinct c-Met properties 
downstream of chronic HGF treatment, namely, PKC-a promotes the 
perinuclear accumulation of c-Met, while PKC-s controls c-Met 
endosomal signalling (Kermorgant et al., 2004).
Perhaps most informative with regards to PKC isoform specificity are the 
knock-out studies which have been undertaken in various laboratories. A 
number of knock-out phenotypes have been established, which is 
indicative of certain non-redundant functions. The PKC-|3 and 6 knock­
out mice bear deficiencies in B-cell signalling (Leitges et al., 1996; 
Mecklenbrauker et al., 2002; Miyamoto et al., 2002), the PKC-y null 
mutants exhibit defective CNS functions (Abeliovich et al., 1993) and the 
PKC-£ knock-outs display impaired NFkB signalling (Leitges et al., 2001). 
Null mice have also been generated and characterised for PKC-s, the 
main focus of this thesis; they show defects in innate immunity (Castrillo 
et al., 2001), demonstrate hypersensitivity to ethanol (Hodge et al., 1999) 
and are impaired in their capacity for ischemic preconditioning (Saurin et 
al., 2002).
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Significantly, the first double PKC knock-out line has recently been 
generated (PKC-e_/7PKC-S'7'), and this combination has proved to be 
embryonic lethal (unpublished data reported by Michael Leitges). As 
such, we can conclude that although there are numerous PKC-e and 
PKC-S specific functions, there is also a significant degree of redundancy 
which must be acknowledged. Future studies involving multiple isoform 
knock-out mice will address the physiological roles of PKC more 
comprehensively.
1.2.3 PKC Structure
As shown in Figure 1.3, each PKC isoform is composed of a combination 
of conserved (C) and variable (V) domains, with a well conserved, C- 
terminal catalytic domain, separated from a more divergent N-terminal 
regulatory domain, by a flexible hinge region (V3). All of the conserved 
domains associated with PKC regulation are present within pkcl, the 
single PKC isoform expressed in S.cerevisiae; pkcl can be considered to 
represent the archetypal PKC (Mellor and Parker, 1998). Within the 
mammalian superfamily these domains have been differentially 
distributed between isoforms. The structural and functional 
characteristics of these domains have been well characterised as 
described below.
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Figure 1.3 The PKC Superfamily. A schematic representation of the 
PKC superfamily domain structure.
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1.2.3.1 The Pseudosubstrate Site
A key feature of all PKC regulatory domains is the pseudosubstrate 
(PSS) site. Although there is some variation among sequences from 
different isoforms (Hofmann, 1997), in each case the motif bears all the 
hallmarks of an optimal PKC consensus, except that the 
phosphorylatable Ser/Thr is replaced with an alanine residue (House and 
Kemp, 1987). This site thus interacts with the catalytic domain, but is not 
phosphorylated, and thereby mediates intramolecular suppression of 
PKC activity prior to allosteric activation (Orr et al., 1992). Mutation of 
this region confers effector-independent activity (Pears et al., 1990), and 
synthetic peptide analogues of these sequences act as potent inhibitors 
of PKC (House and Kemp, 1987).
1.2.3.2 The C1 Domain
The cPKCs and nPKCs each contain a C1 domain that is composed of 
two repeated zinc-finger like motifs, C1a and C1b. Each motif bears a 
conserved series of cysteine and histidine residues (H-Xi2-C-X2-C-Xi3/14- 
C-X2-C-X4-H-X2-C-X7-C; C; X refers to any amino acid) that are 
responsible for the co-ordination of two Zn2+ ions (Hommel et al., 1994; 
Quest et al., 1992).
The C1 domain contributes to phosphatidlylserine binding (Bittova et al., 
2001) and represents the interface for interaction with DAG and phorbol 
ester (Ono et al., 1989), which bind competitively to the same site 
(Sharkey et al., 1984). The crystal structure has been solved for the 
PKC-6  C1b domain complexed with TPA (Zhang et al., 1995). Ligand 
binding does not result in a conformational change, but rather 'caps' a 
hydrophilic site at the top of the domain, thereby forming a contiguous 
hydrophobic surface that facilitates insertion into the lipid bilayer. The 
aPKCs contain just a single zinc-finger like motif each, and are not 
responsive to DAG.
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The degree of equivalency between C1a and C1b motifs appears to vary 
among different PKC isoforms. The C1a and C1b domains in PKC-a 
(Medkova and Cho, 1999) and PKC-S have been shown to be non­
equivalent, for instance, mutation of a highly conserved Proline residue in 
the PKC-S C1a domain has little effect on TPA responsiveness, while 
alteration of the equivalent amino acid in the C1b domain causes a 125- 
fold decrease in phorbol ester binding efficiency (Szallasi et al., 1996). 
Interestingly, the C1a and C1b domains of PKC-S show opposite affinities 
towards DAG and TPA (Stahelin et al., 2004). In contrast, these two 
motifs exhibit comparable affinities for DAG and phorbol ester in PKCs -y 
(Ananthanarayanan et al., 2003) and -e (Stahelin et al., 2005). These 
data suggest that differences with respect to cofactor binding properties 
may contribute to isoform specific regulation.
It is important to note that a number of other proteins contain C1 domains 
and may therefore bind to TPA, including PKD and |32-chimaerin (see 
(Brose and Rosenmund, 2002) for review). When interpreting 
experimental results, it is critical to acknowledge that phorbol ester- 
responsiveness is not solely a property of PKC.
1.2.3.3 The HR1 Domain
The HR1 domain, which is composed of a repeated, conserved motif of 
approximately 55 amino acids (Palmer et al., 1995), is found in yeast 
pkcl (S,cerevisiae) and pck1/2 (S.pombe), and in the PKNs. The HR1 
interacts with both Rac1 and Rho (Flynn et al., 1998), thereby mediating 
activation by small GTPases.
1.2.3.4 The C2/C2-like Domain
The C2 domain is a calcium binding domain found only in the cPKCs, 
explaining the characteristic calcium-dependence of their phospholipid 
binding. Calcium binding C2 domains are found in a number of other 
proteins, including synaptotagmin (Shao et al., 1996), Ras-GAP and PLC- 
y (see (Ponting and Parker, 1996) for a review).
41
Chapter 1: Introduction
A classical C2 domain is absent from both the nPKCs and PKNs, such 
that they are calcium insensitive; they do, however, bear a C2-like 
domain (Pappa et al., 1998; Ponting and Parker, 1996). The C2 domains 
of other proteins have been shown to mediate protein-protein 
interactions, for instance, the C2A and C2B domains of synaptotagmin 
facilitate binding to syntaxin and clathrin respectively (Li et al., 1995). It 
has been postulated that the nPKC/PKN C2-like domains may play 
analogous roles, serving to recruit interacting partners. For instance, the 
binding interface for GAP43 has been mapped to the C2-like fold of PKC- 
6 (Dekker and Parker, 1997) and the Receptor for Activated C-Kinase 
(RACK1) binding site is also located in this domain in PKC-p (Ron et al.,
1995).
Most recently, compelling evidence has been obtained which 
demonstrates that the C2 domain of PKC-6, and probably PKC-6 too, 
comprises a novel phospho-tyrosine binding domain (Benes et al., 2005); 
the crystal structure of this domain complexed with an optimal tyrosine- 
phosphorylated peptide has been solved. This is the first example 
documented of a tyrosine binding module occurring within the structure of 
a protein Ser/Thr kinase, thus linking Tyr-phosphorylation and Ser/Thr 
phosphorylation. The full functional implications of this newly identified 
mode of interaction remain to be investigated; notably, it may contribute 
to PKC isoform-specific functions.
1.2.3.5 The V3 Region
The V3 region represents a flexible hinge domain between the regulatory 
and catalytic domains, which varies in length between different isoforms. 
The V3 region has been shown to be proteolytically cleaved by calpain, to 
yield a co-factor independent catalytic fragment termed PKM (Kishimoto 
et al., 1989). This region of PKC-6 can also be targeted by caspases for 
proteolysis during apoptosis; significantly, an alternatively spliced variant 
of PKC-6 lacks the caspase cleavage site (Sakurai et al., 2001).
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1.2.3.6 The Catalytic Domain
PKC is a member of the extended AGC superfamily of kinases, which 
also includes PKA, PKG, PKB, p70s6K and p90rsk (see The Protein 
Kinase Resource, www.kinasenet.org). These enzymes exhibit a high 
degree of homology with respect to their kinase domains, and parallels 
can be drawn with respect to their structures, and means of regulation by 
phosphorylation (see next section).
The catalytic domain comprises the highly conserved C3 and C4 
domains. The C3 domain largely comprises the ATP binding pocket; a 
point mutation at the ATP binding site renders the enzyme catalytically 
inactive (kinase dead) (Ohno et al., 1990). The C4 domain, contains the 
phosphoryl transfer region and the substrate binding site. Under basal 
conditions, the pseudosubstrate sequence occupies this site, inhibiting 
substrate binding in the absence of allosteric activation.
Crystal structures have recently been solved for the PKC-6 (Xu et al., 
2004) and PKC-i (Messerschmidt et al., 2005) kinase domains, to 2A and 
3A respectively. These structures reveal that the PKC catalytic domain 
comprises a classical bilobal kinase fold, with a smaller, N-terminal lobe, 
consisting mainly of p-sheet, and a larger, predominantly a-helical, C- 
terminal lobe, connected by a linking hinge.
The V5 region, comprised of approximately 50 residues at the extreme C- 
terminus of PKC, is also a functionally significant part of the protein, 
containing the key 'TP' and 'FSY' priming phosphorylation sites (see next 
section). Recent work on PKC-e has demonstrated that the last 8 amino 
acids are also critical with respect to catalytic competence, presumably 
due to their interaction with the catalytic core (Zhu et al., 2005b). 
Interestingly, the two PKC-p splice variants, PKC-pi and PKC-pn, vary 
only in this region, such that any functional differences between them 
must be attributed to these residues; for example, in U937 monocytic
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cells, PKC-Pi localises to the microtubules, whereas PKC-Pn is localised 
in part to secretory granules (Kiley and Parker, 1995).
1.2.4 PKC Activation
As represented in Figure 1.4, the activation of cPKC and nPKC isoforms 
typically involves their recruitment to the membrane and allosteric 
activation by DAG, in the presence of phosphatidylserine. Agonist- 
induced production of DAG may be effected by multiple mechanisms, 
most prominently, receptor tyrosine kinases, and receptors linked to non­
receptor tyrosine kinases, operate through the phosphatidylinositol (4,5)- 
bisphosphate (Ptdlns(4,5)P2)-specific phospholipases Cyi/2 (Ptdlns- 
PLCY1/2); G-protein coupled receptors activate Ptd I ns-PLCp family 
members; and Ras can target Ptdlns-PLCe (Parker and Murray-Rust,
2004). For cPKCs, initial membrane recruitment is a calcium sensitive 
event (Keranen and Newton, 1997), for nPKCs no equivalent mechanism 
has been elucidated, but protein-protein interactions have been 
speculated to play a role. In its inactive state, the PKC C1 and C2 
domains are tethered, upon calcium dependent/independent binding to 
phosphatidyserine, the C1 domain is unleashed, allowing its membrane 
penetration and interaction with DAG (Bittova et al., 2001). DAG binding 
is associated with a PKC conformational change, which results in the 
removal of the psuedosubstrate motif from the catalytic domain, thereby 
relieving autoinhibition.
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Ligands
PKC j  active
G-proteins Iff
inactive
Figure 1.4 Classical Pathway of PKC Activation. A schematic 
representation of the activation of cPKC/nPKC isoforms. 1) Ligand 
binding to a receptor tyrosine kinase or G-protein coupled receptor leads 
to 2) the activation of a phospholipase C isoform, which catalyses the 
production of 3) DAG and 4) IP3, thereby mediating the release of 
calcium. 5) Inactive PKC translocates from the cytosol to the membrane 
for allosteric activation by DAG (in the presence of phosphatdylserine); 
for cPKCs the initial recruitment event is calcium dependent.
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1.2.5 PKC Phosphorylation
1.2.5.1 PKC Priming Phopshorylation sites
The regulation of PKC through co-factor binding is subject to a complex 
amplitude control via the phosphorylation of three key 'priming' sites, 
which are permissive for subsequent allosteric activation (Parekh et al., 
2000). These priming phosphorylation sites are characteristic of AGC 
kinase superfamily members and comprise the activation loop (or T-loop) 
site, the autophosphorylation ('TP') site and the hydrophobic (or 'FSY') 
site. They are conserved throughout the PKC kinase superfamily, and 
throughout evolution, with the exception that the FSY site is substituted 
with glutamate in the aPKCs, and aspartate in the PKNs; these acidic 
residues may mimic phosphorylation (see Figure 1.5).
Phosphorylation of the T-loop site is critical for PKC activity; catalytic 
competence is abolished in a PKC-a T-loop T497 mutant (Cazaubon et 
al., 1994), and impaired in the corresponding PKC-6 T505 mutant (Le 
Good et al., 1998). Based upon the detailed structural analysis of PKA, 
the phosphorylated PKC T-loop was predicted to correctly align active 
site residues for catalytic activity (Cazaubon et al., 1994; Knighton et al., 
1991; Orr and Newton, 1994). This prediction has been borne out 
following the resolution of the PKC-6 structure (Xu et al., 2004).
Phosphorylation of the T-loop site is, in most cases, catalysed by 
polyphosphoinositide-dependent kinase 1 (PDK1) (Chou et al., 1998; Le 
Good et al., 1998). However, recent kinetic analyses indicate that the 
PKC-6 T-loop site may be autophosphorylated (Czerwinski et al., 2005). 
This is consistent with previous data that showed the kinase dead mutant 
of PKC-6 not to be phosphorylated at the T-loop (Liu et al., 2002), as well 
as with the finding that the wild type, but not kinase dead, PKC-6 catalytic 
domain is phosphorylated in bacteria (Xu et al., 2004). It has been 
proposed that the sequence surrounding the PKC-6 T-loop site, uniquely, 
bears attributes of a PKC consensus (Xu et al., 2004).
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The 'TP' and 'FSY' priming phosphorylation sites play more subtle roles in 
maintaining a closed PKC conformer, conferring optimum thermal stability 
and resistance to proteases and phosphatases (Bornancin and Parker,
1997). The PKC-i and PKC-0 crystal structures define important 
intramolecular interactions mediated by the 'TP' and 'FSY' sites 
respectively, which serve to stabilise PKC conformation (Messerschmidt 
et al., 2005; Xu et al., 2004).
The 'TP' site has been shown to represent an autophosphorylation site 
(Flint et al., 1990; Standaert et al., 2001). Removal of the PKC-a TP', 
T638, results in its impaired function, however, mutation of the 
corresponding PKC-pn residue, T641, can be compensated for through 
the phosphorylation of other local sites (see (Newton, 1997)).
The phosphorylation of the hydrophobic 'FSY' site has been shown to 
represent the rate limiting step for the occupation of all three priming 
phosphorylation sites in PKC-a (Bornancin and Parker, 1997). This is 
likely to relate to the observation that the "FSY' site is involved in the 
recruitment of PDK1 (Balendran et al., 2000). Like the 'TP', the 'FSY' site 
is also phosphorylated through an autocatalytic mechanism in cPKCs 
((Behn-Krappa and Newton, 1999; Dutil et al., 1994; Dutil et al., 1998). 
However, the pathway(s) to the phosphorylation of the hydrophobic motif 
in nPKCs remain more elusive. Cenni et al have presented evidence for 
autophosphorylation (Cenni et al., 2002), while Parekh and colleagues 
have shown, under different experimental conditions, that an upstream 
kinase activity is required (Parekh et al., 1999). Previous data from our 
laboratory suggests that an aPKC complex may be responsible for 
phosphorylation of the hydrophobic motif (Ziegler et al., 1999), with a 
parallel, mTOR regulated, amino acid sensing pathway providing a 
permissive signal, possibly through control of a protein phosphatase 
(Parekh et al., 1999).
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A significant observation with regards to the PKC priming phosphorylation 
sites relates to their relative stablility. Unlike PKB, c/nPKC retains its 
priming phosphorylations following the release of its activator, DAG. In 
fact, the closed, but phosphorylated, latent PKC conformer is relatively 
resistant to phosphatases. An important consequence of this behaviour 
is that an accumulation of phosphorylated PKC isoforms is permitted, 
which may serve to integrate information overtime (Parekh et al., 2000).
It is also important to note that the processes of PKC phosphorylation and 
degradation are intimately linked (see Section 1.3.5).
1.2.5.2 Further Autophosphorylation Sites
In addition to the TPV'FSY' priming phosphorylation sites, a number of 
other autophosphorylated PKC residues have been reported including 
T250 in PKC-a (Ng et al., 1999) and multiple sites in PKC-p (Flint et al.,
1990). Notably, phospho-specific antibodies which recognise these sites 
may be applied as markers of active PKC; this can be of use both 
experimentally, allowing the detection of a specific subpopulation of the 
enzyme, and clinically, facilitating the analysis of disease tissues for 
aberrant PKC activation (Ng et al., 1999).
1.2.5.3 Tyrosine Phosphorylation
PKC is also subject to tyrosine phosphorylation. To date this has been 
most thoroughly studied with respect to the PKC-5 isoform, which is 
phosphorylated on multiple tyrosine residues in cells transformed with Src 
or Ras or acutely stimulated with hydrogen peroxide, TPA, EGF or PDGF 
(see (Steinberg, 2004) for a recent review). The roles of certain of these 
sites have been characterised, for example, phosphorylation atTyr-332 
creates a docking site for the SH2 domain of She, mediating an 
interaction relevant to mast cell degranulation (Leitges et al., 2002).
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Figure 1.5 AGC Kinase Priming Phosphorylation Sites. Sequence 
alignments are shown surrounding the three priming phosphorylation 
conserved among the AGC kinases. Stars denote residue identity; dots 
represent a separation of approximately 125 residues between the two 
stretches of sequence. All sequences are human, with the exception of 
Pkc1 from S.cerevisiae. Accession numbers: pkcl, NP_009445; PKC-a, 
NP-002728; PKC-S, AAH43350; PKC-e NP_005391; PKC-£, NP_002735; 
PKN1, NP_998725; PKB, NP_001014432; pTO®^, NP_003152.
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1.2.6 PKC Binding Partners
A number of functionally significant PKC interacting proteins have been 
identified and characterised. Binding partners have been shown to 
influence a variety of PKC properties, including activation, inactivation, 
localisation and substrate engagement (Parker et al., 2003).
The Drosophila InaD (inactivation No-After Potential) protein provides a 
compelling example of a binding partner which influences PKC activation. 
InaD functions as a multivalent scaffolding protein, its five PDZ domains 
facilitate the assembly of a multiprotein signalling complex containing the 
transient receptor potential protein, phospholipase C-p, and InaC (eye- 
PKC). Juxtaposition with regulators serves to control the activity of InaC 
during the visual response (Tsunoda et al., 1997).
Atypical PKCs can also be regulated through protein-protein interactions. 
The binding of cdc42/PAR6/PAR3 influences aPKC activity, within a 
complex implicated in establishing cell polarity (Ohno, 2001).
Conversely, other partners participate in down-regulation; pVHL, an E3 
ubiquitin ligase with activity towards activated atypical PKC-X, was first 
associated with PKC as a binding protein (Okuda et al., 1999; Okuda et 
al., 2001).
Perhaps the most thoroughly studied of the PKC binding partners are 
those that serve to regulate localisation, as exemplified by the Receptors 
for activated c-kinase (RACKs). RACKs bind selectively to activated 
PKCs, but do not represent substrates, rather, it is suggested that they 
anchor translocated PKCs in specific membrane domains, in close 
proximity to appropriate substrates (Mochly-Rosen, 1995). Mapping 
studies have revealed that WD40 motifs in isoform specific RACKs for 
PKC-p (RACK1, (Mochly-Rosen and Gordon, 1998)) and PKC-e (p'-COP, 
(Csukai et al., 1997)), interact with unique peptide sequences in the PKC 
regulatory domains. Other sequences within these PKC isoforms have 
been identified which bear homology with the corresponding RACK
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(pseudo-RACK motifs); it has been postulated that the RACK binding site 
and the pseudo-RACK sequence undergo intra-molecular interaction, 
serving to stabilise an inactive PKC conformation. Synthetic peptides 
based on the RACK binding site sequence interfere with PKC 
redistribution, and thereby act as PKC inhibitors; conversely, peptides 
based on the pseudo-RACK sequence serve to activate the enzyme.
Such peptides have been exploited to regulate specific PKC isoforms 
both experimentally in cellular systems (Ron et al., 1995), and 
therapeutically in animal models (Tanaka et al., 2005; Tanaka et al.,
2004).
Another binding partner that may relate to PKC targeting is actin. PKC- 
pll (Blobe et al., 1996) and PKC-e (Prekeris et al., 1996) have been 
shown to localise with and bind directly to actin; PKC-S has also been 
linked to actin in neutrophils (Lopez-Lluch et al., 2001), as has PKC in 
Aplysia (Nakhost et al., 1998). In the case of PKC-e, the interaction has 
been mapped to an actin binding hexapeptide between the C1a and C1b 
domains (Prekeris et al., 1998); a mutant lacking this motif loses the 
ability to bind to actin in vitro and colocalise with actin in zones of 
adhesion. It has been postulated that interaction with actin stimulates 
PKC-e phosphotransferase activity, while reciprocally, PKC-e promotes 
the stablisation and elongation of actin filaments (through a kinase- 
independent mechanism) (Hernandez et al., 2001). The actin binding site 
has been shown to be important for neurite outgrowth during neuronal 
differentiation, however, this would appear to reflect an indirect effect on 
conformation or localisation, since an actin binding site peptide 
suppresses outgrowth induced by full length PKC-e, but not an isolated 
regulatory domain (Zeidman et al., 2002).
Binding partners can also serve to integrate PKC signalling with inputs 
from other pathways. For example, by binding to both PKA and PKC, 
gravin facilitates coordination of signal transduction events in the filopodia 
of human erythroleukemia cells (Nauert et al., 1997).
51
Chapter 1: Introduction
A final class of PKC interacting proteins comprise the Substrates That 
interact with C-Kinase (STICKs) (Chapline et al., 1993). Substrates are 
considered further in Section 1.2.7.
1.2.6.1 PKC & 14-3-3
A number of studies have explored the physical and functional 
relationships between PKC and 14-3-3 families, which are relevant to 
work presented later in this thesis. Conflicting results have been 
obtained, and a coherent model of the association between these two 
proteins has yet to be defined. Disparity is likely to stem in part from the 
use of different PKC isoforms, cell types and stimuli.
The first study to describe a connection between PKC and 14-3-3 defined 
a 14-3-3 population isolated from sheep brain as a potent inhibitor of PKC 
(Toker et al., 1992). Subsequently, direct binding of 14-3-3t  to PKC-6 in 
Jurkat T cells (Meller et al., 1996), and of 14-3-3^ to myosin II heavy- 
chain-specific PKC in Dictyostelium (Matto-Yelin et al., 1997), was shown 
to correlate with PKC inhibition.
Conversely, work from other groups has implicated 14-3-3 binding in the 
activation of PKC. Tanji and colleagues demonstrated that 14-3-3 
purified from bovine forebrain was able to activate PKC independently of 
phosphatidylserine and calcium (Tanji et al., 1994). Subsequently, it has 
been shown that cPKCs, nPKCs and aPKCs can all bind to 14-3-3^ in 
rodent brain, and that interaction leads to constitutive activity (Dai and 
Murakami, 2003). Interaction was shown not to require phosphorylation, 
and to occur via the C1 domain, in agreement with data from Matto et al 
(Matto-Yelin et al., 1997). It has been postulated that PKC activation may 
result rather non-specifically from the charge properties of these proteins, 
since numerous acidic proteins have been shown to confer the same 
effects (Van Der Hoeven et al., 2000).
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Intriguingly, an element of PKC isoform specificity has been 
demonstrated in certain assay systems exploring 14-3-3 effects. Both 
PKC -a and PKC-e have both been shown to become associated with 14- 
3-3£ upon NGF induced neuronal differentiation in PC12 cells (Gannon- 
Murakami and Murakami, 2002). However, the PKC population 
immunoprecipitated via 14-3-3 was shown to exhibit constitutive and 
autonomous nPKC (PKC-e), but not cPKC (PKC-a), activity. Consistent 
with this, Acs and colleagues found that recombinant 14-3-3^ mediated 
differential activation of PKC isoforms, in a lipid independent manner, with 
PKC-e the most strongly activated (Acs et al., 1995). That interaction with 
14-3-3 can mediate alternative effects on different PKC isoforms may in 
part explain the conflicting results obtained in other studies. It also raises 
interesting questions about the mechanisms and consequences of these 
differential effects, which remain to be investigated.
1.2.7 PKC Substrates
The PKC superfamily comprises a collection of promiscuous kinases with 
broadly overlapping specificities. Many in vitro substrates have been 
reported, demonstrating that PKC is a basophilic kinase (reviewed by 
(Hofmann, 1997)), which strongly disfavours a proline residue at the +1 
position (Zhu et al., 2005a). However, the characterisation of 
physiologically relevant substrates, associated with particular PKC 
isoforms, has proved more challenging (Parker and Murray-Rust, 2004).
Myristoylated alanine-rich C kinase substrate (MARCKS) was one of the 
first PKC substrates to be identified, and its sites of phosphorylation 
conform to a basic consensus (Stumpo et al., 1989). PKC mediated 
phosphorylation has been shown to bring about dissociation of MARCKS 
from the membrane (Thelen et al., 1991). Since one function of 
MARCKS is to sequester PI(4,5)P2, it has been speculated that this 
serves to increase available PI(4,5)P2, resulting in a dynamic 
reorganisation of the microfilaments (see (Larsson, 2005) for review).
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While the presence of an appropriate PKC consensus sequence is clearly 
important in defining a PKC substrate, within a cellular setting, the 
accessibility of the protein to PKC is equally significant. An interesting 
example in this regard is provided by RasGRP3 in B-cells. As a C1- 
domain containing protein, RasGRP3 is recruited to the membrane upon 
DAG production, alongside active PKC, such that phosphorylation at 
T133 can proceed (Zheng et al., 2005). Similarly, PKD is a PKC 
substrate that is responsive to DAG (Yuan et al., 2002); the modulation of 
PKD by PKC plays an important role in antigen receptor signalling in 
lymphocytes (Matthews et al., 2000).
1.2.8 PKC Down-regulation
A characteristic property of the classical and novel PKC isoforms is that 
their chronic activation frequently leads to their down-regulation (Ballester 
and Rosen, 1985; Stabel et al., 1987). This agonist induced inactivation 
results from an increase in the rate of PKC degradation, rather than from 
a decrease in its rate of synthesis (Young et al., 1987). The down- 
regulation of PKC represents an important, yet poorly characterised, 
phase of its 'life cycle'; it may in fact be intrinsic to the tumour promoting 
activity of phorbol esters such as TPA (Young et al., 1987).
The multistage process of carcinogenesis has been extensively studied 
using the development of squamous cell cancers on mouse skin as a 
model (see (Yuspa, 1998) for a review). In this system, TPA serves as a 
powerful tumour promoter, increasing sensitivity to papilloma formation in 
combination with tumour initiators. Identification of PKC as a major 
cellular target of TPA (Castagna et al., 1982) strongly implicated the 
enzyme in the process of carcinogenesis; subsequent work demonstrated 
the involvement of PKC more directly (Dlugosz et al., 1994). Intriguingly, 
an alternative PKC activator, Bryostatin 1, acts as an inhibitor of TPA- 
induced tumour promotion in skin (Hennings et al., 1987). Bryostatin 1 
has been shown to differentially down-regulate various PKC isoforms 
(Szallasi et al., 1994). As such, it has been speculated that TPA-induced
tumour promotion is dependent upon a particular profile of PKC isoform
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activation/inactivation (Hale et al., 2002). Consistent with this, 
overexpression of PKC-6 has been shown to decrease both the incidence 
and promotion of skin tumours in mice (Reddig et al., 1999), while 
overexpression of PKC-e, under the control of the same promoter, 
decreased papilloma burden and accelerated progression to carcinoma 
(Reddig etal.,2000).
The mechanisms that have been implicated to date in the control of PKC 
degradation are described in section 1.3.5.
1.2.9 PKC and Cancer
There has been considerable interest in the potential role of the PKC 
superfamily in cancer progression. This stems largely from the fact that 
the PKC activating phorbol esters also act as potent tumour promoters 
(see above). In addition, PKC has been directly linked to the control of 
many cellular processes relevant to neoplastic transformation, 
carcinogenesis and invasion, including proliferation (Soh and Weinstein, 
2003), apoptosis (DeVries et al., 2002; Mandil et al., 2001) and migration 
(Ivaska et al., 2003).
A number of studies have investigated whether mutations in PKC are 
associated with certain cancers. A mutation in the PKC-a V3 region, 
D279G, has been detected in human pituitary (Alvaro et al., 1993), 
thyroid (Prevostel et al., 1997) and breast (Vallentin et al., 2001) tumours, 
which may serve to target the protein to cell-cell contacts. Additionally, a 
rearrangement and amplification of the PKC-e gene was detected from a 
thyroid cancer cell line, which resulted in the overexpression of a 
truncated, dominant negative form of the protein, which protected cells 
from apoptosis (Knauf et al., 1999).
Other studies have screened for changes in the expression patterns of 
different PKC isoforms in cancer samples. Increased levels of PKC have 
been detected in cells derived from carcinomas of the breast (O'Brian et
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al., 1989) and lung (Takenaga and Takahashi, 1986). Conversely, major, 
isoform-specific reductions of PKC-e, which were shown to occur post- 
transcriptionally, we detected in certain thyroid papillary carcinomas 
(Knauf et al., 2002). Interestingly, Mandil and colleagues showed that 
higher levels of PKC-a, but lower levels of PKC-S, were detected 
specifically in malignant gliomas (Mandil et al., 2001).
Since PKC comprises an enzyme activity subject to acute allosteric 
regulation, it may in fact be more informative to analyse its activation 
state than its protein concentration in addressing its the potential 
involvement in disease (Parker, 1999). This strategy was pioneered by 
Ng and colleagues, who employed a marker of PKC-a activation, the 
phosphorylation of its Thr-250 site, to screen breast tumour samples. 
Activated PKC-a was identified in 11 out of 23 specimens, and notably, 
activation was not shown to correlate with overexpression in all cases (Ng 
et al., 1999). It will be of interest to exploit a similar approach in order to 
analyse the roles of other PKC isoforms in disease.
Despite all of this data, the role of PKC in tumour progression is still 
conjectural. It remains to be established whether an alteration of PKC, 
either by mutation or dysregulated expression, actually represents the 
rate-limiting event in any form of cancer (Parker, 1999). It is currently 
unclear whether the mutations noted above represent causes, or 
consequences, of malignancy. Nevertheless, it is clear that within the 
context of an established tumour, PKC may play an important role. PKC- 
e has recently been shown to correlate with an aggressive, metastatic 
phenotype in breast cancer; in vivo tumour growth of associated samples 
was significantly retarded following RNA interference of PKC-e (Pan et 
al., 2005).
The resolution of this issue is impeded somewhat by the multiplicity of the 
PKC isoforms, which have different, and sometimes opposing, functions. 
The development of isoform selective inhibitors will go some way to
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clarifying this matter, and if a correlation is established, will provide an 
impetus to the development of further such compounds as therapeutics. 
For instance, a PKC-p selective inhibitor is already under analysis as a 
treatment for microvascular complications associated with diabetes (Joy 
et al., 2005).
A number of PKC inhibitors have been assessed as anticancer drugs in 
clinical trials (see (Mackay and Twelves, 2003) for a review), including the 
bryostatins, which are thought to function by mediating the down- 
regulation of certain PKC isoforms (Hale et al., 2002). Although the 
success of these trials has been limited, there is some evidence that 
certain of these compounds may have improved therapeutic efficacy 
when administered in combination with established cytotoxic agents, and 
may also sensitise cells to ionising radiation.
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1.3 Protein Degradation
Most cellular proteins are subject to continuous cycles of synthesis and 
degradation; their half-lives vary enormously, ranging from a few seconds 
to many days (Schimke, 1973). Among the numerous functions of 
intracellular proteolysis are the elimination of abnormal proteins, the 
maintenance of amino acid pools under conditions of starvation, and the 
activation of precursor proteins (Varshavsky, 1996). Significantly here, 
proteolytic pathways also operate to mediate the selective destruction of 
proteins whose concentrations must vary according to time and/or cellular 
context. Metabolic instability is a key property of many regulatory 
proteins, as epitomized by the cyclins (Rechsteiner, 1991).
1.3.1 Proteolysis
Protein degradation is mediated by different proteolytic enzymes, which 
catalyse the hydrolysis of the peptide bond. Many of the cellular 
proteases are localised to the lysosomal and proteasomal compartments 
as described below. Others act at the endoplasmic reticulum (e.g. S2P 
(Ye et al., 2000)), the mitochondria (e.g. paraplegin (Atorino et al., 2003)) 
or within the extracellular milieu (e.g. matrix metalloproteinases 
(Stamenkovic, 2003)).
Additional cytosolic proteases with important cellular functions include the 
calpains and the caspases. Calpains are calcium-dependent cysteine 
proteases, which catalyse the limited proteolysis of a range of substrates, 
to yield often stable fragments whose properties differ from those of the 
intact protein (see (Sorimachi et al., 1997) for a review). Calpains have 
been implicated in the regulation of a range of cellular processes, 
including migration (Franco and Huttenlocher, 2005). The caspases 
comprise another family of cysteine proteases, which operate as a 
cascade to coordinate apoptosis; they target a plethora of substrates for 
limited proteolysis, exhibiting specificity for aspartate residues (reviewed 
by (Earnshaw et al., 1999)).
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1.3.2 Eukaryotic Pathways of Protein Degradation
There are two main routes via which cellular proteins are directed for 
more complete degradation in mammalian cells, the lysosomal and 
proteasomal pathways.
The lysosome comprises an acidic compartment, containing a variety of 
hydrolytic enzymes; the protease complement of the lysosome includes 
many cathepsins (cysteine proteases), some aspartate proteases and 
one zinc protease. Extracellular and plasma membrane proteins may 
undergo lysosomal degradation following internalisation into endosomes, 
which can then fuse with lysosomes for delivery of their contents. 
Cytosolic proteins may be targeted to the lysosome non-selectively 
through autophagic processes, or specifically via the recognition of the 
KFERQ motif (see (Cuervo and Dice, 1998) for review).
The major extralysosomal proteolytic pathway is mediated via the 
proteasome; this system is pertinent to work presented later in this thesis 
and is considered in more detail below.
1.3.3 Ubiquitin/Proteasome System
The ubiquitin/proteasome system is responsible for the regulated 
proteolysis of many target proteins, and plays a critical role in the control 
of numerous cellular processes, most notably, the cell cycle (King et al., 
1996a). An overview of this degradative pathway is represented in Figure 
1.6. Typically, a target protein is flagged for proteolysis with a 
polyubiquitin chain, and is subsequently degraded at the proteasome 
(comprehensively reviewed by (Hershko and Ciechanover, 1998)).
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Figure 1.6 The Ubiquitin/Proteasome System. The ubiquitin/ 
proteasome pathway is represented schematically. A target protein is 
tagged for degradation via the polyubiquitination of a particular lysine 
residue. This process is mediated by the sequential activities of E1, E2 
and E3 enzymes, and may be antagonised through the action of 
deubiquitylating enzymes (DUBs). Polyubiquitinated protein is directed to 
the proteasome for ATP-dependent degradation, generating target 
protein fragment peptides and recycling ubiquitin (ubiquitination may also 
target proteins for other fates eg. endocytosis (d'Azzo et al., 2005)).
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Figure 1.7 Enzymatic Pathway of Ubiquitin Conjugation.
Ubiqutination is mediated by the sequential activities of 3 enzymes. 
Ubiquitin is activated by E1 in an ATP-dependent fashion, transferred to 
the active site of an E2 conjugating enzyme and finally linked to a target 
protein lysine residue in a step catalysed by an E3 ligase.
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1.3.3.1 Ubiquitination
Ubiquitination is an important post-translational modification involving the 
covalent conjugation to substrate proteins of ubiquitin (Ub), a 76 amino- 
acid protein of extraordinary evolutionary conservation. Ubiquitination is 
most commonly associated with targeting proteins for degradation, but 
may also influence protein trafficking and protein-protein interactions (see 
(d'Azzo et al., 2005) for review).
The process of ubiquitination requires the sequential action of three 
enzymes, the E1 Ub-activating enzyme, the E2 Ub-conjugating enzyme 
and the E3 Ub-ligase (see Figure 1.7). Firstly, the C-terminal glycine 
residue of Ub is activated in an ATP-dependent step by E1; this involves 
the intermediate formation of ubiquitin adenylate, with the release of PPi, 
followed by the binding of Ub to a cysteine residue of E1 in a thiolester 
linkage, with the release of AMP. Activated ubiquitin is next transferred to 
an active site cysteine residue of the E2 enzyme. In the third step, 
catalysed by an E3-ligase, ubiquitin is linked by its C-terminus, in an 
isopeptide linkage, to the e-amino group of a substrate protein lysine 
residue (see (Pickart, 2001) for review).
Some substrates are modified with a single Ub moiety, but since Ub itself 
contains seven lysine residues, repetition of the conjugation reaction can 
also result in the formation of polyubiquitin chains. The fate of the 
ubiquitylated protein depends upon the length and the linkage type of the 
ubiquitin chain. In general, substrates with chains of four or more Ub 
molecules, linked via lysine 29 or 48, are efficiently targeted for 
proteasomal degradation, whereas lysine 63-linked chains may be 
involved in membrane protein endocytosis and kinase activation (see 
(Strous and Gent, 2002) for review).
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1.3.3.2 Proteasomal Degradation
The 26S proteasome is a large (approximately 2.5 MDa), multisubunit, 
cytosolic protease composed of a 20S catalytic core particle, which is 
capped on both sides by a 19S regulatory complex (see (Hershko and 
Ciechanover, 1998) and (von Arnim, 2001) for reviews).
The 20S core complex comprises a cylindrical stack of 4 seven 
membered rings enclosing a cavity of three compartments. The two outer 
rings are each composed of 7 a-type proteins, the two inner rings of 7 p- 
type proteins, 3 of which bear protease activity (chymotrypsin-like, 
trypsin-like and caspase-like). The proteasomal hydrolases comprise a 
unique family of threonine protease; proteasome inhibitors target the 
active site threonine (Lee and Goldberg, 1998).
The 19S cap complex is responsible for recognition and unfolding of 
polyubiquitinated proteins, threading the substrates into the core complex 
and removing Ub moieties for recycling. The 'lid' of the cap comprises a 
ring of 8 proteins, the 'base' includes 6 ATPases, which mediate 
unfolding. An 11S cap may also be associated with the proteasome, 
allowing small, non-ubiquitinated proteins to enter the core complex 
(Glickman, 2000).
Typically, the proteasome mediates the hydrolysis of substrates into 8-11 
amino acid peptides, which may be further hydrolysed to amino acids by 
other peptidases, although occasionally limited processing yields 
biologically active fragments.
1.3.4 E3 Ubiquitin Ligases
The E3 ligase component of the ubiquitin system is responsible for 
substrate recognition and therefore confers specificity. As such, the E3s 
represent a functionally important class of proteins, which have been 
much studied in recent years; the following provides an overview of their 
established characteristics.
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1.3.4.1 Degrons
The features of a protein that confer metabolic instability are called 
degrons; they constitute the degradation signals, which are recognised by 
the E3 Ub-ligases (Varshavsky, 1991).
The first degron to be identified comprises the N-terminal amino acid of 
the target protein, and forms the basis of the 'N-end rule' (see 
(Varshavsky, 1996) for a review). This rule relates the in vivo half-life of a 
protein to the identity of its N-terminal residue. Certain N-terminal 
residues, including arginine, lysine, histidine, phenylalanine, leucine, 
tryptophan, tyrosine and isoleucine, confer a destabilising effect on the 
protein, such that its half-life is in the region of 3 minutes. Others, 
including methionine, are stabilising, such that the protein may persist for 
days.
Another motif that has been implicated in protein degradation is the PEST 
sequence (see (Rechsteiner and Rogers, 1996)for a review). The PEST 
motif is a region enriched in proline (P), glutamate (E), serine (S) and 
threonine (T), typically flanked by lysine, arginine or histidine, and 
uninterrupted by positively charged residues. PEST sequences are found 
in a large number of rapidly degraded proteins, including c-myc, c-jun, 
and cyclin E, but their mode of action is not well defined. Perhaps 
significantly, the S/TP phosphodegrons described below are frequently 
found within PEST motifs (Hershko and Ciechanover, 1998).
The destruction box (D-box) is a degron that plays a key role in the 
degradation of mitotic cyclins. It is comprised of a 9-amino acid motif with 
some homology to the following consensus: RAALGXIGN (where bold 
indicates invariant residues; and X, any amino acid) (Hershko and 
Ciechanover, 1998). The D-box is necessary for mitotic cyclin 
degradation both in vitro and in vivo, and can mediate cell cycle stage 
specific degradation of fused reporter proteins via the 
cyclosome/anaphase-promoting complex (APC) (King et al., 1996b).
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Additionally, phosphorylated motifs, or phospho-degrons, are critical to 
the degradation of certain proteasomal targets. For instance, the F-box 
components of the Skp1/Cullin/F-box (SCF) E3 ligases specifically 
recognise phosphorylated substrates (Skowyra et al., 1997). As 
described in Section 1.3.4.4, solution of the Cdc4 crystal structure, in the 
presence of an optimal phospho-degron, provides a rationale for this 
preference (Orlicky et al., 2003).
1.3.4.2 Classes of E3 Ubiquitin Ligases
There are four main classes of E3 ubiquitin ligase. The main N-end rule 
E3, N-recognin, is among the best characterised (see (Varshavsky, 1996) 
for a review). The other classes include the HECT type E3s, the U-boxes 
type E3s and the RING-finger type E3s.
The homologous to E6-AP carboxy terminus (HECT) type E3 Ub-ligases 
are exemplified by E6-AP, which catalyses p53 ubiquitylation in a manner 
dependent upon the human papilloma virus gene product E6. A 
characteristic property of this subclass of E3 ligase is that they participate 
directly in the transfer of Ub to the substrate; Ub is transferred from the 
E2 to an E3 active site cysteine, and from here it is donated to the 
substrate (Pickart, 2001).
The U-box type E3 Ub-ligases are typified by yeast Ufd2. These are the 
most recently identified of the E3 ligases and remain to be thoroughly 
investigated. It would seem though, that a characteristic feature of E3s of 
this class is that they mediate unusual patterns of polyubiquitin chain 
assembly, linking additional Ub moieties to lysines other than the 
established 29, 48 and 63 sites, and thereby producing heterogeneous 
branched structures, with distinct biological functions (Hatakeyama and 
Nakayama, 2003).
The really interesting new gene (RING)-finger type E3s are the final class
of Ub-ligase defined to date (see (Pickart, 2001) for a review). They are
distinguished by the presence of a RING finger structure, comprising a
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series of histidine and cysteine residues, with a characteristic spacing 
that allows for the coordination of two zinc ions in a cross-brace 
formation. The RING finger serves as a molecular scaffold, recruiting 
E2s in a specific and catalytically productive manner. There are two main 
types of RING-type E3s, those comprising a single subunit, the single- 
polypeptide RING-finger (SPRF) Ub-ligases, such as Cbl (Joazeiro and 
Weissman, 2000), and those which contain a RING finger protein as part 
of a multimeric complex, these include the SCF, the Cul2-Elongin B- 
Elongin C (CBC), and the cyclosome/APC, and are structurally 
analogous.
1.3.4.3 SCF E3 Ubiquitin Ligases
The SCF complex has three primary subunits: Skp1, Cullin (Cul) and the 
RING finger protein Rbx1/Roc1/Hrt1 (Deshaies, 1999). This complex can 
interact with an assortment of modular F-box proteins, which all bind to 
Skp1 via a conserved N-terminal F-box domain (see Figure 1.8) (Bai et 
al., 1996). The F-box proteins are responsible for substrate recognition 
and recruitment, which they mediate through a C-terminal substrate 
binding domain (Skowyra et al., 1997).
F-box proteins are defined by the nature of their substrate binding 
domain, which may be based on WD40 domains (Fbw), leucine-rich 
repeats (Fbl) or other sequences (Winston et al., 1999). Typically, they 
recognise phospho-degrons, and thereby allow for sophisticated 
substrate discrimination, which is regulated dynamically by kinase 
signalling (Skowyra et al., 1997). This mechanism is well defined with 
respect to the SCFFbw7 E3 Ub-ligase and is considered in more detail 
below (see Section 1.3.4.4).
Interestingly, the SCF complex itself is also subject to post-translational 
modification. For instance, the cullin subunit undergoes neddylation, 
resulting in a dramatic increase in Ub transfer from the associated E2 to 
target; Nedd8 is a 76-residue protein with homology to ubiquitin (Lammer
et al., 1998). It has been speculated that various components of the SCF
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complex may also be regulated by phosphorylation, for example, Skp1 is 
phosphorylated upon expression in insect cells (Deshaies, 1999); to date 
though, there are no well defined functional consequences associated 
with a particular phosphorylation event.
1.3.4.4 F-box WD40 Protein 7
The SCFFbw7 complex is one of the best characterised of the E3 Ub- 
ligases and is relevant to work described later in this thesis. The 
following provides an overview of the main features of the substrate 
recognition component, F-box WD40 Protein 7 (Fbw7).
Fbw7 is the apparent mammalian homologue of yeast cdc4. It is 
comprised of an N-terminal F-box domain and a C-terminal substrate 
binding domain, the latter is based on 8 WD40 repeats, which fold to form 
an unusual 8-bladed propeller structure (Orlicky et al., 2003). In 
mammalian cells, Fbw7 comprises three isoforms: a, p and y. These 
isoforms differ only with respect to their extreme N-termini, which possess 
signals mediating their differential localisation; Fbw7a is nuclear, Fbw7p 
is cytoplasmic, and Fbw7y is nucleolar (Welcker et al., 2004).
SCFFbw7 has been shown to mediate the poly-ubiquitination and 
subsequent proteasomal degradation of numerous substrates, including 
cyclin E (Moberg et al., 2001; Strohmaier et al., 2001); c-myc (Moberg et 
al., 2004; Welcker et al., 2004; Yada et al., 2004); c-jun (Nateri et al., 
2004); Notch (Gupta-Rossi et al., 2001; Oberg et al., 2001; Wu et al.,
2001) and presenilin (Li et al., 2002; Wu et al., 1998). Interestingly, cyclin 
E degradation has also been demonstrated within the context of a novel 
E3 Ub-ligase, containing Fbw7, Cull, and the RING finger protein Parkin 
(Staropoli et al., 2003). Through the degradation of these target 
substrates, SCFFbw7 plays a critical role in controlling cell cycle 
progression (Feldman et al., 1997), cell growth (Welcker et al., 2004) and 
apoptotic JNK signalling in neurons (Nateri et al., 2004). Fbw7 null mice 
display elevated levels of both cyclin E and Notch 1/4, and die at
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approximately day 10 of gestation from multiple defects, including 
deficiences in hematopoietic and vasular development (Tetzlaff et al., 
2004). Significantly, Fbw7 has been identified as a tumour suppressor 
gene (Mao et al., 2004); it is mutated in a number of cancer cell lines 
(Moberg et al., 2001; Strohmaier et al., 2001) and its loss of function is 
associated with genomic instablility (Perez-Losada et al., 2005; 
Rajagopalan et al., 2004).
Fbw7 recognises and specifically interacts with a phospho-threonine- 
proline (pTP) based motif, termed the cdc4 phospho-degron (CPD), in all 
documented substrates (Nash et al., 2001). The resolution of the crystal 
structure of yeast cdc4 provides a rationale for this mode of recognition, 
defining a dedicated pThr-Pro binding pocket, as well as a deep groove 
which exerts a preference for hydrophobic residues N-terminal to the 
phospho-site (see Figure 1.9). In yeast, phosphorylation of numerous 
sub-optimal CPDs is required for cdc4 catalysed degradation of Sic1, 
setting a threshold that influences the onset of DNA replication (Nash et 
al., 2001). An equivalent mechanism has not been detected in 
mammalian cells to date and there are clear examples in which a single 
site is critical. For instance, a mutation in v-jun, which prevents its 
phosphorylation by GSK3, allows it to escape recognition by Fbw7; it is 
postulated that its increased stability contributes to its transforming 
capacity (Wei et al., 2005). Also significant is the fact that additional 
Fbw7 binding proteins can be recruited using the same mechanism, 
effectively competing with substrates. For instance, the large T antigen 
contains a 'decoy' CPD through which it can bind to Fbw7y and mediate 
its mislocalisation to the nucleoplasm (Welcker and Clurman, 2005).
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Figure 1.8 Schematic representation of the SCF E3 ligase complex.
The organisation of the SCF E3 ubiquitin ligase is represented 
schematically. Skp1, Rbx1 and Cull comprise the core components of 
the complex. The variable F-box protein binds to Skp1 via its F-box 
domain and confers substrate specificity, typically recognising a particular 
phospho-degron in its target protein. The SCF complex facilitates the 
transfer of ubiquitin from the E2 conjugating enzyme to the target protein.
CPD
WD40 Domain
Figure 1.9 Representation of the Crystal Structure of the SCFcdc4 
complex. The crystal structure of the SCFcdc4 E3 ligase in complex with 
an optimal phospho-degron peptide (CPD) is represented. Skp1 is 
shown in green, the F-box domain of cdc4 in red, and the WD40 based 
substrate binding domain of cdc4 in blue. (Figure reproduced from 
(Orlicky et al., 2003)).
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1.3.4.5 VHL
VHL is another tumour suppressor gene with an important role in protein 
degradation. This protein is mutated in familial von Hippel-Lindau (VHL) 
cancer syndrome (Latif et al., 1993) and in the majority of kidney cancers 
(Shuin et al., 1994). It associates with Elongin C, Elongin B, Cullin-2 and 
Rbx1 to form a CBC class E3 Ub-ligase, which is structurally analogous 
to the SCF complex (Stebbins et al., 1999). VHL is a SOCS-box protein, 
which like the F-box protein component of the SCF, confers substrate 
recognition.
The most well established substrate for the VHL E3 ligase to date is 
hypoxia inducible factor-1 a (HIF-1a) (Maxwell et al., 1999) (Cockman et 
al., 2000). Rather than targeting a phospho-degron, VHL specifically 
recognises this substrate via an hydroxylated proline (Ivan et al., 2001; 
Jaakkola et al., 2001); the structural basis of this interaction has been 
defined (Hon et al., 2002). The modification of HIF-1a by proline 
hydroxylases is a process dependent upon iron and molecular oxygen, 
and thus the activity of the VHL Ub-ligase is implicated in oxygen 
sensing. Under normoxic and iron replete conditions, HIF-1a is proline 
hydroxylated and thus targeted for VHL-mediated degradation. However, 
under hypoxic conditions, HIF-1a is not modified and therefore not 
recognised by VHL; under these conditions, the transcription factor 
accumulates and facilitates induction of hypoxia inducible genes, such as 
vascular endothelial growth factor (VEGF) and erythropoietin. Loss of 
VHL function through mutation results in a prolonged accumulation of 
HIF1a, which can contribute to tumour progression by promoting 
vascularisation (reviewed by (Ivan and Kaelin, 2001)).
It has been speculated that further targets exist for the VHL/CBC Ub- 
ligase, including activated aPKCs (Okuda et al., 2001); additional 
substrates, and their associated degrons, remain to be fully 
characterised.
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1.3.4.5.1 VBP1
VHL Binding Protein 1 (VBP1), the focus of some work presented later in 
this thesis, was originally identified from a human B-cell cDNA library as a 
VHL interacting partner, and was shown to colocalise with VHL upon 
coexpression in mammalian cells (Tsuchiya et al., 1996). This prompted 
speculation about a potential role for VBP1 in protein degradation (Brinke 
et al., 1997).
However, VBP1 has also been implicated, and studied much more 
thoroughly, in another context. The amino acid sequence of VBP1 is 
identical to that of a protein called prefoldin 3 (PFD3), a component of the 
prefoldin co-chaperone complex. This complex is involved in the delivery 
of unfolded clients to the TRiC/CCT chaperone, and has been shown to 
be responsible for the folding of actin and tubulin (Geissler et al., 1998; 
Vainberg et al., 1998). Notably, VHL has been shown to be recruited to 
the TRiC/CCT chaperone complex (Feldman et al., 1999), as such, we 
could speculate that its interaction with VBP1 reflects this aspect of its 
life-cycle.
1.3.5 Pathways of PKC Degradation
As described in Section 1.2.8, the chronic activation of cPKC/nPKC 
isoforms by phorbol esters typically leads to their down-regulation 
(Ballester and Rosen, 1985; Stabel et al., 1987), mediating an increase in 
the rate of PKC degradation (Young et al., 1987). The down-regulation of 
PKC represents an important, yet poorly characterised, phase of its 'life 
cycle', which may be intrinsic to the tumour promoting activity of the 
phorbol esters (Young et al., 1987). As such, the further elucidation of 
this process is an important focus for research in our laboratory.
The degron(s) associated with PKC down-regulation remain to be 
defined. There is no evidence to suggest that under basal conditions the 
N-terminal residue is implicated, and this would not be expected to 
contribute to an agonist-induced pathway. In fact, previous work has
suggested that the PKC N-terminus is blocked, such that the protein
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would be inherently recalcitrant to the N-end E3 ligases (D.Schaap and 
P.J. Parker, unpublished data). All PKCs, with the exception of the 
6 isoform, bear a PEST sequence (Lee et al., 1997), but the significance 
of this motif is unclear. Yeast pck1/2 are rapidly degraded proteins which 
can be stabilised by association with rhol; since the rhol binding site lies 
close to the PEST sequence, it has been speculated, but not proven, that 
it may serve to occlude this motif (Arellano et al., 1999). However, since 
PKC-S is known to undergo TPA-induced degradation, an intact PEST 
sequence would not appear to be critical (Srivastava et al., 2002). It is 
also noteworthy that a D-box like motif has been noted in PKC-e 
(RLGLDEFNF, 402-410); again the relevance of this site has not been 
explored (Prekeris et al., 1998).
Early work implicated calpains in the process of PKC-downregulation 
(Kishimoto et al., 1989). However, the evidence presented derived from 
the use of inhibitors of limited specificity (Webb et al., 2000), and Junco et 
al proved subsequently that mutants with differential sensitivities to m- 
calpain were indistinguishable with respect to profiles of TPA-induced 
degradation (Junco et al., 1994). Caspase mediated, limited proteolysis 
of certain PKC isoforms has also been detected, in response to apoptotic 
stimuli, but evidently operates independently of TPA-induced down- 
regulation (Koriyama et al., 1999). It is noteworthy, however, that 
caspase cleavage of PKC-£ can generate a catalytically active fragment 
that is subsequently degraded by the ubiquitin/proteasome system (Smith 
et al., 2000). A role for the lysosomal compartment in TPA-induced PKC 
degradation has also been excluded, since monensin and NH4CI, which 
de-acidify the lysosomal compartment and thereby inhibit its hydrolases, 
have no effect (Lee et al., 1997).
In contrast, there is a growing body of evidence which supports a role for 
the ubiquitin/proteasome system in the agonist-induced down-regulation 
of PKC. Ubiquitination of PKC was first reported following the treatment 
of renal epithelial cells with Bryostatin 1 (Lee et al., 1996b), and has
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subsequently been observed in many other systems. Significantly, 
proteasomal inhibition in these models mediates the accumulation of PKC 
(Junoy et al., 2002; Lee et al., 1997; Leontieva and Black, 2004; Lu et al., 
1998).
PKC activity has been implicated in the pathway(s) of down-regulation. 
Studies focussed on different PKC isoforms have shown that kinase dead 
mutants are down-regulation insensitive (Kang et al., 2000; Ohno et al., 
1990), and that PKC inhibition can prevent down-regulation (Junoy et al.,
2002). Interestingly, studies of mammalian PKCs expressed in yeast 
would suggest that this catalytic input can be mediated in trans (Parker et 
al., 1995).
An intimate association has been established between PKC 
phosphorylation and down-regulation. Experiments with PKC-a and 
PKC-e demonstrated that de-phosphorylation of priming sites is a critical 
step in the process of down-regulation by the ubiquitin-proteasome 
system (Hansra et al., 1999; Lee et al., 1996a; Lee et al., 1997).
Prevostel and colleagues demonstrated that in the case of PKC-a, this 
pathway involved the cavaolae-dependent trafficking of the 
dephosphorylated protein to an endosomal compartment (Prevostel et al., 
2000). However, this is clearly cell type and/or context dependent, since 
another report showed that phosphorylation of PKC-S was required for its 
degradation in NIH 3T3 cells (Srivastava et al., 2002). More recent work 
from Leontieva and colleagues provides support for both of these models 
(see Figure 1.10), revealing two independent pathways of PKC-a 
desensitization operating in response to the same stimuli, one involving 
the ubiquitination and subsequent proteasomal degradation of the 
mature, fully phosphorylated enzyme, the second, a proteasome- 
independent mechanism, requiring caveolar trafficking and 
dephosphorylation (Leontieva and Black, 2004).
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26S
proteasom e
Nuclear membrane
Figure 1.10 Two Pathways of Agonist-Induced PKC-a 
Downregulation in Intestinal Epithelial Cells. Upon activation with 
Bryostatin 1, PKC-a is recruited to the plasma membrane. A portion of 
fully phosphorylated, activated enzyme undergoes ubiquitination within 
this compartment and is targeted for degradation by the proteasome 
(26S). A pool of caveolae-associated PKC-a is transported to the 
perinuclear region, where it undergoes dephosphorylation and eventual 
degradation, via a proteasome-independent mechanism (figure 
reproduced from (Leontieva and Black, 2004)).
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To date, only one E3 Ub-ligase has been specifically associated with the 
down-regulation of PKC; the VHL/CBC complex has been shown to 
mediate the ubiquitination of activated aPKC (Okuda et al., 2001). 
Interestingly, this VHL activity would appear to be independent of proline 
hydroxylation, suggesting additional modes of substrate recognition for 
this complex. Whether additional E3 Ub-ligases participate in the 
pathway(s) of down-regulation of these PKC isoforms, or others, remains 
to be established.
The work described in this thesis was motivated by the theme of PKC 
degradation, and sought to characterise the process further, by screening 
for candidate E3 Ub-ligases, and analysing phosphorylation sites which 
may be implicated as phospho-degrons.
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CHAPTER 2 
Materials and Methods
2.1 Materials
2.1.1 Chemicals and Plasticware
All reagents were obtained from Sigma-Aldrich unless otherwise 
indicated. Acetic Acid, Ammonium Acetate, Dimethyl Sulphoxide 
(DMSO), Glycerol, p-Mercaptoethanol, Magnesium Sulphate, Sodium 
Dodecylsulphate and Triton X-100 were from BDH. Ethanol (EtOH) and 
Methanol (MetOH) were purchased from Fisher. Optimem was from 
Gibco, Agarose from Invitrogen, Dithiothreitol (DTT) from Melford and 
NP-40 was from USB. Plasticware was purchased from Eppendorf, 
Corning, BD Falcon, Sterilin and Scientific Specialities Inc.
2.1.2 Buffers and Media 
Coomassie blue stain
0.1% (w/v) Coomassie-Brilliant Blue, 10% (v/v) acetic acid, 50% (v/v) 
methanol
Coomassie destain
10% (v/v) acetic acid, 10% (v/v) methanol 
CSM drop-out media base (SD-DO base)
0.59g CSM-Ade-His-Leu-Trp-Ura (Bio 101 )/l SD media 
CSM-Leu
40mg/l Ade, 20mg/l His, 50mg/l Trp, 20mg/l Ura in SD-DO base 
CSM-Trp
40mg/l Ade, 20mg/l His, 100mg/l Leu, 20mg/l Ura in SD-DO base 
CSM-Trp/Leu
40mg/l Ade, 20mg/l His, 20mg/l Ura in SD-DO base 
CSM-Trp/Leu/His
40mg/l Ade, 20mg/l Ura in SD-DO base 
CSM-T rp/Leu/His/Ade 
20mg/l Ura in SD-DO base
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CSM-T rp/Leu/His/Ade/X-a-Gal
20ng/ml X-a-Gal (Clontech) in CSM-Trp/Leu/His/Ade 
DNA loading buffer
0.25% (w/v) bromophenol blue, 40% (w/v) sucrose in water
ELISA Coating buffer
15mM Na2C 03, 34.8mM NaHC03) pH 9.6
Imidazole elution buffer
50mMTris, 100mM NaCI, 100-500mM imidazole, 1x protease inhibitor 
cocktail
Imidazole lysis buffer
50mM Tris, 100mM NaCI, 5mM imidazole, 1x protease inhibitor cocktail 
Kinase Assay Mix
20mM Tris pH 7.5, 5mM MgCI2, (+100nM CaCI2 for cPKCs), 1 |xg/|xl 
phosphatidylserine (Lipid Products), 0.2% Triton X-100, 1 ng/ i^l TPA, 50- 
100pM ATP, 2.5-5piCi [y32P]-ATP (added last to start the reaction; 
Amersham)
3x Kinase Assay Sample Buffer
75% (v/v) 4x LDS Sample Buffer (Invitrogen), 0.2M DTT, 4% (v/v) p- 
mercaptoethanol, 5mM EDTA 
LB (Agar)
10g/I Bacto-Tryptone, 5g/l Yeast Extract, 10g/I NaCI (6g agar/400ml LB); 
autoclave (provided by CR-UK research services)
LB-I
16mM MgS04, 10mM KCI, 1.2mM KOH in LB media; filter sterilise
^gam p
100ng/nnl ampicillin in LB 
LBkan
25ng/ml kanamycin (Melford Labs) in LB 
2x LDS Sample Buffer
50% (v/v) 4x LDS Sample Buffer (Invitrogen), 0.2M DTT 
Mowiol Mounting Solution
10% (w/v) Mowiol 4-88 (Calbiochem), 25% (v/v) glycerol, 100mM Tris pH 
8.5; incubate 50°C, 8hrs
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PBS (Ca2*/Mg2t free)
8g/l NaCI, 0.25g/l KCI, 1.43g/l Na2HP04, 0.25g/l KH2P04, pH 7.2; 
autoclave (provided by CR-UK research services)
Ponceau stain
0.1% (w/v) Ponceau S in 5% acetic acid 
1x Protease inhibitor cocktail
1 Complete tablet (EDTA-free, Roche) in 50ml specified buffer 
SD (agar)
0.67% (w/v) Yeast Nitrogen Base (without amino acids), 2% (w/v) 
glucose, (8.8g agar/400ml SD) pH 5.8; autoclave (provided by CR-UK 
research services)
soc
20g/l Tryptone, 5g/l yeast extract, 0.6g/l NaCI, 0.2g/l KCI, 2g/l MgCI2, 
2.5g/l MgS0 4 , 3.6g/l D-glucose; autoclave (provided by CR-UK research 
services)
TAE
0.04M Tris, 0.1% glacial acetic acid, 1mM EDTA pH 8 
TBS
20mM Tris pH 7.5, 0.9% (w/v) NaCI 
TBS-T
0.1% (v/v) Tween-20 in TBS 
TCA buffer
20mM Tris pH 8, 50mM ammonium acetate, 2mM EDTA, 1x protease 
inhibitor cocktail, 100mM PMSF 
TCA-Laemmli loading buffer
3.5% (w/v) SDS, 14% (v/v) glycerol, 120mM Tris, 8mM EDTA, 5% (v/v) p- 
mercaptoethanol, 2mM PMSF, 0.1% (w/v) bromophenol blue, 1x protease 
inhibitor cocktail 
TFBI
30mM KAc, 50mM MnCI2, 100mM RbCI2, 18% (v/v) glycerol; adjust to pH
5.8 with glacial acetic acid; filter sterilise
TFBII
10mM MOPS, 50mM CaCI2) 10mM RbCI2, 18% (v/v) glycerol; adjust to 
pH 7.0 with 1M NaOH; filter sterilise
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T ransfer Buffer
10mM Trizma base, 80mM Glycine, 10% (v/v) MetOH 
5x Trypsin/Versene
0.25% trypsin in versene, pH 7.2; filter sterilise (provided by CR-UK 
research services)
Tryptic Digest Mix
0.04 mg/ml modified trypsin (16 000 U/mg), 10mM ammonium 
bicarbonate, in ice-cold resuspension buffer (supplied with the enzyme, 
Promega)
Versene
0.2g/l EDTA in PBSA, 1.5ml/l 1% phenol red, pH 7.2; autoclave 
(provided by CR-UK research services)
Yeast Cracking Buffer
2% (v/v) Triton-X 100, 1% (w/v) SDS, 100mM NaCI, 20mM Tris pH 8, 
10mM EDTA pH 8 
YP (agar)
11 g/l Yeast Extract, 22g/l Bacto-Peptone (8.8g agar/400ml YP); autoclave 
(provided by CR-UK research services)
YPDA
2% (v/v) Glucose, 0.003% (w/v) Adenine hemisulphate in YP (8.8g 
agar/400ml)
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2.1.3 Pharmacological Agents
Reagent Source Solvent [Stock] [Working]
BIM1 Calbiochem DMSO 2mM 1-2p,M
Bryostatin Alexis EtOH 1mM V M
Calyculin A Calbiochem EtOH 100^iM 100nM
GP6976 Calbiochem DMSO 1mM V M
MG-132 Calbiochem DMSO 42mM 30^M (4hrs) 
10 i^M 
(16hrs)
Staurosporine Calbiochem DMSO 1mM V M
TPA
12-0-
tetradecanoyl-
phorbol-13-
acetate
Sigma DMSO 1.6mM 400nM
Table 2.1 Pharmacological Agents. The pharmacological agents used 
in subsequent experiments are summarised with their sources, solvents 
and stock and working concentrations ([ ]) indicated.
79
Chapter 2: Materials and Methods
2.1.4 Antibodies
2.1.4.1 Primary Antibodies
Name Source Antigen Use Dilution
mouse anti- 
FLAG M5
Sigma FLAG IB 1:1000
rabbit anti- 
BD living 
colours full 
length Av
Clontech GFP
(also
recognises
YFP/CFP)
IP 1:200
mouse anti- 
GFP3E1
CR-UK GFP IB 1:1000
mouse anti 
GFP 
4E12/8
CR-UK GFP IP 1:300
rabbit anti- 
GST (z-5) 
sc-459
Santa Cruz GST IB 1:2000
mouse anti- 
IH A 12 CA5
CR-UK HA IB 1:1000
rabbit anti- 
c-jun p-S63
Cell
Signalling
c-jun
P-S63
IB 1:1000
mouse anti- 
myc 9E10
CR-UK myc IB 1:1000
mouse anti- 
PKC-a 
MC5
in house PKC-a 
V3 domain
IB 1:1000
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rabbit anti- 
PKC-6 (C- 
17) sc-213
Santa Cruz PKC-6
(C-terminus)
IB 1:2000
rabbit anti- 
PKC-6 
p-304
in house 
(PPA-514)
PKC-6
p-304
IB 1:1000 
(+ 1 ng/ml 
blocking 
de-P peptide)
mouse anti- 
PKC-e
BD
Transduction
Laboratories
PKC-e
(1-175)
IB
IP
1:1000 
1 25^g
rabbit anti- 
PKC-e (C- 
15) sc-214
Santa Cruz PKC-8
(C-terminus)
IB 1:5000
rabbit anti- 
PKC-e
in house 
(Ab.130)
PKC-e
C-terminus
IB 1:1000
rabbit anti- 
PKC-e 
P-T566
in house 
(PPA-204)
PKC-e
p-T566
IB 1:1000 
(+ 1 ng/ml 
blocking 
de-P peptide)
rabbit anti- 
PKC-e 
P-T710
in house 
(PPA-218)
PKC-e
P-T710
IB 1:1000 
(+ 1 ng/ml 
blocking 
de-P peptide)
rabbit anti- 
PKC-8 
P-S729
Upstate PKC-e
P-S729
IB 1:1000 
(+ l^g/ml 
blocking 
de-P peptide)
rabbit anti- 
PKC-e 
p-234
in house 
(PPA-501)
PKC-e
p-234
IB 1:1000 
(+ 1 p,g/ml 
blocking 
de-P peptide)
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rabbit anti- 
PKC-e 
p-316
in house 
(PPA-503)
PKC-e
p-316
IB 1:1000 
(+ 1 ng/ml 
blocking 
de-P peptide)
rabbit anti- 
PKC-e 
p-368
in house 
(PPA-505)
PKC-e
p-368
IB 1:1000 
(+ 1|ig/ml 
blocking 
de-P peptide)
mouse anti- 
tubulin
Sigma tubulin IB 1:5000
Table 2.2 Primary Antibodies. Properties of the primary antibodies 
employed are summarised. IB, immuno-blot; IP, immuno-precipitation.
2.1.4.2 Secondary Antibodies
Name Source Use Dilution
Sheep HRP-conjugated anti mouse Amersham WB 1:5000
Donkey HRP-conjugated anti rabbit Amersham WB
ELISA
1:5000 
1:2000
Donkey Cy3-conjugated anti mouse Amersham IF 1:500
Table 2.3 Secondary Antibodies. Properties of the secondary 
antibodies employed are summarised. ELISA, enzyme linked 
immunosorbent assay; IF, immuno-fluorescence; WB, western blotting.
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2.2 Methods
2.2.1 Molecular Biology
Standard molecular biology procedures were performed as described 
(Sambrook et al., 1989).
2.2.1.1 Polymerase Chain Reaction
Polymerase chain reactions (PCRs) were performed using a DNA Engine 
DYAD (MJ Research). The reaction mix incorporated: 1U Pfu 
(Stratagene),1x Pfu buffer, 1.5mM MgCh, 0.4mM ultrapure 
deoxynucleotide triphosphate mix (0.4mM with respect to each dNTP; 
Amersham-Pharmacia), V M  sense primer, V M  antisense primer 
(synthesized in house or purchased from Sigma Geno-Sys) and 100ng 
double stranded DNA (or bacterial colony) template +/-10% DMSO as 
required, made up to a final volume of 50^1 in sterile filtered ( 0 .2 2 jx m  
filter, Millipore), distilled water. Unless otherwise specified, PCRs were 
carried out using the following programme:
Step 1: 94°C, 5mins
Step 2: 94°C, 45 secs; denaturation
Step 3: (lowest primer Tm-3)°C, 45 secs; annealing
Step 4: 72°C, (length of product in bps/500)mins; extension
Cycle back to Step 2 x28 
Step 5: 72°C, 8 mins
Step 6: 4°C, hold
PCR products were examined by agarose gel electrophoresis and 
purified using the QIAquick PCR Purification Kit (Qiagen) or by gel 
extraction.
2.2.1.2 Restriction Digests
Restriction digestions were carried out according to the manufacturer’s 
instructions (NEB).
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2.2.1.3 Agarose Gel Electrophoresis and Gel Purification
Samples were diluted 5:1 in 6x DNA loading buffer and separated on a 
1% agarose gel in 1x TAE buffer, alongside 1 kb ladder DNA markers 
(Invitrogen). 1piM ethidium bromide was incorporated into the gel to allow 
visualisation of DNA on a transilluminator. For use in subsequent 
cloning, bands were excised and DNA was extracted and purified using 
the QIAquick Gel Extraction Kit (Qiagen).
2.2.1.4 Ligation
Ligation reactions were performed using T4 DNA ligase (NEB). The 
reaction mix contained: 400U T4 DNA ligase, 1x ligase buffer, 100ng 
digested vector and an appropriate amount of insert DNA; a 3:1 molar 
ratio of insert:vector was typically employed with a ‘vector only’ control 
carried out in parallel. Ligation reactions were incubated at RT overnight.
2.2.1.5 Preparation of Chemically Competent DH5a for 
T ransformation
High quality chemically competent cells were prepared for transformation 
by heat shock. A single colony of DH5a cells was inoculated into 5ml LB 
and incubated overnight at 37°C with shaking. This overnight culture was 
diluted 1:20 into pre-warmed LB-I and grown to a density of OD6oo=0.4- 
0.5. All subsequent manipulations were performed using pre-cooled 
pipettes and tubes in the cold room. Cells were harvested by 
centrifugation at 2300g for 20mins at 4°C, resuspended in 30ml pre­
chilled TFBI and incubated on ice for 10mins. Cells were then harvested 
by centrifugation and resuspended in 4ml pre-chilled TFBI I. Cells were 
aliquoted into 500^1 volumes in pre-chilled Eppendorf tubes and rapidly 
frozen on a dry ice/EtOH mix. Cells were stored at -70°C.
2.2.1.6 Transformation of Chemically Competent Escherichia Coii 
Chemically competent DH5a or RapidTrans (Active Motif) E. Coli were 
transformed with purified plasmids or ligation reaction products by heat 
shock. Chemically competent cells (50pJ) were mixed with 100ng plasmid
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or 5^ il ligation reaction in pre-cooled 15ml Falcon tubes on ice for 30mins. 
Cells were heat shocked at 42°C for 45secs and then placed on ice for 
2mins. 1 ml LB was added and the transformation mixtures were 
incubated at 37°C with shaking for 45mins. The bacteria were harvested 
by centrifugation at 4000rpm in a benchtop microcentrifuge, resuspended 
in 100^1 LB and spread onto an LBamp/kan agar plate for selection. Plates 
were inverted and incubated overnight at 37°C.
2.2.1.7 Transformation of Competent BL21-CodonPlus Competent 
Cells
A modified heat shock protocol was employed for the transformation of 
competent BL21-CodonPlus (DE3)-RIL cells (Stratagene) for protein 
purification from bacteria. Cells (100jxl) were incubated with 2^110%
XL10-Gold p-mercaptoethanol mix (Stratagene) on ice for 10mins with 
periodic mixing. 1-50ng plasmid DNA was added and incubated for a 
further 30mins on ice. Cells were heated shocked at 42°C for 20 secs, 
placed on ice for 2mins, suspended in 0.9ml warm SOC and incubated at 
37°C with shaking for 1 hr. Bacteria were pelleted by microcentrifugation 
at 3000rpm for 2mins, resuspended in 100^1 SOC and plated onto a 
selective plate. Dishes were inverted and incubated overnight at 37°C.
2.2.1.8 Preparation of Electro-competent DH5a for Transformation
For maximum transformation efficiency of plasmid DNA extracted from 
yeast, high quality competent DH5a were prepared for electroporation. A 
single colony of DH5a cells was inoculated into 10ml LB and incubated 
overnight at 37°C with shaking. This overnight culture was diluted into 11 
pre-warmed LB and grown to a density of OD6oo=0.6. All subsequent 
manipulations were performed using pre-cooled pipettes and tubes in the 
cold room. Cells were incubated on ice for 5mins, pelleted by 
centrifugation at 2300g for 5mins at 4°C and resuspended in an equal 
volume ice-cold water. Cells were then washed, first in 500ml ice-cold 
water, then in 500ml 10% glycerol in ice-cold water. Finally, cells were 
harvested by centrifugation at 2300g for 5mins at 4°C, resuspended in
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2.5ml 10% glycerol in ice-cold water, aliquoted into 50 i^l volumes in pre- 
chilled Eppendorf tubes and rapidly frozen on a dry ice/EtOH mix. Cells 
were stored at -70°C.
2.2.1.9 Transformation of Electro-competent DH5a
Electrocompetent DH5a (50^1) were incubated with 1 l^ DNA extracted 
from yeast in a pre-cooled cuvette (0.4cm gap chamber, Equibio) on ice 
for 30mins. The cuvette was patted dry and transferred to a Biorad Gene 
Pulser. Cells were pulsed at 2.5kV with settings of 200ohms resistance 
and 25^FD capacitance and 250^1 pre-warmed SOC was immediately 
added. The suspension was transferred to a 15ml tube and incubated 
with shaking at 37°C for 1 hr. The entire transformation mix was plated on 
LBamp agar and incubated overnight at 37°C.
2.2.1.10 Plasmid DNA Preparation
A single transformed bacterial colony was inoculated into 5ml |_BKan/Amp 
selection media and incubated overnight at 37°C with shaking. To 
prepare a stock for long-term storage at -70°C, 500[xl overnight culture 
was mixed with 500pJ 30% glycerol in LB and frozen rapidly on an 
EtOH/dry ice mix; the remainder was used for plasmid preparation. For 
small scale DNA purification, the culture was processed using the 
QIAprep Spin MiniPrep Kit (Qiagen). For larger scale DNA purification 
the overnight starter culture was diluted into 100ml LBKan/Amp media, 
grown for a further 16hrs at 37°C with shaking and processed using the 
QIAGEN Plasmid Maxi Kit. The concentration of the purified DNA was 
determined by measuring the OD26o and assuming that a DNA 
concentration of 50[xg/ml gives OD26o=1 • The quality of the DNA was 
considered acceptable if the ratio OD260/OD280 was approximately 1.8.
2.2.1.11 DNA Sequencing
DNA sequencing was carried out using the ABI BigDye Terminator v3.1 
system in accordance with the manufacturer’s protocol. Typically, the 
reaction mix incorporated 150ng plasmid, 3.2pmol primer and 1x BigDye
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Terminator Mix in Sequencing Buffer made up to a final volume of 20(xl in 
filter sterilised, distilled water. Cycle sequencing was performed using 
the following programme:
Step 1 Ramp to 96°C at 2.5°C/sec
Step 2 96°C, 1min; denaturation
Step 3 96°C, 10secs; denaturation
Step 4 Ramp to (primer Tm-3)°C at 1°C/sec
Step 5 (primer Tm-3)°C, 5secs; annealing
Step 6 Ramp to 60°C at 1 °C/sec
Step 7 60°C, 4mins; extension
Cycle back to Step 3 x24
Step 8 12°C, hold
Reaction products were purified using DyeEx 2.0 Spin Kits (Qiagen) and 
sequenced by CR-UK research services on an Applied Biosystems 3730 
DNA Analyser. Sequencing results were opened with EditView software 
and analysed using the DNA Strider package and the GeneStream online 
resource centre (http://www2.igh.cnrs.fr/home.eng.html).
2.2.2 Cloning
2.2.2.1 PKC Constructs
PKC epsilon constructs were cloned by PCR using mouse PKCe cDNA in 
pMT2 as a template (from Dr. Ben Webb). The Entrez Nucleotide 
accession number is AF325507; our stock bears 2 silent mutations: 
A1782G and C1890T.
PKC delta constructs were generated using either rat PKC5 in pC02 
(from Dr Ben Webb; NM_133307) or human PKC6 in pBluebac (Eli Lilly; 
NM_006254) as the PCR template.
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2.2.2.1.1 Yeast 2-Hybrid Constructs
A panel of PKC yeast 2-hybrid bait constructs were cloned into the 
pGBKT7 vector (Clontech) as myc-tagged GAL4 DNA binding domain 
fusion proteins.
PKC-pGBKT7 
Bait Construct
Boundaries within 
PKC ORF (bps)
Full length e 1-2214
e Regulatory domain 1-1197
e Catalytic domain 892-2214
Full length 6 1-2022
6  Regulatory domain 1-1023
b Catalytic domain 856-2022
Table 2.4 Yeast 2-Hybrid Bait Constructs. The domain boundaries of 
full length PKC-e/S, and regulatory and catalytic domain, yeast 2-hybrid 
bait constructs are summarised.
Full length PKCe and individual PKCe regulatory and catalytic domains 
were introduced in frame into pGBKT7 between the Nco I and BamH I 
restriction sites. PKCe sequences were amplified by PCR using primers 
which incorporated a 5’-Nco I site and a 3’-Bgl II site (BamH I and Bgl II 
yield compatible cohesive ends):
1. PKCe F 5’-caacaccataacaataataatattcaataaccttc-3’ (Nco I, e )
2. PKCe R 5’-ataacaaatctctcaaaacatcaaatcttcacc-3’ (Bgl II, e )
r £ reg. F see primer 1
£ reg. R 5’-aataaaaaatctcctaacctaaccaaacttcc-3’ (Bgl II, e )
: e cat. F 5’-caactccataacaaaaattaccaaaatactaacta-3’ (Nco I, e )
e cat. R see primer 2
The resulting products were PCR purified and double digested as 
indicated, alongside pGBKT7. Digested vector and insert were gel 
purified, ligated and transformed into bacteria, from which plasmid DNA 
was purified and sequenced.
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Using a similar strategy, full length rat PKC6 and its regulatory and 
catalytic domains were cloned into the bait vector. PCR primers were 
used to introduce a 5’-EcoR I and a 3’-BamH I site to the PKC6 
sequences to allow ligation into the corresponding restriction sites in 
pGBKT7:
7. PKC6 F: 5’-aaataaaattcataacaccattcctacac-3’ (EcoR I, 6)
8. PKC6 R: 5’-acacaaatcccttccaaaaattactcatatttaa-3’ (BamH I, 6)
6 reg. F: see primer 7
j 6 reg. R: 5’-aaaaaaaatcctccaattactcccctcccaa-3’ (BamH 1, 5)
Ti 6 cat. F: 5’-aatcaaaattcctcttaactaaaaccttaaacc-3’ (EcoR 1, 6)
i.~ 6 cat. R: see primer 8
2.2.2.1.2 GST-tagged Constructs
A series of GST-PKC constructs, with boundaries corresponding exactly 
to those described in 2.2.2.1.1, were created for expression in 
mammalian cells. The PKC sequences were cloned in frame between 
the Xma l-Kpn I sites of a modified pMT2 vector (from Dr. Dick Schaap) 
such that each bears a C-terminal GST tag; stop codons were deleted 
from full length and catalytic domain constructs, and start codons were 
added to the latter. The following primers were employed to generate 
these constructs:
13. PKCe F 5’-aaacacacccaaaataataatattcaataaccttc-3’ (Xma I, e)
14. PKCe R 5’-catctataataccaaaacatcaaatcttcaccaa-3’ (Kpn I, e)
15. e reg. F see primer 13
16. e reg. R 5’-catataaaataccactaacctaaccaaacttcc-3’ (Kpnl.e)
17. e cat. F 5’-catattacccaaaataaaaattaccaaaatactaacta-3’ (Xma I, e)
18. e cat. R see primer 14
19. PKC6 F 5’-aataatacccqaqataacaccattcctacac-3’ (Xma I, 6)
20. PKC6 R 5’-ctaaacaqqtaccattccaaaaattactcatatttaa-3’ (Kpn I, 6)
21. 6 reg. F see primer 19
22. 6 reg. R 5’-aatataaqataccaccaattactcccctcccaa-3’ (Kpn I, 6)
23. 6 cat. F 5’-aatataacccaaaatactcttaactaaaaccttaaacc-3’ (Xma I, 5)
24. 6 cat. R see primer 20
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2.2.2.1.3 GFP-tagged Constructs
GFP-tagged mouse PKCs was obtained from Dr. Johanna Ivaska; the 
PKCe ORF and 3’ UTR were cloned into pEGFP-C1 (Clontech) between 
the Bgl II and Sal I restriction sites (Ivaska et al., 2002). GFP-PKCS (rat) 
in pEGFP-C3 was from Dr. Jyoti Srivastava (Srivastava et al., 2002). 
Bovine PKCa and related phosphorylation site mutants (T497A, T497E, 
T638A, T638E, S657A and S657E) were cloned into pEGFP-C2 by Dr. 
Scott Parkinson.
Human PKCS was introduced into the pEGFP-C1 vector between the 
EcoR I and BamH I sites using the following PCR primers:
25. PKC6 F S’-atattaaaattcaataacqccqttcctacqcatcac -3’ (EcoR 1,6)
26. PKC5 R 5’-taatatqqatcctcaatcttccaqqaqgtqctcq-3’ (BamH 1,6)
PKCa was cloned into the pEGFP-C1 vector between Bgl II and Sal I 
sites. Bovine PKCa in pEGFP-C2 was used as a template with the 
following primers:
27. PKCa F 5’-attataaqatctatqqctqacqtcttcccqqcc-3’ (Bgl II, a)
28. PKCa R 5’-taatatqtcqactcataccqcqctctqcaqqatqq-3’ (Sal I, a)
2.2.2.1.4 RFP-tagged Constructs
RFP-PKCe was cloned by manipulating the GFP-PKCs construct; the 
GFP sequence was removed by digestion of the unique, flanking 
restriction sites, Nhe I and Bgl II, and replaced with RFP (Accession no: 
AF506027). Monomeric RFP cDNA was obtained from Dr. Veronique 
Calleja (Campbell et al., 2002) and amplified using the following primers:
29. RFP F 5’-aatataqctaqcatqqcctcctccqaqqacq-3’ (Nhe I, RFP)
30. RFP R 5’-atataaaqatcttqcqccqqtqqaqtgqcqqccctc-3’ (Bgl II, RFP)
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2.2.2.1.5 His-tagged Constructs
His-tagged PKCa, PKCa-T638A and PKCa-T638E in pKS1 were from Dr. 
Frederic Bornancin (Bornancin and Parker, 1996).
2.2.2.1.6 PKCe and PKC6 Sequencing Primers
All of the PKCe constructs cloned were sequence checked using the 
following primers to achieve full coverage:
a. 5’-cgcatacgctccctgaacac-3’ (436-455, antisense)
b. 5’-cgctgacttggatcggtcg-3’ (1023-1041, antisense)
c. 5’-gcagtccacatcatcgtcttg-3’ (1336-1356, antisense)
d. 5’-caggccaagcgcttggggc-3’ (1195-1213, sense)
e. 5’-ccagattcagcggtcccga-3’ (1488-1506, sense)
f. 5’-cgagatgatggctgggcagc-3’ (1794-1813, sense)
PKC6 sequences were verified using the following:
g. 5’-ctcgtggttcttgatgtagtg-3’ (460-480, antisense)
h. 5’-tcacactttaatccctgtttcacc-3’ (762-785, antisense)
i. 5’-gatcgacgatgacgtggagtg -3’ (1152-1172, sense)
j. 5’-gcctttgtcctgaatgtggaac-3’ (1302-1323, antisense) 
k. 5’-cacatcaagattgctgacttc-3’ (1450-1471, sense)
I. 5’-gaccctgccaagaggctgg-3’ (1750-1768, sense)
PKCa constructs were sequenced using primers from Dr. Angus 
Cameron.
2.2.2.2 PKCe and PKC5 Mutagenesis
2.2.2.2.1 PKCe Autophosphorylation Site Mutants
A panel of PKCe autophosphorylation site mutants were cloned using a 
two-step PCR based mutagenesis strategy: S234A, S234D, S316A, 
S316D, S368A and S368D.
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Mut-F
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Figure 2.1 Site Directed Mutagenesis. The two-step PCR based 
strategy employed for the cloning of mutants is summarised 
diagrammatically. Primers are represented by half arrows; blue zigzags 
denote non-complementary sequences incorporating restriction sites for 
subsequent cloning. The codon targeted for mutagenesis is signified by a 
cross, black corresponds to the wild type sequence, red to the desired 
mutation.
Briefly, in the first round of PCR, primer F and primer Mut-R were used to 
amplify product a from a wild type PKCe template, while primer Mut-F and 
primer R were used to amplify product b; the Mut- primers are antiparallel 
with respect to one another and harbour the appropriate mutation in the 
codon of interest (X). Products a and b were separated from the wild 
type PKCe template by agarose gel electrophoresis, purified by gel 
extraction and used in combination as a PCR template for step two. The 
second round of PCR was performed using external primers F and R, 
which amplify full length, mutated PKCe and incorporate Xma I and Kpn I 
sites respectively. The primers used to construct these PKCe mutants 
were as follows:
31. PKCe F see primer 13
32. PKCe R see primer 14
33. S234A Mut-F 5’-aacaaaataaacacccaacaattcaac-3’ (mutation, e)
34. S234A Mut-R 5’-actaaaccattaaacacccacctcatc-3’ (mutation, e)
35. S234D Mut-F 5’-aacaaaataaacaaccaacaattcaac-3’ (mutation, e)
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36. S234D Mut-R 5’-actaaaccattaatcacccacctcatc-3’ (mutation, s )
37. S316A Mut-F 5’-aacaaaatcaccaacactaaccaaaaaaaa-3’ (mutation. 2 )
38. S316A Mut-R 5’-cctcctttaaccaacattaataattttatc-3’ (mutation, 2)
39. S316D Mut-F 5’-aacaaaatcaccaacaataaccaaaaaaaa-3’ (mutation. 2 )
40. S316D Mut-R 5’-cctcctttaaccatcattaataattttatc-3’ (mutation, 2 )
41. S368A Mut-F 5’-caaaaaaccttaacatttaacaaccaaaa-3’ (mutation, e )
42. S368A Mut-R 5’-cctcaattatcaaataccaaaaccttcca-3’ (mutation, e )
43. S368D Mut-F 5’-caaaaaaccttaaattttaacaaccaaaa-3’ (mutation, e )
44. S368D Mut-R 5’-cctcaattatcaaaatccaaaaccttcca-3’ (mutation, e )
A triple PKCe autophosphorylation site mutant S234A/S316A/S368A 
(PKCe3A) was also constructed by sequential cycles of mutagenesis: 
S234A was used as the template for S316A cloning and the resulting 
S234A/S316A double mutant was used as the template for S368A 
alteration.
The PKCe autophosphorylation mutants were ligated into pMT2-GST as 
described in the previous section. Subsequently, all were introduced into 
pEGFP-C1; PKCe3A was also transferred to pRFP-C1. Subcloning was 
achieved by exploiting unique EcoR V (bps 593-598) and EcoR I sites 
(2170-2175) within the PKCe ORF. GFP-PKCe and RFP-PKCe were 
digested to remove the EcoR V/EcoR I fragment, and following gel 
purification, these were replaced by ligation of mutant fragments digested 
with the same enzymes.
2.2.2.2.2 PKC6 Autophosphorylation Site Mutants
A set of human PKC6 putative autophosphorylation site mutants were 
generated by two-step PCR based mutagenesis: S57A/T58A, T141A, and 
S304A. External primers in round 2 incorporated a 5’ EcoR I site and a 3’ 
BamH I site for in frame ligation into pEGFP-C1:
45. PKCS F see primer 26
46. PKC5 R see primer 27
47. 57A/58A Mut-F 5’-cxrtaaataaaaci(icqacattcaatacccac-3’ (mutation, 5)
48. 57A/58A Mut-R 5’-ataaacatcaaacaccqccttccactcaaa-3' (mutation, 6)
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49. T141A Mut-F 5’-accaaattcccaacaatQaaccQCCQc-3’ (mutation, 6)
50. T141A Mut-R 5’-acxiQcaattcatcactaaaaacttaQC-3’ (mutation, 6)
51. T304A Mut-F 5’-CQaaaatcaaacacaacctcctcaaaa-3’ (mutation, 6)
52. T304A Mut-R 5’-ctctaaQaaaactacatctaatctcca-3’ (mutation, 6)
2.2.2.2.3 F-box WD40 (Fbw) Protein and c-jun Constructs
2.2.2.2.3.1 GFP>tagged Fbw7 C-terminal Clone
The C-terminal region of Fbw7 (encoding amino acids 283-629; F7C) was 
recovered in pACT2 from positive clone 19 following the yeast 2-hybrid 
screen described in section 2.2.3. This partial insert was subcloned 
directly into the mammalian pEGFP-C1 vector by PCR, using primers 
complementary to the vector sequence adjacent to the library insert (F: 
5032-5012, R: 4990-4964; see Appendix A2). The primers incorporated 
a 5' Kpn I site and a 3' Age I site to facilitate in-frame ligation between the 
Kpn l/Xma I sites of pEGFP-CI; Age I and Xma I yield complementary 
cohesive ends.
53. F7C F S’-aatacaaataccaatcatataaccataaaaQcc-S’ (Kpn I, PACT2)
54. F7C R 5’-ataaaaaccaatCCcaatatctacaattcataaatctctca-3’ (Age I, pACT2)
2.2.2.2.3.2 Full length F-box WD40 (Fbw) Protein and c-jun 
Constructs
FLAG-tagged mouse Fbw1 (Miura et al., 1999), mouse Fbw2 (Miura et 
al., 1999), zebrafish Fbw4 (Maruyama et al., 2001) and mouse Fbw6/7 
(AF391192; referred to subsequently as Fbw7p; (Maruyama et al., 2001)) 
were obtained from Professor Shigetsugu Hatakeyama. Fbwsl, 4 and 7 
are in pcDNA3, Fbw2 in pCI-neo. Empty pcDNA3.1 expressing a FLAG- 
tag alone was provided by Dr. Sylvie Lachmann. FLAG-tagged human 
Fbw7p in plRES2-EGFP (NM_018315; (Nateri et al., 2004)), GFP-Fbw7p 
in pEGFP-C2 (EcoR I/Sal I) and myc-c-jun-FLAG in pCMV were from 
Anett Jandke. FLAG-tagged Fbw7a (Welcker et al., 2004b) and 
Fbw7aABD1 (Welcker et al., 2004a) in 3pX-FLAG-myc-CMV-24 were 
provided by Dr. Bruce Clurman (NM_033632); these constructs contain 
an amino acid change, A626T, and lack the 2 C-terminal residues.
94
Chapter 2: Materials and Methods
GFP-tagged Fbw7a was cloned in frame into pEGFP-C1 between Bgl II 
and Sal I. FLAG-Fbw7a was used as a PCR template with the following; 
Fbw7a-R was designed to accommodate the C-terminal mutation 
harboured by this construct:
55. Fbw7a F 5’-attataaqatctatqaatcaqqaactactctctataa-3’ (Bgl II, F7a)
56. Fbw7a R 5’-taatatqtcqactcattccacatcaaaqtccaqc-3’ (Sal I, F7a)
2.2.2.2.3.3 Fbw7a Mutagenesis
Fbw7a S18A and S18D mutants were generated by two-step PCR.
Since the codon for S18 is so close to the N-terminus, the first round of 
PCR was performed using an external F primer complementary to the 
vector sequence upstream of Fbw7a paired with the Mut-R primer; this 
generated a larger product for more convenient subsequent manipulation. 
In round two, regular external primers were used to incorporate a 5’ Bgl II 
site and a 3’ Sal I site for in frame ligation into pEGFP-C1:
57. Fbw7a F see primer 65
58. Fbw7a R see primer 66
59. round 1 F 5’-cqqtqqqaqqtctatataaqc-3’ (vector)
60. S18A Mut-F 5’-cqaactqqaqqcqctctqaqaqq-3’ (mutation, F7a)
61. S18A Mut-R 5’-cctctcaqaqcqcctccaqttcq-3’ (mutation, F7a)
62. S18D Mut-F 5’-cqaactqqaqqcqatctqaqaqq-3’ (mutation, F7a)
63. S18D Mut-R 5’-cctctcaqatcqcctccaqttcq-3’ (mutation, F7a)
The N-terminal domain of Fbw7a (bps 1-204) was also generated as a 
GFP construct. GFP-wt Fbw7a, S18A and S18D were used as PCR 
templates with the following primers:
64. F7a-N F see primer 65
65. F7a-N R 5’-taatatqtcqacqcctccaqqtctaqqttctactcc-3’ (Sal I, F7a)
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Fbw7a constructs were sequenced using the following primers:
I. 5’-cctcatcttgttcaccaga-3’ (antisense)
m. 5’-caggaactgctctctgtgggcagc-3’ (sense)
n. 5’-gccaaaattctccagtagcg-3’ (antisense)
0 . 5’-ggggacctcagagcagccaatggc-3’ (sense)
P- 5’-gcagctcagacatgtcgctactgg-3’ (sense)
q- 5’-gtgggacatacaggtggagtatgg-3’ (sense)
r. 5’-ccagagactgaaacctgtctag-3’ (sense)
s. 5’-ggtcccaacaagcatcagagtgc-3’ (sense)
2.2.2.2.4 VHL Binding Protein 1 (VBP1) Constructs
2.2.2.2.4.1 His-tagged VBP1 for protein purification
His-tagged human VBP1 (BC046094), cloned between the EcoR I/Sal I 
sites of the bacterial expression vector pET-28a, was provided by Dr. 
Chengtao Her (Her et al., 2003). This construct bears two mutations: 
A2G and K196E.
2.2.2.2.4.2 GFP-tagged VBP1
Human VBP-1 cDNA (BC046094) was obtained from the IMAGE 
consortium (IMAGE no: 6058145) and used as a PCR template with the 
following primers to facilitate cloning between the EcoR I and Xma I sites 
in pEGFP-C1:
66. VBP1 F 5’-tcttctaaattcAataqcaaccattaaaaacaq-3’ (EcoR I, VBP1)
67. VBP1 R 5’-acacaacccqqqttatactttattcttaataaaatc-3’ (Xma I, VBP1)
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2.2.3 Yeast Two-Hybrid Analysis
The MATCHMAKER GAL4 System 3 (Clontech) was employed for yeast 
two-hybrid analysis according to the manufacturer’s recommendations.
2.2.3.1 Yeast Culture
2.2.3.1.1 Yeast Strain AH109
Yeast 2-hybrid analysis was performed using the Saccharomyces 
cerevisiae strain AH109 (Clontech); its genotype is as follows: MATa, 
trp 1-901, leu2-3, 112, ura3-52, his3-200, gal4A, gal80A, LYS2 ::
GAL 1 uas-GAL 1 tata-HIS3, GAL2uas-GAL2Tata-ADE2, URA3 : :  M ELIuas- 
MEL1 TATA' lacZ.
2.2.3.1.2 Yeast Media and Maintenance
Wild type AH 109 were cultured in YPDA liquid media or on YPDA Agar 
plates. AH 109 transformants were maintained using an appropriate SD 
based nutrient drop-out medium for selection.
CSM-drop-out media Selection
-TRP bait vector
-LEU prey vector
-TRP/LEU bait/prey cotransfection
-TRP/LEU/HIS medium stringency interaction
-TRP/LEU/HIS/ADE high stringency interaction
-TR P/L E U/HI S/AD E/X-a-G a I high stringency interaction with 
blue/white verification
Table 2.5 Nutritional Markers for Yeast Selection. The nutritional 
markers employed for yeast 2-hybrid screening using AH 109 yeast, and 
pGBKT7/pACT2 vectors
Yeast stocks were streaked onto agar plates and incubated at 30°C for 2- 
6 days. In order to establish an overnight culture, a single colony was 
picked into 1ml media in an Eppendorf tube and vortexed extensively; this 
cell suspension was used to inoculate 5ml media and incubated at 30°C
with shaking for 16hrs. Glycerol stocks were prepared for long-term
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with shaking for 16hrs. Glycerol stocks were prepared for long-term 
storage at -70°C by diluting 250^1 sterile glycerol into 500ptl overnight 
culture and snap freezing on an EtOH/dry ice mixture.
2.2.3.1.3 Yeast T ransformation
Yeast transformations were performed according to the Gietz 2-Hybrid 
TRAFO Protocol (Agatep et al., 1998). For high efficiency co­
transformation, yeast were transformed sequentially; the bait construct 
was introduced into AH109 and the resulting transformants were used to 
prepare competent cells for the subsequent introduction of prey/library.
The basic protocol for 10 transformations (1 Ox) was as follows. A single 
colony from a freshly streaked stock plate was picked into 5ml liquid 
YPDA and incubated with shaking at 30°C overnight. An appropriate 
volume of this overnight culture was used to inoculate 50ml warm YPDA 
at 5x106cells/ml. The culture was incubated with shaking at 30°C until 
the cell density reached 2x107cells/ml (3-5hrs); transformation efficiency 
is highest when cells have completed 2-4 cycles of division. Cells were 
harvested by centrifugation at 3000g for 5mins, washed in 25ml sterile 
water, and harvested again. The yeast were resuspended in 1ml 100mM 
LiAc, pelleted at 14,000rpm for 15secs in a benchtop microfuge, diluted in 
500^ ,1 100mM LiAc and aliquoted into 50^1 volumes. Competent cells 
were then harvested by microcentrifugation at 14,000rpm for 15secs and 
resuspended in the following: 240^1 50% (w/v) PEG (average MW = 
3,350), 36pil 1M LiAc, 50^1 2mg/ml YEASTMAKER carrier DNA 
(Clontech), 0.1-1 ng plasmid DNA made up to a final volume of 360^1 in 
sterile water (ingredients were added in this order). The transformation 
mix was vortexed vigourously, incubated at 30°C for 30mins and heat 
shocked at 42°C for 30mins (with gentle shaking every 5mins). Finally, 
the yeast were harvested by microcentrifugation at 6000rpm for 15sec, 
resuspended in 1ml distilled, filter sterilised water and plated onto the 
appropriate CSM-drop out agar (typically 10O^I/plate). Plates were 
inverted and incubated at 30°C for 3-10 days to recover transformants.
98
Chapter 2: Materials and Methods
For sequential transformation the protocol was essentially the same 
except that in the initial overnight culture bait transformants were grown in 
25ml of the appropriate CSM-drop out media to maintain plasmid 
expression (yeast were then subcultured in YPDA for two doublings 
without significant loss of expression). In order to carry out 30 
transformations (30x), all volumes were scaled up by a factor of 3 and the 
heat shock was extended to incubation at 42°C, 40mins.
2.2.3.2 Yeast Two-Hybrid System: Preliminary Characterisation
AH109 were co-transformed with a panel of bait/prey vectors in order to 
characterise the yeast 2-hybrid system. The pGBKT7-PKC constructs 
were introduced alongside an empty prey vector (pGADT7, Clontech) to 
test for bait expression, toxicity and autoactivation of reporter genes.
AH 109 co-transformed with empty pGBKT7/pGADT7 provided a negative 
control.
2.2.3.2.1 Test for Bait Expression and Toxicity
Yeast protein extracts were prepared from co-transformed yeast by TCA 
precipitation to verify bait expression. A single colony was used to 
inoculate 5ml CSM-TRP/LEU and grown overnight with shaking at 30°C. 
The overnight culture was vortexed vigorously, diluted into 50ml YPDA 
and grown to OD6oo=0.4-0.6 (OD6oo x total volume = OD units). Cells 
were chilled rapidly by the addition of 1 volume of ice and harvested by 
centrifugation at 1000g for 5mins at 4°C. Yeast were then washed in 
50ml ice cold water, recovered by centrifugation and snap frozen on an 
EtOH/dry ice mixture. The pellet was thawed on ice for 20mins and 
resuspended in 100pJ ice-cold TCA buffer/7.5 OD units. The cell 
suspension was then transferred to a screw cap microfuge tube 
containing 100^1 glass beads (425-600nm) and 100[il 20% TCA/7.5 OD 
units. Cells were disrupted using a bead-beater at the highest setting 
3x30secs (FastPrep FP120, Bio101); this process was followed under a 
light microscope, successfully ruptured yeast appear as darkened
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‘ghosts’. The supernatant was removed to a fresh tube and the beads 
were resuspended in a mixture of 250pl TCA and 250^120% TCA for 
another round of agitation. The second supernatant was pooled with the 
first and proteins were pelleted by microcentrifugation at 14,000rpm for 
10mins at 4°C. Protein extracts were solubilised in 10ptl TCA-Laemmli 
buffer/OD unit, boiled at 100°C, 10mins, cleared by centrifugation at 
14,000rpm for 10mins at RT and analysed by Western blotting.
5ml cultures were established from the same co-transformed AH109 and 
incubated overnight at 30°C with shaking. Growth was assayed by 
measuring OD6oo in order to determine whether bait expression conferred 
toxicity.
2.2.3.2.2 Test for Bait Autoactivation of Reporter Genes
AH109 co-transformed with pGBKT7/PKCs and pGADT7 were plated on 
selective media to test for autoactivation of reporter genes; additionally, 
pGBKT7-p53/pGADT7-T antigen expressing yeast were used as a robust 
positive control for protein-protein interaction (vectors from Clontech). 
Single colonies were picked and streaked onto CSM-TRP/LEU, CSM- 
TRP/LEU/HIS or CSM-TRP-LEU/HIS/ADE/X-a-gal agar plates for 
selection at increasing stringency. Following incubation at 30°C for 6 
days plates were photographed by the CR-UK Photographic Department.
2.2.3.3 GAL4 cDNA Library Preparation
A mouse brain MATCHMAKER cDNA library of 3.5x106 independent 
clones was obtained from Clontech. This library is constructed in the 
pACT2 vector and provided in E.Coli BNN132.
Serial dilutions of the library were spread onto LBamp plates and incubated 
at 37°C for 20hrs. Colonies were counted and the library titre was 
determined to be 1.28x10® cfus/ml. The library was then amplified to 
obtain enough plasmid for screening in yeast; 3x coverage of the library 
was considered sufficient (1.05x107cfus, 82pl library). In order to plate
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the library at near confluency, E.coli were spread at a density of 140 000 
cfus/245mm square plate; 82|xl library was mixed with 37.5ml LB and 
distributed at 500pJ/plate over 75 245mm square LBamp plates using 
ColiRoller Plating Beads (Novagen). The plates were inverted and 
incubated at 37°C for 20hrs. 10ml 25% (v/v) glycerol/LB was added to 
each plate and colonies were harvested by shaking the beads and then 
scraping with a sterile spreader. Cell suspensions were pooled and 
shown to be equivalent to 101 of a regular overnight bacterial culture by 
O D 6oo- Plasmid DNA from 500ml cell suspension was isolated and 
purified over 6 Megaprep columns (Qiagen) for screening by yeast 2- 
hybrid. The remainder was aliquoted (5x1 mis and 10x50mls) and frozen 
at -70°C for future use.
2.2.3.4 Yeast Two-Hybrid Screen
2.2.3.4.1 Library Transformation
pGBKT7-PKCe bait was transformed into AH109 as described. Fresh 
transformant colonies were then used to prepare competent cells for 
subsequent introduction of the cDNA library; screening of 106 
independent clones was judged to be a suitable target for 2-hybrid 
analysis.
A small scale test run was performed to optimise conditions and estimate 
transformation efficiency: yeast were co-transformed with PKC-e bait and 
a dilution series of the library. The aim was to determine the lowest 
concentration of DNA required to screen 106 cfus in an effort to 
circumvent the problem of introducing >1 library plasmid into a given cell. 
A dilution series of co-transformants was plated on CSM-TRP/LEU and 
incubated at 30°C for 4 days. Colonies were counted and the 
transformation efficiency was estimated at 104cfu/ng when a 1x 
transformation was carried out using 0.5ng library DNA.
In order to screen 106cfus in the final yeast 2-hybrid screen, this protocol 
was scaled up 120x using a total of 60 i^g library DNA. This was achieved
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could be readily handled and efficiently heat shocked. In the final step, 
pellets were each resuspended in 15ml distilled, filter sterilised water and 
pooled; the suspension was plated at 2ml/plate over 30 245mm square 
CSM-TRP/LEU/HIS plates and incubated at 30°C for 5 days. A dilution 
series was plated onto CSM-TRP/LEU in parallel, colonies were counted 
and it was determined that a total of 1.4x105 cfus had been screened.
2.2.3.4.2 Sequential Rounds of Yeast Two-Hybrid Screening
Positive clones recovered following incubation on CSM-TRP/LEU/HIS 
plates (medium stringency) were screened for interaction at higher 
stringency. Colonies were restreaked onto 22x22 grids on 245mm 
square CSM-TRP/LEU/HIS/ADE plates alongside a pGBKT7- 
p53/pGADT7-T antigen positive control and incubated at 30°C for 3 days. 
Positive colonies were then subjected to a final round of selection; yeast 
were restreaked onto CSM-TRP/LEU/HIS/ADE/X-a-gal agar plates and 
incubated for a further 5 days at 30°C.
2.2.3.4.3 Plasmid Rescue and Purification
A single colony of AH 109 co-transformed with pGBKT7-PKCs/pACT2- 
putative interacting library clone was picked from the final CSM- 
TRP/LEU/HIS/ADE/X-a-gal selection plate and used to inoculate 4ml 
CSM-TRP/LEU/HIS. The culture was grown at 30°C with shaking for 1-3 
nights until OD6oo^0.8. 1ml was removed to establish a glycerol stock, 
the remainder was split between 2 screw cap tubes and microcentrifuged 
at 13,000rpm for 2mins. The yeast were washed in 500pil water, pooled, 
and recovered by microcentrifugation. The pellets were resuspended in 
200^1 yeast cracking buffer, glass beads (425-600^m) were added up to 
the meniscus and 200fxl phenol:chloroform:isoamylalcohol was 
introduced. The mix was vortexed 3x30secs, with 30secs incubation ice 
in between, and microcentrifuged at 13,000rpm for 10mins at 4°C. 150^1 
aqueous layer was removed to a tube containing 500^1 85% (v/v) EtOH, 
1M ammonium acetate, mixed with 10 inversions and microcentrifuged at 
13,000rpm for 30mins at 4°C. Precipitated plasmid DNA was washed in
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250^1 70% EtOH and resuspended in 50pl distilled, sterile filtered water. 
Extracted plasmid DNA (V I)  was electroporated into competent DH5a 
and plated onto LBamp plates to select for the library vector.
DH5a colonies transformed with the positive library vectors were 
inoculated into 5ml LBamp overnight cultures. 500pl of each was used to 
establish a glycerol stock and plasmid DNA was purified from the 
remainder by mini-prep.
2.2.3.4.4 Sequence analysis
Recovered library vectors from positive AH 109 colonies were sequenced 
using the following primers:
t. 5’-taccactacaatggatg-3’ (pACT2 5153-5137, sense)
u. 5’-agatggtgcacgatgcacag-3’ (pACT2 4939-4920, antisense)
2.2.4 Protein Purification
His-tagged VBP1 was expressed in bacteria and purified using Ni-NTA 
agarose according to the manufacturer’s instructions (Qiagen). Briefly, 
pET-VBP1 was transformed into BL21-CodonPlus bacteria and plated 
onto LBkanagar. A single colony was used to inoculate a 50ml overnight 
starter culture, this was subsequently diluted into 11 LBkan and grown to 
OD6oo=0.5 . An aliquot of this culture (1ml) was removed (non-induced 
control) and expression was induced in the remainder with the addition of 
0.4mM IPTG; cells were incubated overnight at 16°C with shaking. After 
the removal of 1ml (post-induction control) the culture was harvested by 
centrifugation at 4000g for 20mins. The pellet was resuspended in 20ml 
Imidazole Lysis Buffer and sonicated 6x10secs with 30sec intervals on 
ice. Lysates were cleared at 55 OOOrpm for 1 hr at 4°C using a 70Ti rotor 
in an XL70 ultracentrifuge (Beckman) and the supernatant was decanted. 
The pellet was resuspended in 20ml 8M urea (insoluble extract). 1ml of 
the supernatant was removed (protein expression control) and the 
remaining 20ml soluble extract was subjected to a native protein
purification protocol. Ni-NTA agarose (1ml) was washed in 5ml Imidazole
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purification protocol. Ni-NTA agarose (1ml) was washed in 5ml Imidazole 
Lysis Buffer x3 and the final slurry was transferred to the soluble protein 
extract; this mix was tumbled at 4°C for 1 hr. The beads were washed 6x 
in 5ml Imidazole Lysis Buffer and the purified protein was eluted using 
step gradients of imidazole. Ni-NTA agarose was recovered by 
centrifugation in a benchtop centrifuge at 1000 rpm for 1min. Beads were 
resuspended in 100mM Imidazole Elution Buffer and recovered again by 
centrifugation; the supernatant containing eluted protein was transferred 
to a fresh tube. The same procedure was repeated using 200mM, 
300mM, 400mM and finally 500mM Imidazole Elution Buffers. Samples 
of all controls and eluted fractions were subjected to SDS-PAGE and 
protein expression was visualised by Comassie staining. The eluate 
containing the majority of the purified protein was then dialysed against 
50mM Tris pH 7.5, 100mM NaCI and stored at4°C.
2.2.5 Mammalian Cell Culture
2.2.5.1 Cell lines
COS7 (african green monkey kidney), 293 (human embryonic kidney), 
HeLa (human cervical carcinoma) and NIH3T3 (mouse embryonic 
fibroblast) cells were obtained from CR-UK research services, RCC (renal 
carcinoma) cells were from Dr. Xavier Iturrioz. PKCe knock out MEFs 
(e 7 ) and e_/'MEFs re-expressing PKCe (clone 5) were established by 
Richard Whelan (Ivaska et al., 2002). e_/'M E FS  re-expressing GFP-e, 
and GFP-e 234A/316A/368A (e3A) were generated by Dr. Angus 
Cameron; e ' M E F S  were stably transfected with pBABE GFP-PKCe 
constructs to generate polyclonal cell lines from which subpopulations 
expressing similar levels of GFP were isolated by 3 successive rounds of 
Fluorescent Activated Cell Sorting (FACS).
2.2.5.2 Cell culture and transfection
All cells, with the exception of NIH3T3, were maintained in Dulbecco’s 
modified Eagle’s medium (DMEM, provided by CR-UK Research 
Services) supplemented with 10% foetal calf serum (PAA laboratories;
104
Chapter 2: Materials and Methods
10% E4) in a humidified 5% CO2 incubator at 37°C. Where serum 
starvation was necessary, media was typically replaced with 0.1% E4 for 
16 hrs. NIH3T3 were cultured in DMEM with 10% donor calf serum (PAA 
laboratories). e/_MEFs and clone 5 cells were supplemented with 
100ng/ml hygromycin, GFP/PKC expressing e'/_MEFs with 5ng/ml 
puromycin.
Transient transfections were performed using Lipofectamine 2000 
(Invitrogen) following the manufacturer’s instructions for the appropriate 
cell lines. Typically, DNA/lipofectamine in Optimem was added directly to 
the culture media, incubated for 6hrs and then replaced with warm E4 
10%. Subsequent manipulations were typically performed 24hrs post­
transfection.
2.2.6 Preparation of total cell extracts
Cells seeded in 24 well dishes were washed with PBS and harvested by 
scraping into 100^1 boiling 2x LDS sample buffer. Extracts were boiled at 
100°C for 5mins and briefly sonicated to shear genomic DNA.
2.2.7 GST Pull down and Immunoprecipitation
2.2.7.1 GST Pull-Down
Cells seeded in 6 well dishes were washed in ice-cold PBS and 
harvested in 400^1 pre-chilled lysis buffer containing: 50mM Tris pH 7.5, 
150mM NaCI, 0.5% (v/v) NP40, 0.1 mM NasVO^ 10mM NaF, 1x protease 
inhibitor cocktail. Cells were resuspended thoroughly by pipetting, 
incubated on ice for 10mins and subjected to microcentrifugation at 14 
OOOrpm for 10mins at 4°C. The resulting pellet was stored at -20°C and 
resuspended in 2x LDS sample buffer by sonication where the insoluble 
fraction was of interest, and a 50 1^ aliquot of the supernatant was diluted 
in 2x LDS sample buffer (total cell lysate); the remainder was used for 
GST pull-down. The cell lysate was pre-cleared by tumbling with 25pJ 
Sepharose 4B (Amersham) pre-equilibrated in lysis buffer for 30mins at 
4°C. Beads were pelleted by pulsing at 4 OOOrpm in a microcentrifuge
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and the cleared lysate was transferred to a fresh tube containing 25|xl 
pre-equilibrated Glutathione Sepharose 4B (Amersham) and incubated 
for a further 2hrs on a rotating wheel at 4°C. The beads were washed by 
tumbling 3x10mins in lysis buffer and then boiled in 2x LDS sample buffer 
(typically 50[xl) at 100°C for 5mins.
GST pull downs performed to analyse 14-3-3p p rote in-protein interactions 
were carried out using a similar protocol with the following modifications. 
The lysis buffer comprised: 50mM Tris pH 7.5, 150mM NaCI, 0.5% (v/v) 
Triton X-100, 0.1mM NasVO^ 10mM NaF, 1x protease inhibitor cocktail 
and 10nM Calyculin. Glutathione Sepharose 4B bearing GST or GST- 
tagged, bacterially expressed 14-3-3(3 was used in place of Glutathione 
Sepharose 4B (prepared by Dr. Adrian Saurin and stored at 4°C), and 
beads were tumbled overnight at 4°C with cell lysates; where included, 
competing phosphopeptides were used at l^g/ml.
2.2.7.2 Native Immunoprecipitation
All immunoprecipitations were performed under non-denaturing 
conditions unless otherwise stated. The protocol followed was the same 
as that for GST-pull downs with the following modifications. Cell lysates 
were pre-cleared using 25\i\ Protein A/G (CR-UK research services) 
equilibrated in lysis buffer. Immuno-complexes were typically captured 
using pre-equilibrated 25^1 Protein A/G and 1p,g antibody. For 
immunoprecipitation of FLAG-tagged proteins, anti-FLAG M2-agarose 
affinity gel (Sigma) was employed instead.
2.2.7.3 Denaturing Immunoprecipitation of PKCe from Clone 5 cells
Enrichment of PKCe from clone 5 cells was achieved by 
immunoprecipitation under denaturing conditions. In this case, confluent 
clone 5 cells were harvested from 15cm dishes into 2ml denaturing lysis 
buffer containing: 1% SDS, 20mM Tris pH 7.5. Cell lysates were boiled 
at 100°C for 10mins, sonicated and then diluted 1:10 into lysis buffer 
containing: 50mM Tris pH 7.5, 150mM NaCI, 1% (v/v) Triton X-100,
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0.1 mM Na3V0 4 , 10mM NaF, 1x protease inhibitor cocktail. Pre-clearing 
was performed as above with volumes scaled up proportionally. Cleared 
lysates were then tumbled overnight at 4°C with 1.25ng anti PKC-e (BD 
Transduction Laboratories). Immuno-complexes were recovered by 
incubation with Protein A on a rotating wheel for 1 hr at 4°C and 
processed as described above.
2.2.8 Polyacrylamide Gel Electrophoresis (PAGE)
Unless otherwise indicated, polyacrylamide gel electrophoresis was 
performed using the NuPAGE system as recommended by the 
manufacturer (Invitrogen). Samples were loaded onto 4-12% Bis-Tris 
Gels and run at 200V (constant) in NuPAGE MOPS SDS Running Buffer. 
All samples were run alongside RPN800 Full Range Rainbow Markers 
(Amersham). Protein bands were then visualised either by Coomassie 
staining or Western blotting.
2.2.9 Coomassie blue staining
NuPAGE gels were submerged in Coomassie blue stain and incubated at 
RT for 30mins with shaking. Gels were then destained in Coomassie 
destain at RT with shaking until clear bands were visible against a clean 
background (2-16hrs). Images were captured using an Epson 
Expression 1680 Pro scanner and Adobe Photoshop CS software.
2.2.10 Western Blotting
Proteins separated on NuPAGE gels were transferred electrophoretically 
onto polyvinylidene difluoride (PVDF) membranes (Millipore) pre-soaked 
in MetOH. A wet transfer system was employed (Biorad) with all 
components pre-equilibrated in cold transfer buffer. Unless otherwise 
specified, transfers were carried out at constant voltage and 400mA/hour 
at 4°C; the efficiency of transfer was verified by Ponceau S staining. All 
subsequent incubations were performed with shaking. Membranes were 
first blocked with 2% (v/v) BSA/TBS-T for 1 hr at RT and then incubated 
with primary antibody diluted in TBS-T either for 1 hr at RT or overnight at
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4°C. Where primary antibodies were phospho-specific, 1 jig/ml of the 
corresponding blocking dephospho-peptide was included in this 
incubation. Membranes were washed 3x10mins in TBS-T, incubated with 
HRP-conjugated secondary antibody in TBS-T for 1 hr at RT and then 
washed again 3x10mins. Blots were developed by enhanced 
chemiluminescence (ECL) according to the manufacturer’s guidelines 
(Amersham) and exposed to Hyperfilm (Amersham). For quantitative 
analysis, an image of a film was captured using an Epson Expression 
1680 Pro scanner and Adobe Photoshop CS; densitometry was 
performed using NIH image software (ImageJ 1.34).
2.2.11 Ubiquitination assays
Ubiquitination assays were performed using over-expressed proteins.
The candidate ubiquitin ligase and the putative substrate were co­
expressed in the presence of HA-tagged ubiquitin. The putative substrate 
was then isolated by immunoprecipitation, and probed for ubiquitin by 
western blotting against the HA epitope. The protocols employed were 
modified to optimise the detection of high molecular weight, ubiquitinated 
proteins.
2.2.11.1 Cell transfection and lysis
293 cells were transfected with a FLAG-tagged ubiquitin ligase, GST- 
tagged PKC and HA-tagged ubiquitin at a ratio of 2:2:1. The cells were 
incubated for 24hrs post-transfection and treated +/- 10p,M MG132 
overnight. Cells were processed by GST pull-down as described in 
Section 2.2.7.1, using the following modified lysis buffer: 50mM Tris pH 
7.5, 150mM NaCI, 1% NP40, 2mM EDTA, 2mM EGTA, 10mM N- 
ethylmaleimide (NEM, Sigma), 50nM ALLN (Calbiochem), 2mM NaV0 3 , 
50mM NaF, 1x protease inhibitor cocktail.
2.2.11.2 SDS-PAGE of poly-ubiquitinated protein
Poly-ubiquitinated proteins were separated by SDS-PAGE using Hoefer 
Pharmacia Biotech gel apparatus as recommended (Sambrook et al.,
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1989). To facilitate the resolution of high molecular weight species, 6% 
running gels were prepared: 6% (v/v) AcrylaGel (National Diagnostics), 
0.16% (v/v) Bis-AcrylaGel (National Diagnostics), 0.1% (w/v) SDS,
0.375M Tris pH 8.8, 0.03% (v/v) TEMED, 0.1% ammonium persulphate; 
with 3% stacking gels: 3% (v/v) AcrylaGel (National Diagnostics), 0.08% 
(v/v) Bis-AcrylaGel (National Diagnostics), 0.1% (w/v) SDS, 0.125M Tris 
pH 6.8, 0 .1% (v/v) TEMED, 0.1% ammonium persulphate. Gels were run 
at 18mA overnight in SDS-PAGE running buffer: 0.025M Trizma base,
0.192M Glycine, 0.1% SDS.
2.2.11.3 Western blotting of poly-ubiquitinated protein
Poly-ubiquitinated proteins were processed for Western blotting as 
described in Section 2.2.10, with the following modified transfer buffer: 
25mM Trizma base, 0.15% (w/v) SDS, 200mM Glycine, 20% (v/v) MetOH 
(not pH adjusted).
2.2.12 In Vitro Kinase Assays
2.2.12.1 PKC Autophosphorylation
Recombinant human PKCe and PKC6 purified from insect cells 
(Calbiochem) were tested for autophosphorylation. Reaction mixes were 
prepared in screw cap tubes and typically comprised 50^1 kinase assay 
mix and 25ng-1ng PKCe/S. Reactions were started with the addition of 
ATP, and incubated at 30°C with shaking (Microtherm incubator, Camlab) 
over the indicated timecourses. Reactions were stopped with 25pil 3x 
kinase assay sample buffer, boiled for 5mins at 100°C and resolved by 
PAGE. Gels were stained by Coomassie, scanned, and then exposed to 
a pre-blanked phosphor screen overnight; analysis was performed using 
the Storm 860 Phosphorlmaging System (Molecular Dynamics). 
Subsequently, PKC bands were removed into sterile tubes using a clean 
scalpel. These bands, alongside a dilution series of the ATP stock, were 
counted using a 2min Cerenkov programme in a Beckman LS6000IC 
scintillation machine in order to calculate 32P incorporation and 
stoichiometry.
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2.2.12.2 VBP1 Phosphorylation
PKCe/o, catalysed phosphorylation of purified VBP1 was assayed using 
the same basic protocol described above (Section 2.2.12.1). Typically, 
reactions were performed in 50^1 kinase assay mix, with 25-250ng 
PKCe/a and 250ng-5jxg purified His-VBP1 (or an MBP control) for 0-2hrs. 
Proteins were resolved by SDS-PAGE, using a 14% running gel and a 
9% stacking gel. Phosphorylation was visualised using the 
Phosphorlmager as described in Section 2.2.12.1. Following 
autoradiography, VBP1 bands were excised and counted.
2.2.12.3 Fbw7a Peptide Phosphorylation
The following Fbw7a derived peptides (prepared by the CR-UK Peptide 
Synthesis Laboratory) were assayed as PKC substrates:
Fbw7a 6-22: N-LSVGSKRRRTGGSLRGN-C
Fbw7a wt 11-22: N-KRRRTGGSLRGN-C
Fbw7a S18A 11-22: N-KRRRTGGALRGN-C
A PKC5 pseudosubstrate sequence (Ala-»Ser) was also employed as a 
control:
PKCt PSS: N-RKRQGSVRRRV-C (bold = Ala in PKC£)
Reactions were performed using 50^1 standard kinase assay mix with
0.2mM peptide substrate and the following PKC isoforms: 25ng a 
(produced by Phil Whitehead), 15ng 6, 12.5ng e or 250ng % (produced by 
Phil Whitehead). Assays were incubated at 30°C for the indicated 
timepoints, and stopped by spotting 15 1^ onto P81 paper (Whatman) and 
washing 3x5mins in 30% acetic acid. P81 strips were then counted 
alongside the ATP stock mix in order to quantitate 32P incorporation (see 
Section 2.2.12.1).
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2.2.12.4 Fbw7a Peptide Array Assays
A peptide array representing the N-terminal region of Fbw7a was 
produced on a cellulose membrane using the Intavis Multipep peptide 
synthesizer (prepared by the CR-UK Peptide Synthesis Laboratory). The 
array comprised 20x12-mer peptide spots, which walked along the 
Fbw7a sequence from residue 1-31, one amino acid at a time.
Kinase assays were performed in 15ml falcon tubes, with the peptide 
array cellulose strip laid along the length of the tube. All incubations were 
performed at RT, with the tube positioned on a rocking shaker such that 
the strip was constantly covered by moving buffer. The strip was blocked 
in 3ml of the following buffer for 30mins: 20mM Tris pH7.5, 5mM MgCL, 
0.2% Triton X-100, 0.5% Tween-20. The blocking mix was decanted and 
replaced with an equal volume of equilibration buffer for a further 30mins: 
20mM Tris pH7.5, 5mM MgCI2) 0.2% Triton X-100, Ipg/pl 
phosphatidylserine (Lipid Products), 1 ng/pil TPA, 100^iM ATP, 0.5% 
Tween-20. This buffer was removed and the strip was finally incubated in 
2ml full kinase assay mix, with either no enzyme, 10ptg purified PKC-a or 
100^ig purified PKC-a. The reaction was started with the addition of 
[y32P]-ATP and incubated for 15mins. To stop the reaction, the kinase 
assay mix was removed and the strip was washed 2x15mins in 15ml 30% 
acetic acid, 3x15mins in TBS-T and 3x5mins in water. Phosphorylation 
was visualised using the Phosphorlmager as described in Section 
2 .2 .12 .1.
2.2.12.5 F-box WD40 Immuno-complex Assays
COS7 cells were plated onto 10cm dishes and transfected with a series 
of FLAG-tagged F-box WD40 protein constructs (and an empty FLAG 
vector control). 24hrs post-transfection, Fbw fusion proteins/associated 
partners were recovered by anti-FLAG immunoprecipitation. Washed 
beads were incubated in 60pil kinase assay mix with 50ng PKCs for 
30mins at 30°C with shaking. Reactions were stopped with 30pil 3x 
kinase assay sample buffer and boiled at 100°C for 5mins. Proteins were
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resolved by PAGE and phosphorylation was visualised using the 
Phosphorlmager as described in Section 2.2.12.1.
2.2.12.6 Immuno-complex Activity Assays
COS7 cells were plated and transfected on 6-well dishes with a panel of 
GFP-PKCe wild type/mutants constructs. Transfected cells were treated 
in the presence or absence of 400nM TPA for 45mins, and GFP-PKCe 
fusions were captured by immunoprecipitation, using standard lysis buffer 
plus 10nM Calyculin A, with Protein A/anti-GFP (4E12/8). Washed PKCe- 
bearing beads were incubated in 50ptl kinase assay mix with either 5^g 
MBP, 1(tyg Protamine Sulphate or 10 i^g pseudosubstrate peptide (N- 
RKRQGSVRRRV-C). Reactions were started with the addition of ATP 
and incubated at 30°C with shaking over the indicated timecourse. In 
order to assess the lipid dependency of these activities, a second set of 
reactions were performed in the absence of phosphatidylserine/TPA, 
using the pseudosubstrate peptide as substrate.
MBP assays were stopped with 25^1 kinase assay sample buffer, boiled 
at 100°C for 5mins and resolved in duplicate by PAGE. One gel was 
stained by Coomassie and MBP phosphorylation was visualised using the 
Phosphorlmager (see Section 2.2.12.1), and quantified by excising and 
counting the bands, alongside a dilution series of the ATP stock (see 
Section 2.2.12.1). The other gel was analysed by western blotting for 
GFP. Relative activity was determined as a function GFP-PKCe 
expression. MBP assays are representative of 3 separate experiments; 
relative specific activity is plotted with error bars to denote standard 
deviation.
Protamine and pseudosubstrate peptide assays were divided into two 
aliquots. One aliquot (12.5^1) was removed to 6.25^1 kinase assay 
sample buffer, boiled at 100°C for 5mins, resolved by PAGE, and 
analysed by western blotting against GFP. The other aliquot (25jxl) was 
spotted onto P81 paper (Whatman) and washed 3x5mins in 30% acetic
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acid. P81 strips were then counted alongside the ATP stock in order to 
quantitate 32P incorporation (see Section 2.2.12.1). Relative activity was 
determined as a function of PKC-e expression.
2.2.13 Phosphopeptide Mapping
Putative PKC-e/6 in vitro autophosphorylation sites were analysed by 
phosphopeptide mapping by the Protein Analysis Laboratory, CR-UK.
The samples tested correspond to the PKC-e/6 gel pieces described in 
Section 2.2.12.1.
2.2.13.1 Tryptic Digests
PKC-e/6 samples were subjected to in-gel tryptic digestion as follows. 
Excised bands were destained using 25mM ammonium 
bicarbonate/acetonitrile (Rathburn Chemicals) and washed with water for 
20 mins. They were then equilibrated with 25 mM ammonium 
bicarbonate (10mins), dehydrated with acetonitrile (10 mins) and dried in 
a SpeedVac (10 mins); this process was repeated, this time with a longer 
drying period (45 min). Gel pieces were next rehydrated in 5\i\ tryptic 
digest mix (200ng modified trypsin) and incubated on ice for 45 min. 30ptl 
of 25mM ammonium bicarbonate was added and samples were 
incubated for a further 4hrs at 37°C; digestions were stopped by placing 
the tubes on dry ice. Samples were defrosted and the supernatant was 
decanted to a 0.2 ml siliconized, thin walled tube (Bioquote). Two further 
rounds of extraction were performed, using 30^1 of 5% (v/v) formic acid in 
water, with a 15min incubation in a sonicating water bath. Peptides from 
the three extractions were pooled and dried in a SpeedVac. Finally, the 
peptides were twice resuspended in 50pJ water and dried to completion in 
a SpeedVac to remove all volatile salts.
2.2.13.2 Reverse Phase High Performance Liquid Chromatography
Tryptic peptide extracts were fractionated by reverse-phase high 
performance liquid chromatography using an ABI130A Separation 
System with a Vydac 1mm x 150mm C8 reverse phase column, run at
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50^1/min. Fractions were counted using a 2min P32 programme in a 
Beckman LS6000IC scintillation machine, and those containing 
radiolabelled peptides were analysed by mass spectrometry and Edman 
degradation.
2.2.13.3 Matrix-Assisted Laser Desorption Ionization Time-Of-Flight 
Mass Spectrometry
An aliquot (5%) of each radiolabelled fraction was analysed by Matrix- 
Assisted Laser Desorption Ionization Time-Of-Flight (MALDI-TOF) mass 
spectrometry. All mass spectra were recorded with an Applied 
Biosystems 4700 Proteomics Analyzer in MS Reflector Positive mode, 
with a fixed laser intensity of 4488, and a focus mass of 1800Da. a- 
cyano-4-hydroxycinnamic acid (10pg/pl in 50% (v/v) acetonitrile, 0.1% 
(v/v) trifluoacetic acid) was used as the matrix. Spectra were internally 
calibrated with 20fmols of angiotensin 1, or a trypsin autolysis peptide. 
The peptide masses were searched against the National Center for 
Biotechnology Information (NCBI) non-redundant database using the 
Protein Prospector MS-FIT or Mascot programs. One missed cleavage 
per peptide and an initial mass tolerance of 10 ppm were used in all 
searches.
2.2.13.4 Edman Degradation
The remainder of each radiolabelled fraction (95%) was subjected to 
solid-phase Edman degradation using an ABI Procise Sequencer and 
sequelon acrylamine membranes. Fractions were stored in the dark over 
night, and then scintillation counted using a 10min P32 programme in a 
Beckman LS6000IC scintillation machine; this relatively long count time 
was employed to reduce standard error.
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2.2.14 Raising Phosphospecific Antibodies
Polyclonal phospho-specific antibodies were raised against the following 
sites: PKCe (mouse) p-S234, p-S316, p-S368; PKCS (human) p-S304; 
Fbw7a (human) p-S18.
2.2.14.1 Peptide Synthesis
The following 9/10-mer phospho-peptides were synthesized by the CR- 
UK Peptide Synthesis Laboratory for use as immunising antigens:
PKCe p-S234: N-DEVGpSQRFS-C 
PKCe p-S316: N-KITNpSGQRR-C 
PKCe p-S368: N-RKALpSFDNR-C 
PKC6 p-S304: N-SRRSDpSASSE-C 
Fbw7a p-S18: N-RTGGpSLRGN-C
Equivalent dephospho-peptides were also prepared for each site for use 
as blocking peptides.
2.2.14.2 Peptide Coupling
Phospho-peptides were coupled to Keyhole Limpet Haemocyanin (KLH) 
prior to immunisation. Typically, 10mg KLH was dialysed against PBS 
overnight at 4°C and mixed with 10mg phospho-peptide in a total of 980^1 
PBS. Where peptide solubility was not complete (PKCe p-S234), 5^ 1 
Triton X-100 was added and the solution was sonicated. Coupling was 
initiated with the addition of 5pJ 50% glutaraldehyde (BDH) and incubated 
at RT for 15mins. A further 2.5pJ 50% glutaraldehyde was added and the 
mix was incubated for 15mins at RT. The reaction was then quenched 
with 200ptl 1M Glycine, made up to 20ml in PBS and aliquoted 6x3.3ml 
for immunisation. In the case of PKCe p-S368, the protocol was modified 
to account for the presence of an internal lysine which could couple to 
KLH and potentially affect the antibodies generated; in this case 8mg of 
glutaraldehyde coupled peptide was combined with 2mg uncoupled 
peptide for immunisation.
115
Chapter 2: Materials and Methods
2.2.14.3 Immunisation
Antibodies were raised against KLH-coupled phopsho-peptides by Harlan 
Sera-Lab. Three rabbits were immunised with each antigen and test 
bleeds were collected at day 35 (TB1), 49 (TB2) and 63 (TB3) post­
immunisation, the terminal bleed-out (TBO) was harvested at day 77.
Phospho-Site Rabbits Immunised
PKCe p-S234 PPA-499,500,501
PKCe p-S316 PPA-502,503,504
PKCe p-S368 PPA-505,506,507
PKCS p-S304 PPA-513,514,515
Fbw7a p-S18 PPA-525,526,527
Table 2.6 Phosphospecific Antibodies. The phosphospecific 
antibodies raised are summarised. The optimal antibody for each 
antigen, which was used in the experiments presented in subsequent 
results chapters, is indicated in bold.
2.2.14.4 Antibody Characterisation by ELISA
Fbw7a p-S18 second test bleeds were characterised by ELISA prior to 
use in Western blotting. Plates were prepared bearing either the 
phospho-S18 peptide or corresponding dephospho-S18 peptide coupled 
to BSA, and incubated with a dilution series of each test bleed +/- 
blocking peptide.
1mg phospho/dephospho-S18 peptide was mixed with 1mg BSA in a total 
of 1ml TBS. Coupling was initiated with the addition of 5pil 50% 
glutaraldehyde and incubated at RT for 15mins. A further 2.5^1 50% 
glutaraldehyde was added and left for 15mins at RT. The reaction was 
then quenched with 200pJ 1M Glycine. BSA-coupled peptides were 
diluted to 10ng/ml in ELISA Coating Buffer and aliquoted at 10Opil/well 
over a plastic 96-well plate; coating was allowed to proceed overnight at 
4°C. Wells were washed with 3x200^1 0.5% Tween-20/TBS, blocked with 
200^11% BSA/TBS for 1 hr at 37°C and washed again with 3x200ptl 0.5%
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Tween-20/TBS. Plates were then incubated overnight at 4°C with a 
dilution series of each test bleed (10'3,10'4, 10'5, 10"6) +/- l^g/ml blocking 
peptide in 200|xl/well TBS; de-phosphopeptide was used to block in 
phospho-peptide wells and vice versa. Wells were washed with 3x200^1 
0.5% Tween-20/TBS, incubated with 200nl/well 1:2000 HRP-conjugated 
anti-rabbit secondary antibody in TBS for 1 hr at 37°C, and washed again 
with 3x200^1 0.5% Tween-20/TBS. Finally SIGMAFAST o- 
phenylendiamine dihydrochloride substrate was prepared according to 
the manufacturer’s instructions and incubated at 10Opil/well; the reaction 
was stopped in the linear range with 100^1 2N H2S 04 and quantified at 
490nm using a plate reader (Dynatech).
2.2.15 Immunofluorescence
2.2.15.1 Coverslip preparation
Cells were seeded on acid washed glass coverslips (provided by CR-UK 
research services) and transfected/stimulated as indicated in figure 
legends. Carrier controls were performed in parallel for each solvent. 
Cells were washed in PBS and fixed in 4% (w/v) paraformaldehyde/PBS 
for 10mins at RT. For visualisation of GFP/RFP-tagged proteins, 
coverslips were then washed and mounted as described below. Where 
staining was required, cells were first permeablized and blocked by 
incubation in 0.2% Triton X-100/2% BSA/PBS for 10mins at RT. Cells 
were then incubated either with primary antibody or 1:200 Alexa Fluor 
546 Phalloidin (Molecular Probes) diluted in 2% BSA/PBS for 45mins at 
RT. Cells were washed 3x10mins in PBS with shaking and for antibody 
staining incubated in the dark with fluorescent dye-conjugated secondary 
antibody for 45mins at RT. Coverslips were washed 3x1 Omins in PBS, 
once in water and mounted onto glass slides (Western Laboratory 
Services) using Mowiol mounting media; slides were incubated for 1 hr at 
37°C to allow the mountant to set and then stored at 4°C.
117
Chapter 2: Materials and Methods
2.2.15.2 Confocal Microscopy
Images were acquired as recommended by the CR-UK Light Microscopy 
Laboratory using an upright laser scanning confocal microscope (LSM 
510, Carl Zeiss Jena) equipped with a 63x/1.4 Plan-Apochromat Oil Ph3 
objective. GFP was excited with the 488nm line of an Argon laser, Cy3 
with a 543nm HeNe laser; individual channels were scanned sequentially 
line by line with averaging set at 8. Each image represents a single 
1 .O^ irn ‘Z’ optical section with a pixel size of approximately 0.1 jxm. Each 
confocal image is representative of at least 3 separate experiments.
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CHAPTER 3 
PKC-e Yeast 2- Hybrid Analysis
3.1 Introduction
Cellular behaviour is controlled by complex networks of proteins, which 
signal, integrate and interpret environmental and internal cues. These 
proteins rarely act as single, isolated species, but rather assemble into 
dynamic complexes in which they regulate and support each other. 
Protein-protein interactions influence many aspects of protein function, 
binding partners can direct association with upstream regulators and 
downstream targets, mediate recruitment to an appropriate cellular 
location or impose integration with other signalling systems. As such, 
one valuable means of characterising a protein is by identifying those 
other proteins with which it interacts.
A number of functionally significant PKC binding proteins have been 
defined to date, including activators (e.g. cdc42/PAR6/PAR3 complex 
(Ohno, 2001)), inactivators (e.g. pVHL (Okuda et al., 1999)), substrates 
(e.g. MARCKS (Stumpo et al., 1989)), anchors (e.g. InaD (Tsunoda et al., 
1997)) and scaffolds which may facilitate cross-talk (e.g. gravin (Nauert et 
al., 1997)). These examples illustrate the importance of protein-protein 
interactions in the regulation and function of PKC, but by no means 
constitute an exhaustive list of binding partners.
In order to further develop our understanding of the novel PKC isoform 
PKC-e, we therefore resolved to screen for additional interacting proteins. 
This was undertaken with a particular interest in the detection of binding 
partners which might relate to the down-regulation of PKC, an important 
yet poorly characterised process, which represents a focus of ongoing 
research in our laboratory. To date, only one ubiquitin ligase, pVHL, has
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been identified with activity towards PKC (Okuda et al., 2001), and as 
noted above, pVHL was in fact first linked to PKC as a binding partner.
Advances in the field of proteomics have led to the development of many 
methods for identifying binding partners. Interaction between proteins 
can be inferred from genetic interaction or mRNA co-expression, detected 
by recovery of protein complexes followed by identification by mass 
spectroscopy, or screened for by phage display or a variation of the yeast 
2-hybrid system. We chose to exploit the yeast 2-hybrid approach (Fields 
and Song, 1989) in order to identify PKC binding partners. This 
technique is well established, relatively straightforward and shows high 
sensitivity. The interactions detected are direct, and the isolated putative 
binding partners are immediately available as cDNAs. Also, once a 
system has been established, it is amenable to screening with numerous 
different baits, a feature exploited in our laboratory.
This chapter describes the preparation and characterisation of a yeast 2- 
hybrid system, the screens that were performed to detect PKC-e binding 
partners and the putative interacting proteins which were identified.
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3.2 Results
3.2.1 MATCHMAKER SYSTEM 3
Yeast 2-hybrid analysis was performed using MATCHMAKER System 3 
(Clontech, 1999) as summarised in Figure 3.1. In this system, a bait 
protein is expressed as a fusion with the GAL4 DNA-binding domain 
(DNA-BD), alongside a cDNA library in which each clone is constructed 
as a fusion with the GAL4 activation domain (AD). Where the bait and 
the library proteins interact, the DNA-BD and the AD are brought into 
close proximity, thus activating transcription from the GAL4 promoter. 
Three separate reporter genes are under the control of this promoter in 
the yeast strain AH109: HIS3, ADE2 and MEL1, which code for essential 
genes in the biosynthetic pathways for histidine and adenine, and for a- 
galactosidase respectively. As such, protein-protein interactions can be 
detected by nutritional selection using media lacking His or Ade, and/or 
by blue/white screening using X-a-Gal indicator plates.
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PROTEIN INTERACTION
PKC GAL4
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HIS3, ADE2, MEL1
REPORTER ■ -GAL4
NO INTERACTIONJ LIBRARY 
^PROTEIN
GAL4
AD
PKC
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Figure 3.1 MATCHMAKER System 3. Yeast 2-hybrid analysis was 
performed using MATCHMAKER System 3 (Clontech). In this system, a 
bait protein, such as PKC, is expressed as a fusion with the GAL4 DNA- 
binding domain (DNA-BD), alongside a cDNA library in which each clone 
is constructed as a fusion with the GAL4 activation domain (AD). Where 
the bait and the library proteins interact, the DNA-BD and the AD are 
brought into close proximity, thus activating transcription from the GAL4 
promoter. Three separate reporter genes are under the control of this 
promoter in the yeast strain AH 109: HIS3, ADE2 and MEL1.
E Catalytic
- H  MYC ■ E Regulatory
M M  MYC
GAL4 MYC b Regulatory b Catalytic
- ■ I  MYC - b Regulatory -----
{ U t i l  MYC 5 Catalytic
■G A Ll MYC - E Regulatory
Figure 3.2 PKC Yeast 2-Hybrid Bait Constructs. A panel of PKC yeast 
2-hybrid baits were cloned into pGBKT7 as myc-tagged GAL4 DNA 
binding domain fusion proteins. Full length mouse PKC-e was prepared 
as a bait, alongside its individual regulatory and catalytic domains, which 
bear an overlapping sequence derived from the hinge region. 
Corresponding rat PKC-6 constructs were generated in parallel.
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3.2.2 Yeast 2-Hybrid: Preliminary Characterisation
Prior to undertaking the yeast 2-hybrid screen, it was first necessary to 
validate the system by confirming that the bait constructs could be 
expressed and did not autoactivate the reporter genes used to detect 
interactions.
3.2.2.1 Bait Expression
A panel of PKC bait constructs were generated for yeast 2-hybrid 
analysis. Full length PKC-e and 6, as well as their individual regulatory 
and catalytic domains, were cloned as myc-tagged, GAL4 DNA-BD fusion 
proteins (see Figure 3.2).
Bait expression in yeast was confirmed by Western blotting, as shown in 
Figure 3.3. Although each of the constructs bears a myc tag, not all were 
readily detectable by Western blotting against the myc epitope. Full 
length PKC-e and 6, and the PKC-6 catalytic domain, were not visualised 
using the 9E10 antibody under the conditions employed; they could, 
however, be detected with PKCe/6 specific primary antibodies. This 
suggests that the expression level of these bait constructs is relatively 
low, a conclusion supported by a comparative blot in which PKC-e and 
PKC-e catalytic domain baits are probed alongside each other (see 
Figure 3.3vii).
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Figure 3.3 PKC Bait Expression in AH109 Yeast. Yeast were co­
transformed with a PKC bait, or empty pGBKT7 negative control, and 
empty pGADT7 prey vector. Protein extracts were prepared by TCA 
precipitation and bait expression was analysed by western blotting; 
extracts were probed as follows: i) PKC-e bait (e), anti-PKC.ePPA-130; ii) 
PKC e-regulatory domain bait (eR), anti-myc 9E10 (30min exposure); iii) 
PKC e-catalytic domain bait (eC), anti-myc 9E10 (5min exposure); iv) 
PKC-6 bait (6), anti-PKC6C-17; v) PKC S-regulatory domain bait (6R), 
anti-myc (5 min exposure); vi) PKC 6-catalytic domain bait (SC), anti- 
PKCS C-17; vii) PKC e bait comparison, anti-PKC.ePPA-130.
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3.2.2.2 Bait Toxicity
As interacting partners are detected according to growth on selective 
media in the yeast 2-hybrid system, it was also important to establish that 
bait expression did not confer toxicity. This was investigated by 
comparing the growth rates of yeast transformed with bait constructs to 
yeast transformed with an empty bait plasmid. Growth in liquid media 
was followed, by measuring the OD6oo of the culture (see Figure 3.4). 
None of the bait constructs proved to be lethal, however all slowed down 
the growth rate of the yeast to a certain extent.
3.2.2.3 Bait Autoactivation of Reporter Genes
Since the detection of protein-protein interactions by yeast 2-hybrid 
analysis relies on the specific up-regulation of reporter genes, it was 
necessary to verify that the bait constructs did not have any intrinsic DNA 
binding and/or transcriptional activating properties. This was achieved by 
plating yeast co-transformed with bait plasmids/empty library plasmid on 
selective media at increasing stringency (see Figure 3.5). Yeast 
expressing empty bait plasmid/empty library plasmid were used as 
negative controls, while yeast co-expressing murine p53 bait and SV40 
large T-antigen prey provided a robust positive control for protein-protein 
interaction (Li and Fields, 1993).
The TRP1 and LEU2 genes are the selective markers for the bait and 
prey vectors respectively. Since all of the yeast tested were transformed 
with both vectors, all grow on the -TRP/LEU drop-out plates. However, 
H/S3, ADE2 and MEL1 represent the reporter genes for protein-protein 
interaction. As such, while the positive controls are able to grow on -HIS 
and -HIS/ADE nutritional selection plates and are positive for blue/white 
screening in the presence of X-a-gal, the negative controls do not 
survive. Yeast expressing the PKC bait constructs behave like the 
negative control, indicating that they are unable to autoactivate reporter 
gene transcription and are therefore amenable to yeast 2-hybrid analysis 
using this system.
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Figure 3.4 PKC Bait Transformant Growth Assays. AH 109 yeast were 
co-transformed with a PKC bait, or empty pGBKT7 negative control (BD), 
and empty pGADT7 prey vector. 5ml cultures were established in 
triplicate in -TRP/LEU media and incubated for 24hrs at 30°C with 
shaking. Untransformed yeast (WT) were grown in fully supplemented 
SD media in parallel. Proliferation was assayed by measuring OD6oo in 
order to determine whether bait expression affects growth rate; error bars 
denote standard deviation, e, PKC-e; 6, PKC-6; R, regulatory domain; C, 
catalytic domain.
-T/L/H -T/L/H/A/X
Figure 3.5 PKC Bait Reporter Gene Autoactivation Assay. AH109 
yeast co-transformants expressing PKC bait/empty pGADT7 were plated 
onto media selective for the vectors (-T/L), for medium stringency 
interaction (-T/L/H) and for high stringency interaction (-T/L/H/A/X) to test 
for autoactivation of reporter genes. pGBKT7-p53/pGADT7-T Ag were 
co-transformed as positive controls, pGBKT7/pGADT7 as negative 
controls. Plates were incubated at 30°C for 6 days and photographed, e, 
PKC-e; 6, PKC-6; R, regulatory domain; C, catalytic domain.T, 
Tryptophan; L, Leucine; H, Histidine; A, Adenine; X, +X-a-gal.
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3.2.3 PKCs Yeast 2-Hybrid Analysis
Full length PKC-e was used as the bait construct for the yeast 2-hybrid 
analysis described in this section.
3.2.3.1 Yeast 2-Hybrid Screen
A mouse brain cDNA library in the vector pACT2 was employed in this 
yeast 2-hybrid screen (Clontech); since PKC is abundant in the brain, and 
is subject to downregulation in cells of CNS origin (Kotsonis et al., 2001), 
we reasoned that this library would prove an appropriate source of PKC-e 
interacting partners. Details of the pACT2 vector and of the library's 
construction are given in Appendix A1.
The PKC-e bait and the mouse brain cDNA library were transformed 
sequentially for yeast 2-hybrid analysis with the aim of screening 106cfus. 
A total of 1.4x105 cfus were in fact screened, it is likely that the process of 
scaling up to the volumes required for a library screen reduced the 
efficiency of transformation. A large number of putative positive binding 
partners were nevertheless identified and the range of the screen was 
judged to be sufficient. The screening process employed is summarised 
in Figure 3.6.
The first round of yeast 2-hybrid screening was performed at medium 
stringency by plating co-transformed yeast onto -TRP/LEU/HIS media; a 
total of 980 colonies were recovered. In order to screen these clones for 
interaction at higher stringency, colonies were re-streaked onto - 
TRP/LEU/HIS/ADE as shown in Figure 3.6b. 129 colonies demonstrated 
robust protein-protein interaction on this selection media; the remaining 
transformants appeared as small, pink colonies because adenine 
deficiency results in the accumulation of a red oxidized, polymerized 
derivative of 5-aminoimidazole ribotide in yeast vacuoles (Clontech,
1999). The positive clones were subjected to a final round of selection; 
colonies were re-streaked onto CSM-TRP/LEU/HIS/ADE/X-agal agar 
plates to test for the activation of the third reporter gene by blue/white
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selection (see Figure 3.6c). All 129 colonies displayed growth and blue 
colouration on the highest stringency selection media and were 
considered to express putative PKC-e binding proteins.
Following this final round of selection, pACT2 library vectors were 
recovered from the 129 positive AH109 colonies. Isolated plasmids were 
reintroduced into yeast expressing PKC-e bait to confirm the interactions 
detected; the data obtained is summarised as part of Table 3.2. The level 
of reproducibility was generally poor (see Discussion), and subsequent 
analyses were therefore performed in mammalian cells, as described in 
Chapter 4.
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a) Transform yeast: 1.4 x 105 cfus b)
1
Medium stringency: 980 colonies
-H IS /A D E ^
High stringency: 129 colonies
-HIS/ADE/X-cx-gal 
High stringency (blue/white): 129 colonies
Figure 3.6 Sequential Rounds of Yeast 2-Hybrid Screening with a 
PKC-e bait and a mouse brain cDNA library. AH109 yeast were co­
transformed sequentially with pGBKT7-PKCe bait, followed by 1.4x105 
mouse brain cDNA library cfus. Transformants were plated directly onto 
medium stringency plates and incubated at 30°C for 5 days. Positive 
colonies from this round of selection were then replated onto higher 
stringency plates and incubated at 30°C for a further 3 days (b). The 
remaining positive clones were restreaked onto high stringency media + 
X-agal for a final round of screening with blue/white selection and 
incubated for 5 days at 30°C (c).
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3.2.3.2 Putative Binding Partner Sequence Analysis
The pACT2 library plasmids recovered from the 129 positive AH109 
colonies were sequenced in order to identify the clones encoded. Library 
inserts were checked in both directions, the raw sequencing data are 
archived in Appendix A1.
Clones were identified by BLAST searching the NCBI nucleotide 
database (www.ncbi.nih.gov/BLAST/), using the default search 
parameters (Altschul et al., 1997). The results of one such search are 
represented in Figure 3.7 to illustrate the information provided by this 
facility. Data regarding the highest scoring match for each clone is 
summarized in Tables 3.1 and 3.2.
In most cases, the library insert represented a coding sequence and the 
accession number of the top scoring mRNA match was used to retrieve 
the full length sequence from the Entrez Nucleotide database. However, 
in some cases, the library insert was best aligned with non-coding 
sequence and was disregarded for subsequent analyses. This approach 
was undertaken as a means of avoiding false positives and of reducing 
the clones studied to a practical number, however, as addressed in 
Section 3.3, there are circumstances under which such clones may in fact 
represent valid interacting partners.
Where the library insert comprised coding sequence, an alignment was 
performed against the corresponding full length cDNA using the 
GeneStream online resource (www2.igh.cnrs.fr/home.eng.html) in order 
to determine which part of the ORF was represented in the library vector. 
A number of clones were identified which lacked the 5’ portion of the 
cDNA, presumably due to inefficient library construction by oligo (dT) 
priming. The frame of any such partial insert was confirmed with respect 
to its N-terminal GAL4 AD/HA fusion; frame-shifted clones were not 
pursued in subsequent studies. It was important to perform these 
analyses carefully, since there were a small number of cases in which the
library vector contained a mutation which had to be accounted for in
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designating the reading frame; for example, clone 19 contained an 
adapter sequence deletion (see Appendix A1.3).
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a)
Distribution of 61 Blast Hits on the Query Sequence
Mouse-over to show defline and scores, dick to show alignments
Q u e r y
Color key fo r alignm ent scores■1 1 I I I I I0 150 300 450 600 750 900
b) Sequences producing significant alignments:
Score
(Bits)
E
Value
3- 20149753 ref NM 138669.1 Mus musculus RIKEN cDNA 1810047C2 3 1061 0.0 mm
13529583 ab BC005503.1 Mus musculus RIKEN cDNA 1810047C23... 106 i 0.0 mm
<?i 26347130 dbi AKO7 8 309.1 Mus musculus adult male olfactory... 1061 0.0 m
qi 26344629 dbi AK075795.1 Mus musculus 10 day old male pane... 1061 0.0 IS
qi 6207901B ref NM 001014142.1 Rattus norveqicus similar to ... 664 0.0
qi 53734271 ab BC083771.1 Rattus norvegicus similar to RIKEN... 664 0.0 IS
qi 61806999 ab AC114558.13 Mus musculus chromosome 3, clone RP2 385 2e-103
q ' 67970334 dbi A3169428.1 Macaca fascicularis testis cONA, ... 23.7. 3e-74
qi 55727343 emb CR858139.1 Pongo pygmaeus mRNA; cDNA DKF2p46... 278 3e-71
34 57098018 ref XM 540023.1 PREDICTED: Canis familiaris simi... 133 3e-68
q - 21750052 dbi AX091635.1 Homo sapiens cDNA FLJ34316 fis, cion 250 6e-63 IS
q'r 14714702 ab BC010493.1 Homo sapiens hypothetical protein ... 250 6e-63 mm
34 50503627 emb CR622820.1 full-length cDNA clone CS0DN004YB... 250 6e-6 3 m
qi 50503376 emb CR622569.1 full-length cDNA clone CS0DI010YB... 250 6e-6 3 IS
q' 50496543 emb CR615741.1 full-length cDNA clone CS0DM009YA... 2 50. 6e-6 3 IS
37 50493993 emb CR613186.1 full-length cDNA clone CS0DF002YF... 250 6e-6 3 IS
qi 50491062 emb CR610255.1 full-length cDNA clone CS0DI005YA... 250 6e-63 IS
3- 504 8 505 3 erab CR604246.1 full-length cDNA clone CS0DJ005YK... 2-50 6e-6 3 IS
31 66894887 ab DO033678.1 Homo sapiens FLJ11200 gene, VIRTUA... 2?Q 6e-63
ISqi 48146672 emb CR457278.1 Homo sapiens full open reading fr... 250 6e-63
qi 55623583 ref XH 517560.1 PREDICTED: Pan troglodytes simil... 248 3e-62 mm3'. 7023716 dbi AK002062.1 Homo sapiens cDNA FLJ11200 fis, clone 242 2e-60
3 7 50483298 emb CR602491.1 full-length cDNA clone CS0DC013YL... 242 2e-60 m
qi 66384988 ab 00033679.1 Pan troglodytes FLJ11200 gene, VIR... 242 2e-60
DEIq- 9922937 ref NM 018359.1 Homo sapiens hypothetical protein FL 242 2e-60
21291658 ab AC10 6 8 9 7,5 Homo sapiens BAC clone RPii-27909 fro u? 29-23
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Figure 3.7 Positive Yeast 2-hybrid Clone 1 Forward Sequence 
BLAST Search Results. Following the final round of PKC-e yeast 2- 
hybrid screening, mouse brain library plasmids were recovered from 
positive clones and sequenced. Clones were identified by BLAST 
searching the NCBI nucleotide database
(http://www.ncbi.nih.gov/BLAST/), using the default parameters. The 
results obtained with the clone 1 forward sequence are presented, a) top 
portion of results screen, states the number of database hits and 
represents their alignment with the input sequence on a colour coded 
diagram; b) middle portion of results screen, lists the accession numbers 
and identities of the database hits and indicates the score of the 
alignment (in bits) and the E value, which estimates the statistical 
significance of the match; c) the results for the highest scoring database 
entry, displays the alignment between the input sequence and top hit.
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Table 3.1 Forward sequence data for putative positive yeast 2-hybrid 
clones. 129 mouse brain cDNA clones were recovered from positive 
yeast colonies following three rounds of yeast 2-hybrid screening with a 
PKC-e bait. Library insert sequence data was obtained, using a pACT2 
forward primer, and the sequence immediately following the library 
adapter was analysed using the NCBI BLAST database.
x, no good quality sequence data obtained; N/H no sequences with 
significant homology identified; N/l CDS boundaries not indicated in 
mRNA sequence; clone no. underlined, different results obtained with 
forward and reverse sequences; shaded row, clone meets all of selection 
criteria required to be considered for further analysis (see text).
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!Clone Score Accession No. Name Insert Start 
(base no.)
mRNA Start 
(base no.)
CDS? In
Frame?
Alignment From 
(amino acid no.)
1 1061 NM_138668.1 RIKEN :1810047C23 1 377 Y Y 98 (of 461)
2 817 BC047068.1 RIKEN:2810432D09 1 40 Y
(+60bps 5’)
Y 1 (of 163) 
(+20aa N-)
3 1197 AC127259.3 BAC:RP24304A20 (chr.9) 1 105051 - - -
4 543 BC009091.1 zinc finger protein 162 1 2266 N
(3’UTR)
584-90/608-653
5 46.1 AC129777.4 BAC:RP23281 H23 (chr.8) 195 78014 - - -
6 971 BC040338.1 autocrine motility factor 
receptor
1 441 Y N
7 801 AK011889.1 RIKEN:2610205H19 
0-44 protein homologue
1 16 Y
(+185bp 5’)
N
8 X X X X X X X X
9 1068 BC065790.1 sorcin 1 5 Y N -
10 N/H - - - - - - -
11 718 AC123791.4| BAC:RP24304L14(chr.15) 29 134173 - - -
341 NM_011244.2| retinoic receptor gamma 1 556 Y Y 102 (of 458)
12 829 AC087558.13| C57BL/6J clone rp23-282p18 
(chr.2)
1 193091
13 908 AY339599.2 mitochondrial genome; NADH 
dehydrogenase subunitl gene
1 2894 Y N
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14 X X X X X X X X
15 638 AC149283.2 BAC:RP23-233021(chr.7) 1 203904 - - -
16 X X X X X X X X
17 771 NM_033561.1 Williams-Beuren syndrome 
region 1 homologue; wbscrl
1 1467 N
(3’UTR)
18 230 AC025669.19 RP235016 (chr.14) 1 77762 - - -
19 492 NM_080428.2 F-box and WD-40 domain 
protein 7
1 1008 Y Y 283 (of 629)
20 733 BC051999.1 amyloid beta precursor-like 
protein 2
1 2834 N
(3’UTR)
21 805 AK028350.1 RIKEN:3732426M05 
Na+/H+ exchanger 6 
homologue
1 1166 N/l
22 331 NM_029929.2 Vacuolar protein sorting 33A 1 2593 N
(3’UTR)
23 422 NM_029929.2 Vacuolar protein sorting 33A 1 2593 N
(3’UTR)
24 X X X X X X X X
25 973 XM_134593.4 RIKEN:4932417I16 1 513 Y N -
26 498 NM_009182.2 ST8 alpha-N-acetyl- 
neuraminide alpha-2,8- 
sialyltransferase3
9 3615 N
(3’UTR)
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27 432 NM_146200.1 eukaryotic translation initiation 
factor 3, 
subunit 8
1 2004 Y Y 649 (of 911)
28 X X X X X X X X
29 387 NM_019722.3| ADP-ribosylation factor-like 2 1 4 Y
(+33bps 5’)
Y 1 (of 184) 
(+11 aa N-)
30 525 AC 102892.9 RP24-362B10 (chr.5) 1 97972 - - -
31 224 AY339599.2 mitochondrial genome; cox2 2 7587 Y N -
32 X X X X X X X X
33 103 BC079561.1 N-deacetylase/N- 
sulfotransferase 1
5 4678 N
( 3 ’U T R )
34 167 BC057207.1 tetratricopeptide repeat 
domain 3
1 2212 Y N
35 688 NM_030225.3 dihydrolipoamide S- 
succinyltransferase (E2 
component of 2-oxo-glutarate 
complex)
1 1933 N
(3’UTR)
36 541 AL831750.8 RP23-37L2 (chr.x) 1 112295 - - -
37 624 AC153860.4 BAC:RP23170C11 1 54028 - - -
418 NM_011844.3 monoglyceride lipase 105 1 N
(5’UTR)
38 624 AC153860.4 BAC:RP23170C11 1 54028 - - -
418 NM_011844.3 monoglyceride lipase 105 1 N
(5’UTR)
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39 X X X X X X X X
40 708 NM_138599.2 translocase of outer 
mitochondrial membrane 70 
homologue
1 1626 Y Y 493 (of 611)
41 684 AC122022.4 BAC:RP24-372J5 (chr.5) 1 7755 - - -
42 936 NM_080635.1 eukaryotic translation initiation 
factor 3, 
subunit 3 (gamma)
1 8 Y Y 2 (of 352)
43 781 AK034899.1 expressed in non-metastatic 
cells 1 protein 
(NM23A/nme1/nucleoside 
diphosphate kinase
1 210 Y Y 56 (of 152)
44 X X X X X X X X
45 839 AC115744.9 RP23-479M19 (chr.12) 1 154016 - - -
46 835 BC060066.1 TBC1 domain protein 22B 1 2037 N
(3’UTR)
47 X X X X X X X X
48 513 NM__001001566.1 D1Bwg1363e; chondroitin 
polymerizing factor
1 2738 N
(3’UTR)
49 932 AC084069.28 rp23-257b17 (chr. 13) 1 124011 - - -
50 955 AY339599.2 mitochondrial genome; cox1 
gene
1 5486 Y N
51 224 XM_132762.6 Predicted: RasGEF domain 
protein 1a
16 2149 N
(3’UTR)
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52 X X X X X X X X
53 1055 NM_138584.1 spastic paraplegia 21 
homologue (spg21)
1 187 Y
(+23bps 5’)
N
54 490 BC031782.1 engulfment and cell motility 1 1 1973 N
(3’UTR)
55 315 NM_024227.2 mitochondrial ribosomal 
protein L28
1 34 Y Y 2 (of 257)
56 52 AC120549.21 RP23-172L16 (chr.1) 2 68214 - - -
57 511 XM_225630.3 rat acyl-Coenzyme A binding 
domain containing 5 (Acbd5)
1 361 Y Y 121 (of 705)
58 486 NM_175212.2 RIKEN: 4930438D12 1 421 - - -
59 X X X X X X X X
60 646 BC096426.1 IMAGE:2615937 1 209 Y
(+91 bps 5’)
N
61 X X X X X X X X
62 813 BC060998.1 DNA polymerase beta 1 764 Y N -
63 X X X X X X X X
64 270 BC037027.1 glutathione peroxidase 3 1 36 Y
(+24bps 5’)
Y 1 (of 226) 
(+8aas N-)
65 460 MUSGABAAS GABA-a/benzodiazepine 
receptor alpha-1 subunit
1 373 Y
(+81 bps 5’)
Y 1 (of 455) 
(+ 27aas N-)
66 194 AF144695 ER01L 1 2088 N - -
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67 632 AC109280.9 RP23400B7(chr.18) 1 115172 - - -
68 X X X X X X X X
69 X X X X X X X X
70 X X X X X X X X
71 182 AL845502.5 RP23395A21 (chr.4) 1 145946 - - -
72 620 AC125179.4 RP23321N8 (chr.16) 1 182977 - - -
73 686 NM_011034.2 peroxiredoxin 1 (prdxl) 1 16 Y
(+59bp 5’)
N
74 716 BC094421.1 IMAGE:6413494 1 19 - - -
404 Y13832.1 GT12 1 21 ? - -
151 NM_019161.1 rat pb-cadherin 245 2522 Y ? ?
75 656 NM_028325.1 zinc finger CCHC domain 12 
(zcchc12)
1 647 Y Y 90 (of 402)
76 563 AL683822.8 RP2394I24 (chr.x) 1 33043 - - -
77 452 AY339599.2 LA9 mitochondrion 1 16168 - - -
78 276 AC129314.4 RP23365D12 (chr.1) 18 14474 - - -
79 X X X X X X X X
80 375 BC064081.1 RIKEN: 1500031H01 1 494 - - -
81 111 XM_344970.2 rat Ser/Thr kinase 32C 1 2083 N
(3’UTR)
82 833 AB003304.1| beta-type 20S proteasome 
subunit X (psmb5)
1 263 Y Y 86 (of 264)
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83 266 AC099860.13 RP235C23 (chr.1) 2 163902 - - -
84 X X X X X X X X
85 301 AK122387.1 mKIAA0844 1 2545 N
(3’UTR)
86 605 NM_010250.2 GABA-A receptor, subunit 
alpha 1
1 2785 N
(3’UTR)
87 X X X X X X X X
88 359 NM_011983.1 homer homologue 2 1 1141 N
(3’UTR)
89 218 AK075620.1 ferritin light chain 1 42 67 Y
(+143bps 5’)
N
90 670 NM_133206.2 zinc and ring finger 1 1 463 Y N -
91 539 BC003794.1 stress-induced 
phosphoprotein 1
22 1762 N
(3’UTR)
92 708 NM_007727.1 contactin 1 1 3091 Y Y 948 (of 1020)
93 904 BC064825.1 importin 7 20 3564 N - -
94 500 AC124461.3 RP24-144C5 (chr.7) 1 54983 - - -
95 X X X X X X X X
96 X X X X X X X X
97 414 BC036961.1 IMAGE:4505120 2 838 - - -
98 615 AL645625.15 RP23183L1 (chr.4) 1 149634 - - -
99 751 BC094422.1 eukaryotic translation initiation 1 999 Y Y 327 (of 407)
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factor 4A2
100 226 AF041861 synaptojanin 2, zeta isoform 2 1258 Y N -
101 X X X X X X X X
102 163 NM_031037.2 rat guanine nucleotide binding 
protein, beta 2
1 82 N
(5' UTR)
103 434 NM_013494.2 carboxypeptidase E 1 890 Y Y 267 (of 476)
104 850 BC052462.1 protein tyrosine phosphatase, 
receptor type, S
1 4192 Y Y 1344 (of 1500)
105 969 BC094421.1 IMAGE:6413494 1 19 - - -
613 MMU320506 Gt12 gene 181 97056 - - -
106 874 NM_009721.2 ATPase, Na+/K+ transporting, 
beta 1 polypeptide (Atp1b1)
1 944 Y Y 149 (of 304)
107 440 NM_010324.1 glutamate oxaloacetate 
transaminase 1 (gotl)
1 7 Y
(+48bp 5’)
Y 1 (of 413) 
(+16bps N-)
108 313 NM_016743.1 Nel-like 2 (Nell2) 1 92 Y Y 306 (of 819)
109 545 NM_027782.1 potassium channel 
tetramerisation domain 
containing 6 (kctd6)
1 743 Y Y 169 (of 237)
110 571 AC124745.4 BAC clone RP23-236012 
(chr.14)
1 24910
111 765 NM_007422.2 adenylosuccinate synthetase 
(adss)
1 194 Y Y 67 (of 456)
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112 X X X X X X X X
113 X X X X X X X X
114 515 NM_172624.1 dipeptiylpeptidase 9 (dpp9) 1 2555 Y Y 792 (of 862)
115 X X X X X X X X
116 333 BC025165.1 glycoprotein m6b 1 48 Y
(+104bps 5')
N
117 163 AC126430.3 BAC RP24-406F17 1 45579 - - -
118 X X X X X X X X
119 240 AK077923.1 von Hippel-Lindau binding 
protein 1
2 32 Y Y 2 (of 196)
120 X X X X X X X X
121 305 AK077923.1 von Hippel-Lindau binding 
protein 1
7 36 Y N
122 684 BC027319.1 ATPase, Na+/K+ transporting, 
beta 1 polypeptide
1 1756 N
(3'UTR)
224 BC049225.1 
(minus strand)
protein expressed in non­
metastatic cells 7 (nme7)
273 1668
123 176 NM_007438.3 aldolase 1, isoform A (Aldoa) 1 590 Y Y 144 (of 364)
124 444 NM_173446.1 clone AW121567 53 1984 N
(3' UTR)
125 161 AC154237.1 BAC RP24-162018 (chr.17) 77 100662 - - -
126 902 AK043846.1 RIKEN:A830039K17 1 150 - - -
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127 X X X X X X X X
128 430 BC025597.1 calcium/calmodulin-dependent 
protein kinase II gamma
10 1820 N
(3'UTR)
129 X X X X X X X X
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Table 3.2 Reverse sequence data for putative positive yeast 2-hybrid 
clones. 129 mouse brain cDNA clones were recovered from positive 
yeast colonies following three rounds of yeast 2-hybrid screening with a 
PKC-e bait. Library insert sequence data was obtained, using a pACT2 
reverse primer, and the sequence immediately following the Xho I site 
was analysed using the NCBI BLAST database.
Isolated library plasmids were reintroduced into yeast expressing a PKC-e 
bait in four separate experiments, the number of times the original 
interaction was detectably reproduced is indicated (each *  denotes 1 
reproduction).
x, no good quality sequence data obtained; N/H no sequences with 
significant homology identified; N/l CDS boundaries not indicated in 
mRNA sequence; clone no. underlined, different results obtained with 
forward and reverse sequences; shaded row, clone meets all of selection 
criteria required to be considered for further analysis (see text).
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Clone Score Accession No. Name Insert Start 
(base no.)
mRNA 
Start 
(base no.)
CDS? Reproducibility
1 704 NM_138668.1 RIKEN:1810047C23 26 1540 N
(3'UTR)
*
2 N/H X X X X X *
3 1150 AC127259.3 RP24304A20 (chr.9) 40 102074 - *
4 N/H - - - - - *
5 436 AC109233.10 RP23219N5 (chr.16) 92 108799 - *
6 825 BC040338.1 autocrine motility factor 
receptor
21 3274 N
(3'UTR)
* * *
7 676 AK011889.1 RIKEN :2610205H19 
0-44 protein homologue
26 764 Y
8 X X X X X X X
9 714 AC140364.4 RP2475K5 (chr.5) 52 105797 - * * *
10 N/H - - - - - * * *
11 718 AC123791.4| RP24304L14 (chr.15) 30 133362 - * * *
12 N/H - - - - - * *
13 908 AY339599.2 mitochondrial genome; 
NADH dehydrogenase 
subunit 1 gene
30 3705 Y *
14 X X X X X X X
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15 638 AC149283.2 RP23-233021(chr.7) 20 199549 - *
16 X X X X X X X
17 N/H - - - - - *
18 848 AC025669.19 RP235016 (chr.14) 46 76099 - *
19 920 NM_080428.2 F-box and WD-40 domain 
protein 7
43 2117 Y * * *
20 X X X X X X *
21 1005 AK028350.1 RIKEN:3732426M05 
Na+/H+ exchanger 6 
homologue
48 2755 N/l *
22 X X X X X X *
23 X X X X X X *
24 163 AC124598.5 BAC.RP2322P3 19 87372 - -
25 581 XM_134593.4 RIKEN:4932417I16 82 2924 N
(3'UTR)
26 N/H - - - - - * *
27 X X X X X X *
28 X X X X X X *
29 X X X X X X *
30 X X X X X X *
31 N/H - - - - - *
32 X X X X X X X
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33 708 BC079561.1 N-deacetylase/N- 
sulfotransferase 1
18 6072 N
(3'UTR)
*
34 763 BC057207.1 tetratricopeptide repeat 
domain 3
24 3571 Y *
35 X X X X X X *
36 779 BC022960.1 BC022960 139 1118 Y *
37 724 NM_011844.3 monoglyceride lipase 21 1354 Y *
38 581 NM_011844.3 monoglyceride lipase 21 1354 Y *
39 954 NM_011844.3 monoglyceride lipase 1 1354 Y * *
40 N/H - - - - - *
41 706 AC122022.4 BAC:RP24-372J5 (chr.5) 19 7394 - -
42 X X X X X X *
43 N/H - - - - - * *
44 X X X X X X *
45 815 AC115744.9 RP23-479M19 (chr.12) 116 154486 - *
46 N/H - - - - - *
47 X X X X X X -
48 248 NM_001001566.1 D1Bwg1363e; chondroitin 
polymerizing factor
50 3012 N
(3'UTR)
*
49 1108 AC084069.28 
(plus strand)
rp23-257b17 (chr. 13) 19 122345 * *
50 955 AY339599.2 mitochondrial genome; cox1 19 6941 Y * *
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51 155 XM_132762.6 Predicted: RasGEF domain 
protein 1a
40 2260 N
(3'UTR)
*
52 X X X X X X X
53 706 NM_138584.1 spastic paraplegia 21 
homologue (spg21)
21 1640 N
(3'UTR)
*
54 434 BC031782.1 engulfment and cell motility 
1
218 2306 N
(3'UTR)
*
55 315 NM_024227.2 mitochondrial ribosomal 
protein L28
19 1034 Y
(+3'UTR)
* *
56 X X X X X X X
57 654 AL845257.2 clone:RP23280K4 20 54344 - *
58 X X X X X X *
59 X X X X X X X
60 N/H - - - - - *
61 325 BC020992.1 similar to DEAD/H box 
polypeptide 26
39 852 N/l *
62 854 BC060998.1 DNA polymerase beta 19 1197 Y *
63 751 NM_133694.1 F-box and leucine-rich 
repeat protein 15 (fbxl 15)
31 1315 Y *
64 X X X X X X *
65 157 AC133618.3 BAC:CH230-71N8 19 71193 - *
66 833 AC154575.2 RP23-248E1 (chr.14) 19 70958 - *
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67 N/H X X X X X *
68 827 AC113285.9 clone:RP23407l6 19 213772 - * *
69 N/H X X X X X *
70 X X X X X X X
71 478 AL845502.5 RP23395A21 (chr.4) 24 143637 - -
72 841 AC125179.4 RP23321N8 (chr.16) 47 185111 - -
73 X X X X X X X
74 642 BC028971.1 GTL2, imprinted maternally 
expressed untranslated 
mRNA
19 1190
75 X X X X X X X
76 973 AL683822.8 RP2394I24 (chr.x) 19 35595 - -
77 452 BC002052.1 H3 histone 3A mRNA 29 1077 - -
78 X X X X X X X
79 714 XM_622593.1 RIKEN: 1500031H01 22 1331 - -
80 745 BC064081.1 RIKEN: 1500031H01 26 1327 - -
81 X X X X X X X
82 628 AB003304.1| beta-type 20S proteasome 
subunit X
152 874 Y
83 474 AC099860.13 RP235C23 (chr.1) 29 161449 - *
84 X X X X X X X
85 X X X X X X *
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86 605 NM_010250.2 GABA-A receptor, subunit 
alpha 1
19 4062 N
(3'UTR)
*
87 X X X X X X X
88 458 NM_011983.1 homer homologue 2 19 1655 N
(3'UTR)
*
89 139 AK075620.1 ferritin light chain 1 21 922 N
(3'UTR)
90 335 NM_133206.2 zinc and ring finger 1 54 2366 N
(3'UTR)
* *
91 335 BC003794.1 stress-induced 
phosphoprotein 1
30 2070 N
(3'UTR)
*
92 761 NM_007727.1 contactin 1 20 3829 N
(3'UTR)
*
93 283 BC064825.1 
(plus strand)
importin 7 18 2286 N
(3’UTR)
* *
94 934 AC124461.3 
(plus strand)
RP24-144C5 (chr.7) 30 53689 *
95 X X X X X X *
96 599 NM_028815.3 leucine-rich repeats and IQ 
motif containing 2 (Lrriq2)
29 5492 N
(3'UTR)
*
97 492 BC036961.1 IMAGE:4505120 19 2346 N
(3'UTR)
*
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98 X X X X X X *
99 652 BC094422.1 eukaryotic translation 
initiation factor 4A2
21 1879 N
(3'UTR)
*
100 484 AC092480.27 
(plus strand)
rp23-387f2 (chr.17) 1 129048
101 X X X X X X X
102 163 NM_031037.2 rat guanine nucleotide 
binding protein, beta 2
96 1552 N
(5'UTR)
103 434 NM_013494.2 carboxypeptidase E 1 890 Y * *
104 650 BC052462.1 protein tyrosine 
phosphatase, receptor type, 
S
1 5561 N
(3'UTR)
*
105 620 BC024818.1 GTL2, imprinted maternally 
expressed untranslated 
mRNA, with apparent 
retained intron
19 1338 *
135 BC094421.1 IMAGE:6413494 350 1356 -
131 MMU320506 Gt12 gene 352 103392 -
106 993 NM_009721.2 ATPase, Na+/K+ 
transporting, beta 1 
polypeptide (Atp1b1)
19 1614 Y
N
(+3'UTR)
* *
107 640 NM_010324.1 glutamate oxaloacetate 
transaminase 1 (gotl)
18 1890 N
(3'UTR)
* *
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108 313 BC051968.1 Nel-like 2 (Nell2) 26 3125 N
(3'UTR)
* *
109 406 NM_027782.1 potassium channel 
tetramerisation domain 
containing 6 (kctd6)
54 1584 N
(3'UTR)
* *
110 952 AC124745.4 BAC clone RP23-236012 
(chr.14)
21 22262 *
369 NM_025832.2 NMDA receptor regulated 1- 
like (Nargll)
328 3875 N
(3'UTR)
111 525 NM_007422.2 adenylosuccinate 
synthetase (adss)
22 2553 N
(3'UTR)
*
112 X X X X X X X
113 609 BC080776.1 ubiquitin-activating enzyme 
E1C
18 2091 N
(3'UTR)
* *
114 396 NMJ72624.1 dipeptiylpeptidase 9 (dpp9) 149 3332 N
(3’UTR)
*
115 X X X X X X X
116 523 BC025165.1 glycoprotein m6b 19 1460 N
(3'UTR)
*
117 569 AC126430.3 BAC RP24-406F17 75 46746 - *
118 X X X X X X X
119 478 AK077923.1 von Hippel-Lindau binding 28 1575 N * *
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protein 1 (3'UTR)
120 X X X X X X X
121 305 AK077923.1 von Hippel-Lindau binding 
protein 1
144 1575 N
(3'UTR)
*
122 640 BC027319.1 ATPase, Na+/K+ 
transporting, beta 1 
polypeptide
23 2216 N
(3'UTR)
*
381 BC049225.1 
(plus strand)
protein expressed in non­
metastatic cells 7 (nme7)
20 1477 N
(3'UTR)
123 285 NM_007438.3 aldolase 1, isoform A 
(Aldoa)
21 1438 N
N
(3'UTR)
124 773 NM_173446.1 clone AW121567 131 3140 N
(3'UTR)
125 357 AL451076.14 RP2343020 (chr.X) 19 7299 - *
126 X X X X X X X
127 X X X X X X *
128 X X X X X X X
129 X X X X X X X
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3.2.3.3 Elimination of Commonly Occurring False Positives
Following sequence analysis, the remaining putative positive clones were 
checked against a table of commonly occurring potential false positives 
(listed at www.fccc.edu:80/research/labs/golemis/main_false.html; see 
Table 3.3); any clones corresponding to these classes of protein were 
disregarded for further analysis.
Commonly Occurring 
Yeast 2-Hybrid False Positives
Corresponding
Clones
Heat Shock Proteins -
Ribosomal proteins 55
Cytochrome Oxidase -
Mitochondrial proteins 40
Proteasome Subunits 82
Ferritin -
tRNA synthase -
Collagen-related proteins -
Zinc Finger Proteins 4, 75
Vimentin -
Inorganic pyrophosphatase -
Proliferating Cell Nuclear Antigen -
Elongation Factors -
Lamin -
Ubiquitin -
Table 3.3 Commonly Occurring Yeast 2-Hybrid False Positives.
Putative positive mouse brain cDNA clones, isolated after three rounds of 
yeast 2-hybrid screening with a PKC-e bait, were sequence analysed.
Any clone representing an in-frame coding sequence was checked 
against a list of commonly occurring potential false positives 
(www.fccc.edu:80/research/labs/ golemis/main_false.html).
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3.2.3.4 Putative Binding Partners: Protein Degradation
Following multiple rounds of high stringency screening, selection based 
on sequence characteristics, and elimination of commonly occurring 
potential false positives, 23 candidate PKC-e binding partners remained 
(highlighted in bold on Tables 3.1 and 3.2). Since the primary aim of this 
screen was to identify candidate proteins on the pathway(s) of PKC 
down-regulation, it was striking that two of these clones* had established 
associations with the ubiquitin/proteasome system: clone 119, von-Hippel 
Lindau binding protein 1 (VBP1) (Tsuchiya et al., 1996); and clone 19, the 
C-terminal region of F-box WD40 Protein 7 (Fbw7) (Maruyama et al., 
2001). These clones were therefore selected for further investigation.
Clones 119 and 19 were re-streaked onto selective media alongside 
negative and positive controls (see Figures 3.8 and 3.9). When co­
transformed with PKC-e bait, both of these clones reproducibly facilitate 
growth on high stringency drop-out media and allow for positive 
blue/white selection, and therefore represent putative PKC-e interacting 
proteins.
* At the time that this work was undertaken, the database entry 
corresponding to clone 63, F-box and leucine-rich repeat protein 15, had 
not been submitted (the sequence was identified only as 'Similar to 
hypothetical protein MGC11279'). This match was made in a more 
recent re-analysis of the data. If in frame, clone 63 would represent a 
good candidate for further analysis, but it was not pursued in this project.
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p53/T \
V e/119 e/AD 1
-T/L -T/L/H -T/UH/A/X
Figure 3.8 PKC-e/Clone 119 Yeast 2-Hybrid Interaction. AH 109 yeast 
co-transformed with PKC-e bait/positive yeast 2-hybrid clone 119 (VBP1) 
were plated onto media selective for the vectors (-T/L), for medium 
stringency interaction (-T/L/H) and for high stringency interaction (- 
T/L/H/A/X). pGBKT7-p53/pGADT7-T Ag co-transformants were used as 
positive controls, pGBKT7/pGADT7 co-transformants as negative 
controls.
T, Tryptophan; L, Leucine; H, Histidine; A, Adenine; X, + X-a-gal.
-T/L/H -T/L/H/A/X
Figure 3.9 PKC-e/Clone 19 Yeast 2-Hybrid Interaction. AH109 yeast 
co-transformed with PKC-e bait/positive yeast 2-hybrid clone 19 (C- 
terminal portion of Fbw7) were plated onto media selective for the vectors 
(-T/L), for medium stringency interaction (-T/L/H) and for high stringency 
interaction (-T/L/H/A/X). pGBKT7-p53/pGADT7-T Ag co-transformants 
were used as positive controls, pGBKT7/pGADT7 co-transformants as 
negative controls.
T, Tryptophan; L, Leucine; H, Histidine; A, Adenine; X, + X-a-gal.
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3.2.4 PKCe-Regulatory Domain and PKCe-Catalytic Domain Screens
The PKC-e regulatory and catalytic domain bait constructs described in 
Section 3.2.2.1 were employed in parallel yeast 2-hybrid screens 
performed in our laboratory by Dr. Adrian Saurin. These screens were 
carried out using a human cardiac cDNA library as PKC-e has a well 
established role in the phenomenon of ischaemic preconditioning in the 
heart (Saurin et al., 2002).
It is important to note that among the putative binding partners identified 
with the PKC-e regulatory domain bait was 14-3-3|3; the relationship 
between PKC-e and 14-3-3 is relevant to work presented in Chapter 6.
3.3 Discussion
A yeast 2-hybrid system was established with which to screen a mouse 
brain cDNA library for PKC-e interacting proteins, and subsequently, a 
human cardiac library for PKC-e regulatory/catalytic domain binding 
partners.
The system was characterised prior to the screen. All of the bait 
constructs tested were expressed in yeast, and although full length PKC-e 
was expressed at a lower level than its individual domains, it was 
detectable and judged to be suitable for screening.
The yeast survived transformation with all of the baits, although the 
growth rate was impaired to a certain extent by each of the constructs. 
This is an important consideration given that detection of binding partners 
is based upon growth on selective media in the 2-hybrid system. The 
negative influence of PKC-S on growth rate deterred us from attempting a 
counter-screen of PKC-e binding partners in yeast.
Inhibition of yeast growth is consistent with a degree of bait toxicity, but
may alternatively reflect a functional effect of mammalian PKC in yeast;
overexpression of PKC-e is known to extend the doubling time in
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Schizosaccharomycespombe (Goode et al., 1994). Notably, the PKC 
constructs that were expressed at the lowest levels were those with the 
most profound effects on growth rate, suggesting that a bait's expression 
may be restricted by the capacity of the yeast to tolerate its effects.
Full length PKC-e bait was employed to conduct a yeast 2-hybrid screen 
in which 1.4x105 mouse brain cfus were examined as potential PKC-e 
interacting partners. Although this was not as comprehensive as the 
intended 106 cfus, it was deemed to be sufficiently extensive. The yeast 
were subjected to numerous rounds of selection, with increasingly 
stringent criteria, as the requirements of the screen evolved. We sought 
to find a balance between successfully eliminating false positives and 
avoiding the generation of false negatives, while confining the study to a 
manageable size.
The initial screen was conducted at medium stringency, utilizing only the 
HIS3 reporter gene for protein-protein interactions in order to include 
even weak or transient partners. However, because such a large number 
of clones were isolated using this approach (980), subsequent rounds of 
selection were focussed towards the rejection of false positives.
Positive colonies were plated first onto -HIS/ADE, and then onto - 
HIS/ADE/X-a-gal media. Since the three corresponding reporter genes 
are under the control of distinct GAL4 upstream activating sequences in 
the MATCHMAKER 3 system, the use of them all eliminated false 
positives interacting either with sequences surrounding the GAL4 binding 
site, or with transcription factors bound to specific TATA boxes. As 
successive rounds of screening were employed, during which extraneous 
plasmids could be lost, this method also addressed the issue of multiple 
library vectors occurring in positive clones and complicating results. 
Ultimately, all but 129 clones were rejected; however, it is important to 
acknowledge that a number of false negatives are likely to have been 
sacrificed under these more rigorous conditions.
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Following the final round of selection, library plasmids from the surviving 
yeast were recovered, retested and sequenced. The level of 
reproducibility achieved was disappointing and it was therefore necessary 
to confirm interactions carefully in mammalian cells, as described in 
Chapter 4. However, poor reproducibility is a well documented drawback 
of the yeast 2-hybrid approach (Ashman et al., 2001). Variation in 
plasmid copy number among separate experiments has been proposed 
as one source of disparity (Stephens and Banting, 2000). Since PKC-e 
seems to confer some negative effects on yeast growth, it is possible that 
there was a degree of selection against the bait which contributed to this 
problem.
Sequence analysis of the isolated library vectors facilitated the 
identification and preliminary characterisation of the putative positive 
clones. In order to validate the screen, the compiled results were first 
examined for known PKC interacting partners. One previously 
characterised PKC interacting partner was represented by clone 108, 
NEL-like protein 2 (NELL2). NELL2 is a cytoplasmic, thrombospondin-1 
like protein with 6 EGF-like repeats which is strongly expressed in neural 
tissues (Kuroda and Tanizawa, 1999). It was originally isolated as a 
PKC-p interacting partner by yeast 2-hybrid analysis with a regulatory 
domain bait (Kuroda et al., 1999), but was subsequently shown also to 
interact strongly with PKC-e and PKC-^, and to be phosphorylated by 
PKC (Kuroda and Tanizawa, 1999). The PKC binding site was mapped 
to the EGF-like domains of NELL2; consistent with this, clone 108, which 
starts from residue 306, contains this region (EGF-like repeats begin at 
residue 399).
The detection of the same binding partner from multiple, separate clones 
is another good indicator that a screening process has been effective. 
One such example is provided in this screen by clones 74 and 105; 
although identified as mRNAs with different accession numbers, the 
inserts encode sequences corresponding to Gtl2, with different but
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overlapping insert boundaries. While this observation is encouraging in 
terms of reproducibility, the functional significance of Gtl2 as an 
interacting partner is questionable since this sequence is thought to act 
as an RNA (Schuster-Gossler et al., 1998).
There are other examples of proteins detected more than once in this 
screen which are potentially physiologically relevant, for example clones 
37,38 and 39 all correspond to the 5'UTR and CDS for monoglyceride 
lipase. However, in this case, the duplicates encode exactly the same 
region of sequence and thus represent identical, rather than independent, 
copies of the same clone. This occurrence could be explained by the fact 
that an amplified library was employed for the screen. Alternatively, it 
could be the result of contamination; the fact that the clone numbers are 
consecutive indicates that they were picked from the same area of the 
original screen plate, which would be consistent with this latter 
interpretation.
Among the other yeast 2-hybrid hits were numerous classes of positive 
clones: uncharacterised and characterised cDNAs; coding and non­
coding regions; full length and partial inserts; and in frame and frame- 
shifted sequences with respect to GAL4. Only clones expressing 
identifiable, in-frame, coding sequences immediately after the library 
adaptor sequence were followed up in further studies, however, as 
touched upon in Section 3.2.3.2, yet more true positives may have been 
wrongly excluded by these criteria due to the capacity of yeast to permit 
unconventional transcriptional and translational processes. Firstly, 
positive clones can occasionally be transcribed in the reverse orientation 
from a cryptic promoter, such that the protein expressed does not 
correspond to the sequence encoded after the library adapter (Chien et 
al., 1991). Secondly, yeast are capable of permitting translational read- 
through. Therefore, where there appears to be just 5' UTR or a short 
peptide represented by an insert, there may be a second ORF beyond 
the stop codon which could be expressed. Finally, yeast can sometimes
accommodate translational frameshifts (Clontech, 1999). In a number of
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cases a large ORF was identified but was in the wrong reading frame with 
respect to the GAL4 AD, it is possible that some such clones may have 
represented true positives. This possibility could have been tested by 
western blotting for the HA-epitope harboured by all preys, and analysing 
the sizes of the proteins encoded.
Clones expressing in-frame, coding sequence were next checked against 
a list of well-documented and commonly occurring false positives, these 
proteins seem to be inherently adhesive and undergo 'irrelevant' 
interactions with many baits (Stephens and Banting, 2000). A number of 
such clones were detected in this screen, and were not pursued further.
For the remaining putative positives, it was important to establish which 
part of the corresponding protein was encoded by a partial clone, and 
whether this was likely to be accessible to PKC in a mammalian cell. For 
example, F3/contactin (clone 92) is a GPI-anchored, cell-surface neural 
recognition molecule (Gennarini et al., 1989). As such, the region of 
F3/contactin represented by clone 92 is unlikely to be exposed to PKC in 
the context of the full length protein, and this interaction is unlikely to 
have any physiological relevance.
Following three rounds of yeast 2-hybrid screening, selection based on 
sequence features, elimination of commonly occurring false positives and 
rejection of partial sequences deemed to be of uncertain physiological 
significance, a collection of putative PKC-e binding partners remained. 
Since the primary aim of this screen was to identify binding proteins with 
potential relevance to PKC degradation, it was striking that two of these 
clones have established associations with the ubiquitin/proteasome 
system: clone 19, the C-terminal region of F-box WD40 Protein 7 (Fbw7) 
and clone 119, von-Hippel Lindau binding protein 1 (VBP1). Notably, the 
VBP1 sequence was also represented by clone 121, however, an 
insertion at base 6 renders almost the entire sequence out of frame. It is 
conceivable that the yeast were able to accommodate this frameshift, as
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described above, in order to translate the wild type protein, but this 
possibility was not tested.
Clones 19 and 119 were selected for further analysis in the context of 
PKC down-regulation. It was beyond the scope of this project to 
investigate any of the other putative PKC-e binding partners, but many of 
them remain as potentially interesting candidates for investigation in the 
future; this is discussed further in Chapter 7.
In conclusion, yeast 2-hybrid analysis identified two putative PKC-e 
binding partners, Fbw7 and VBP1, with potential roles in PKC down- 
regulation. In the following chapter, the interactions between these 
proteins and PKC are investigated in mammalian cells, and their 
functional relationships are explored. Additionally, a parallel 2-hybrid 
screen, performed with the regulatory domain bait, identified 14-3-3(3 as a 
PKC-e binding protein; this interaction is explored further in Chapter 6.
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CHAPTER 4
PKC & Protein Degradation:
F-box WD40 Protein 7 & VBP1
4.1 Introduction
A characteristic property of the classical and novel PKC isoforms is that 
their chronic activation frequently leads to their inactivation and/or 
degradation (Ballester and Rosen, 1985; Stabel et al., 1987). This 
process of down-regulation is an important, yet poorly characterised, part 
of the 'life cycle' of PKC, and may in fact be intrinsic to the tumour 
promoting activity of the phorbol esters (Young et al., 1987). As such, the 
elucidation of the PKC degradation pathway(s) represents an important 
goal for research, and the focus of ongoing work in our laboratory. As 
described in Chapter 3, yeast 2-hybrid screening with a PKC-e bait 
identified two interacting partners with links to the ubiquitin proteasome 
system, von Hippel-Lindau (pVHL) Binding Protein 1 (VBP1) and F-box 
WD40 Protein 7 (Fbw7); these proteins represent strong candidates for 
further investigation in this context.
VBP1 was originally identified from a human B-cell cDNA library by 
Tsuchiya and colleagues (Tsuchiya et al., 1996), and has subsequently 
been shown to be highly conserved, and therefore likely to perform an 
important function (Brinke et al., 1997). Although its precise role remains 
elusive, VBP1 has been implicated in the activity of the prefoldin co­
chaperone complex (Geissler et al., 1998), (Vainberg et al., 1998), and 
demonstrated to interact with pVHL (Tsuchiya et al., 1996). VHL is a 
tumour suppressor gene which is mutated in familial VHL cancer 
syndrome (Latif et al., 1993) and in the majority of kidney cancers (Shuin 
et al., 1994). pVHL associates with Elongin C, Elongin B, Cullin-2 and
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Rbx1 to form a ubiquitin ligase complex (Stebbins et al., 1999) in which 
pVHL confers substrate recognition. Its best established substrate to 
date is hypoxia inducible factor-1a (HIF-1a) (Maxwell et al., 1999) 
(Cockman et al., 2000), but significantly, pVHL has been also been 
connected to the degradation of activated aPKC-X (Okuda et al., 2001). 
Since VBP1 interacts both with PKC and pVHL, it constitutes an 
interesting candidate for further analysis with respect to this pathway.
Fbw7 is the substrate recognition component of a well characterised 
Skp1/Cullin1 /F-box (SCF) class E3 ubiquitin ligase. In mammalian cells, 
Fbw7 is represented by three isoforms: a, p and y (Welcker et al., 2004a). 
SCFFbw7 has been shown to mediate the poly-ubiquitination of numerous 
substrates, thereby targeting them for proteasomal degradation. In each 
case, the substrate binding domain of Fbw7 recognises and specifically 
interacts with a phospho-threonine/proline (pTP) based motif termed the 
cdc4 phospho-degron (CPD) (Nash et al., 2001). Established SCFFbw7 
substrates include: cyclin E (Moberg et al., 2001; Strohmaier et al., 2001); 
c-myc (Moberg et al., 2004; Welcker et al., 2004a; Yada et al., 2004); c- 
jun (Nateri et al., 2004); Notch (Gupta-Rossi et al., 2001; Oberg et al., 
2001; Wu et al., 2001) and presenilin (Li et al., 2002; Wu et al., 1998).
The ubiquitin ligase activity of SCFFbw7 plays a critical role in controlling 
cell cycle progression (Feldman et al., 1997), cell growth (Welcker et al., 
2004a) and apoptotic JNK signalling in neurons (Nateri et al., 2004). 
Significantly, Fbw7 has been identified as a tumour suppressor gene 
(Mao et al., 2004) and is found to be mutated in a number of cancer cell 
lines (Moberg et al., 2001; Strohmaier et al., 2001).
This chapter describes the examination of the functional relationships 
between PKC and VBP1/Fbw7. Data is presented which validates the 
interactions detected by yeast 2-hybrid analysis in Chapter 3. VBP1 and 
Fbw7 are then investigated as candidate proteins on the PKC down- 
regulation pathway(s), and conversely, as downstream PKC targets.
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4.2 Results
4.2.1 PKC Protein-Protein Interactions in Mammalian Cells
4.2.1.1 VBP1/PKC Protein-Protein Interactions
VBP1 was identified as a PKC-e interacting protein by yeast 2-hybrid 
analysis. Before the functional significance of this interaction could be 
explored, it was first important to confirm that binding could also be 
detected in the context of a mammalian cell.
GFP-VBP1 was cloned and tested for interaction with PKC-e by GST pull­
down in COS7 cells. Preliminary mapping data was also obtained using 
GST-tagged PKC-e domain constructs. Figure 4.1 demonstrates that the 
interaction between PKC-e and VBP1 is reproducible in mammalian cells 
and maps to the catalytic domain of PKC-e. (see Figure 6.13 in Chapter 
6 for an example of a similar experiment, performed in the opposite 
orientation).
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Figure 4.1 Detection and Mapping of the Interaction Between PKC- 
e/VBP1 in Mammalian Cells by GST Pull-down. COS7 cells were 
seeded on 6-well plates and co-transfected with GST/GST-PKC-e 
constructs and GFP-VBP1. 24hrs post-transfection, lysates were 
prepared and subjected to GST pull down. Samples were resolved by 
SDS-PAGE and analysed by Western blotting with anti-GST and anti- 
GFP 3E1 antibodies, e , full length PKC-e; R, regulatory domain; C, 
catalytic domain. This data is representative of three independent 
experiments.
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4.2.1.2 Fbw7/PKC Protein-Protein Interactions
The substrate binding domain of Fbw7 was identified as a PKC-e 
interacting protein by yeast 2-hybrid analysis. As was the case for VBP1, 
prior to investigating the functional consequences of this interaction, it 
was first necessary to validate binding in a mammalian system.
Yeast 2-hybrid clone 19 represents the C-terminal portion of Fbw7. As 
shown in Figures 4.2 and 4.3, this region comprises the WD40 domain 
responsible for substrate recognition and is shared among all isoforms of 
Fbw7. The sequence encoded by clone 19 was sub-cloned directly from 
the library vector pACT2, to the mammalian expression vector pEGFP- 
C1, and tested for interaction with PKC-e by GST pull-down in COS7 
cells. Figure 4.4 reveals that the interaction between PKC-e and the 
substrate binding domain of Fbw7 is reproducible in mammalian cells 
and, as was the case for VBP1, requires the catalytic domain of PKC-e.
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Fbw7a (NM 033632)
MNQELLSVGSKRRRTGGSLRGNPSSSQVDEEQMNRWEEEQQQQLRQQEEEHTARNGEWGVEPRPGGQNDSQQGQLEENNNRFISVDEDSSGNQE
EQEEDEEHAGEQDEEDEEEEEMDQESDDFDQSDDSSREDEHTHTNSVTNSSSIVDLPVHQLSSPFYTKTTK-
Fbw7B (NM 018315)
MCVPRSGLILSCICLYCGVLLPVLLPNLPFLTCLSMSTLESVTYLPEKGLYCQRLPSSRTHGGTESLKGKNTENMGFYGTLKMIFYK-
Fbw7v (NM 001013415)
MSKPGKPTLNHGLVPVDLKSAKEPLPHQTVMKIFSISIIAQGLPFCRRR- 
Conserved region
-MKRKLDHGSEVRSFSLGKKPCKVSEYTSTTGLVPCSATPTTFGDLRAANGQGQQRRRITSVQPPTGLQEWLKMFQSWSGPEKLLALDELIDSCEPT 
QVKHMMQVIEPQFQRDFISLLPKELALYVLSFLEPKDLLQAAQTCRYWRILAEDNLLWREKCKEEGIDEPLHIKRRKVIKPGFIHSPWKSAYIRQH 
RIDTNWR|RGELKSPKVLKGHDDHVITCLQFCGNRIVSGSDDNTLKVWSAV|TGKCLRTLVGHTGGVWSSQMRDNIIISGSTDRTLKVWNAE|TGE 
CIHTLYGHTSTVRCMHLHEKRWSGSRDATLRVWDIE|TGQCLHVLMGHVAAVRCVQYDGRRWSGAYDFMVKVWDPE|TETCLHTLQGHTNRVYS 
LQFDGIHWSGSLDTSIRVWDVE|TGNCIHTLTGHQSLTSGMELKDNILVSGNADSTVKIWDIK|TGQCLQTLQGPNKHQSAVTCLQFNKNFVITS 
S DDGTVKLWDLK|TGEFIRNLVTLESGGSGGWWRIRASNTKLVCAVGSRNGTEETKLLVLDF|DVDMK
Figure 4.2 Human Fbw7 isoforms and Clone 19 Protein Sequences. The protein sequences of the three Fbw7 isoforms were 
retrieved from the NCBI Entrez Nucleotide database using the accession numbers indicated. The isoform specific N-termini are 
represented separately, and the conserved C-terminal region is shown with the following features highlighted (Orlicky et al., 2003): 
F-box domain (red text); 8 WD40 repeats of the substrate binding domain (green); residue 1 of positive yeast 2-hybrid clone 19 
(blue). Nuclear localisation sequences are shown in bold.
169
Chapter 4: F-box WD40 Protein 7 & VBP1
Unique N-term inus
1
a  I i
=-box Substrate Bindinq
707
I I I I I I I LL  f
1
. I I _.  I . .  I I r .  i . r
627
I I "  "I I I I I LP I----------------- 1
1
■ W  iHiLBl i  I I -r
589
I i I I " I ' I I L
Clone 19 -| ft
Figure 4.3 Domain Structure of Human Fbw7 Isoforms and Clone 19.
The three human Fbw7 isoforms (a, |3 and y) and positive yeast 2-hybrid 
clone 19 are represented to scale with the following features highlighted 
(Orlicky et al., 2003): isoform specific N-termini (shades of yellow), 
conserved linker regions (black), F-box domain (red); 8 WD40 repeats of 
the substrate binding domain (green).
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Figure 4.4 Detection and Mapping of the PKC-e/clone 19 Interaction 
in Mammalian Cells by GST Pull-down. COS7 cells were seeded on 6- 
well plates and co-transfected with GST/GST-PKC-e constructs and GFP- 
19 (substrate binding domain of Fbw7). 24hrs post-transfection, lysates 
were prepared and subjected to GST pull down. Samples were resolved 
by SDS-PAGE and analysed by Western blotting with anti-GST and anti- 
GFP 3E1 antibodies, e, full length PKC-e; R, regulatory domain; C, 
catalytic domain. This data is representative of three separate 
experiments.
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4.2.2 VBP1/Fbw7 and PKC Degradation
Since VBP1 and Fbw7 were shown to represent valid PKC-s binding 
partners, and both have established links to the ubiquitin-proteasome 
system, these proteins were next investigated in the context of PKC 
degradation.
4.2.2.1 VBP1 and PKC Down-Regulation
4.2.2.1.1 VBP1 and TPA Induced PKC Down-Regulation
We sought to investigate whether VBP1 could influence the down- 
regulation of PKC, either under basal conditions, or in response to a 
chronic phorbol ester treatment.
NIH3T3 cells were transfected with RFP-PKC-s, +/- GFP alone or GFP- 
VBP1. The influence of VBP1 on PKC levels was assessed both under 
basal conditions, and over a timecourse of TPA treatment. Figure 4.5 
shows that, under the conditions employed, there is no detectable effect 
of VBP1 overexpression on TPA induced PKC degradation.
4.2.2.1.2 VBP1 and pVHL Induced PKC Down-Regulation
We originally hypothesized that VBP1 might participate in the process of 
PKC down-regulation because of its association with pVHL, a known PKC 
E3 ubiquitin ligase (Okuda et al., 2001). As such, Dr Xavier Iturrioz 
endeavoured to establish whether VBP1 might play a role specifically in 
the VHL-mediated pathway of PKC degradation, which he was studying 
in our laboratory.
There was no discernable influence of VBP1 on the interaction detected 
between pVHL and PKC-S by GST pull-down in COS7 cells. Similarly, no 
significant co-localisation could be observed between VBP and 
pVHL/PKC-5 positive structures in COS7 by immunofluorescence. All 
other experiments relating to pVHL mediated PKC down-regulation were 
performed on the endogenous proteins in renal carcinoma cells; these
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these cells are poorly transfectable and so it was not possible to test the 
effect of VBP1 over-expression in this system.
The observations here and those of Dr Iturrioz were not consistent with a 
role for VBP1 in PKC degradation. Subsequent work was therefore 
focussed on the investigation of Fbw7 as a candidate PKC E3 ubiquitin 
ligase, and as described in section 4.2.3, on both proteins as potential 
PKC substrates.
Lysate, IB: PKC-e
Lysate, IB: GFP
0 2 8 16 24 24
- - - - -  +
0 2 8 16 24 24 TPA (hrs)
+ MG132
GFP GFP-VBP
Figure 4.5 TPA Induced Degradation of PKC-e in the presence or 
absence of VBP-1. NIH3T3 cells were transfected with RFP-PKC-e +/- 
GFP/GFP-VBP1. 24hrs post-transfection cells were treated +/- 400nM 
TPA over a timecourse of a further 24hrs. Samples were harvested 
simultaneously in sample buffer, resolved by SDS-PAGE and analysed 
by western blotting with anti-PKC-£ and anti-GFP 3E1 antibodies.
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4.2.2.2 Fbw7 and PKC down-regulation
4.2.2.2.1 PKC Interaction with Full Length Fbw7 and Fbw Isoform 
Specificity
The results presented in Section 4.2.1.2 confirm that the interaction 
between PKC-e and the Fbw7 C-terminal region can be detected in 
mammalian cells. However, in order to begin to study the functional 
relationship between the two proteins, it was necessary to determine 
whether PKC-e could also interact with the full length Fbw7 protein. The 
presence of the Fbw7 N-terminal region could potentially affect 
conformation, localisation and/or other protein-protein interactions, all of 
which might influence PKC binding. Also, this region is of particular 
significance with respect to the study of protein degradation, as it is the F- 
box domain, which is lacking in clone 19, that links Fbw7 to the rest of the 
SCF complex (Bai et al., 1996).
GST-pull down experiments were performed using GST-PKC-e, or a GST 
control, and FLAG-tagged, full length Fbw7 (Fbw7(3). The isoform 
specificity of the interaction, with respect to Fbw7, was also investigated 
in this experiment. Other members of the F-box WD40 family, Fbwsl, 2, 
and 4, were counter-screened for interaction with PKC-e. All of these 
proteins possess an F-box domain and a substrate recognition domain 
which is based on WD40 repeats, however, other parts of the proteins are 
variable and the WD40 domains target different motifs and therefore 
confer differential substrate specificities (Maruyama et al., 2001; Miura et 
al., 1999).
Figure 4.6 demonstrates that full length Fbw7p is able to bind to PKC.
The use of a FLAG-tagged fusion reinforces the finding that the 
interaction is not artefactually dependent on a GFP tag. However, this 
data also reveals that the interaction is not isoform specific with respect to 
the Fbw protein family.
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The central panel of Figure 4.6 shows that the Fbw proteins are 
differentially expressed, with the level of Fbw7p so low as to be 
undetectable in the lysate under these conditions. Consequently, it is 
important to consider the efficiency of the pull-down rather than the actual 
amount of Fbw protein recovered. For example, Fbw4 is expressed at a 
comparable level as Fbw1, as judged from the lysate, but is represented 
by a more intense band in the pull down; the efficiency of the interaction 
can therefore be concluded to be significantly higher, and Fbw4 
concluded to be preferred as a PKC binding partner. As such, although 
the Fbw7p pull down band is relatively weak in intensity, it may represent 
a significant enrichment given the low level of Fbw7p expression. In 
subsequent experiments FLAG-Fbw7 was immunoprecipitated using an 
anti-FLAG antibody, and immunoblotted for anti-FLAG, to facilitate 
detection and enable more accurate comparison.
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Figure 4.6 Detection of the Interaction Between PKC-e and Full 
Length Fbw7 by GST Pull-down, and Counter-screening for Fbw 
Protein Isoform Specificity. COS7 cells were seeded on 6-well plates 
and co-transfected with GST/GST-PKC-e and FLAG-Fbw constructs 
(indicated with black arrows; the grey arrow signifies that Fbw7 was not 
detectable in the lysate). 24hrs post-transfection, lysates were prepared 
and subjected to GST pull down. Samples were resolved by SDS-PAGE 
and analysed by Western blotting with anti-GST and anti-FLAG 
antibodies. This data is representative of two separate experiments.
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Figure 4.7 shows an experiment, in which the interactions between PKC-e 
and the Fbw proteins are verified in the reverse orientation. These blots 
also confirm, with yet another combination of fusion constructs, that the 
tags are not responsible for the interactions (here, PKC-e bears an N- 
terminal GFP tag, as opposed to the C-terminal GST tag in the previous 
figure). The top panel of Figure 4.7 illustrates that all of the FLAG-tagged 
Fbws are detectable from the immunoprecipitated material, and so the 
efficiency of interaction can be directly compared. Fbws 4 and 7 undergo 
the most effective interactions with PKC-e, with Fbw1 significantly less 
efficient.
105 
7 5 -
5 0 -
Fbw7 |p; f l a g , 
Fbw1
Fbw2 IB: FLAG
Fbw4
Lysate,IB: GFP
IP:FLAG, IB: GFP
F1 F2 F4 F7
GFP-8
Figure 4.7 PKC-e/Fbw Protein Interactions Detected in the Reverse 
Orientation by Coimmunoprecipitation. COS7 cells were seeded on 
6-well plates and co-transfected with FLAG-Fbw (F1/2/4/7) constructs 
(indicated by black arrows) and GFP-PKC-e. 24hrs post-transfection, 
lysates were prepared and coimmunoprecipitation was performed using 
anti-FLAG M2-agarose affinity gel. Samples were resolved by SDS- 
PAGE and analysed by Western blotting with anti-FLAG and anti-GFP 
3E1 antibodies. This data is representative of three independent 
experiments.
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4.2.2.2.2 Interaction with Fbw7: PKC Isoform Specificity +/- MG-132
The isoform specificity of the PKC/Fbw interaction was next investigated 
with respect to PKC. At least one member of each subgroup of the PKC 
superfamily was counter-screened for interaction with Fbw7p (classical: 
a > Pi> Pul novel: 6, e ; atypical: £). Figure 4.8 reveals that all isoforms 
tested bind to Fbw7p; this is perhaps not surprising considering that the 
interaction maps to the well conserved catalytic domain of PKC. The 
PKC catalytic domain contains the 'TP' phosphorylation site. This site 
and the surrounding sequence, in at least some of the PKC isoforms, 
aligns well with the CPD motif which is recognised by Fbw7 (Figure 4.9).
Co-immunoprecipitations were performed in the presence or absence of 
the proteasome inhibitor MG-132, and an enhanced recovery of PKC was 
achieved + MG-132. Such a result could indicate that under normal 
conditions the population of PKC that interacts with Fbw7p is targeted for 
degradation, supporting the hypothesis that SCFFbw7 represents a PKC 
E3 ligase. However, the top panel of Figure 4.8 indicates that MG-132 
stabilizes Fbw7p itself; as such, the increased recovery of PKC may be 
explained by the availability of a larger pool of Fbw7p with which to 
immunoprecipitate. It is noteworthy though, that the augmented 
enrichment of PKC-£ in the presence of MG-132 seems to exceed the 
stabilization of Fbw7p.
Somewhat surprisingly, there is a reduction in the level of PKC-e detected 
in the lysate following treatment with MG-132, which would be expected 
to protect proteins from down-regulation. However, this is consistent with 
observations made by Dr. Amir Faisal in our laboratory, who has 
demonstrated that MG-132 stimulates caspase-dependent proteolysis of 
PKC-e in RAW264.7 cells (unpublished data).
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Figure 4.8 Detection of the Interactions Between Fbw7p and the PKC 
family by Coimmunoprecipitation, in the Presence and Absence of 
MG132. COS7 cells were seeded on 6-well plates and co-transfected 
with FLAG-Fbw7 and GFP-PKC ( a ,  p i,  p i l ,  6 , e, Q constructs. 32hrs post­
transfection, cells were treated +/- 30^iM MG-132 for a further 16hrs. 
Lysates were prepared and coimmunoprecipitation was performed using 
anti-FLAG M2-agarose affinity gel. Samples were resolved by SDS- 
PAGE and analysed by Western blotting with anti-FLAG and anti-GFP 
3E.
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<M>pTP<K/R> 4 Optimal CPD
LLpTPPQSGKK cyclin E T380
LPpTPPLSPSR c-myc T58
VLpTPPDQLVI PKC-a
ELpTPTDKLFI PKC-p,
VLpT PPDGQEV PKC-pn
RLpSYSDKNLI PKC-6
VLpTLVDEAIV PKC-e
QLpT PDDEDAI PKC-C
Figure 4.9 Fbw7 Substrate Recognition Motifs and PKC 'TP' Sites.
Nash et al (Nash et al., 2001) defined a high affinity consensus 
phosphopeptide binding motif for Fbw7 termed the cdc4 phospho-degron 
(CPD). This sequence is shown with hydrophobic residues (O) and 
disfavoured residues (<>) indicated. CPDs from established Fbw7 
substrates are shown, aligned with the 'TP' phosphorylation sites of 
different PKC isoforms. The critical phospho-threonine residue of the 
CPD is indicated (red); and the amino acid in the +4 position relative to 
this is highlighted (blue).
179
Chapter 4: F-box WD40 Protein 7 & VBP1
4.2.2.2.3 Fbw7 and PKC Ubiquitination
In order to address the possibility that Fbw7 can facilitate PKC 
degradation more directly, cell based ubiquitination assays were 
performed (Figure 4.10). In this system, the putative PKC substrate (or 
GST control) is expressed in the presence or absence of a FLAG-tagged 
F-box protein, with or without HA-tagged ubiquitin. PKC is then isolated 
by GST-pull down, and probed for ubiquitin by immunoblotting against the 
HA epitope. An adapted Western blotting protocol is employed, to 
facilitate the detection of high molecular weight, poly-ubiquitinated 
protein, which manifests as a ladder of differently sized species.
Enhanced ubiquitination is detected from the precipitated material only in 
the presence of PKC-e, and only where HA-Ub was included in the 
transfection. Co-expression of an Fbw protein is also shown to be 
required, but ubiquitination was not mediated in an isoform specific 
manner. The experimental design assumes that the HA-immunoreactive 
protein detected must correspond to ubiquitinated PKC, following partial 
purification by GST pull-down. However, we cannot exclude the 
possibility that the assay is in fact detecting a ubiquitinated PKC 
interacting protein. Examination of the lysates probed for FLAG-Fbw 
reveals a significant ladder of products, suggesting that the Fbws may 
themselves be poly-ubiquitinated. Since the Fbws are known to bind to 
PKC under these conditions, it is feasible that they represent at least a 
fraction of the ubiquitinated material detected following the pull-down.
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Figure 4.10 Fbw/PKC-e Ubiquitination assays. 293 cells were seeded 
on 6-well plates and transfected with GST/GST-PKC-b (-e represents 
GST control) +/- FLAG-Fbw constructs and +/- HA-ubiquitin (Ub.). 48hrs 
post-transfection, lysates were prepared in ubiquitination assay lysis 
buffer and subjected to GST pull-down. Samples were resolved by SDS- 
PAGE and analysed by Western blotting with anti-FLAG, anti-GST and 
anti-HA antibodies. GST pull-downs were processed using modified 
protocols to facilitate resolution and transfer of any high molecular weight, 
poly-ubiquitinated proteins (see Materials and Methods). This data is 
representative of two separate experiments. (The Fbws are indicated 
with black arrows; the grey arrow signifies that Fbw7 is not detectable in 
the lysate).
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4.2.2.2.4 Fbw7 and PKC Down-regulation
4.2.2.2.4.1 Fbw7 and Depletion of Phospho-c-jun and PKC-e
When Fbw7 is co-expressed with an established substrate, such as c-jun 
and c-myc, a depletion of the substrate can be observed by Western 
blotting (Nateri et al., 2004), (Welcker et al., 2004b). We therefore tested 
the effect of Fbw7 co-expression on PKC levels in different cell lines, 
alongside a c-jun control.
Figure 4.11 shows the optimisation of this co-expression assay with the c- 
jun control. In Figure 4.11a, c-jun was co-transfected with FLAG/FLAG- 
Fbw7p in 293 cells; Fbw7p mediated c-jun degradation has previously 
been demonstrated in this system (Nateri et al., 2004). However, c-jun 
depletion in the presence of Fbw7p is not apparent in this experiment, 
even following a UV treatment, which clearly enhances the level of 
phospho-c-jun, the species specifically recognised by Fbw7. The same 
test was next performed in a different cell line. As shown in Figure 4.11 b, 
an Fbw7p dependent reduction of c-jun could be detected in HeLa cell 
lysates; this effect was more evident when lysates were probed for 
phospho-S63 than for total c-jun.
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-  -  + +
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IP:FLAG, IB: FLAG 
Lysate, IB: P-c-jun (S63)
Lysate, IB: total c-jun
FLAG-Fbw7|3
UV
b) HeLa
+
c-jun
IP:FLAG, IB: FLAG 
Lysate, IB: P-c-jun (S63)
Lysate, IB: total c-jun 
FLAG-Fbw7|3
Figure 4.11 Fbw7|3 and Phospho-c-jun Depletion, a) 293 cells were 
seeded onto poly-lysine coated 6-well plates and tranfected with 
FLAG/FLAG-Fbw7 (Nateri et al., 2004) and myc-c-jun-FLAG. 24hrs post­
transfection, cells were treated +/- 40J/m2 UV and incubated for a further 
hour. Lysates were prepared and immunoprecipitation was performed 
using anti-FLAG M2-agarose affinity gel. Samples were resolved by 
SDS-PAGE and analysed by Western blotting with anti-FLAG (Fbw7 and 
total c-jun) and anti-phospho-c-jun Ser-63 antibodies, b) HeLa cells were 
seeded onto 6-well plates and tranfected with FLAG/FLAG-Fbw7 (Nateri 
et al., 2004) and myc-c-jun-FLAG. 24hrs post-transfection, lysates were 
prepared and immunoprecipitation was performed using anti-FLAG M2- 
agarose affinity gel. Samples were resolved by SDS-PAGE and analysed 
by Western blotting with anti-FLAG (Fbw7 and total c-jun) and anti- 
phospho-c-jun Ser-63 antibodies.
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The effect of Fbw7(3 co-expression on PKC levels was therefore tested in 
HeLa cells, alongside this c-jun control; Fbw7a and Fbw1 were also 
studied in parallel. Figure 4.12a again demonstrates the Fbw7p 
dependent depletion of phospho-c-jun, and reveals that this phenomenon 
is not observed in the presence of Fbw1, or even with the alternative 
Fbw7 isoform, Fbw7a. Figure 4.12b shows that the same pattern of 
behaviour is detected when PKC-e is expressed as the putative substrate, 
with a parallel tubulin blot confirming equal loading, suggesting that PKC- 
e may also represent an Fbw7 client. The effect of TPA on this process 
was analysed since TPA can induce PKC down-regulation, however, 
there was not a substantial difference apparent between 
treated/untreated cells. Notably, TPA induced an increase in phospho-c- 
jun levels.
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Figure 4.12 Fbw7p and Depletion of Phospho-c-jun and PKC-e. a)
HeLa cells were seeded onto 6-well plates and transfected with 
FLAG/FLAG-Fbw7 constructs (-, FLAG control; p, Fbw7p; a, Fbw7a; 1, 
Fbw1) and myc-c-jun-FLAG. 24hrs post-transfection, cells were treated 
+/- 400nM TPA for 1 hr and then harvested in sample buffer. Samples 
were resolved by SDS-PAGE and analysed by Western blotting with anti- 
FLAG (Fbw7 and total c-jun) and anti-phospho-c-jun Ser-63 antibodies, 
b) HeLa cells were seeded onto 6-well plates and transfected with GFP- 
PKC-e and FLAG/FLAG-Fbw constructs (-, FLAG; p, Fbw7p; a, Fbw7a;
1, Fbw1). 24hrs post-transfection, cells were treated +/- 400nM TPA for 
1 hr. Lysates were prepared and immunoprecipitation was performed 
using anti-FLAG M2-agarose affinity gel. Samples were resolved by 
SDS-PAGE and analysed by Western blotting with anti-FLAG and anti- 
GFP 3E1 antibodies. This data is representative of two separate 
experiments.
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4.2.2.2.4.2 Fbw7 and Depletion of PKC 'TP' Phosphorylation Site 
Mutants
This same co-expression assay was used to determine the requirements 
of Fbw7p mediated PKC depletion with respect to PKC phosphorylation 
status.
As shown in Figure 4.9, the PKC TP' phosphorylation site bears a degree 
of homology with the CPD motif recognised by Fbw7. We hypothesized 
that the PKC 'TP' site may therefore be necessary for this apparent down- 
regulation to occur, such that a corresponding alanine mutant may be 
resistant. Since the 'TP' site of PKC-a represents an almost optimal 
CPD, we reasoned that a potential difference in stability between a wild 
type and TP'-alanine mutant might be best detected using this isoform.
Co-expression experiments were performed using both His-tagged and 
GFP-tagged PKC-a wild type and 'TP' mutants (Figure 4.13). These blots 
confirm that, like PKC-e, PK C-a is depleted in an Fbw7p dependent 
manner and confirm that the fusion tag has no bearing on this effect. 
However, it is also revealed that a phosphorlyated T P ’ site is not required 
for this process to be observed; no difference in depletion is detectable 
between wild type PKC-a and either its TP'-alanine or 'TP'-glutamate 
mutants.
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< -  GFP-a 
+  His-aWild type
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G F P -a His-a
Figure 4.13 Fbw7p and Depletion of PKC-a 'TP' Mutants, a) HeLa 
cells were seeded onto 6-well plates and co-transfected with 
FLAG/FLAG-Fbw7p and PKC constructs. His-PKC-a and GFP-PKC-a 
were examined, and wild type constructs were compared to 'TP' site 
(T638) mutants. 24hrs post-transfection, cells were harvested in LDS 
sample buffer. Samples were resolved by SDS-PAGE and analysed by 
Western blotting with anti-PKCa MC5 antibodies.
+ -  + 
+ +
Lysate: GFP 
IP:FLAG, IB: FLAG 
Lysate: tubulin
+ FLAG-Fbw7 
MG-132
G F P -P K C -a G FP
Figure 4.14 Fbw7(3 and Depletion of PKC-a: Proteasomal 
Dependence and Specificity. HeLa cells were seeded onto 6-well 
plates and co-transfected with FLAG/FLAG-Fbw7|3 and GFP/GFP-PKC-a. 
24hrs post-transfection, cells were treated +/- 30^M MG-132 for 4hrs. 
Lysates were prepared and immunoprecipitation was performed using 
anti-FLAG M2-agarose affinity gel. Samples were resolved by SDS- 
PAGE and analysed by Western blotting with anti-FLAG, anti-GFP 3E1 
and anti-tubulin antibodies.
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4.2.2.2.4.3 Fbw7 Dependent PKC Depletion is not Mediated by the 
Proteasome and is not Specific
SCFpbw7 mediated degradation of its substrates occurs via the 
proteasome. As such, where Fbw7 is functioning as a ubiquitin ligase, 
substrate down-regulation should be blocked by treatment with the 
proteasome inhibitor MG-132. Fbw7p dependent depletion of PKC-a was 
investigated +/- MG-132. As shown in Figure 4.14, treatment with MG- 
132 does not prevent PKC-a depletion in this system, indicating that this 
effect is not mediated by the ubiquitin-proteasome system.
A further co-expression experiment was performed using GFP in place of 
a putative Fbw7 substrate. Figure 4.14 reveals that a reduced level of the 
GFP control is also detectable in the presence Fbw7p.
Since the apparent depletion of PKC in the presence of Fbw7p is neither 
proteasome-dependent, nor a specific event, we must conclude that this 
result represents an experimental artefact and that our data does not 
support a role for Fbw7 in PKC degradation under basal conditions.
4.2.2.2.5 Fbw7 and TPA induced PKC-e Degradation
As noted earlier, PKC degradation can be promoted by chronic phorbol 
ester treatment. Therefore, we sought to determine whether Fbw7 might 
play a role in TPA-induced degradation of PKC. We reasoned that the 
protection of PKC from TPA induced degradation by a dominant negative 
ubiquitin ligase would be more clearly detected than an augmentation of 
its down-regulation by a wild-type protein. Since clone-19 corresponds to 
the Fbw7 substrate binding domain, but lacks the F-box domain required 
for its association with the rest of the SCF ubiquitin ligase complex, it 
represents a putative dominant negative and was used as such.
NIH3T3 cells were transfected with RFP-PKC-e, +/- GFP or GFP-19.
Cells were treated with TPA and incubated over a 24hr time course.
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Figure 4.15 shows that, under the conditions employed, there is no 
detectable effect of clone-19 on TPA induced PKC degradation.
As was the case for VBP1, our data regarding Fbw7 was not consistent 
with a role in PKC degradation. Consequently, we pursued an alternative 
working hypothesis, and investigated whether, VBP1/Fbw7 might 
represent downstream targets for PKC.
— — —  ~~- ------------------------- — *
W** fPW 0** 0**' 0 * IN *  wm
Lysate, IB: PKC-e 
Lysate, IB: GFP
0 2 8 16 24 24
- - - - -  +
GFP
0 2 8 16 24 24 TPA (hrs)
- - - - - +  MG132
GFP-Fbw7 SBD
Figure 4.15 TPA Induced Degradation of PKC-e in the presence or 
absence of dominant negative Fbw7. NIH3T3 cells were transfected 
with RFP-PKC-e +/- GFP/GFP-Fbw7 substrate binding domain (SBD). 
24hrs post-transfection cells were treated +/- 400nM TPA over a 
timecourse of a further 24hrs. Samples were harvested simultaneously in 
sample buffer, resolved by SDS-PAGE and analysed by western blotting 
with anti-PKC-e and anti-GFP 3E1 antibodies.
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4.2.3 VBP1/Fbw7 as candidate PKC targets
In order to address the possibility that PKC may influence the function of 
VBP1 or Fbw7, these proteins were analysed as candidate PKC 
substrates. There is a precedent for proteins identified as PKC binding 
partners to also behave as substrates (Chapline et al., 1993; Hyatt et al., 
1994); such proteins represent a subgroup of PKC interacting proteins, 
referred to as STICKs (Substrates That Interact with C-Kinase).
4.2.3.1 VBP1 as a candidate PKC substrate
4.2.3.1.1 VBP1 purification
In order to test VBP1 as a potential PKC substrate it was first necessary 
to prepare purified protein for use in an in vitro kinase assay. His-VBP1 
was produced in bacteria and purified using Ni-NTA agarose. Aliquots 
were removed at each stage of the purification process (Figure 4.16). 
Clear induction of VBP1 expression was observed following induction 
with IPTG. After lysis and ultracentrifugation, the majority of the protein 
was detected in the insoluble fraction, consistent with previous reports 
that VBP1 occurs in inclusion bodies when expressed in bacteria (Simons 
et al., 2004). Nevertheless, there was also a significant amount of VBP1 
present in the supernatant and this was judged to be sufficient for our 
requirements. We therefore carried out a native purification protocol on 
Ni-NTA agarose using the soluble extract. His-VBP1 was eluted with 
step gradients of imidazole, with the bulk of the protein eluting at 200mM 
and above. Precipitation of purified VBP1 was observed upon prolonged 
storage, as such, fresh batches were prepared routinely.
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Pre Post Pellet SN 100mM 200mM
IPTG IPTG Elution Elution
Figure 4.16 Purification of His-VBP1. His-tagged VBP1 was produced 
and purified from BL21-CodonPlus bacteria (see Materials and Methods). 
Aliquots of the culture were removed before and after induction with 
0.4mM IPTG overnight at 16°C (Pre/Post IPTG). Post-lysis, the insoluble 
fraction was resuspended in 8M urea for analysis (Pellet), and an aliquot 
of the supernatant was removed (SN). The remainder of the soluble 
extract was subjected to a native protein purification protocol using Ni- 
NTA agarose. The purified protein was eluted with step gradients of 
imidazole (100m M /200m M ). The samples shown are loaded such that 
pairs are comparable: Pre/Post, 1/200,000 culture volume; Pellet/SN, 
1/4000 total fraction; 100mM/200mElution, 1:400 total fraction.
191
Chapter 4: F-box WD40 Protein 7 & VBP1
4.2.3.1.2 VBP1 In Vitro Kinase Assays
In vitro kinase assays were performed using recombinant human PKC-e 
and His-VBP1 as a putative substrate. Figure 4.17a shows that 
phosphorylation of His-VBP1 is dependent upon PKC-e, increasing over 
time, and with increasing substrate concentration. In a similar 
experiment, enhanced phosphorylation was also detected with increasing 
enzyme concentration (figure 4.17b). In both panels of this figure, it is 
apparent that VBP1 undergoes a bandshift over the course of the assay, 
with at least 2 upper bands emerging (see Discussion).
It is noteworthy that autophosphorylation of PKC-e is detected using this 
assay; this phenomenon is investigated further in the next chapter.
4.2.3.1.3 VBP1 & MBP In Vitro Kinase Assays
The efficiency of PKC catalysed VBP1 phosphorylation was explored, 
using a well characterised substrate, myelin basic protein (MBP), as a 
control (Figure 4.18);.
Both PKC-e and PK C-a were shown to phosphorylate VBP1, although a 
difference in substrate specificity was apparent between the two 
enzymes, with PKC-e catalysing VBP1 phosphorylation relatively more 
effectively. However, the stoichiometry of VBP1 phosphorylation, with 
either isoform, was poor in comparison to MBP. As such, VBP1 was 
concluded to represent a relatively poor substrate for PKC and was not 
investigated further.
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Figure 4.17 VBP1 In Vitro Kinase Assays, a) PKC-e catalysed 
phosphorylation o fV B P I was assayed at varying substrate concentration. 
0.5ng/5p,g His-VBP1 was incubated in kinase assay buffer with 25ng 
PKC-e. Reactions were started with [y32P]-ATP, incubated for 0-2hrs at 
30°C  with shaking, and stopped with the addition of kinase assay sample 
buffer. Samples were resolved by SDS-PAGE and exposed to a 
phosphor screen; phoshorylation was visualised using the Storm 860 
Phosphorlmaging System, b) PKC-e catalysed phosphorylation o fV B P I 
was assayed at varying enzyme concentration. 0.2^ig His-VBP1 was 
incubated in kinase assay buffer with 25/250ng PKC-e. Reactions were 
started with [y32P]-A TP, incubated for 0-2hrs at 30°C  with shaking, and 
stopped with the addition of kinase assay sample buffer. Samples were 
processed as described in a). This data is representative of three 
independent experiments.
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Substrate pmol ATP/pmol substrate
PKC-e PKC-a
MBP 0.18 0.72
VBP1 0.03 0.02
s a  -  e a  
MBP VBP1
Figure 4.18 MBP & VBP1 In Vitro Kinase Assays. PKC-e/a catalysed 
phosphorylation of purified MBP/VBP1 was assayed in vitro. 5|mg 
MBP/VBP1 was incubated in kinase assay buffer with 25ng PKC-e/150ng 
PKC-a. Reactions were started with [y32P]-ATP, incubated for 0/30mins 
at 30°C with shaking, and stopped with the addition of kinase assay 
sample buffer. Samples were resolved by SDS-PAGE and exposed to a 
phosphor screen; phoshorylation was visualised using the Storm 860 
Phosphorlmaging System. The MBP/VBP1 bands were excised and 
counted alongside the ATP stock to allow calculation of stoichiometry. 
These results are representative of two separate experiments.
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4.2.3.2 Fbw7 as a candidate PKC substrate
4.2.3.2.1 Fbw7 complex kinase assays
In order to address whether Fbw7 may represent a downstream target of 
PKC, in vitro kinase assays were performed using recombinant human 
PKC-e and immunoprecipitated Fbw7p as a putative substrate. The other 
members of the Fbw family, which were characterised in section 4.2.2.2.1 
with respect to PKC binding, were analysed in parallel (See Figure 4.19). 
Since the F-box proteins were immunoprecipitated, this assay would 
potentially enable the detection of any Fbw-associated proteins which 
may represent additional PKC substrates.
Figure 4.19b confirms that all of the Fbw proteins were expressed and 
recovered by immunoprecipitation. Figure 4.19a reveals that again, 
autophosphorylation of PKC-e is detectable by in vitro kinase assay, and 
thereby confirms that the assay conditions employed facilitated activity. 
There is a general elevation of phosphorylation apparent in the material 
immunoprecipitated via Fbw1, regardless of PKC-e; presumably an active 
kinase is recruited within this complex. However, there is very little 
evidence of PKC-e dependent substrate phosphorylation detected using 
this approach. There is a just single, subtle difference apparent between 
samples incubated +/- PKC-e; interestingly, the size of the putative 
substrate is approximately the same as the size of FLAG-Fbw7(3 itself.
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Figure 4.19 Fbw Immuno-complex In Vitro Kinase Assays. COS7  
cells were plated onto 10cm dishes and transfected with FLAG/FLAG- 
tagged Fbw constructs (Fbw1/2/4/7). 24hrs post-transfection, Fbw fusion 
proteins, and associated partners, were recovered by anti-FLAG 
immunoprecipitation. Washed beads were incubated in kinase assay mix 
+/- 50ng purified PKCe, reactions were started with [y32P]-ATP, incubated 
for 30mins at 30°C with shaking and stopped with the addition of kinase 
assay sample buffer. Proteins were resolved by SDS-PAGE, Comassie 
stained and scanned (b). Phoshorylation was then visualised using the 
Storm 860 Phosphorlmaging System (a). Fbws detected by Coomassie 
are denoted with black arrows, grey arrows indicate the equivalent 
positions on the Phosphorlmage.
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4.2.3.2.2 Fbw7 Phosphorylation Site Prediction.
The possibility that Fbw7 represents a PKC substrate was explored 
further using bioinformatics. A database has been developed which 
facilitates the prediction of PKC phosphorylation sites, based on its 
established preferences with regards to the residues surrounding a 
candidate phospho-Ser/Thr ((Fujii et al., 2004); 
mpr.nci.nih.gov/MPR/ScanProteinForPKCSitesPage.aspx,). The amino 
acid sequences of the three Fbw7 isoforms were searched against this 
database.
Within the region common to all Fbw7 isoforms, encompassing the F-box 
and substrate binding domains (see Figure 4.3), there were 2 sites which 
scored within the top 1 percentile as predicted sites: T165 and T226 
(residue numbers based on Fbw7a sequence). Within the unique regions 
of Fbw7p and y, none of the Ser/Thr residues were predicted to represent 
significant candidates as PKC substrates. However, as shown in Figure 
4.20, within the isoform specific sequence of Fbw7a, there are two highly 
scoring putative sites: Ser-10, which is within the top 1 percentile with 
respect to PKC-6 and the top 0.2 percentile for PKC-£; and Ser-18, which 
is within the top 0.2 percentile for both PKC isoforms. We therefore 
sought next to test whether this region of Fbw7a constitutes a true PKC 
phosphorylation site.
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Predicted Phosphorylation Sites in fbw7a
Citation: Fujii K. Zhu G. Liu Y. Hallam J. Chen L. Herrera J. Shaw S. Kinase Peptide
Specificity: Improved Determination and Relevance to Protein Phosphorylation. Proc Natl
Acad Sci U S A .  2004 in press.
Prediction Percentile
Site Num Sequence P0 Position HydrophobicityPKC-delta PKC-zeta
1 - - M N Q E L L -  - V G  KRRR 7 0.04 66 58
2 E L L .  V G -  - K R R R -GG 10 -0.04 1 C.06
3 VG K R R R -  - G G  L R GN P 15 -0.11 13 21
4 KRRR G G -  - L R G N P 18 -0.19 WL 0.1 0.2
5 L R G N P -  -  QVDEEQ 24 -0.04 30 16
6 G L RGNP -  -  QVDEEQM 25 0.04 53 54
7 LRGNP -  - QVDEEQMN 26 0.00 76 85
8 L R Q Q E E E H -  - A RN G EV VG 53 -0.05 72 51
9 P R P G G Q N D -  - Q Q G Q L E E N 72 -0.12 61 49
10 E E N N N R F I -  - V D E D .. GN 86 -0.13 75 90
11 R F I . V D E D -  -  GNQEEQE 91 -0.09 94 69
12 F I . V D E D  -  - G N Q E E Q E E 92 -0.06 90 83
13 E E E E M D Q E -  - D D F D Q  DD 122 -0.31 99 97
14 QE D D F D Q -  - D D  RE DE 128 -0.37 99 98
15 DDFDQ D D -  -  R E D E H JH 131 -0.29 84 83
16 DFDQ DD -  - R E D E H  H 132 -0.23 90 92
17 D R E D E H -  - H  N V N 138 -0.17 54 57
18 R E D E H - H - : - N  V N 140 -0.13 46 41
19 E DE H H N -  - V  N I V 142 0.11 27 32
20 EH H N V -  - N  I V D L 144 0.25 64 75
21 H N V N -  -  I V D L P V 146 0.39 72 20
22 H N V  N -  -  I V D L P V H 147 0.38 34 20
23 N V N -  - I V D L P V H Q 148 0.36 56 65
24 V D L P V H Q L -  -  P F Y  K 158 0.52 61 95
25 DLPVHQL -  - P F Y  K K 159 0.39 68 38
Figure 4.20 Predicted PKC Phosphorylation Sites in Fbw7a. The
amino acid sequence of Fbw7a was searched against the Mammalian 
Phosphorylation Resource database for prediction of PKC 
phosphorylation sites (Fujii et al., 2004). The results for the isoform 
specific sequence of Fbw7a (1-167) are shown. The orange box 
indicates a prediction score within the top 1 percentile, the red box 
indicates a score within the top 0.2 percentile.
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4.2.3.2.3 Fbw7a Peptide Array Kinase Assay
PKC catalysed phosphorylation of the Fbw7a N-terminal region was first 
investigated using a peptide array. As illustrated in Figure 4.21, the array 
comprises 20x12-mer peptide spots, which walk along the Fbw7a 
sequence from residue 1-31, one amino acid at a time. Kinase assays 
had to be performed in a large enough volume to completely immerse the 
cellulose strip upon which the peptide array was spotted, as such, pilot 
studies were carried out using PKC-a, which is purified in-house and 
therefore available in relatively large quantities, with the view to repeating 
the assay with PKC-e, and other isoforms, subsequently.
Figure 4.21a shows that although there is a degree of background under 
the conditions employed, PKC-dependent phosphorylation of the array is 
evident. Elevated phosphorylation can be detected broadly across array; 
it does not correspond unequivocally with the presence of a particular 
residue. As such, the array does not identify a particular site of 
phosphorylation, but it does highlight the importance of the context in 
which a residue is placed.
Since the results obtained using the peptide array kinase assay were 
ambiguous, it was not repeated using other PKC isoforms, instead an 
alternative approach was employed as described below.
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a)
a ., m # No PKC 
10jig PKC-a 
100^g PKC-a
1 2 3 4 5 6 7  8 9  10 11 1213  14 1516 17 18 19 20
b) M N Q E L L S V G S K R R R T G G S L R G N P S s s Q V D E E
1 M N Q E L L S V G S K R
2 N Q E L L S V G S K R R
3 Q E L L S V G S K R R R
4 E L L s V G S K R R R T
5 L L s V G S K R R R T G
6 L s V G S K R R R T G G
7 s V G S K R R R T G G S
8 V G S K R R R T G G S L
9 G S K R R R T G G S L R
10 S K R R R T G G S L R G
11 K R R R T G G S L R G N
12 R R R T G G s L R G N P
13 R R T G G s L R G N P S
14 R T G G s L R G N P s s
15 T G G s L R G N P s s s
16 G G 5 L R G N P s s s Q
17 G S L R G N P s s s Q V
18 S L R G N P s s s Q V D
19 L R G N P s s s Q V D E
2 0 R G N P s s s Q V D E E
Figure 4.21 Fbw7a Peptide Array Kinase Assays. A peptide array 
representing the N-terminal region of Fbw7a was synthesized on a 
cellulose membrane, a) 3 identical arrays were blocked and equilibrated 
in kinase assay buffer (-PKC/[y32P]-ATP). Kinase assays were performed 
with no enzyme, 10^ig purified PKC-a or 100^g purified PKC-a.
Reactions were started with [y32P]-ATP, incubated for 15mins, and 
washed 2x15mins 30% acetic acid, 3x15mins TBS-T and 3x5mins in 
water. Phosphorylation was visualised using the Storm 860 
Phosphorlmaging System, b) The array comprises 20x12-mer peptide 
spots, which walk along the Fbw7a sequence from residue 1-31, one 
amino acid at a time. Red text indicates S18, the predicted 
phosphorylation site. Other candidate Ser/Thr residues are highlighted in 
blue.
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4.2.3.2.4 Fbw7a S18 Peptide Kinase Assays
A panel of peptides were synthesized with which to further analyse the 
Fbw7a N-terminal region as a PKC substrate in vitro. Fbw7a 6-22 
includes both highly scoring predicted sites (S10 and S18): 
LSVGSKRRRTGGSLRGN, while Fbw7a wt 11-22: KRRRTGGSLRGN 
includes just S18; a S18A mutant peptide corresponding to the latter was 
also synthesized. A peptide based on the PKC-5 pseudosubstrate 
sequence, in which the alanine residue is replaced by a phosphorylatable 
serine, was employed as a positive control.
Figure 4.22 shows that the Fbw7a derived peptides are phosphorylated 
in a PKC dependent manner over time, and that there are some subtle 
isoform specific variations in catalytic behaviour towards this substrate.
All of the PKC isoforms phosphorylate peptides 6-22 and 11-22 with 
similar efficiency, indicating that S10 cannot represent the single site of 
phosphorylation. Since phosphorylation is diminished in the S18A 
mutant, we can conclude that S18 represents the single site of 
phosphorylation in this peptide.
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Figure 4.22 Fbw7a Peptide In Vitro Kinase Assays, a) Reactions were 
performed in 50^1 kinase assay mix, with 0.2mM peptide substrate* and 
the following PKC isoforms: 25ng a, 15ng 6, 12.5ng e or 250ng t- Assays 
were started with [y32P]-ATP, incubated at 30°C over the indicated 
timecourse, and stopped by spotting 15pil onto P81 paper and washing 
3x5mins in 30% acetic acid. P81 strips were then counted.
* Peptide substrates: PKC-t 'PSS': RKRQGSVRRRV; Fbw7a 6-22: 
LSVGSKRRRTGGSLRGN, Fbw7a wt 11-22: KRRRTGGSLRGN. b) 
Reactions were performed in 50(il kinase assay mix, with 50ng PKC- 
e and 0.2mM peptide substrate: Fbw7a wt 11-22, or Fbw7a 11-22 S18A. 
Assays were started with the addition of [y32P]-ATP, incubated at 30°C 
over the indicated timecourse, and stopped by spotting 15^1 onto P81 
paper and washing 3x5mins in 30% acetic acid. P81 strips were then 
counted. These assays were performed in triplicate; error bars denote 
standard deviation.
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4.2.3.2.5 Fbw7a S18 Phospho-specific antibody
In order to investigate whether Fbw7a S18 is phosphorylated in 
mammalian cells, we raised phospho-specific antibodies. Three rabbits 
were immunized with a 9-mer phospho-peptide, corresponding to Fbw7a 
pS18, coupled to Keyhole Limpet Haemocyanin. The sera obtained were 
analysed for antigen recognition by ELISA as shown in Figure 4.23.
Serum PPA-525 binds to the Fbw7a antigen in a quantitative manner, 
however, it does not show phospho-specificity; it may represent a useful 
antibody with which to detect total Fbw7a protein. PPA-526 and PPA- 
527, however, demonstrate both quantitative binding to the antigen and 
phospho-specificity. In both cases, non-specific recognition of the de- 
phospho antigen can be reduced by incubation with the blocking de- 
phosphopeptide. PPA-527 shows the most significant differential 
between interaction with phospho- and de-phosphopeptides, this serum 
was therefore employed to screen for S18 phosphorylation in cells (+ 
blocking peptide).
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Test bleed PPA-525
——  P- peptide 
— - de-P-peptide 
—  P-peptide + blocking 
— de-P-peptide + blocking
10 s 10-4
Antibody Dilution
Test bleed PPA-526
— P-peptide
—  de-P-peptide 
- — P-peptide + blocking
—  de-P-peptide + blocking
10-* 10-4
Antibody Dilution
io-<
Test bleed PPA-527
—  P-peptide
—  de-P-peptide
—  P-peptide + blocking
—  de-P-peptide + blocking
10- *
Antibody Dilution
Figure 4.23 Fbw7a S18 Phosphospecific Antibody Characterisation.
3 rabbits (PPA-525/526/527) were immunised with a KLH-coupled 9-mer 
phospho-peptide corresponding to Fbw7a p-S18: N-RTGGpSLRGN-C. 
The 2nd test bleed was collected at day 49 and assayed by ELISA for 
binding to the antigen (P-peptide), or the corresponding de- 
phosphopeptide control (de-P peptide). Assays were performed using a 
dilution series of the test bleed +/- blocking peptide. ELISAs were 
developed using OPD substrate, stopped within the linear range with 2N 
H2S 04 and quantified at 490nm using a plate reader. Assays were 
performed in triplicate; error bars denote standard deviation.
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4.2.3.2.6 Characterisation of Fbw7a S18 Phosphorylation in cells.
The phosphorylation of Fbw7a S18 in mammalian cells was investigated, 
using Fbw7a S18A as a negative control. Serum PPA-527 lacked the 
necessary specificity to detect Fbw7a pS18 uniquely within a lysate, as 
such, GFP-Fbw7a was immunoprecipitated prior to Western blotting to 
provide a cleaner sample.
FleLa cells were transfected with GFP-Fbw7a/Fbw7a S18A and treated 
with or without the phosphatase inhibitor Calyculin A. As shown in Figure 
4.24, in the presence of Calyculin A, phosphorylation of S18 is clearly 
detectable in the wild type protein, but not in the corresponding alanine 
mutant. This confirms that the phospho-specific antibody is effective 
under these conditions, and importantly, that this site can indeed become 
phosphorylated in the context of a mammalian cell.
In order to test whether PKC is responsible for this phosphorylation event 
in cells, a panel of inhibitors were tested in the same experiment. While 
the broad specificity kinase inhibitor, staurosporine, completely 
suppressed phsophorylation, neither the cPKC/PKD inhibitor G66976, nor 
the cPKC/nPKC inhibitor BIM1 had a significant effect. The identity of the 
kinase responsible for phosphorylation of Fbw7a S18 under these 
conditions remains to be established.
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IP, IB: p-S18
Lysate, IB: GFP
Calyculin A 
Inhibitor
S18A wild type Fbw7a
Figure 4.24 Phosphorylation of Fbw7a S18 in Mammalian Cells.
HeLa cells were plated onto a 24-well plate and transfected with GFP- 
Fbw7a or Fbw7a S18A control. 24hrs post-transfection, cells were pre­
treated +/- a panel of kinase inhibitors for 15mins: BIM1 (Bim), 2|iM; 
Go6976 (Go), V M ; Staurosporine (STS), 1 ptM. The media was then 
supplemented +/- 100nM Calyculin A and cells were incubated for a 
further 45mins. Lysates were prepared and subjected to 
immunoprecipitation with anti-GFP 4E12/8. Samples were analysed by 
Western blotting using anti-GFP 3E1 and anti-pS18 (PPA-527, + 0.1 pig/ml 
dephosphopeptide).
4.2.3.2.7 Fbw7a S18 Phosphorylation and localisation.
The three isoforms of Fbw7 display different patterns of localisation; 
Fbw7a resides in the nucleus, Fbw7|3 is cytoplasmic, and Fbw7y 
nucleolar. The sequence determinants, within the isoform specific N- 
termini, which dictate these localisations have been investigated by 
Welcker and colleagues (Welcker et al., 2004a).
As indicated in Figure 4.2 there are two nuclear localisation signals 
(NLSs) within Fbw7a (11-14 and 169-172). It has been shown that either 
is sufficient to facilitate Fbw7a nuclear localisation, but it remains to be 
established whether these sites are differentially regulated in cells. Since 
it is well established that phosphorylation can influence the function of 
NLSs (Jans and Flubner, 1996), we sought to explore whether occupation 
of S18 would affect the nearby NLS 11-14, and perhaps affect Fbw7a 
localisation in the absence of a second functional site.
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Figure 4.25 confirms that the localisations of our GFP-Fbw7a/p 
constructs are consistent with previous reports, and demonstrates that 
Fbw7a remains in the nucleus even when co-expressed with PKC-e 
(Figure 4.25b). A panel of truncated Fbw7a constructs were generated, 
which correspond to amino acids 1-68; these constructs would be reliant 
upon NLS 11-14 for nuclear localisation. This region was cloned as a 
wild type sequence, with an alanine mutation at Ser-18 (S18A), to abolish 
any potential phosphorylation, or with the corresponding aspartate 
mutation, to mimic phoshorylation with a negative charge (S18D). Figure 
4.25 shows that neither mutation drastically alters localisation under 
these conditions. Work is ongoing to explore the effect of this 
phosphorylation event more extensively.
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GFP-Fbw7a GFP-Fbw7p
b)
GFP-Fbw7a RFP-PKC-e merge
GFP-Fbw7a 1 -68 GFP-Fbw7a 1 -68 GFP-Fbw7a 1 -68
Wild type S18A S18D
Figure 4.25 Fbw7a/p Localisation in HeLa Cells. FleLa cells were 
seeded on glass coverslips in 24-well dishes and transfected with a) 
GFP-Fbw7a or Fbw7p; b) GFP-Fbw7a + RFP-PKC-e; c) GFP-Fbw7a 1- 
68 wildtype, S18A or S18D. Cells were washed in PBS, fixed in 4% (w/v) 
paraformaldehyde/PBS for 10mins at RT, washed 3x10mins in PBS and 
once in water, and finally mounted onto glass slides using Mowiol 
mounting media. Images were acquired using an upright laser scanning 
confocal microscope (LSM 510, Zeiss) equipped with a 63x/1.4 Plan- 
Apochromat Oil Ph3 objective. GFP was excited with the 488nm line of 
an Argon laser, Cy3 with a 543nm HeNe laser; individual channels were 
scanned sequentially line by line with averaging set at 8. Each image 
represents a single 1.0pm ‘Z’ optical section with a pixel size of 
approximately 0.1pm.
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4.3 Discussion
Yeast 2-hybrid screening with a PKC-s bait identified two interacting 
partners with links to the ubiquitin-proteasome system: VBP1 and Fbw7. 
Since PKC down-regulation is an important yet poorly characterised 
process, and a focus of ongoing research in our laboratory, these 
proteins represented interesting candidates for further investigation.
The protein-protein interactions detected by the yeast 2-hybrid system 
take place within the yeast cell nucleus and as such lack physiological 
context. It was therefore important to test whether these interactions 
could be detected in mammalian cells prior to studying their functional 
consequences. PKC binding to VBP1/Fbw7 was explored by in COS7 
cells using over-expressed proteins. GST pull-downs were performed 
both with full length PKC-s and its individual regulatory (sR) and catalytic 
(sC) domains; it was revealed that the VBP1 and Fbw7 binding sites 
mapped to PKC-s catalytic domain. Further studies were carried out by 
co-immunoprecipitation, such that the interactions were tested in both 
orientations, with different combinations of tags; the binding partners 
were shown to associate with PKC under all conditions tested. It would 
have been preferable to further validate these findings by testing the 
interactions between endogenous proteins; however, at the time of the 
experiments, antibodies were not available against either VBP1 or Fbw7. 
It was therefore concluded that both proteins had been shown to interact 
with PKC-s as effectively as possible. The yeast 2-hybrid screen 
described in Chapter 3 was judged to have successfully identified valid 
binding partners, and these proteins were pursued in further studies.
Investigations were initiated to study the functional significance of the 
PKC/VBP1 and PKC/Fbw7 interactions. These binding partners were 
first explored as candidates on the PKC degradation pathway(s), with the 
most detailed studies focussed on Fbw7.
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Fbw7 is the substrate recognition component of a well characterised SCF 
E3 ubiquitin ligase, whose substrates include cyclin E (Moberg et al.,
2001; Strohmaier et al., 2001), c-myc (Moberg et al., 2004; Welcker et al., 
2004a; Yada et al., 2004) and c-jun (Nateri et al., 2004). Fbw7 mediates 
substrate recognition within this complex, interacting with specific 
phosphorylated pTP motifs via its C-terminal, WD40 repeat based 
substrate binding domain (Orlicky et al., 2003). Since yeast 2-hybrid 
screening revealed that PKC interacts directly with this C-terminal 
domain, PKC represented a strong candidate as an additional Fbw7 client 
protein.
The isoform specificity of the PKC/Fbw interaction was investigated, firstly 
with respect to the F-box WD40 protein. Three other members of the 
Fbw family (Fbw1/2/4) were tested for interaction, and PKC-e was shown 
to bind to them all. Since Fbw-mediated ubiquitination is a process 
executed with a high degree of selectivity, this promiscuity is not 
consistent with the notion that PKC may represent an Fbw substrate. 
Using the same panel of Fbw proteins, Yada et al were able to 
demonstrate an impressive specificity for Fbw7 binding using phospho-c- 
myc, a validated Fbw7 substrate (Yada et al., 2004).
PKC isoform specificity was also explored. Fbw7 was shown to interact 
with all of the members of the PKC superfamily tested, this is likely to 
relate to the fact that the interaction maps to the well conserved PKC 
catalytic domain. Notably, all of the PKC isoforms bear some variation of 
the conserved 'TP' phosphorylation site within this region, a feature which 
bears some similarity to the Fbw7 pTP substrate recognition motif. While 
it is tempting to speculate that this site may confer Fbw7 binding, and as 
such direct subsequent ubiquitination and degradation by the 
proteasome, the data do not support this conclusion. If an optimal pTP 
motif was required to mediate recognition by Fbw7, PKC-6, which has the 
most poorly conserved 'TP' site, would be predicted to bind less efficiently 
than PKC-a, which bears many of the optimal features (hydrophobic
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residues at -1 and -2, phospho-threonine, which is favoured over 
phospho-serine, and a proline reside at +1). Although PKC-6 perhaps 
binds less efficiently, the difference is not substantial. It would have been 
worthwhile to test this assumption using TP site mutants.
Fbw7/PKC co-immunoprecipitations were performed in the presence or 
absence of the proteasome inhibitor MG-132, and an enhanced recovery 
of PKC was achieved +MG-132. Such a result could indicate that under 
normal conditions, the population of PKC that interacts with Fbw7 is 
targeted for degradation, and thus support the hypothesis that SCFFbw7 
represents a PKC E3 ligase. However, MG-132 appears to stabilize 
Fbw7, and as such it seems more likely that the enrichment of PKC is 
explained by the availability of a larger pool of Fbw7 with which to 
immunoprecipitate. It is noteworthy however, that there is a more 
significant increase in the recovery of PKC-£ +MG-132, which exceeds 
the stabilisation Fbw7. It therefore remains possible that in this case, an 
additional effect on Fbw7 mediated turnover is conferred by the 
proteasome inhibitor. However, there is not a corresponding depletion of 
PKC-£ from the lysate detectable in the presence of Fbw7 and absence 
of MG-132.
PKC down-regulation was explored further using cell-based ubiquitination 
assays. These assays were performed using the same panel of Fbw 
proteins described above (Fbw1/2/4/7), and elevated ubiquitination was 
detected in the presence of each of them. If this ubiquitinated protein 
corresponds to PKC, the implication is that, at least under these 
conditions, the PKC/Fbw interaction has a functional consequence. As 
noted with regards to the protein-protein interaction data, a greater 
degree of specificity may be expected from a true PKC E3 ubiquitin 
ligase, but given its relatively low expression level, the stoichiometry of 
ubiquitination mediated by Fbw7 may be significant. However, this 
interpretation of the data is flawed because it is not possible to distinguish 
whether the high molecular weight species in the pull-down represent
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ubiquitinated PKC, ubiquitinated Fbw protein associated with PKC, or 
another ubiquitinated PKC binding partner. F-box proteins are known to 
autoubiquitinate (Galan and Peter, 1999) and immunoblotting of the 
lysates suggests that there may be a ladder of FLAG-immunoreactive 
products consistent with such a process. As such this experiment is not 
conclusive. These assays were not optimised further, but one possibility 
would be to repeat the process, incorporating differential stringengy 
washes of precipitated material prior to SDS-PAGE; this would be likely to 
dissociate bound (Fbw) proteins from the PKC, while leaving any 
covalently attached ubiquitin unaffected. Here though, alternative studies 
were undertaken instead to establish whether Fbw7 has a detectable 
effect on PKC down-regulation.
Fbw7 mediated turnover of its substrates has often been explored 
through co-expression studies, in which the presence of Fbw7 causes a 
detectable and specific depletion of a steady state client protein such as 
c-jun (Nateri et al., 2004), or c-myc (Welcker et al., 2004b). This system 
was employed to test PKC as a potential substrate, using phospho-c-jun, 
as a positive control.
The depletion of phospho-c-jun in the presence of Fbw7 was shown to be 
cell type specific, apparent in HeLa, but not 293s. The effect of Fbw7 on 
PKC was therefore tested in HeLa cells, and a similar reduction in protein 
level was detected. This finding initially suggested that Fbw7 may indeed 
mediate PKC down-regulation. However, subsequent experiments 
revealed that this effect was neither specific, nor dependent on the 
proteasome. As such, we had to conclude that this result represented an 
experimental artefact.
Since this artefactual protein depletion was not observed when Fbw1 or
Fbw7a controls were co-transfected with PKC/c-jun, it seems unlikely to
reflect a general flaw in the design of the experiment. Neither is it caused
by the influence of a particular fusion protein, as both GFP- and His-
tagged proteins were tested. It therefore remains that this effect is either
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caused indirectly, through an effect on an additional Fbw7 substrate, or 
reflects an unusual property of the Fbw7p construct.
We reasoned that the protection of PKC from TPA induced degradation 
by a dominant negative ubiquitin ligase may be more clearly detectable 
than an augmentation of its down-regulation by a wild-type protein. Since 
yeast 2-hybrid clone-19 corresponds to the Fbw7 substrate binding 
domain, but lacks the F-box domain required for its association with the 
rest of the SCF ubiquitin ligase complex, it represents a putative 
dominant negative. We used GFP-19 to further investigate whether Fbw7 
might play a role in PKC-degradation, either under basal conditions, or in 
response to a chronic phorbol ester treatment. No protection was 
afforded to PKC by co-transfection with GFP-19 under these conditions.
The effects of Fbw7 on PKC-downregulation in response to other stimuli 
were not explored in this work. Previous data from our laboratory has 
described a cell cycle dependent pathway of PKC-6/e degradation (Olivier 
et al., 1996). Given the role of Fbw7 in the control of the cell cycle, this 
would have been a relevant context in which to explore its relationship 
with PKC (Moberg et al., 2001), (Strohmaier et al., 2001).
The experiments undertaken to investigate Fbw7 as a candidate PKC 
specific E3 ubiquitin ligase proved problematic, and were not conclusive. 
While none of the data supports a role for Fbw7 in PKC degradation, it 
does not convincingly disprove this possibility either. It would perhaps 
have been more informative to study the effects of Fbw7 by pulse chase, 
to avoid the artefactual results detected when assessing overall 
expression; or by using RNAi to knock-down Fbw7 and studying the 
endogenous proteins.
The investigation of VBP1 as a candidate on the pathway of PKC 
degradation was more limited. VBP1 showed no discernable effect on 
either steady state levels of PKC, or on the profile of TPA-induced
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degradation. Neither was there a detectable effect of VBP1 on the 
interaction between PKC and the established E3 ubiquitin ligase pVHL.
VBP1 was first identified as a pVHL interacting protein, prompting 
speculation about a potential role for VBP in protein degradation (Brinke 
et al., 1997). However, VBP1 has also been implicated, and studied 
much more thoroughly, in another context. The amino acid sequence of 
VBP1 is identical to that of a protein called prefoldin 3 (PFD3), a 
component of the prefoldin co-chaperone complex. This complex is 
involved in the delivery of unfolded clients to the TRiC/CCT chaperone, 
and has been shown to be responsible for the folding of actin and tubulin 
(Geissler et al., 1998; Vainberg et al., 1998). Since protein-protein 
interactions are inherent to the biological activity of VBP1/PFD3, it is 
conceivable that it may represent the type of 'inherently sticky' protein 
which will be commonly isolated by yeast 2-hybrid screening; the 
TRiC/CCT y-subunit was also identified as a PKC-e catalytic domain 
interacting protein by Adrian Saurin in our laboratory (unpublished data). 
It is also feasible that VBP1 may play a role in PKC folding, rather than in 
PKC degradation; we did not investigate this possibility. Notably, VHL is 
known to be recruited to the TRiC/CCT chaperone complex (Feldman et 
al., 1999), as such, we could speculate that its interaction with VBP1 
reflects this aspect of its life-cycle.
A major aim of this chapter was to further characterise the elusive 
mechanism of PKC down-regulation. However, neither Fbw7 nor VBP1 
was positively associated with this process by the experiments 
undertaken. There were clear limitations to the approaches which were 
employed, but due to a lack of any supporting data, we did not pursue 
alternative strategies in this work. Instead, we explored the converse 
relationship between PKC and VBP1/Fbw7, addressing whether these 
proteins might represent downstream targets for PKC.
VBP1 was tested as a potential PKC substrate. Firstly, VBP1 was
purified for use in kinase assays. Although the bulk of the protein was
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insoluble in bacteria, we were able to obtain enough soluble VBP1 to 
carry out a non-denaturing purification, and thereby increase our chances 
of recovering native protein. This purified VBP1 behaved as a typical 
substrate, with PKC-catalysed phosphorylation increasing over time, and 
with increasing enzyme/substrate concentrations.
However, when analysed alongside Myelin Basic Protein (MBP), an 
established PKC substrate, VBP1 phosphorylation was shown to occur 
with a relatively inefficient stoichiometry. It could be argued that this may 
reflect the fact that MBP bears multiple PKC consensus sequences 
(Ramwani and Moscarello, 1990), such that more than one 
phosphorylation event may occur per molecule. However, the bandshift 
observed during a timecourse of phosphorylation suggests that this may 
also hold true for VBP1.
It is important to acknowledge that the purified VBP1 employed as a 
kinase assay substrate may not have existed in a native conformation; 
this protein has a propensity to aggregate (Simons et al., 2004), and a 
certain amount of precipitation was observed during prolonged storage. 
Therefore, we cannot exclude the possibility that a small population of 
correctly folded VBP1 is acting as a high stoichiometry substrate. An 
additional consideration to bear in mind is that under physiological 
conditions, VBP1 forms part of the prefoldin complex; perhaps within this 
context, it would be held in a conformation more conducive to 
phosphorylation. Work was undertaken to try to isolate the prefoldin 
complex from mammalian cells for use as an in vitro kinase assay 
substrate. Antibodies specific for different prefoldin subunits were 
obtained (from Dr. Nick Cowan) to facilitate the immunoprecipitation of 
the complex, however, they proved to be of insufficient specificity for this 
purpose, under the conditions employed. Dr. Cowan's group have 
demonstrated that it is possible to assemble a functional prefoldin 
chaperone using bacterially expressed constituent subunits; it would be of 
interest to test this complex as a potential substrate.
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Fbw7 was next investigated as a candidate PKC substrate. Kinase 
assays performed using immuno-precipitated Fbw1/2/4/7p revealed 
negligible PKC-dependent phopshorylation of either the Fbw proteins 
themselves, or of any associated proteins. However, there was a subtle 
increase detected in the phosphorylation of Fbw7p immuno-precipitated 
material in the presence of PKC, with the putative substrate running at 
approximately the same size as Fbw7p itself. Since the concentration of 
the corresponding protein was relatively low, as judged by Comassie 
staining, it is possible that this phosphorylation event is occurring at a 
reasonable stoichiometry.
The amino acid sequences of the three Fbw7 isoforms were submitted to 
a database which predicts the capacity of any given Ser/Thr residue to 
behave as a PKC substrate, based on the established preferences of 
PKC with respect to adjacent residues (Fujii et al., 2004). The sequence 
common to all of the Fbw proteins was predicted to bear two reasonably 
scoring PKC phosphorylation sites. These sites are not optimal, but 
could perhaps account for the low level phosphorylation of an Fbw7p 
sized protein observed in Figure 4.19.
Phosphorylation within a unique region of one of the Fbw7 proteins could 
potentially contribute to isoform specific behaviours. These regions were 
therefore also analysed. While the distinct regions of the p and y 
isoforms do not bear any highly scoring predicted sites, the Fbw7a 
isoform specific N-terminus possesses two: S10 and S18. In a series of 
kinase assays using Fbw7a derived peptides as substrates, we were able 
to demonstrate in vitro that at least one of these sites, S18, is effectively 
phosphorylated by a number of PKC isoforms. If the phosphorylation of 
the Fbw7a derived peptides is compared to the phosphorylation of the 
positive control in these experiments, then PKC-£ shows the lowest 
relative activity towards this substrate. However, this may in fact reflect a 
preference for the control peptide, rather than against the test peptides,
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since the control is based on PKC-^'s own pseudosubstrate sequence, 
and is therefore “naturally” optimised for this isoform.
Fbw7a S10 remains to be further investigated as a candidate phospho- 
acceptor. It would have been more informative in this regard had we 
synthesized the S18A mutation within the context of the Fbw7a 6-22 
peptide, and/or included a S10A mutation. In order to resolve this issue, 
kinase assays could be carried out again using the Fbw7a 6-22 and 
Fbw7a 11-22 peptides and this time incubated to completion; if greater 
32P- incorporation was detected in the longer peptide, we could surmise 
that more than one site was being phosphorylated. Alternatively, in vitro 
phosphorylated Fbw7a 6-22 peptide could be analysed by Edman 
degradation; N-terminal amino acids could be removed sequentially from 
the peptide and scintillation counted, to establish the positioning of the 
phosphate group(s).
A parallel study of PKC-catalysed Fbw7a phosphorylation was carried out 
using a peptide array; phosphorylation of the array was shown to occur in 
an unexpectedly broad manner. There is clearly a degree of specificity, 
for example, there is negligible phosphorylation of peptides 19 and 20, 
despite the presence of three serine residues. However, across the rest 
of the array, phosphorylation does not correspond clearly to the presence 
or absence of a particular residue. Since there is a certain amount of 
PKC-dependent phosphorylation detected on spots 2-6, S18 does not 
appear to be the sole phospho-residue under these conditions; 
phosphorylation of S10 could potentially account for this result. 
Meanwhile, the presence of S18 could account for the elevation of counts 
at spots 9/10 and 14. This observation is perhaps informative with 
respect to the importance of context to PKC activity. Spots 9/10 bear 
both an intact KRRR sequence, and a C-terminal arginine residue; these 
sequence features are perhaps important in directing PKC mediated 
phosphorylation, as PKC is a basophilic kinase.
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A phospho-specific antibody was raised against Fbw7a S18 in order to 
test whether this site can be phosphorylated in cells; the anti-sera was 
characterised by ELISA and a S18A mutant was cloned for use as a 
negative control. Using this phospho-specific antibody, it was revealed 
that Fbw7a S18 is indeed phosphorylated in mammalian cells, as 
treatment with the Ser/Thr phosphatase inhibitor Calyculin A, enabled its 
detection on wild type, but not S18A protein. It will be informative in the 
future, in terms of dissecting the potential function of this site, to try to 
stimulate its phosphorylation with different treatments, rather than merely 
protecting it from dephosphorylation.
A panel of inhibitors were screened for their capacity to attenuate the 
effect of Calyculin A, thereby addressing the identity of the kinase 
responsible in cells. Phosphorylation of Fbw7a S18 was clearly blocked 
by pre-treatment with the broad specificity kinase inhibitor, staurosporine. 
However, neither the cPKC/PKD inhibitor G66976, nor the cPKC/nPKC 
inhibitor BIM1 had a significant effect. As such, we have yet to confirm 
whether PKC represents a kinase responsible for cellular phosphorylation 
of Fbw7a S18. It will be interesting to follow up this experiment by testing 
a broader selection of inhibitors. It remains possible that an aPKC, or 
related PKN, could catalyse phosphorylation of this site. Alternatively, 
within the context of the cell, perhaps another basophilic kinase performs 
this function.
It is noteworthy that Fbw7a is a nuclear protein. Consequently, one 
working hypothesis would be that the S18 kinase can also localise to the 
nucleus. In this respect it may be significant that PKCS/e catalytic 
domains are known to translocate to the nucleus during apoptosis; as 
such, it will be important to analyse S18 phosphorylation in response to 
apoptotic stimuli. An alternative possibility is that Fbw7a is 
phosphorylated in the cytoplasm, perhaps directly after translation, during 
a phase of the cell cycle when the nuclear envelope is not intact, or 
following hypothetical nuclear export; there is currently no evidence of
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Fbw7 nuclear shuttling. All of the PKC/Fbw interaction studies were 
performed using cytoplasmic Fbw7p; it may be informative to test whether 
Fbw7a binding to PKC can be detected by co-immunoprecipitation, to 
assess whether these proteins are exposed to one another. 
Immunofluorecence data would suggest not.
The localisation of Fbw7a is likely to be an important factor in controlling 
the phosphorylation of S18, however, the converse may also be true. We 
began to address the functional consequences of S18 phosphorylation by 
focussing on its potential influence on the Fbw7 specific nuclear 
localisation signal (NLS 11-14); it is well established that phosphorylation 
close to a NLS can alter its ability to direct nuclear localisation (Jans and 
Hubner, 1996). The experiments conducted to date, in which phospho- 
specific mutations have been incorporated into a truncated form of 
Fbw7a, do not support this hypothesis. However, it may be more 
meaningful to examine the effect of S18 phosphorylation on nuclear 
localisation within the context of the full length protein. This experiment 
would need to be performed using an Fbw7a mutant, which lacks the 
second NLS (169-172), which may otherwise compensate for any effects. 
It is reasonable to assume that there may be conditions under which one 
or the other NLS functionally dominates, for example binding partners or 
other post-translational modifications could mask either NLS. As such, 
any regulatory input controlling the other site would have detectable 
effects. It will also be of interest to determine whether S10 can be 
phosphorylated too; additional occupation of this site would flank the NLS 
with phosphate groups and potentially mediate more profound effects.
In summary, VBP1 and Fbw7 were identified as PKC-e binding partners 
and selected for further study as candidates on the PKC degradation 
pathway(s); however, the data presented in this chapter did not support 
such a role for either protein. Nevertheless, at least in the case of Fbw7, 
evidence for a functional interaction with PKC was obtained. PKC was 
shown to phosphorylate Fbw7a S18 in vitro, and this site was shown to
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be occupied in mammalian cells; the PKC dependence of the latter 
remains to be established. While there is currently limited data on the 
phosphorylation of F-box proteins, the potential importance of such post- 
translational modifications has been commented upon in the literature 
(Gao and Karin, 2005). The functional significance of this particular 
Fbw7a phosphorylation event remains to be determined, but it is possible 
that this site may play an important regulatory role, in an isoform specific 
manner, adding another level of complexity to the function of this key 
tumour suppressor.
The theme of post-translational modification is explored further in the 
remainder of this work. The phosphorylation of PKC itself has been 
shown to play an important role in regulating its down-regulation (Hansra 
et al., 1999; Lee et al., 1996; Leontieva and Black, 2004; Srivastava et 
al., 2002). As such, we reasoned that the characterisation of PKC 
phosphorylation sites may provide further insights into this elusive 
process. The following chapter provides an account of the mapping of 
novel PKC-e and PKC-6 autophosphorylation sites undertaken to this 
end.
220
Chapter 5: Identification of Novel PKC-e/S Phosphorylation Sites
CHAPTER 5 
Identification of Novel 
PKC-e/6 Phosphorylation Sites
5.1 Introduction
PKC activity is controlled by a complex network of regulatory inputs. 
Seminal work in the field determined that cPKC/nPKC isoforms are 
subject to acute allosteric control by diacylglycerol (Hug and Sarre, 1993; 
Nishizuka, 1986), and possibly other bioactive lipids (Nishizuka, 1995), 
which facilitate PKC activation in the presence of phosphatidylserine (and 
Ca2+ in the case of the cPKCs). However, subsequent studies have 
revealed that this basic level of regulation is fine-tuned by a number of 
other modulatory inputs, including the phosphorylation of three key 
'priming' sites, permissive for subsequent allosteric activation (Parekh et 
al., 2000).
The three PKC priming phosphorylation sites comprise the activation loop 
(or T-loop) site, the autophosphorylation (or TP') site and the 
hydrophobic (or 'FSY') site. These phospho-residues are conserved 
throughout the PKC superfamily, and throughout evolution, with the 
exception that the FSY site is substituted with glutamate in the aPKCs, 
and aspartate in the PKNs; these acidic residues may mimic 
phosphorylation.
Phosphorylation of the T-loop site is catalysed by polyphosphoinositide- 
dependent kinase 1 (PDK1) (Chou et al., 1998; Le Good et al., 1998). 
This phosphorylation is predicted to correctly align active site residues 
and is critical for catalytic activity (Cazaubon et al., 1994; Orr and 
Newton, 1994). The two other priming sites play more subtle roles in
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maintaining a closed PKC conformer, with optimum thermal stability and 
resistance to proteases and phosphatases (Bornancin and Parker, 1997). 
The 'TP' site has been shown to represent an autophosphorylation site 
(Flint et al., 1990; Standaert et al., 2001), as has the hydrophobic motif in 
cPKCs ((Behn-Krappa and Newton, 1999; Dutil et al., 1994; Dutil et al.,
1998). However, the pathway(s) leading to the phosphorylation of the 
hydrophobic motif in nPKCs remain more elusive. Cenni etal have 
presented evidence for autophosphorylation (Cenni et al., 2002), while 
Parekh and colleagues have shown, under different experimental 
conditions, that an upstream kinase activity is required (Parekh et al.,
1999). Previous data from our laboratory suggests that an aPKC 
complex may be responsible for phosphorylation of the hydrophobic motif 
(Ziegler et al., 1999), with a parallel, mTOR regulated, amino acid 
sensing pathway providing a permissive signal, possibly through control 
of a protein phosphatase (Parekh et al., 1999). Work is ongoing to 
resolve the identity of the nPKC hydrophobic site kinase.
In addition to these priming phosphorylation sites, a number of other PKC 
phospho-residues have been reported including Thr-250 in PKC-a (Ng et 
al., 1999), multiple PKC-p autophosphorylation sites (Flint et al., 1990), 
and numerous phospho-tyrosines within PKC-6 (see (Steinberg, 2004) for 
recent review). The influences of certain of these phosphorylation events 
on PKC activity have been defined, as discussed in the following chapter, 
while others remain to be characterised.
PKC phosphorylation status is well documented to influence its TPA- 
induced degradation. Experiments with PKC-a and PKC-e demonstrated 
that de-phosphorylation of priming phosphorylation sites is a critical step 
in the process of down-regulation by the ubiquitin-proteasome system 
(Hansra et al., 1999; Lee et al., 1996; Lee et al., 1997). However, this is 
clearly cell type and/or context dependent, since data from our laboratory 
showed that phosphorylation of PKC-6 was required for its degradation in 
NIH 3T3 cells (Srivastava et al., 2002). More recent work from Leontieva
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and colleagues provides support for both of these models, revealing two 
independent pathways of PKC-a desensitization operating in response to 
the same stimuli, one involving the ubiquitination and subsequent 
proteasomal degradation of the mature, fully phosphorylated enzyme, the 
second, a proteasome-independent mechanism, requiring caveolar 
trafficking and dephosphorylation (Leontieva and Black, 2004). Since 
phosphorylation plays such a key role in determining PKC down- 
regulation, we hypothesized that analysis of PKC phosphorylation sites 
may provide further insights into this process, and as PKC activity has 
also been implicated in PKC down-regulation (Goode et al., 1995; Kang 
et al., 2000; Lu et al., 1998; Ohno et al., 1990; Srivastava et al., 2002), 
sites of autophosphorylation were of particular interest.
This chapter describes the identification of novel phosphorylation sites 
within PKC-e, and also PKC-S, by phosphopeptide mapping and the 
subsequent analysis of these sites within mammalian cells using 
phospho-specific antibodies.
5.2 Results
5.2.1 In Vitro Phosphorylation & Phosphopeptide Mapping
Phosphopeptide mapping studies were performed in collaboration with 
the Protein Analysis Laboratory (CR-UK); the approach employed is 
summarised in Figure 5.1. PKC is first incubated in an in vitro kinase 
assay with [y32P]-ATP, to yield radiolabelled, phosphorylated protein. 
Following resolution by SDS-PAGE and staining by Coomassie, the PKC 
band is excised and subjected to in-gel tryptic digestion. The tryptic 
peptides are fractionated by reverse phase high performance liquid 
chromatography (HPLC), and fractions are counted to locate 32P-labelled 
phosphopeptides. Radiolabelled fractions are then analysed by both 
mass spectrometry and Edman degradation.
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Mass spectrometry facilitates the identification of the peptides present 
within a hot fraction; peptide masses are matched against an 'in silico' 
tryptic digest of the whole protein. Additionally, spectral features 
characteristic of phosphopeptides are searched for: phosphorylation adds 
80Da to the mass of the de-phosphopeptide, and post source decay of 
the phosphopeptide in the mass spectrometer flight tube, which releases 
phosphoric acid, causes a loss of 98Da, which is detected as a broad 
peak.
Edman degradation then enables the identification of the residue number 
of the phosphorylation site within a phosphopeptide. Amino acids are 
sequentially removed from the N-terminus of the tryptic peptide and 
scintillation counted, elevated counts indicate the presence of an 32P- 
labelled residue.
By combining the data obtained from mass spectrometry and Edman 
degradation, it is therefore possible to identify a given phosphopeptide, 
and locate the phosphorylation site within it.
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PKC In Vitro Kinase Assay with [v32P]-ATP
i
PAGE, Coomassie staining, excision of PKC band
i
In gel tryptic digest
i
Fractionation of peptides by HPLC
i
Identification of [y32P]-labelled peptides by counting
/  \
Mass Spectrometry Edman degradation
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Figure 5.1 PKC Phosphopeptide Mapping. PKC phosphorylation sites 
were identified by phosphopeptide mapping. In this system, PKC is first 
incubated in an in vitro kinase assay with [y32P]-ATP. The kinase assay 
mix is resolved by SDS-PAGE, the gel is stained using Coomassie and 
the PKC band is excised and counted. An in-gel tryptic digest is 
performed to generate a set of peptides, which are then fractionated by 
reverse phase high performance liquid chromatography (HPLC). 
Fractions are counted, and those containing [y32P]-labelled peptides are 
analysed both by mass spectrometry, to identify the phosphorylated 
peptide, and Edman degradation, to locate the phospho-site within the 
peptide.
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5.2.1.1 PKC-e In Vitro Phosphorylation & Phosphopeptide Mapping
5.2.1.1.1 PKC-e In Vitro Phosphorylation
In vitro kinase assays were performed using recombinant human PKC-e, 
commerically purified from insect cells. As shown in Figure 5.2, 
increased phosphorylation was detected with increasing enzyme 
concentration and incubation time. The stoichiometry of phosphorylation 
was calculated from four separate experiments at 0.775±0.106pmol 
PCVpmol PKC-e.
The requirements for PKC-e phosphorylation were also investigated, 
alongside an MBP substrate control. In vitro kinase assays were 
performed in the presence or absence of phosphatidylserine/TPA mixed 
micelles, with or without the cPKC/nPKC inhibitor BIM1. Phosphorylation 
was significantly reduced in the absence of lipids, and was inhibited by 
BIM1 in a dose dependent manner (Figure 5.3); PKC-e phosphorylation 
was inhibited to a lesser extent than MBP phosphorylation (see 
discussion).
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Figure 5.2 Phosphorylation of PKC-e In Vitro. PKC-e phosphorylation 
was assayed by in vitro kinase assay. 25-1 OOng of purified recombinant 
human PKC-e was prepared in kinase assay buffer. Reactions were 
started with [y32P]-ATP (50^M ATP, 5piCi; 40Ci/mmol), incubated for 0- 
2hrs at 30°C with shaking, and stopped with the addition of sample 
buffer. The whole reaction mix was resolved by SDS-PAGE and 
phoshorylation was visualised using the Storm 860 Phosphorlmaging 
System. Data is representative of 3 separate experiments.
uM BIM1 
PS/TPA
Figure 5.3 Lipid Dependence of MBP/PKC-e Phosphorylation & 
Inhibition by BIM1. In vitro kinase assays were performed using 50ng of 
purified recombinant human PKC-s, either alone or with 5jxg of MBP 
substrate. Reactions were prepared in kinase assay buffer +/- 
phosphatidylserine/TPA mixed micelles (PS/TPA), and +/- BIM1. 
Reactions were started with [y32P]-ATP (50^M ATP, 5^Ci; 40Ci/mmol), 
incubated for 30mins at 30°C with shaking, and terminated with the 
addition of sample buffer. Samples were resolved by SDS-PAGE, gels 
were stained with Coomassie and phosphorylation was visualised using 
the Storm 860 Phosphorlmaging System (a). Bands were excised and 
counted (b); phosphorylation is expressed as a percentage of the 
uninhibited control.
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5.2.1.1.2 PKC-e Phosphopeptide mapping
In vitro phosphorylated PKC-e was analysed by phosphopeptide 
mapping. The amino acid sequence of PKC-e is shown in Figure 5.8, and 
an in silico tryptic digest is provided for reference (see Appendix A2.1). 
Tryptic digests, reverse phase HPLC, mass spectrometry and Edman 
analysis were performed by the Protein Analysis Laboratory (CR-UK).
5.2.1.1.2.1 Generation & Fractionation of Phosphorylated PKC-e 
Tryptic Peptides
Purified recombinant human PKC-e was incubated in an in vitro kinase 
reaction with [y32P]-ATP. 32P-labelled, phosphorylated protein was 
resolved by SDS-PAGE, stained using Coomassie and subjected to in-gel 
tryptic digest. Tryptic peptides were fractionated by reverse phase HPLC 
and each fraction was counted. As shown in Figure 5.4, there were four 
major peaks in 32P detection, corresponding to four or more 
phosphopeptides of differing hydrophobicity: Fractions 6/7, Fractions 
18/19, Fractions 27/28 and Fractions 35/36.
Fractions 6/7 correspond to peptides which elute from the HPLC column 
in the breakthrough volume. These peptides are likely to fall below the 
minimum mass routinely scanned by mass spectrometry in the Protein 
Analysis Laboratory (<800Da), and to be contaminated with any non­
volatile species carried over from peptide processing (eg. SDS-PAGE gel 
components, salts); as such, these fractions were not analysed further. 
However, fractions 18/19, 27/28 and 35/36 were all investigated by both 
mass spectrometry and Edman degradation as described below.
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Figure 5.4 Phosphorylated PKC-e Tryptic Peptide Fractionation.
An in vitro kinase assay was performed using 1 pig of purified recombinant 
human PKC-e. The reaction was started with [y3 2 P]-ATP (50^M ATP, 
5piCi; 40Ci/mmol), incubated for 2hrs at 30°C with shaking, and stopped 
with the addition of sample buffer. Following resolution by SDS-PAGE  
and staining by Coomassie, PKC-ewas excised and subjected to in-gel 
tryptic digestion at 37°C for 4hrs. Peptides were extracted and 
fractionated by reverse phase high performance liquid chromatography, 
using an ABI 130A Separation System, with a Vydac 1mm x 150mm C 8  
reverse phase column at 50nl/min. Fractions were counted and those 
containing [y3 2 P]-labelled phospho-peptides were retained for further 
analysis.
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5.2.1.1.2.2 Analysis of Phosphorylated PKC-e Fraction 18
An aliquot of Fraction 18 was analysed by Matrix-Assisted Laser 
Desorption Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry.
As shown in Figure 5.5a, a peptide was detected whose mass 
corresponds to that predicted for the tryptic fragment occurring between 
PKC-e residues 225-236, plus 80Da, the mass of a phosphate moiety.
The equivalent de-phosphopeptide is not observed on this spectrum, 
however, a related peak, representing the decay product of the 
phosphopeptide, is apparent. This data suggests that an in vitro 
phosphorylation site is located between PKC-e residues 225-236, but 
does not distinguish between the two candidate residues: Thr-228 and 
Ser-234.
The remainder of Fraction 18 was analysed by Edman degradation; N- 
terminal residues were derivatized, sequentially released and scintillation 
counted. As shown in Figure 5.5b, the major peak in 32P detection occurs 
at residue 10, which corresponds to Ser-234 within the phosphopeptide 
identified by mass spectrometry. Counts are also somewhat elevated in 
the two fractions adjacent to residue 10. It is likely that the increased 
radioactivity detected at position 11 results from the inefficient removal of 
Pro-229 by Edman degradation, and the subsequent staggering of 32P- 
Ser-234 detection. Ser 234 would occur at position 9 in the event that 
trypsin digests C-terminal to Lys-225 as indicated in grey. There are no 
counts above background at either residue 3 or 4, and there is thus no 
evidence for phosphate incorporation at Thr-228.
Mass spectrometric analysis and Edman degradation of Fraction 18 
therefore provide complementary data sets which together unequivocally 
identify Ser-234 as an in vitro PKC-e phosphorylation site.
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Figure 5.5 Analysis of Phosphorylated PKC-e Fractions 18 by Mass 
Spectrometry and Edman Degradation. PKC-e was in vitro 
phosphorylated in the presence of [y3 2 P]-ATP (50pM ATP, 5^iCi; 
40Ci/mmol), isolated and digested with trypsin. Tryptic peptides were 
fractionated by reverse phase HPLC and counted. P-labelled 
phosphopeptides were detected in Fraction 18 and analysed by mass 
spectrometry and Edman degradation, a) An aliquot (5%) of fraction 18 
was analysed by Matrix-Assisted Laser Desorption Ionization Time-Of- 
Flight (MALDI-TOF) mass spectrometry using an Applied Biosystems 
4700. Peptide masses were searched against an 'in silico' digest (Protein 
Prospector, UCSF) and assigned as indicated. Phosphorylation 
increases peptide mass by 80Da (+ P 0 4) and phosphopeptide post source 
decay decreases this mass by 98Da, detected as a broad peak (-H 3 PO 4 ).
b) The remainder of Fraction 18 (95% ) was subjected to solid-phase 
Edman degradation using an ABI Procise Sequencer. Residue number is 
shown (in blue) and the sequence of the peptide identified by mass 
spectroscopy is indicated (an alternative digest is shown in grey). 
Fractions corresponding to individual residues were scintillation counted.
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5.2.1.1.2.3 Analysis of Phosphorylated PKC-e Fractions 27/28
Samples from Fractions 27 and 28 were analysed by MALDI-TOF mass 
spectrometry. A peptide corresponding in mass to PKC-e residues 365- 
377 was identified in Fraction 27 (Figure 5.6a), and a peptide from 366- 
377 was detected in Fraction 28 (Figure 5.6b), reflecting an alternative 
digestion product; the additional lysine present in the former peptide must 
confer an effect on hydrophobicity which decreases retention time on the 
column. Both spectra reveal the characteristic peaks associated with the 
corresponding phosphopeptides: an 80Da increase in mass due to 
phosphorylation, and a related 98Da loss from this due to 
phosphopeptide post source decay.
This data indicates that an in vitro phosphorylation site is located between 
PKC-e residues 365-377. There is only one Ser/Thr residue within this 
region: Ser-368. Edman degradation is consistent with this observation 
(Figure 5.6c), with 32P-labelled residues detected at positions 3 and 4; 
these would correspond to phospho-Ser-368 when trypsin digests either 
C-terminal to Lys-365 or Arg-364 respectively.
Mass spectrometric analysis and Edman degradation of Fractions 27/28 
thereby identify Ser-368 as an in vitro PKC-e phosphorylation site.
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Figure 5.6 Analysis of Phosphorylated PKC-e Fractions 27/28 by 
Mass Spectrometry and Edman Degradation. PKC-e was in vitro 
phosphorylated in the presence of [y32P]-ATP (50^M ATP, 5\iC\\ 
40Ci/mmol), isolated and digested with trypsin. Tryptic peptides were 
fractionated by reverse phase HPLC and counted. P-labelled 
phosphopeptides were detected in Fractions 27/28 and analysed by mass 
spectrometry and Edman degradation, a) An aliquot (5%) of fraction 27 
was analysed by Matrix-Assisted Laser Desorption Ionization Time-Of- 
Flight (MALDI-TOF) mass spectrometry using an Applied Biosystems 
4700. Peptide masses were searched against an 'in silico' digest (Protein 
Prospector, UCSF) and assigned as indicated. Phosphorylation 
increases peptide mass by 80Da (+PO4) and phosphopeptide post source 
decay decreases this mass by 98Da, detected as a broad peak (-H3PO4).
b) Fraction 28 was analysed by mass spectrometry as described in a).
c) The remainder (95%) of fraction 28 was subjected to solid-phase 
Edman degradation using an ABI Procise Sequencer. Residue number is 
shown (in blue) and the sequence of the peptide identified by mass 
spectroscopy is indicated (an alternative digest is shown in grey). 
Fractions corresponding to individual residues were scintillation counted.
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5.2.1.1.2.4 Analysis of Phosphorylated PKC-e Fraction 36
An aliquot of fraction 36 was analysed by MALDI-TOF mass 
spectrometry. As shown in Figure 5.7a, a peptide of the same mass as 
PKC-e residues 302-319 was detected. There was direct evidence for 
phosphorylation of this peptide, since one peak was apparent at a mass 
80Da greater, corresponding to the addition of P0 4 , and another peak 
was observed at a mass 98Da less than this, representing post source 
decay of phosphoric acid from the phosphopeptide. This data suggests 
that an in vitro phosphorylation site is located between PKC-e residues 
302-319, which could correspond to either Thr-309, Thr-314 or Ser-316.
The remainder of Fraction 36 was analysed by Edman degradation.
There is a single major peak in 32P detection at residue 15, corresponding 
to Ser-316 within the phosphopeptide identified by mass spectrometry. 
Together, the data identify Ser-316 as an in vitro PKC-e phosphorylation 
site.
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Figure 5.7 Analysis of Phosphorylated PKC-e Fraction 36 by Mass 
Spectrometry and Edman Degradation. PKC-e was in vitro
phosphorylated in the presence of [y32P]-ATP (50^M ATP, 5^iCi; 
40Ci/mmol), isolated and digested with trypsin. Tryptic peptides were 
fractionated by reverse phase HPLC and counted. P-labelled 
phosphopeptides were detected in Fraction 36 and analysed by mass 
spectrometry and Edman degradation, a) An aliquot (5%) of fraction 36 
was analysed by Matrix-Assisted Laser Desorption Ionization Time-Of- 
Flight (MALDI-TOF) mass spectrometry using an Applied Biosystems 
4700. Peptide masses were searched against an ’in silico' digest (Protein 
Prospector, UCSF) and assigned as indicated. Phosphorylation 
increases peptide mass by 80Da (+PO4) and phosphopeptide post source 
decay decreases this mass by 98Da, detected as a broad peak (-H3PO4).
b) The remainder (95%) of fraction 36 was subjected to solid-phase 
Edman degradation using an ABI Procise Sequencer. Residue number is 
shown (in blue) and the sequence of the peptide identified by mass 
spectroscopy is indicated. Fractions corresponding to individual residues 
were scintillation counted.
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5.2.1.1.3 Novel PKC-e In Vitro Phosphorylation Sites
Human PKC-e residues Ser-234, Ser-316 and Ser-368 were identified as 
in vitro phosphorylation sites, which are likely to be modified by an 
autocatalytic mechanism (see discussion). The following analyses 
demonstrate how these sites compare to optimal PKC phosphorylation 
consensus sequences, where they are located within the full length 
protein, and how they are conserved, both among PKC-e sequences from 
different species, and among different PKC isoforms.
5.2.1.1.3.1 Novel PKC-e Phosphorylation Sites as Consensus 
Sequences
In the previous chapter, a database predictive for PKC consensus 
sequences was employed to screen for substrates in siiico (Fujii et al., 
2004). The newly identified, putative PKC-e autophosphorylation sites 
were analysed retrospectively using this tool, to test their potential as 
phospho-acceptors in relation to established substrates (Table 5.1). With 
the exception of Ser-368, these sites score relatively poorly, however, this 
is also the case for the 'TP' autophosphorylation site T710. It should be 
noted however, that these scores are based upon PKC-6 preferences, 
and so are indicative, but not be wholly representative, of PKC-e 
behaviour.
Phospho-Site Protein Scan Score Percentile
Ser-234 40 Bottom 95
Ser-316 20 Bottom 95
Ser-368 2 Top 5
Thr-710 76 Bottom 95
Table 5.1 Predicted PKC Phosphorylation Sites in PKC-e. The amino 
acid sequence of human PKC-e was searched against the Mammalian 
Phosphorylation Resource database for prediction of PKC  
phosphorylation sites. The scores obtained for selected phosphorylation 
sites (as PKC-6 phospho-acceptors) are shown, and the percentile in 
which this score falls is indicated. Residues scoring below the fifth 
percentile have been classed as unlikely to represent substrates (Fujii et 
al., 2004).
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5.2.1.1.3.2 Positioning of Novel PKC-e Phosphorylation Sites
Figures 5.8 and 5.9 illustrate the positioning of the PKC-e in vitro 
phosphorylation sites within the full length protein. Ser-234 falls between 
the C1a and C1b diacylglycerol/phorbol ester binding domains, in close 
proximity to the PKC-e actin binding site, while both Ser-316 and Ser-368 
are located within the variable V3 region.
5.2.1.1.3.3 Conservation of Novel PKC-e Phosphorylation Sites
Figure 5.10a reveals that PKC-e Ser-234, Ser-316 and Ser-368 are all 
conserved among mammalian species, and are also found in the PKC-e 
sequence from the pufferfish, although the residues N-terminal to 'S316' 
are variable in the latter. However, corresponding residues were not 
identified in the e-type PKC isoforms from Drosophila (PKC98E), 
Caenorhabditis (pkc-1, TTX-4), Aplysia (Apl II), nor in the yeast PKCs.
An alignment was performed between human PKC-e and human PKC-ri, 
the most closely related member of the PKC superfamily. None of the 
three PKC-e phosphorylation sites are conserved in PKC-ri, and the 
surrounding sequences are relatively divergent. It is notable though, that 
within the loosely conserved region between the C1a and C1b domains, 
there is a glutamate residue in PKC-q equivalent to PKC-e Ser-234 
(Figure 5.10b); acidic glutamate/aspartate residues can behave as 
'mimics' for phosphorylated residues in certain contexts.
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361 NNIRKALSFDNRGEEHRAASSPDGQLMSPGENGEVRQGQAKRLGLDEFNFIKVLGKGSFG 
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Figure 5.8 Annotated PKC-e Amino Acid Sequence. The amino acid sequence of human PKC-e (NP_005391) is presented with 
the following features highlighted: C2-like domain, pink; pseudosubstrate sequence, red; C1 domains, turquoise; actin binding 
motif, maroon; V3, underlined; ATP binding site, green; kinase domain, blue; priming phosphorylation sites, grey (T-loop, T566; 
TP',T710; 'FSY', S729); newly identified phosphorylation sites, yellow (S234, S316, S368).
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Figure 5.9 PKC-e Domain Structure & Positioning of Phosphorylation Sites S234, S316 & S368. The domain structure of 
PKC-e is represented diagrammatically, with the positioning of the newly identified phosphorylation sites highlighted (red text), and 
the surrounding sequences shown. Conserved (C1, C2-like, C3, C4) and variable regions (V1, V2, V3, V4,V5) are indicated.
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Figure 5.10 PKC-e S234, S316 & S368 Conservation. Alignments were performed using ClustalX software between a) PKC-e 
amino acid sequences from different species, and b) human amino acids sequences for PKC-e and the related nPKC-r], to 
investigate the conservation of human PKC-e residues S234, S316 and S368, three newly identified phosphorylation sites. C1a/b 
domains are highlighted (green lines) and an actin binding motif {Prekeris, 1998 #674} is indicated (blue bracket).
244
Chapter 5: Identification of Novel PKC-e/6 Phosphorylation Sites
5.2.1.2 PKC-6 In Vitro Phosphorylation & Phosphopeptide Mapping
PKC-6 phosphopeptide mapping was performed using the same 
approach that successfully identified novel PKC-e phosphorylation sites. 
The full length PKC-6 sequence is shown in Figure 5.17, and an in silico 
tryptic digest is provided for reference (Appendix A2.2). Tryptic digests, 
reverse HPLC, mass spectrometry and Edman degradation were 
performed by the Protein Analysis Laboratory (CR-UK).
5.2.1.2.1 PKC-6 In Vitro Phosphorylation
In vitro kinase assays were performed using recombinant human PKC-6 
purified from baculovirus. As was the case for PKC-e, increased PKC-6 
phosphorylation was detected over time (Figure 5.11). There was also a 
slight PKC-6 band shift apparent from the Coomassie stained gel 
following in vitro kinase assay incubation, consistent with a 
phosphorylation event. The stoichiometry of phosphorylation was 
calculated from 2 separate experiments at 0.74±0.07pmol PCVpmol 
PKC-6.
Phosphorimage 
Coomassie stain
0 5 15 30 mins
Figure 5.11 Phosphorylation of PKC-6 In Vitro. PKC-6 phosphorylation 
was assayed by in vitro kinase assay. 300ng of purified recombinant 
human PKC-6 was prepared in kinase assay buffer. Reactions were 
started with [y32P]-ATP (50^M ATP, 5piCi; 40Ci/mmol), incubated for 0- 
30mins at 30°C with shaking, and stopped with the addition of sample 
buffer. Samples were resolved by SDS-PAGE, stained with Coomassie 
and scanned; phoshorylation was visualised using the Storm 860 
Phosphorlmaging System. Data is representative of three separate 
experiments.
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5.2.1.2.2 PKC-6 Phosphopeptide mapping
In vitro phosphorylated PKC-6 was analysed by phosphopeptide mapping 
as described above (section 5.2.1). Two separate experiments were 
performed (1 and 2), generating different but overlapping data sets.
5.2.1.2.2.1 Generation and Fractionation of Phosphorylated PKC-6 
Tryptic Peptides
Purified recombinant human PKC-6 was incubated in an in vitro kinase 
reaction with [y32P]-ATP, either for 30mins (1), or 2hrs (2).
Phosphorylated PKC-6 was subjected to in-gel tryptic digestion, 
generating a set of peptides which were then fractionated by reverse 
phase HPLC; parallel digestion with an alternative protease, AspN, was 
also performed, but this provided no interpretable information on 
phosphorylation sites (data not shown). Each tryptic fraction was counted 
in order to locate 32P-labelled phosphopeptides. As shown in Figure 
5.12, experiments 1 and 2 yielded products with the same patterns of 
fractionation, but with slightly different profiles; the most striking 
differences being the relative depletion of peak e and enrichment of peak 
f in experiment 2. This variation is in part explained by the use of 
different HPLC columns (see figure legend). It may also reflect 
differences in PKC-6 phosphorylation status due to altered kinase assay 
incubation time, and/or efficiency of tryptic digestion.
In both cases, there were 5 major peaks in 32P detection (a-e), 
representing 5 or more different phosphopeptide populations. Mass 
spectrometry and Edman degradation were performed on the fractions 
corresponding to each peak, from each experiment. The data obtained is 
summarised in Tables 5.2 and 5.3. In the following sections, mass 
spectra and Edman degradation results are shown for those sites that 
could be positively identified; data regarding additional candidate sites is 
also described.
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Figure 5.12 Phosphorylated PKC-6 Tryptic Peptide Fractionations.
In vitro kinase assays were performed using 500ng of purified 
recombinant human PKC-6. The reaction was started with [y32P]-ATP  
(50[xM ATP, 5nCi; 40Ci/mmol), incubated for 30mins (1) or 2hrs (2) at 
30°C with shaking, and stopped with sample buffer. Following resolution 
by SDS-PAGE and staining by Coomassie, PKC-6was excised and 
subjected to in-gel tryptic digestion at 37°C for 4hrs. Peptides were 
extracted and fractionated by reverse phase HPLC, using an ABI 130A  
Separation System, with a Vydac 1mm x 150mm C8 reverse phase 
column at 50fil/min. Fractions were counted and those containing [y32P]- 
labelled phosphopeptides were retained for further analysis.
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Experiment 1
Fraction Mass Spectrometry Edman
(Residue
No)
Site(s)
Identified
a 139-144 1 x Met-ox 
FPTMNR
2 & 3 T-141?
b - 2 X
c - 3 X
d NT NT X
e 298-318 + 2 x P 04 
ASRRSDSASSEPVGIYQGFEK
2 & 5 S-299
S-302
Table 5.2 PKC-6 Phosphopeptide Mapping (1). Phosphopeptide 
mapping studies were performed on in vitro phosphorylated PKC-6 as 
described in Figure 5.11 (1). Fractions were analysed by MALDI mass 
spectrometry and Edman degradation. The mass spectrometric data is 
summarised; the residue numbers of tryptic peptides identified are given, 
and post-translational modifications are indicated (P 04) phosphate; Met- 
ox, oxidized methionine). Where a phosphopeptide was identified, only 
the phosphorylated peptide is noted; associated species are shown in 
subsequent figures. The results of analysis by Edman degradation are 
presented; the residue numbers corresponding to the most significantly 
kp-labelled fractions are recorded. Phosphorylation sites which have 
been positively identified are indicated (black text). Candidate sites which 
are consistent with the data, but not unequivocally assigned, are also 
shown (grey text). -, no phosphopeptide/candidate phosphopeptide 
identified; NT, not tested; x no site assigned.
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Experiment 2
Fraction Mass Spectrometry Edman
(Residue
No)
Site(s)
Identified
a - 1 & 2 X
b - 2 X
c - NT X
d 133-144 1 x Met-ox 
SEDEAKFPTMNR 
133-145 1 x Met-ox 
SEDEAKFPTMNRR
9,10 & 11 T-141?
e 301-318 + 1 x P 04 
RSDSASSEPVGIYQGFEK
302-318 + 1 x P 04 
SDSASSEPVGIYQGFEK
298-318 + 2 x P 0 4 
ASRRSDSASSEPVGIYQGFEK
1-5, 10 & 
11
S-304
Table 5.3 PKC-6 Phosphopeptide Mapping (2). Phosphopeptide 
mapping studies were performed on in vitro phosphorylated PKC-6 as 
described in Figure 5.11 (2). Fractions were analysed by MALDI mass 
spectrometry and Edman degradation. The mass spectrometric data is 
summarised; the residue numbers of tryptic peptides identified are given, 
and post-translational modifications indicated (P 04) phosphate; Met-ox, 
oxidized methionine). Where a phosphopeptide was identified, only the 
phosphorylated peptide is noted; associated species are shown in 
subsequent figures. The results of analysis by Edman degradation are 
presented; the residue numbers corresponding to the most significantly 
kp-labelled fractions are recorded. Phosphorylation sites which have 
been positively identified are indicated (black text). Candidate sites which 
are consistent with the data, but not unequivocally assigned, are also 
shown (grey text). no phosphopeptide/candidate phosphopeptide 
identified; NT, not tested; x no site assigned.
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5.2.1.2.2.2 Analysis of Phosphorylated PKC-6 Fraction 1e
An aliquot of fraction 34, representing peak 1e, was analysed by MALDI- 
TOF mass spectrometry. As shown in Figure 5.13a, a peptide 
corresponding in mass to PKC-6 residues 298-318, plus two phosphate 
moieties, was detected. An additional peak was observed at a mass 
98Da less than this, representing post source decay of one phosphoric 
acid molecule from the doubly phosphorylated peptide.
Selected peptide ions from this first analysis were then subjected to high- 
energy collision to obtain fragment ions. The MALDI-TOF/TOF data 
recovered is shown in Figure 5.13b. Again, the doubly phosphorylated 
peptide, and its single site post source decay product, are evident from 
the spectrum. However, in this case, the product of double phospho-site 
decay is observed, as well as a singly phosphorylated peptide which has 
decayed in flight. Together, this data clearly demonstrates that two PKC- 
6 sites can be in vitro phosphorylated simultaneously, between residues 
298-318; these could correspond to Ser-299, Ser-302, Ser-304, Ser-306 
or Ser-307.
Fraction 33 from peak 1e was analysed by Edman degradation (Figure 
5.13c). Two major increases in 32P incorporation were detected at 
residues 2 and 5; these corresponding to Ser-299 and Ser-302 within the 
doubly phosphorylated peptide identified by mass spectrometry.
Although the increase in counts above background is relatively small, the 
scintillation counting procedure was optimised to reduce standard error, 
such that this difference is meaningful; fractions were stored in the dark 
overnight and then subjected to a relatively long count, of 10mins.
Together, the data identify Ser-299 and Ser-302 as in vitro PKC-6 
phosphorylation sites, which can be occupied simultaneously.
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Figure 5.13 Analysis of Phosphorylated PKC-5 Fraction 1e by Mass 
Spectrometry and Edman Degradation. PKC-6 was in vitro
phosphorylated in the presence of [y32P]-ATP (50^iM ATP, 5^iCi; 
40Ci/mmol) for 30mins, isolated and digested with trypsin. Tryptic 
peptides were fractionated by reverse phase HPLC and counted. 32P- 
labelled phosphopeptides were detected in Fractions 33/34 and analysed 
by mass spectrometry and Edman degradation, a) An aliquot of fraction 
34 was analysed by Matrix-Assisted Laser Desorption Ionization Time-Of- 
Flight (MALDI-TOF) mass spectrometry using an Applied Biosystems 
4700. Peptide masses were searched against an 'in silico' digest (Protein 
Prospector, UCSF) and assigned as indicated. Phosphorylation 
increases peptide mass by 80Da (+PO4) for each phosphorylated residue 
and phosphopeptide post source decay decreases this mass by 98Da, 
detected as a broad peak (-H3PO4). b) Phosphopeptide ions selected 
from analysis (a) were subjected to high energy collision to obtain 
fragment ions. MALDI-TOF/TOF data is presented with the 
phosphopeptide species indicated, c) Fraction 33 was subjected to 
solid-phase Edman degradation using an ABI Procise Sequencer.
Residue number is shown (in blue) and the sequence of the peptide 
identified by mass spectroscopy is indicated. Fractions corresponding to 
individual residues were scintillation counted.
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5.2.1.2.2.3 Analysis of Phosphorylated PKC-6 Fraction 2e
Fraction 34 from peak 2e was analysed by MALDI-TOF mass 
spectrometry. As shown in Figure 5.14a, a peptide corresponding in 
mass to PKC-6 residues 298-318, plus two phosphate moieties, was 
detected, as had been observed in experiment 1 (see above). A related 
peak was observed 98Da less than this, representing post source decay 
of one phosphoric acid molecule from the doubly phosphorylated peptide.
Fraction 35 from peak 2e was also analysed by MALDI-TOF mass 
spectrometry (Figure 5.14b). From this spectrum, evidence was obtained 
for the occurrence of a singly phosphorylated peptide corresponding in 
mass to PKC-6 residues 301-318, and for an alternative digestion 
product, from residues 302-318. In each case, the corresponding de- 
phosphopeptide, phosphopeptide and phosphopeptide decay product 
were all apparent.
Together, these data suggested that at least two PKC-6 sites could be in 
vitro phosphorylated, either independently, or simultaneously, between 
residues 298-318; these could correspond to Ser-299 and Ser-302, as 
identified in the previous section, and/or Ser-304, Ser-306 or Ser-307.
Fractions corresponding to peak 2e were further investigated by Edman 
degradation (Figure 5.14c). 32P incorporation above background was 
evident in multiple fractions, namely 1-5 and 10/11. This is consistent 
with the identification of multiple phosphopeptide species by mass 
spectrometry, and with the presence of multiple candidate phospho- 
acceptor residues within them. Ser-299, already identified as an in vitro 
PKC-6 phosphorylation site, could contribute to the elevated radioactivity 
detected at residue 2, where the peptide represents 298-318. 
Phosphorylation of Ser-302, which has also been shown to be occupied 
in vitro, could account for 32P incorporation at residue 1 where the peptide 
is 302-318 (although tryptic cleavage adjacent to a phosphorylated amino 
acid is unusual), position 2 in peptide 301-318, and position 5 in peptide
254
Chapter 5: Identification of Novel PKC-e/6 Phosphorylation Sites
298-318. However, the most significant level of phosphorylation detected 
here is at residues 3 and 4, and these can only correspond to S304, in 
peptides 302-318 and 301-318 respectively. It is not clear whether the 
elevated counts at positions 10/11 derive from phosphorylation of peptide 
298-318 at an additional serine, or from a separate phospho-peptide, not 
identified by mass spectrometric analysis of these fractions.
Together, these data reinforce the finding that Ser-299 and Ser-302 
represent in vitro PKC-6 phosphorylation sites, and identify an additional 
site within the same region, Ser-304.
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Figure 5.14 Analysis of Phosphorylated PKC-6 Fraction 2e by Mass 
Spectrometry and Edman Degradation. PKC-6 was in vitro 
phosphorylated in the presence of [y32P]-ATP (50pM ATP, 5\iC\, 
40Ci/mmol) for 2hrs, isolated and digested with trypsin. Tryptic peptides 
were fractionated by reverse phase HPLC and counted. 32P-labelled 
phosphopeptides were detected in Fraction 34/35 and analysed by mass 
spectrometry and Edman degradation. Aliquots of a) Fraction 34 and b) 
Fraction 35 were analysed by Matrix-Assisted Laser Desorption Ionization 
Time-Of-Flight (MALDI-TOF) mass spectrometry using an Applied 
Biosystems 4700. Peptide masses were searched against an 'in silico' 
digest (Protein Prospector, UCSF) and assigned as indicated. 
Phosphorylation increases peptide mass by 80Da (+P04) and 
phosphopeptide post source decay decreases this mass by 98Da, 
detected as a broad peak (-H3PO4). c) Fraction 35 was subjected to 
solid-phase Edman degradation using an ABI Procise Sequencer.
Residue number is shown (in blue) and the sequences of the peptides 
identified by mass spectroscopy are indicated. Fractions corresponding 
to individual residues were scintillation counted.
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5.2.1.2.2.4 Analysis of Phosphorylated PKC-6 Fractions 1a & 2d
Fractions representing peaks 1a and 2d were analysed by MALDI-TOF 
mass spectrometry (Figures 5.15a and 5.16a). A peptide corresponding 
in mass to PKC-6 residues 139-144 (with an oxidized methionine) was 
identified in Fraction 8 from 1a, and peptides corresponding to the same 
region, with missed cleavages, 133-144/5, were identified in Fraction 27 
from 2d. That this region of PKC-6 co-fractionates with 32P-labelled 
phosphopeptides in two separate forms suggests that it may bear an in 
vitro phosphorylation site. Thr-141 is the only Ser/Thr residue which 
appears in all of the candidate peptides; Ser-133 is also present in the 
longer peptide. However, no direct mass spectrometric evidence was 
obtained for phosphorylation of either site, neither a phosphopeptide, nor 
an associated decay product, were observed related to any of the de- 
phosphopeptides detected. The data is thus consistent with, but not 
proof for, phosphorylation at Thr-141.
These fractions were also investigated by Edman degradation (Figures 
5.15b and 5.16b). The major peaks in 32P detection from peak 1a occur 
at residue 2 (Fractions 4/5) and residue 3 (Fractions 7/8); the latter would 
correspond to Thr-141 in the peptide 139-144, the former cannot relate to 
this peptide. The most significant elevation in counts detected following 
Edman degradation of Fractions 26/7 from 2d was found between 
residues 9-11. Thr-141 would be positioned at residue 9 in the peptides 
133-144/5; the increased radioactivity detected at positions 10-11 could 
result from the inefficient removal of Pro-138 by Edman degradation, 
which would cause staggering of 32P-Thr-141 detection. However, an 
analysis of the PKC-6 sequence reveals an alternative scenario which 
could theoretically account for this result: if Ser-57 and Thr-58 were both 
phosphorylated (either independently or together), these could account 
for phosphate incorporation detected at residues 9 and 10 in the peptides 
49-67, and residues 10-11 in the peptide 48-67.
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These data cannot unambiguously identify the phosphorylation site(s) 
present within Fractions 1a and 2d. The data is most compelling for Thr- 
141 as a candidate, but the lack of direct mass spectrometric evidence for 
phosphorylation, and the fact that the Edman degradation data is also 
consistent with at least one alternative interpretation, prevent a definitive 
conclusion being drawn.
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Figure 5.15 Analysis of Phosphorylated PKC-6 Fraction 1a by Mass 
Spectrometry and Edman Degradation. PKC-6 was in vitro 
phosphorylated in the presence of [y32P]-ATP (50pM ATP, 5futCi; 
40Ci/mmol) for 30mins, isolated and digested with trypsin. Tryptic 
peptides were fractionated by HPLC and counted. 3 P-labelled 
phosphopeptides were detected in Fractions 5-8 and analysed by mass 
spectrometry and Edman degradation, a) An aliquot of Fraction 8 was 
analysed by MALDI-TOF mass spectrometry using an Applied 
Biosystems 4700. Peptide masses were searched against an ’in silico' 
digest (Protein Prospector, UCSF) and assigned as indicated. Met-ox, 
oxidised methionine. Fractions b) 4/5 and c) 7/8 were subjected to solid- 
phase Edman degradation using an ABI Procise Sequencer. Residue 
number is shown (in blue) and the sequence of a candidate peptide 
identified by mass spectroscopy is indicated. Fractions corresponding to 
individual residues were scintillation counted.
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Figure 5.16 Analysis of Phosphorylated PKC-6 Fraction 2d by Mass 
Spectrometry and Edman Degradation. PKC-6 was in vitro 
phosphorylated in the presence of [y32P]-ATP (50^M ATP, 5pCi; 
40Ci/mmol) for 2hrs, isolated and digested with trypsin. Tryptic peptides 
were fractionated by reverse phase HPLC and counted. 32P-labelled 
phosphopeptides were detected in Fraction 26/27 and analysed by mass 
spectrometry and Edman degradation, a) An aliquot of Fraction 27 was 
analysed by Matrix-Assisted Laser Desorption Ionization Time-Of-Flight 
(MALDI-TOF) mass spectrometry using an Applied Biosystems 4700. 
Peptide masses were searched against an 'in silico' digest (Protein 
Prospector, UCSF) and assigned as indicated. Met-ox, oxidised 
methionine, b) Fractions 26/27 were subjected to solid-phase Edman 
degradation using an ABI Procise Sequencer. Residue number is shown 
(in blue) and the sequence of a candidate peptide identified by mass 
spectroscopy is indicated. Fractions corresponding to individual residues 
were scintillation counted.
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5.2.1.2.3 Novel PKC-6 In Vitro Phosphorylation Sites
Human PKC-6 residues Ser-299, Ser-302 and Ser-304 were identified as 
in vitro phosphorylation sites, which are likely to be modified by an 
autocatalytic mechanism (see discussion). The following 
characterisations reveal how these sites compare to optimal PKC 
phosphorylation consensus sequences, show how they are positioned 
within the full length protein, and indicate how they are conserved, both 
among PKC-6 sequences from different species, and among different 
PKC isoforms.
5.2.1.2.3.1 Novel PKC-6 Phosphorylation Sites as Consensus 
Sequences
The newly identified PKC-6 candidate autophosphorylation sites were 
analysed using a predictive database to test their potential as phospho- 
acceptors in relation to established PKC-6 substrates (Table 5.4). An 
additional candidate residue, Thr-141, was also screened. With the 
exception of Ser-299, these sites score relatively poorly, however, this is 
also the case for the 'TP' autophosphorylation site Ser-645.
Phospho-Site Protein Scan Score Percentile
Thr-141 24 Bottom 95
Ser-299 4 Top 5
Ser-302 17 Bottom 95
Ser-304 18 Bottom 95
Ser-645 17 Bottom 95
Table 5.4 Predicted PKC Phosphorylation Sites in PKC-6. The amino 
acid sequence of human PKC-6 was searched against the Mammalian 
Phosphorylation Resource database for prediction of PKC 
phosphorylation sites. The scores obtained for selected phosphorylation 
sites (as PKC-6 phospho-acceptors) are shown, and the percentile in 
which this score falls is indicated. Residues scoring below the fifth 
percentile have been classed as unlikely to represent substrates (Fujii et 
al., 2004).
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5.2.1.2.3.2 Positioning of Novel PKC-6 Phosphorylation Sites
Figures 5.17 and 5.18 illustrate the positioning of the in vitro phospho- 
residues within the full length protein. As was the case for two of the 
three PKC-e sites mapped, Ser-299, Ser-302 and Ser-304 are all located 
within the variable V3 region. Thr-141, which was assigned as an 
additional candidate phospho-site, lies just N-terminal to the PKC-6 
pseudosubstrate sequence.
5.2.1.2.3.3 Conservation of Novel PKC-5 Phosphorylation Sites
Alignments were performed to investigate the conservation of 
phosphorylation sites Ser-299, Ser-302 and Ser-304 among PKC-6 
sequences from different species. (Figure 5.19a). Human PKC-6 Ser-299 
is shown to be well conserved; a Ser/Thr occurs at the equivalent site 
among all of the species represented, flanked by basic residues at the -2 
and +2/3 positions. The two other sites, however, are more divergent. 
Serine residues corresponding to human PKC-6 Ser-302 are apparent 
from chicken and dog sequences, while equivalents to Ser-304 are 
evident from chicken and rabbit sequences. This analysis is complicated 
somewhat by the fact that the number of amino acids within this part of 
the V3 region is variable. If the alignments are configured differently, 
additional similarities can be drawn. For instance, in the sequences from 
rat, mouse and dog, Thr residues lie C-terminal to acidic Asp-303 
equivalents; these could be thus be considered to relate to Ser-304. 
Similarly, all three sites are conserved in xenopus PKC-6 if the alignment 
is shifted by one reside (xenopus has a single amino acid insertion after 
the residue corresponding to Ser-299). No homology was detected 
between any of the sites and the 6-type PKCs from Drosophila 
(PKCdelta), Aplysia (Apl II) or Caenorhabditis (tpa-1).
The sequence surrounding human PKC-6 amino acids 299-304 was also 
aligned against other members of the PKC superfamily. No homology 
was detected, even in comparison with PKC-0, the most closely related 
isoform. Intriguingly, a certain degree of similarity was detected between
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this sequence and part of pck2, one of the two PKC isoforms in S.pombe, 
although some of the basic context, likely to be important in directing PKC 
activity, is lost from the latter. Nevertheless, it is noteworthy that this 
loosely conserved, putative consensus sequence for phosphorylation is 
located between the two C1 domains of pck2, in an equivalent position to 
the newly identified PKC-e Ser-234 phosphorylation site.
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1 MAPFLRIAFNSYELGSLQAEDEANQPFCAVKMKEALSTERGKTLVQKKPTMYPEWKSTFD
61 AHIYEGRVIQIVLMRAAEEPVSEVTVGVSVLAERCKKNNGKAEFWLDLQPQAKVLMSVQY
121 BBDVDCKQSMRSEDEAKFPTMNl^^MMB^YIKNHEFIATFFGQPTFCSVCKDFVW 
181 GLNKQGYKCRQCNAAIHKKCIDKIIGRCTGTAANSRDTIFQKERFNIDMPHRFKVHNYMS
241 PTFCDHCGSLLWGLVKQGLKCEDCGMNVHHKCREKVANLCGINQKLLAEALNQVTQRASR
301 RSDSASSEPVGIYQGFEKKTGVAGEDMQDNSGTYGKIWEGSSKCNINNFIFHKVLGKGSF
361 GKVLLGELKGRGEYFAIKALK
421 
481 
541 
601 rKSPRDYSNFDQEFLNEKARLSYSDKNLIDSMDQSAF
661 AGFSFVNPKFEHLLED
Figure 5.17 Annotated PKC-6 Amino Acid Sequence. The amino acid sequence of human PKC-6 (NP_006245) is presented 
with the following features highlighted: C2-like domain, pink; pseudosubstrate sequence, red; C1 domains, turquoise; V3, 
underlined; ATP binding site, green; kinase domain, blue; priming phosphorylation sites, grey (T-loop, 'TP', 'FSY'); newly identified 
phosphorylation sites, yellow (S299, S302, S304); candidate phosphorylation site (T141), yellow box.
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Figure 5.18 PKC-6 Phosphorylation Sites S299, S302 & S304. Three 
novel phosphorylation sites within human PKC-6 were identified by 
phosphopeptide mapping: S299, S302 & S304. The domain structure of 
PKC-6 is represented diagrammatically, with the positioning of the newly 
identified phosphorylation sites highlighted (red text), and the surrounding 
sequence shown. Conserved (C1, C2-like, C3, C4) and variable regions 
(V1, V2, V3, V4.V5) are indicated.
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Figure 5.19 PKC-6 S299, S302 & S304 Conservation. Alignments were 
performed using ClustalX software between a) PKC-6 amino acid 
sequences from different species, and b) amino acids sequences for 
human PKC-6 293-308 and S.pombe pck2, to investigate the 
conservation of human PKC-6 residues S299, S302 and S304, three 
newly identified phosphorylation sites. C1a/b domains are highlighted 
(green lines).
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5.2.2 PKC-e/6 Phosphorylation in Mammalian Cells
Having identified novel PKC-e/6 in vitro phosphorylation sites, we next 
sought to determine whether they could be phosphorylated in mammalian 
cells. In order to investigate this possibility, phosphospecific antibodies 
were raised (see Chapter 2). Briefly, 9-mer phosphopeptides were 
synthesized, based on the sequences surrounding the phospho-sites, for 
immunisation; equivalent dephosphopeptides were also produced to use 
as blocking reagents. Three rabbits were immunized with each 
phosphopeptide and test bleeds were harvested. Sera were analysed by 
Western blotting for site and phospho-specificity as described below.
5.2.2.1 PKC-e Phosphorylation in Mammalian Cells
5.2.2.1.1 PKC-e Phospho-specific Antibody Generation & 
Characterisation
Since S234/S316/S368 phosphorylation sites were mapped from purified 
PKC-e incubated in an in vitro kinase assay, we reasoned that this would 
provide an appropriate sample with which to test the antibodies raised. 
Aliquots of PKC-e were taken prior to the assay, from a control assay 
performed in the absence of ATP, and from a test assay carried out under 
normal conditions. Western blotting was performed using the second test 
bleeds from immunized rabbits; the blots shown in Figure 5.20a represent 
the most effective of the three sera raised for each phospho-site; all 
subsequent western blotting analyses were performed using these sera. 
Samples were also probed for phosphorylation of the three PKC priming 
sites: the T-loop site, 'TP' site and FSY site (Figure 5.20b).
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a) De-Phospho Phospho
b)
c)
DEVGSQRFS DEVGpSQRFS Ser-234
KITNSGQRR KITNpSGQRR Ser-316
RKALSFDNR RKALpSFDNR Ser-368
D e .pspec
0 -  +
pspec
0 -  +
IB: PKC-e 
IB: p-T-loop 
IB: p-‘TP’
IB: p-FSY
P mix"0"-5^  Blocking 
IB: p-234
0 -  +
IB: p-316 
IB: p-368
0 -  +
Figure 5.20 In Vitro Phosphorylation of PKC-e
S234, S316, S368 & Priming Site Phospho-Specific Antibodies, a)
Phospho/de-phosphopeptides were synthesized based on the sequences 
surrounding PKC-e phospho-sites Ser-234, Ser-316 and Ser-368; 
antibodies were raised against the phosphopeptides. b) In vitro kinase 
assays were performed using 25ng of purified human PKC-e. An aliquot 
of the starting material was harvested prior to incubation (0) and the 
assays were started in the presence (+) or absence (-) of 100^M ATP. 
Reactions were incubated at 30°C with shaking for 30mins, and stopped 
with sample buffer. Samples were resolved by SDS-PAGE and analysed 
by western blotting using the phospho-specific antibodies raised: p-S234 
(PPA-501), p-S316 (PPA-503) and p-S368 (PPA-505). These sera were 
used to probe samples in the presence or absence of V g /m l of different 
blocking peptides: De-Pspec, de-phosphopeptide specific for 
corresponding site (eg. S234 de-phosphopeptide for p-S234 serum); 
pspec phosphopeptide specific for corresponding site (eg. 234 
phosphopeptide for p-S234 serum); P mixnon'spec, two non-specific 
phosphopeptides (eg. 316 and 368 phosphopeptides for p-S234 serum), 
c) The same samples were probed for total protein (sc-214) and PKC-e 
priming phosphorylation sites: T-loop (PPA-204), T P ’ (PPA-218) and FSY 
(anti p-S729). These results are representative of 2 separate 
experiments.
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The anti p-S234/p-S316/p-S368 sera were tested in the presence or 
absence of blocking peptides to assess specificity. The appropriate de- 
phosphopeptide was included to reduce non-specific signals, the 
corresponding phosphopeptide was tested for its ability to compete 
against specific phospho-signals, and a mixture of alternative 
phosphopeptides was employed to establish whether antibodies were 
site, or merely phospho-serine, specific. In each case an increased 
signal was detected following incubation with in vitro kinase assay mix, 
but only in the presence of ATP; there was a certain level of basal 
phosphorylation apparent at the S368 site. Signals could be competed 
with the corresponding phosphopeptide, indicating phospho-specificity, 
but not with a mixture of other phospho-serine containing 
phosphopeptides, confirming sequence specificity also. Phosphorylation 
at the PKC priming sites, the T-loop, the 'TP' and the 'FSY', did not 
increase over the course of the in vitro kinase assay.
In a similar experiment, PKC-e aliquots were removed over a timecourse 
of in vitro phosphorylation, and probed for p-S234/p-S316/p-S368 in the 
presence of the de-phosphopeptide. Phosphorylation at each site 
increased over time; again a basal occupation of Ser-368 was detected 
(Figure 5.21).
Phospho/sequence-specific antibodies were thus obtained for all three 
novel PKC-e in vitro phosphorylation sites: S234, S316 and S368.
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Figure 5.21 Timecourse of In Vitro Phosphorylation of PKC-e
Purified recombinant human PKC-e was prepared in kinase assay buffer 
in the presence of 10nM okadaic acid. Reactions were started with 
100|aM ATP, incubated for 0-480mins at 30°C with shaking, and 
terminated with sample buffer. 25ng samples were resolved by SDS- 
PAGE and analysed by western blotting using phospho-specific 
antibodies p-S234 (PPA-501), p-S316 (PPA-503) and p-S368 (PPA-505) 
in the presence of 1 ng/ml de-phosphopeptide. A parallel blot was run to 
probe for total protein (sc-214).
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5.2.2.1.2 Phosphorylation of PKC-e S234/S316/S368 in Mammalian 
Cells
We first wished to establish whether PKC-e residues S234, S316 and 
S368 could be phosphorylated in mammalian cells. To this end, GFP- 
tagged PKC-e was over-expressed in COS7 cells to provide an abundant 
source of phosphorylatable protein which could be partially purified by 
immunoprecipitation to facilitate detection with crude test bleeds. Since 
in vitro phosphorylation of these sites was predicted to occur by an 
autocatalytic mechanism, cells were stimulated with a phorbol ester PKC 
activator, TPA, in the presence or absence of a cPKC/nPKC inhibitor, 
BIM1. The phosphospecific antibodies raised against the novel PKC- 
s sites were used for western analysis. Although the phospho-specificity 
of the sera had been established in vitro, alanine mutants of the 
corresponding sites were employed as a negative controls (S234A for p- 
S234 analysis, S316A for p-S316 analysis, and S368A for p-S368 
analysis).
As shown in Figure 5.22, an increased signal is detectable at all three 
sites in response to TPA, suggesting that S234, S316 and S368 are 
phosphorylated in mammalian cells in upon PKC activation. Such signals 
are not observed from the corresponding alanine mutant samples, further 
confirming the phosphospecificity of the antibodies. TPA induced 
phosphorylation of the wild type protein is largely inhibited by BIM1, which 
again, is consistent with a requirement for PKC activity.
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Figure 5.22 Phosphorylation of PKC-e S234/S316/S368 in 
Mammalian Cells. COS7 cells were seeded on 6-well plates and 
transfected with GFP-PKC-e (WT) or one of a panel of GFP-PKC-e 
mutants (S234A/S316A/S368A). 24hrs post-transfection, cells were pre­
treated +/- 1jiM BIM1 for 15mins and stimulated +/- 400nM TPA for a 
further 45mins. Lysates were prepared and subjected to 
immunoprecipitation with anti GFP 4E12/8. Samples were analysed by 
Western blotting using phospho-specific antibodies: p-S234 (PPA-501), 
P-S316 (PPA-503) and p-S368 (PPA-505) in the presence of blocking de- 
phosphopeptide, or anti GFP 3E1. Each serum was tested using the 
alanine mutant of the corresponding site as a negative control. These 
results are representative of 2 separate experiments.
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A similar experiment was carried out using Clone 5, a cell line derived 
from PKC-e knock-out MEFS which stably re-express untagged PKC-e to 
high levels (Figure 5.23). Cells were treated in the presence or absence 
of TPA, PKC-e was recovered by denaturing immunoprecipitation and 
samples were probed with the phospho-specific antibodies. 
Phosphorylation was detected at each site in response to TPA, 
confirming that the apparent phosphorylation described above is not 
artefactually dependent on the GFP-tag.
The immunoprecipitation protocol employed to isolate PKC-e from Clone 
5 cells was the most effective of several approaches tested. A number of 
different antibodies were screened and protocols based on the affinity of 
PKC for heparin sulphate and protamine sulphate were explored as 
alternative means of partial purification; the efficiency of PKC-e recovery 
was poor under all conditions tested. Consequently, although sufficient 
material was obtained from Clone 5 cells for analysis with the phospho- 
antibodies, it was not possible to recover enough endogenous PKC-e 
from other cell lines to test phosphorylation under more physiological 
conditions.
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Lysate: PKC-e
IP: PKC-e, IB: p-234
IP: PKC-e, IB: p-316
IP: PKC-e, IB: p-368
TPA
Figure 5.23 Phosphorylation of untagged PKC-e S234/S316/S368.
Clone 5 cells were seeded on 15cm dishes. Confluent cells were 
stimulated +/- 400nM TPA and incubated for 45mins. Lysates were 
prepared and subjected to denaturing immunoprecipitation with anti PKC- 
e. Samples were analysed by Western blotting using phospho-specific 
antibodies: p-S234 (PPA-501), p-S316 (PPA-503) and p-S368 (PPA-505) 
in the presence of blocking de-phosphopeptide, or anti PKC-e.
Serum Serum  starved Serum  Serum starved
L I ’ Lysate: GFP
IP: GFP, IB: p-234
IP: GFP, IB: p-316
IP: GFP, IB: p-368
TP A  
+  Bryostatin
Figure 5.24 Activation of PKC-e Phosphorylation by TPA/Bryostatin 
+/- serum. COS7 cells were seeded on 6-well plates and transfected with 
GFP-PKC-e. 32hrs post-transfection, cells were either serum starved 
(0.1% E4) or incubated with fresh 10% E4 (serum) for a further 16hrs. 
Cells were treated +/- 400nM TPA or 1 |tM Bryostatin for 45mins. Lysates 
were prepared and subjected to immunoprecipitation with anti GFP 
4E12/8. Samples were analysed by Western blotting using phospho- 
specific antibodies: p-S234 (PPA-501), p-S316 (PPA-503) and p-S368 
(PPA-505) in the presence of blocking de-phosphopeptide, or anti GFP 
3E1. These results are representative of 2 separate experiments.
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5.2.2.1.3 Activation of PKC-e Phosphorylation in Mammalian Cells
The process of PKC-e phosphorylation was further analysed through the 
use of an additional stimulus, Bryostatin 1 (Figure 5.24); these 
experiments were performed in the presence or absence of serum. In the 
presence of serum, both TPA and Bryostatin 1 were shown to induce 
PKC-e phosphorylation. However, in samples from serum starved cells, 
while TPA induced phosphorylation was observed, Bryostatin 1 had no 
effect.
5.2.2.1.4 Inhibition of PKC-e Phosphorylation in Mammalian Cells
An additional inhibitor was also tested to gain further insight into the 
mechanism of PKC-e phosphorylation. The inhibitor G66976, which 
shows relative specificity for cPKCs, was tested alongside BIM1 (Figure 
5.25). TPA induced phosphorylation at all three sites proved insensitive 
to Go6976, suggesting that catalysis is mediated by an nPKC.
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Figure 5.25 Inhibition of PKC-e S234/S316/S368 Phosphorylation.
COS7 cells were seeded on 6-well plates and transfected with GFP-PKC- 
e (WT). 24hrs post-transfection, cells were pre-treated +/- V M  GP6976 
or 1 jxM BIM1 for 15mins and stimulated +/- 400nM TPA for a further 
45mins. Lysates were prepared and subjected to immunoprecipitation 
with anti-GFP 4E12/8. Samples were analysed by Western blotting using 
phospho-specific antibodies: p-S234 (PPA-501), p-S316 (PPA-503) and 
P-S368 (PPA-505) in the presence of blocking de-phosphopeptide, or anti 
GFP3E1.
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5.2.2.1.5 PKC-e Phosphorylation in Mammalian Cells: Cis/Trans?
The data presented is consistent with the hypothesis that PKC-e 
phosphorylation is catalysed by an nPKC, possibly by 
autophosphorylation. However, this could be mediated through either an 
intra- or inter-molecular event; preliminary work was undertaken to 
address this issue.
GFP-tagged PKC-e regulatory domain was expressed in COS7 cells, this 
construct bears all three potential phospho-sites, but lacks a kinase 
domain with which to perform intra-molecular phosphorylation. Cells 
were treated with TPA, +/- Calyculin A to inhibit dephosphorylation, or 
Bryostatin 1, in the presence or absence of serum (Figure 5.26a). In the 
presence of serum, increased phosphorylation was detected at all sites in 
response to PKC activation, as had been observed in the full length 
protein; the signal was augmented by co-treatment with Calyculin A 
suggesting that these sites are subject to dephosphorylation. In the 
absence of serum, TPA + Calyculin A was the only treatment which 
facilitated increased phosphorylation of the PKC-e regulatory domain. 
Additionally, a fast migrating PKC-e species was detected by all antisera 
in the absence, but not presence, of serum. This species could 
correspond to either a dephosphorylated or a proteolytically cleaved form 
of the protein, since it is detectable even in the presence of Calyculin A, 
the latter seems more likely.
Phosphorylation of a kinase dead mutant was also investigated; S368 did 
not show an increase in phosphorylation in response to TPA (Figure 
5.26b).
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Figure 5.26 PKC-e Regulatory Domain & PKC-e Kinase Dead 
S234/S316/S368 Phosphorylation, a) COS7 cells were seeded on 6- 
well plates and transfected with GFP-PKC-e regulatory domain. 32hrs 
post-transfection, cells were either serum starved (0.1% E4) or incubated 
with fresh 10% E4 (serum) for a further 16hrs. Cells were treated +/- 
400nM TPA +/- 100nM Calyculin A or V M  Bryostatin 1 for a further 
45mins. Lysates were prepared and analysed by Western blotting using 
phospho-specific antibodies: p-S234 (PPA-501), p-S316 (PPA-503) and 
P-S368 (PPA-505) in the presence of blocking de-phosphopeptide, or anti 
GFP 3E1. b) COS7 cells were seeded on 6-well plates and transfected 
with GFP-PKC-e kinase dead. 24hrs post-transfection, cells were pre­
treated +/- 1 BIM1 for 15mins and then stimulated +/- 400nM TPA for 
a further 45mins. Lysates were prepared and analysed by Western 
blotting using the phospho-specific antibody against p-S368 (PPA-505) in 
the presence of blocking de-phosphopeptide.
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5.2.2.2 PKC-6 Phosphorylation in Mammalian Cells
5.2.2.2.1 PKC-6 Phospho-specific Antibody Generation &
Characterisation
Human PKC-6 residues S299, S302 and S304 were identified as in vitro 
phosphorylation sites. Immunizations are now underway to raise 
phospho-specific antibodies against S299, however, to date, test bleeds 
have been obtained only from rabbits immunized with p-S304. These 
sera were tested directly using PKC-6 overexpressed in mammalian cells 
+/- TPA, with a S304A control.
Figure 5.27 shows the data obtained using the most effective of the three 
anti p-S304 sera. This figure reveals that S304 is phosphorylated in 
mammalian cells in response to TPA. Antibody specificity is evidenced 
by the fact that no signal is detected in cells transfected with a S304A 
mutant.
Further studies of PKC-6 phosphorylation await the production of 
additional phospho-specific antibodies.
IP: GFP 
IB: p-304
Lysate: GFP
S304AWT
Figure 5.27 Phosphorylation of PKC-6 S304 in Mammalian Cells.
COS7 cells were seeded on 6-well plates and transfected with GFP-PKC- 
6 (WT) or GFP-PKC-6 S304A. 24hrs post-transfection, cells were 
stimulated +/- 400nM TPA for 45mins. Lysates were prepared and 
subjected to anti GFP 4E12/8 immunoprecipitation. Samples were 
analysed by Western blotting using a phospho-specific antibody, p-S304 
(PPA-514), in the presence of blocking de-phosphopeptide, and anti GFP 
3E1. These results are representative of 2 separate experiments.
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5.3 Discussion
PKC activity and PKC phosphorylation have been shown to play critical 
roles in regulating TPA-induced PKC degradation, but the details of this 
process remain to be fully characterised. We hypothesized that the 
identification of PKC phosphorylation sites induced upon PKC activation 
may therefore provide insights into the pathway(s) of down-regulation. 
Phosphopeptide mapping studies were undertaken, first focused on 
phosphorylated PKC-e, and later, using the same approach, on 
phosphorylated PKC-6.
Our preliminary experiments confirmed that phosphorylation of PKC-e/6 
increased with increasing enzyme concentration and incubation time in 
vitro. In each case, phosphorylation was calculated to occur with 
significant stoichiometry. However, once phosphorylation sites were 
mapped it became apparent that this figure actually reflects the sum of 
phosphate incorporation across multiple sites. No further quantitative 
studies have been undertaken to date to investigate the stoichiometry to 
which individual sites are occupied.
Since in vitro kinase assays were performed using purified PKC-e/6, we 
hypothesized that the detected phosphorylation was mediated by an 
autocatalytic mechanism, either in cis or trans. However, although the 
purity of the preparations used was 2:95% (Calbiochem), we could not 
exclude the possibility that a small amount of a contaminating kinase 
could be responsible for the PKC phosphorylation detected. Therefore, 
further in vitro kinase assays were performed to investigate the 
requirements of PKC-e phosphorylation.
In vitro PKC-e phosphorylation was demonstrated to occur more 
efficiently in the presence than absence of phosphatidylserine/TPA mixed 
micelles. Since PKC is a lipid-dependent kinase, this is consistent with, 
but not proof of, a requirement for PKC activity. In vitro phosphorylation
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was also shown to be inhibited by BIM1, a cPKC/nPKC inhibitor, in a 
dose dependent fashion. This is more compelling as evidence for 
autophosphorylation, however, the possibility remains that an alternative 
cPKC/nPKC co-purified with PKC-e. Although BIM1 is shown to be 
inhibitory towards PKC-e phosphorylation, a relatively high concentration 
(10-50nM) is required to detect a significant 50% inhibition (IC50 with 
respect to PKC-e: 0.132nM, Calbiochem). This could suggest that a 
contaminating kinase, partially and non-specifically inhibited by BIM1, is 
functioning here. However, this observation may in fact be indicative of 
an autophosphorylation event. cPKC autophosphorylation has a Km for 
ATP (1.5nM) approximately 10-fold lower than that for phosphorylation of 
exogenous substrates (Huang et al., 1986); as such, a higher 
concentration of an ATP competitive inhibitor such as BIM1 would be 
expected to be required to achieve a comparable level of inhibition.
Phosphopeptide mapping was undertaken to identify the sites of nPKC 
phosphorylation in vitro, first focussing on PKC-e. Counting of 
fractionated, 32P-labelled phospho-PKC-e tryptic peptides revealed the 
existence of at least four phosphopeptide populations of differing 
hydrophobicity. Analysis of three of these fractions facilitated the 
identification of three novel PKC-e phosphorylation sites: S234, S316 and 
S368. In each case, the data obtained allowed the phosphorylation site 
to be assigned unequivocally. Mass spectrometry not only identified the 
relevant de-phosphopeptide, but provided direct evidence of 
phosphorylation, detecting both the corresponding phosphopeptide and 
its post source decay product. Edman degradation provided 
complementary data, with 32P detected specifically in a fraction 
corresponding to a Ser residue within the identified peptide. The only 
species which was not detected during the analysis of PKC-e was the de- 
phosphopeptide containing Ser-234. Stoichiometric analysis would 
suggest that this phosphorylation event did not proceed to completion; we 
therefore assume that the de-phosphopeptide eluted in a shifted fraction 
with respect to the phosphopeptide, due to a difference in hydrophobicity.
284
Chapter 5: Identification of Novel PKC-e/6 Phosphorylation Sites
The fourth of the 32P-labelled fractions detected from the phospho-PKC-e 
tryptic digest comprised the breakthrough volume from the reverse phase 
HPLC column, and was considered unsuitable for further analysis. The 
counts detected in this fraction could have derived either from free 
phosphate, released by hydrolysis during peptide processing, or from 
small, hydrophilic phosphopeptides that passed directly through the 
column. It is possible that there are further PKC-e residues, in addition to 
those successfully mapped, which are phosphorylated in vitro. 
Alternatively, the phosphopeptides present in these early fractions may 
represent distinct digestion products of sequences surrounding already 
identified sites. The phosphopeptides from which p-S316 (302-319) and 
P-S368 (365-377) were identified both contain missed sites for cleavage 
by trypsin (K312 and R372 respectively); if digested to completion these 
would yield smaller, more hydrophilic peptides, with lower column 
retention times. Analysis of the breakthrough volume by Edman 
degradation would have been informative in this respect, as the 
positioning of S316/S368 within alternative tryptic peptides would be 
predictable.
Phosphopeptide mapping of in vitro phosphorylated PKC-6 was 
undertaken using the same approach. The data obtained after the first 
experiment was not complete; it was possible to match comprehensive 
mass spectrometric data with Edman degradation results from only one 
fraction. The experiment was therefore repeated, using slightly different 
conditions, and phospho-PKC-6 was analysed by digestion with both 
trypsin and AspN, an alternative protease that would generate a different 
set of peptides, to provide complementary data. We obtained no mass 
spectrometric evidence of phosphorylation from any of the AspN derived 
samples, even when the protocol was repeated with a fresh sample; it 
appears that these peptides are not amenable to mass spectrometry. 
Certain peptides do not 'fly' effectively in a mass spectrometer flight tube 
as a result of inherent sequence properties which can influence the
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efficiency of ionization and/or ion suppression phenomena; it is perhaps 
unusual though that none of the phosphopeptides yielded mass 
spectrometric data. The second experiment using trypsin yielded a 
different, but overlapping data set, to the first. This variation is likely to be 
accounted for by differences in kinase assay incubation time and 
efficiency of tryptic digestion. Both experiments revealed the existence of 
at least five phosphopeptide populations which were studied further.
PKC-6 residues Ser-299 and Ser-302 were identified as in vitro 
phosphorylations sites which could be occupied simultaneously; evidence 
relating to these sites was obtained from both experiments with trypsin. 
Ser-304 was also detected as a phospho-site, however, this observation 
was made only in the second experiment. It is possible that this reflects 
the increased kinase assay incubation time employed in experiment two; 
we could speculate that Ser-304 represents a minor site which can 
become phosphorylated over time, perhaps by virtue of its proximity to a 
preferred site such as Ser-299/302. We have not investigated whether 
these phosphorylation events proceed in a specific order; this could be 
tested over a timecourse once phospho-specific antibodies have been 
produced against all three sites, and/or by using alanine mutants. Neither 
have we explored further whether a population of PKC-6 can occur which 
is triply phosphorylated in this region, or whether certain combinations of 
phosphorylation events are mutually exclusive. These questions could be 
readily addressed in the future using de-phosphorylated, phosphorylated 
and doubly phosphorylated peptides based on this region as PKC- 6 in 
vitro kinase assay substrates.
An additional PKC-6 residue, Thr-141, was identified as a candidate 
phosphorylation site, but the related data was somewhat ambiguous.
Two different dephosphopeptides containing this residue were shown to 
co-fractionate with phosphopeptides, and Edman degradation data 
placed the 32P-labelled residue in the position which would correspond to 
Thr-141 in both cases. However, no mass spectrometric evidence of
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phosphorylation was obtained regarding either peptide. It is possible that 
these phosphorylated peptides do not fly effectively in the mass 
spectrometer flight tube. Alternatively, this co-fractionation may be 
merely coincidental. In order to test this hypothesis further, it would be 
worthwhile to repeat the phosphopeptide mapping process using wild 
type PKC-6 in comparison with a T141A mutant.
Certain of the other PKC-6 derived phosphopeptides, which could be 
detected by counting post-fractionation, were completely unaccounted for 
due to an absence of any corresponding mass spectrometric data. Those 
unidentified species present within the early HPLC fractions, representing 
small/hydrophilic peptides, may well bear established phospho-sites 
within alternatively digested peptides. For instance where counts were 
detected at residue 2 of the breakthrough volume by Edman degradation, 
S-299 would represent a strong candidate, since complete digestion 
would place this residue within a very short peptide (ASR(R)). However, 
it is also feasible that additional phosphorylation sites remain undetected. 
To address this issue, we plan to re-examine phospho-PKC-6 derived 
peptides using an alternative mass spectrometer, the 4000 Q TRAP 
LC/MS/MS System (Applied Biosystems). This system provides an 
alternative means of phosphopeptide mapping in a single LC/MS/MS run. 
Briefly, initial precursor ion and neutral loss scans are employed to 
identify which peptide ions are releasing a phosphate ion, these are then 
automatically selected for high sensitivity ion trap MS/MS scanning, to 
determine the sequence of, and phosphorylation site on, the 
phosphopeptide.
Since the issue of nPKC autophosphorylation is somewhat contentious, 
we were interested to determine whether we could observe in this system 
the phosphorylation of either the 'TP' site, which is well documented to be 
autophosphorylated (Parekh et al., 2000), or the hydrophobic motif, which 
is reported to be autophosphorylated in mammalian cells under some 
conditions (Cenni et al., 2002). We obtained no evidence for in vitro
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phosphorylation of either residue; however, we cannot exclude either 
event as a possibility. Firstly, we may have overlooked phosphorylation 
of these sites in our studies. In the case of PKC-e, it seems unlikely that 
either site falls within a tryptic fragment hydrophilic enough to elute in the 
breakthrough volume (TP: EEPVLpTLVDEAIV; FSY: GFpSYFGEDLMP), 
and all other phosphopeptides were accounted for. However, in the case 
of PKC-6, there were clearly phosphopeptides which remained 
unidentified. One phosophopeptide was detected in the breakthrough 
volume with a 32P-labelled residue at position 2; this could conceivably 
correspond to the PKC-6 'TP' site, which is predicted to fall within a short 
peptide (LpSYSDK). Alternatively, these sites may already have been 
occupied in the purified, recombinant PKC preparations used in these 
assays, such that no further phosphorylation would be possible. This 
latter notion is supported by Western blotting performed with phospho- 
specific PKC-e anti-sera, which detected 'TP' and 'FSY' site 
phosphorylation in the starting material, and showed no increase at either 
site over the course of the in vitro kinase assay. Alternative studies are 
now underway in our laboratory to investigate phosphorylation of the 
PKC-e hydrophobic motif (S729); an RNAi library will be employed to 
systematically knock-down all kinases, and the effects on phosphorylation 
of S729 will be monitored. As such, the remainder of this work was 
focussed upon the characterisation of the novel nPKC phosphorylation 
sites which were identified.
The characteristics of the novel in vitro PKC-e/6 phosphorylation sites 
were examined. Since PKC is a basophilic kinase, it followed that all of 
the sites detected display a degree of basic context. This was reflected 
experimentally by the fact that a number of the phospho-residues 
occurred within alternatively digested peptides; there were multiple 
Lys/Arg residues flanking some of these sites at which trypsin could cut. 
However, none of the assigned phosphorylated motifs comprised a highly 
optimal consensus sequence. In the previous chapter, a database 
predictive for PKC phosphorylation sites was exploited to screen for
288
Chapter 5: Identification of Novel PKC-e/6 Phosphorylation Sites
potential substrates in silico (Fujii et al., 2004). If the PKC-e /6 sequences 
themselves are searched using this tool, the in vitro phosphorylation sites 
score poorly in general. However, this is also the case for the established 
'TP' autophosphorylation sites, PKC is in fact biased against 
phosphorylating residues immediately N-terminal to proline (Zhu et al., 
2005). These observations reflect the fact that phosphorylation is 
determined both by the sequence specificity of the kinase, and by the 
accessibility of the substrate. As such, a favoured consensus will not be 
phosphorylated if inaccessible, and conversely, a less optimal sequence 
may be modified if appropriately positioned. The process of 
autophosphorylation (intramolecular) clearly presents a unique scenario 
in this respect, in which the candidate site is inherently juxtaposed with 
the kinase; this in part explains the propensity for PKC to phosphorylate 
sub-optimal motifs within its own sequence.
With the exception of PKC-e residue Ser-234, all of the PKC-e/6 in vitro 
phosphorylation sites distinguished occur within the variable V3 domain, 
between the regulatory and catalytic domains. The V3 region is one of 
the most divergent regions of the PKC sequence, and consistent with 
this, none of the sites located in this domain were conserved in other 
PKC family members. Post-translational modification of these unique 
residues may thus be postulated to contribute to PKC isoform specificity.
PKC-e residue Ser-234, in contrast, is located between the C1a and C1b 
diacylglycerol/phorbol ester binding sites. Although not conserved among 
other PKC isoforms, it is notable that PKC-r], the most closely related 
family member to PKC-e, bears a glutamate residue in the equivalent 
position, which may be predicted to behave as a phospho-mimic. 
Interestingly, a motif within S.pombe pck2, which shows homology to the 
region surrounding the PKC-6 V3 domain phosphorylation sites, also falls 
between the C1 domains. We could speculate that the PKC-6 
phosphorylation consensus sequence, and PKC-e S-234 phospho- 
residue location, have been conserved to a certain extent over evolution.
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However, this proposition is confounded by the fact that equivalent sites 
are not apparent in sequences from Caenorhabditis or Drosophila as 
discussed below.
The conservation of an amino acid sequence through evolution is 
indicative that it may play an important functional role. As such, PKC 
sequences from other organisms were examined for homology with the in 
vitro phosphorylation sites identified in human PKC-e/6. All three PKC-e 
sites were retained among mammalian species but were not detected in 
lower organisms. The analysis of PKC-6 sites was somewhat 
complicated by the variability of amino acid number as well as sequence, 
within this region. However, Ser-299 appeared to be conserved among a 
number of species, from xenopus to mammals, and residues 
corresponding to Ser-302 and Ser-304 were evident in a number of other 
organisms. In contrast, no homology was detected between this region of 
PKC-6 and sequences from Drosophila, Aplysia or Caenorhabditis. Since 
these sites are conserved among higher organisms, we could speculate 
that they may be functionally relevant, but less critical than the three 
established priming sites, which are largely conserved across all 
organisms and isoforms.
Having identified novel PKC-e/6 phosphorylation sites in vitro, we next 
sought to characterise their modification in cells. To this end, we raised 
phospho-specific antibodies against the following sites in PKC-e: p-S234, 
P-S316 and p-S368, and PKC-6 p-S304; we are awaiting the production 
of phospho-sera recognising PKC-6 p-S299. The anti PKC-e antibodies 
were first used to probe in vitro phosphorylated material; consistent with 
the fact that these sites had been mapped from such samples, 
occupation of all three sites could be detected, increasing over the 
timecourse of the kinase assay. The phospho- and sequence 
specificities of these antibodies were validated by using different blocking 
peptides; the signals detected could be effectively competed using the 
appropriate blocking phosphopeptides. Subsequently, the antibodies
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were also tested using alanine mutants of the corresponding sites in cells 
as negative controls, a degree of non-specific binding was encountered 
under these conditions, with a low level signal detected in alanine mutant 
samples, however, differences between wild type and mutant phospho- 
recognition were apparent post-stimulation.
The PKC-e antibodies were utilized to investigate the process of PKC-e 
phosphorylation in mammalian cells; equivalent studies remain to be 
performed for PKC-6. Phosphorylation of overexpressed GFP-PKC-e at 
sites S234, S316 and S368 was observed in cells in response to the 
phorbol ester PKC activator, TPA. Phosphorylation could also be 
detected from untagged PKC-e expressed to high levels in a MEF cell 
line, Clone 5, proving that this process is not artefactually dependent on 
the N-terminal GFP. To date it has not been possible to establish a 
protocol for PKC-e enrichment sufficiently effective to facilitate the 
analysis of the endogenous protein; further methods remain to be tested. 
Additionally, the phospho-sera will be affinity purified; a more 
concentrated and specific population of antibodies may be amenable to 
probing a whole cell lysate. Once conditions have been established with 
which to visualise phosphorylation of the endogenous protein, it will be of 
interest to assay these sites in response to more physiological stimuli (eg. 
growth factors for fibroblasts, LPS for macrophages).
TPA induced PKC-e phosphorylation was shown to occur in a manner 
that was inhibited by BIM1, a cPKC/nPKC inhbitior, but not by G66976, 
an inhibitor more selective cPKC (IC50 for PKC-a = 2.3nM; PKC-e, no 
inhibition (Martiny-Baron et al., 1993)), indicating a requirement for nPKC 
activity. Combined with the in vitro data discussed earlier, this strongly 
suggests that phosphorylation is mediated by autocatalysis. However, 
this data does not definitively exclude the possibility that another nPKC is 
responsible, and does not address whether the putative 
autophosphorylation of PKC-e occurs in cis or trans.
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Preliminary experiments were undertaken in order to explore whether 
PKC-e undergoes intra- or inter-autophosphorylation. Firstly, 
phosphorylation of the GFP-PKC-e regulatory domain was analysed; this 
construct bears all three potential phospho-sites, but lacks a kinase 
domain with which to perform intra-molecular catalysis. Increased signal 
was detected at each site in response to PKC activation, suggesting that 
phosphorylation can be performed in trans (by an endogenous PKC). It 
would be of interest to determine whether overexpression of the 
regulatory domain can competitively inhibit phosphorylation of a co­
expressed wild type protein; this would also be indicative of trans­
autophosphorylation. Autophosphorylation was next explored in the 
context of the full length protein using a kinase dead PKC-e construct; a 
low level signal was detected, which could constitute either basal 
phosphorylation, or some non-specific recognition by the antibody, but 
elevated phosphorylation was not detected at S234, S316 or S368 in 
response to TPA. This data can be interpreted in a number of ways. It 
would be consistent either with a dominance of intra-molecular 
phosphorylation, or with a trans-autophosphorylation event, where PKC-e 
dimerisation may be required. However, it is also plausible that the 
conformation of the kinase dead PKC-e may be disrupted, such that these 
sites are less accessible to the relevant kinase, or more accessible to the 
antagonistic phosphatase. An unlikely, but nevertheless possible, 
alternative is that the site is already fully occupied under basal conditions; 
this could be checked by treating parallel samples +/- phosphatase prior 
to western analysis.
In order to try to address this issue in a more tractable system, we have 
obtained a PKC-e mutant (M486A) that has been modified to facilitate its 
inhibition by a specific compound (1-Na), which has no effect on the wild 
type protein (provided by Dr. Bob Messing). The PKC-e M486A mutant 
bears a FLAG-tag, such that there is a convenient difference in size 
between it and GFP-wild type PKC-e. We designed an experiment in
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which FLAG-PKC-e M486A would be co-expressed with GFP-PKC-e, and 
cells would be stimulated with TPA in the presence or absence of BIM1 or 
1-Na. We reasoned that should cis-autophosphorylation predominate, 
phosphorylation of PKC-e M486A at S234, S316 and S368 would be 
inhibited using 1-Na, despite the presence of the wild type protein. 
However, if autophosphorylation occurs in trans, PKC-e M486A 
phosphorylation should be inhibited by BIM1 but not by 1-Na. 
Unfortunately, preliminary work has indicated that TPA-induced 
phosphorylation of this mutant is not readily detectable. It seems that the 
mutation incorporated may influence properties of the enzyme other than 
its inhibition profile; this awaits further investigation. In the meantime, the 
issue of intra-/inter- molecular autophosphorylation remains in question. 
An alternative possibility would be to characterise the 
autophosphorylation process kinetically. The initial rate of an intra­
molecular autophosphorylation is first order with respect to enzyme 
concentration, while that of an inter-molecular autophosphorylation is 
second order (Wang and Wu, 2002). As such, initial rates of PKC-e 
autophosphorylation could be measured at different enzyme 
concentrations, and should initial rate be shown to increase with 
concentration, we could conclude an inter-molecular process occurs. 
However, the use of this approach may be complicated by the nature of 
the PKC in vitro kinase assay system. The requirement for lipid micelles 
to activate the enzyme would need to be considered, establishing 
conditions under which the number of micelles exceeds the number of 
PKC molecules at all concentrations; this could be accomplished by using 
a physically defined, homogenous micelle system, such as that described 
by Hannun and colleagues (Hannun et al., 1985). To aid interpretation, it 
would also be worthwhile to explore the possibility of trans­
phosphorylation by investigating whether PKC undergoes dimerisation; 
this could be achieved by measuring Fluorescence Resonance Energy 
Transfer (FRET) between GFP-PKC-e and RFP-PKC-e by Fluorescence 
Lifetime Imaging Microscopy (Peter et al., 2005).
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The phosphorylation of both full length PKC-e and its regulatory domain 
were examined in response to an alternative stimulus, Bryostatin 1. 
Although Bryostatin 1 is a potent PKC activator, it induces only a subset 
of the effects observed in response to TPA and often inhibits those which 
it does not promote (Szallasi et al., 1994). The mode of action of 
Bryostatin 1 is of particular interest, since it has demonstrated potential 
therapeutic value and is the subject of numerous clinical trials (Mutter and 
Wills, 2000). In comparison with TPA, Bryostatin 1 has been shown to 
render PKC more susceptible to dephosphorylation (Lee et al., 1996), to 
facilitate a differential pattern of localisation (Leontieva and Black, 2004; 
Wang et al., 1999), and significantly, to cause the down-regulation of 
some isoforms but the protection of others (Szallasi et al., 1994); these 
effects are clearly inter-related but the mechanism of action remains to be 
fully characterised. In this context, it is noteworthy that there was a 
dichotomy between the induction of full length PKC-e phosphorylation in 
response to TPA and Bryostatin 1; while both activators induced 
phosphorylation in the presence of serum, only TPA mediated this effect 
in serum starved cells. It will be of interest to determine the basis of this 
difference. Given the propensity of Bryostatin 1 to encourage 
dephosphorylation, it would be worthwhile to perform the same 
experiments in the presence of Calyculin A, and also to monitor the 
occupation of the priming sites; if these sites are dephosphorylated, PKC 
will lack the catalytic competence to mediate autophosphorylation. The 
fact that this difference manifests only under serum starved conditions is 
also intriguing, suggesting that protection from dephosphorylation can be 
conferred.
The phosphorylation of the PKC-e regulatory domain was also affected by 
the presence of serum. Under standard conditions, PKC activation was 
shown to induce phosphorylation, and this was augmented by Calyculin 
A, implying that S234, S316 and S368 are subject to dephosphorylation.
In the absence of serum, however, only Calyculin A detectably increased 
phosphorylation; again this may suggest that serum imparts some
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protection from dephosphorylation. That this effect is more pronounced 
with respect to the regulatory domain than the full length protein may 
reflect its more open and accessible conformation.
Since the novel PKC-e and PKC-6 sites identified in vitro have proven to 
be phosphorylated in mammalian cells, it is of interest next to explore 
their functional relevance. The addition of a phosphate group can affect 
many properties of a protein, from its activity to protein-protein 
interactions, and significantly here, its down-regulation. Some specific 
predictions could be made regarding the potential influences of certain of 
the novel PKC-e/6 sites by virtue of their positioning. For example PKC-e 
residue S234 lies within the C1 domain, its phosphorylation could 
therefore be postulated to influence lipid binding and/or association with 
actin. The candidate PKC-6 phospho-site T141 falls close to the 
pseudosubstrate sequence, we could speculate that incorporation of a 
bulky negative charge so close to this autoinhibitory motif could affect 
PKC-6 conformation and activity. These hypotheses remain to be tested.
Using S234, S316 and S368 mutant constructs, the influence of these 
phosphorylation events on PKC down-regulation, as well as on other 
properties, was tested. The following chapter describes the functional 
analysis of these novel PKC-e phosphorylation sites.
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CHAPTER 6 
Characterisation of PKC-e 
Phospho-Site Mutants
6.1 Introduction
Reversible protein phosphorylation is one of the most common forms of 
post-translational modification, with approximately one third of all cellular 
proteins estimated to be phosphorylated at any one time (Mann et al., 
2002). The introduction of a phosphate moiety to a specific amino acid 
residue can have profound effects on the modified protein, both in terms 
of conformation and function; phosphorylation is known to regulate many 
aspects of protein behaviour, including activity, down-regulation, 
localisation and binding partner interactions.
It is well established that PKC is regulated at the level of phosphorylation. 
PKC activity is dependent upon the phosphorylation of three conserved 
priming sites (T-loop, 'TP' and 'FSY'), which provide permissive signals 
for subsequent allosteric activation (Parekh et al., 2000). Significantly, 
these priming site phosphorylation events are inter-related; for PKC-a, 
'FSY' phosphorylation is the rate-limiting step for modification at the other 
sites, and subsequently, in combination with TP' site phosphorylation, 
influences phosphatase sensitivity (Bornancin and Parker, 1996; 
Bornancin and Parker, 1997). An intimate association also exists 
between PKC phosphorylation and down-regulation; however, this 
relationship is cell type/context dependent (Lee et al., 1996; Srivastava et 
al., 2002). It has been demonstrated that at least two pathways of PKC 
degradation operate, with different requirements for phosphorylation; one 
involves the ubiquitination and proteasomal degradation of the mature, 
fully phosphorylated enzyme, the second, a proteasome-independent 
mechanism, requires caveolar trafficking and dephosphorylation
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(Leontieva and Black, 2004). The localisation of PKC too can be 
regulated by phosphorylation, for instance, autophosphorylation of PKC-a  
priming sites affects its carbachol induced membrane occupancy in 
neuroblastoma cells, by determining sensitivity to DAG (Stensman et al., 
2004). In addition, phosphorylation is also known to effect PKC protein- 
protein interactions, for example, phosphorylation of PKC-6 atTyr-332 
creates a docking site for the SH2 domain of She, mediating an 
interaction relevant to mast cell degranulation (Leitges et al., 2002).
In the previous chapter, three residues were identified within human PKC- 
e, S234, S316 and S368, which become phosphorylated, probably via an 
autocatalytic mechanism, upon PKC activation. This chapter describes 
the investigation of the functional consequences of phosphorylation at 
these sites. This work was carried out using the phospho-specific 
antibodies detailed in the previous chapter, and a set of phosphorylation 
site mutants. Single S234, S316 and S368 alanine mutants were cloned 
to abolish each site individually, alongside a triple alanine mutant lacking 
all three potential phospho-acceptors, and single aspartate mutants were 
generated to mimic some of the properties of the phosphorylated 
residues with negative charge. These tools were used to explore the 
effects of phosphorylation on PKC-e down-regulation, and on other 
properties including priming site phosphorylation, activity, localisation and 
protein-protein interactions.
6.2 Results
6.2.1 Phosphorylation of Other Sites
The phosphorylation of one residue within a protein can influence the 
subsequent phosphorylation of other sites, and/or its susceptibility to 
dephosphorylation. Therefore, PKC-e phosphorylation sites S234, S316 
and S368 were investigated with respect to their effects on each other, 
and on the phosphorylation of the priming T-loop, 'TP' and 'FSY' sites. A 
panel of single alanine and aspartate mutants were expressed in COS7 
cells, treated in the presence or absence of TPA, enriched by
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immunoprecipitation and tested with an array of phospho-specific 
antibodies. Figure 6.1 shows that in each case, mutation of a particular 
phospho-acceptor residue affects only phosphorylation at that site. 
Consistent with previous results, S234, S316 and S368 are 
phosphorylated upon TPA treatment, while phosphorylation of the priming 
sites is detectable basally, and is not responsive to TPA.
A PKC-e construct lacking all three newly identified phosphorylation sites, 
S234A/S316A/S368A (e3A), was tested in the same way, to determine 
whether their combined occupation can affect priming site 
phosphorylation. All of the priming sites were phosphorylated similarly in 
the wild type and the mutant proteins (Figure 6.2).
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IP: GFP, IB: GFP
IP: GFP, IB: p-S234
IP: GFP, IB: p-S316
IP: GFP, IB: p-S368
IP: GFP, IB: p-T-loop
IP: GFP, IB: p-’TP
IP: GFP, IB: p-’FSY'
TPA
S368S234 S316
Figure 6.1 Priming Site & Autophosphorylation Site Phosphorylation 
of wild type, S234A/D, S316A/D & S368A/D PKC-e. COS7 cells were 
seeded on 6-well plates and transfected with wild type (WT) PKC-e and a 
panel of autophosphorylation site (S234, S316, S368) alanine mutants 
(Ala) and phosphomimetics (Asp). 24hrs post-transfection cells were 
treated +/- 400nM TPA for 1 hr. Lysates were prepared and subjected to 
immunoprecipitation with anti-GFP 4E12/8. Samples were analysed by 
Western blotting using anti-GFP 3E1 and phospho-specific antibodies 
raised against the T-loop (T566), 'TP' (T710), 'FSY' (S729), S234, S316 
and S368 sites (+ V g /m l corresponding dephosphopeptide). Data is 
representative of two separate experiments.
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IP: GFP, IB: p-S316 
IP: GFP, IB: p-S368
TPA
Figure 6.2 Priming Site & Autophosphorylation Site Phosphorylation 
of wild type PKC-e & PKC-e3A. COS7 cells were seeded on 6-well 
plates and transfected wild type (WT) PKC-e and a triple alanine mutant 
(S234A/S316A/S368A; PKC-e3A). 24hrs post-transfection cells were 
treated +/- 400nM TPA for 1 hr. Lysates were prepared and subjected to 
immunoprecipitation with anti-GFP 4E12/8. Samples were analysed by 
Western blotting using phospho-specific antibodies raised against the T- 
loop (T566), 'TP1 (T710), 'FSY' (S729), S234, S316 and S368 sites 
(+1^ig/ml corresponding dephosphopeptide). Data is representative of 3 
independent experiments.
6.2.2 Enzyme Activity
Modification by phosphorylation can influence enzyme activity, for 
example, the PKCa T-loop site must be phosphorylated in order for the 
protein to be catalytically competent (Cazaubon and Parker, 1993), and 
the TP' site, which is subsequently autophosphorylated, also influences 
activation state (Bomancin and Parker, 1996). As such, we sought to 
explore whether phosphorylation of residues S234, S316 and/or S368 
affected PKC-e activity.
COS7 cells were transfected with a panel of PKC-e wild type and mutant 
constructs and treated with TPA to induce autophosphorylation. PKC-e
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species were isolated by immunoprecipitation and employed on beads in 
a series of in vitro kinase assays.
Firstly, phosphorylation of MBP was assessed. As shown in Figure 6.3, 
although some subtle variations were detected in activity between 
different PKC-e mutants, there was not a profound loss or gain of activity 
associated with any particular phospho-residue alteration. We also 
explored whether autophosphorylation site occupation could affect lipid 
independent PKC activity. Protamine sulphate is a PKC substrate which 
directly activates the enzyme through charge effects associated with its 
binding (Chauhan and Chauhan, 1992). We speculated that changes in 
PKC phosphorylation status may either negate or enhance the activating 
effect of protamine, thereby influencing its phosphorylation; however, 
again, no significant difference was observed between wild type and 
mutant proteins (Figure 6.4). Finally lipid dependence was tested with 
respect to the phosphorylation of an optimised PKC substrate, a peptide 
based upon the pseudosubstrate sequence of PKC-£, in which the 
alanine residue has been replaced with a phosphorylatable serine (Figure 
6.5). In these assays, all PKC-e species were shown to be responsive to 
lipid activation, and once more, there were no striking differences in 
activity associated with phospho-site mutation.
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Figure 6.3 MBP Phosphorylation Catalysed by Wild Type, S234A/D, 
S316A/D & S368A/D PKC-e. COS7 cells were seeded on 6-well plates 
and transfected with wild type (WT) PKC-e and a panel of 
autophosphorylation site (S234, S316, S368) alanine mutants (Ala) and 
phosphomimetics (Asp). 24hrs post-transfection cells were treated +/- 
400nM TPA for 1 hr. Lysates were prepared and subjected to 
immunoprecipitation with anti-GFP 4E12/8. Immunoprecipitated material 
was washed and incubated in kinase assay buffer with 5^g MBP 
substrate. Assays were started with [y32P]-ATP, incubated at 30°C for 
10mins and stopped with the additon of kinase assay sample buffer. 
Samples were resolved by SDS-PAGE and a) Coomassie stained, 
exposed to a Phosporimager and counted; or b) analysed by Western 
blotting using anti-GFP 3E1. Relative activity was determined as a 
function of PKC-e immunoreactivity. Data is representative of 2 separate 
experiments; error bars denote the range of specific activities observed.
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Figure 6.4 Protamine Phosphorylation Catalysed by Wild Type, 
S234A/D, S316A/D & S368A/D PKC-e. COS7 cells were seeded on 6- 
well plates and transfected with wild type (WT) PKC-e and a panel of 
autophosphorylation site (S234, S316, S368) alanine mutants (Ala) and 
phosphomimetics (Asp). 24hrs post-transfection cells were treated +/- 
400nM TPA for 1 hr. Lysates were prepared and subjected to 
immunoprecipitation with anti-GFP 4E12/8. Immunoprecipitated material 
was washed and incubated in kinase assay buffer (-PS/TPA) with 10ng 
protamine sulphate. Assays were started with [y32P]-ATP, incubated at 
30°C for 10mins and stopped by a) spotting 15^1 onto P81 paper and 
washing 3x5mins in 30% acetic acid. P81 strips were then counted; or b) 
adding sample buffer. Samples were resolved by SDS-PAGE and 
analysed by Western blotting using anti-GFP 3E1. c) represents a longer 
exposure of the same blot, to highlight the presence of a proteolytic 
fragment in the e3A sample (indicated by arrow). Relative activity was 
determined as a function of PKC-e immunoreactivity.
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Figure 6.5 Pseuodosubstrate Peptide Phosphorylation Catalysed by 
Wild Type, S234A/D, S316A/D & S368A/D PKC-e. COS7 cells were 
seeded on 6-well plates and transfected with wild type (WT) PKC-e and a 
panel of autophosphorylation site (S234, S316, S368) alanine mutants 
(Ala) and phosphomimetics (Asp). 24hrs post-transfection cells were 
treated +/- 400nM TPA for 1 hr. Lysates were prepared and subjected to 
immunoprecipitation with anti-GFP 4E12/8. Immunoprecipitated material 
was washed and incubated in kinase assay buffer, in the presence or 
absence of phosphatidyl serine/TPA (PS/TPA), with 10^g 
pseudosubstrate peptide. Assays were started with [y32P]-ATP, incubated 
at 30°C for 10mins and stopped by spotting 15|xl onto P81 paper and 
washing 3x5mins in 30% acetic acid; P81 strips were then counted. 
Parallel samples were resolved by SDS-PAGE and analysed by Western 
blotting using anti-GFP 3E1; relative activity was determined as a function 
of PKC-e immunoreactivity.
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Interestingly, western analysis of immunoprecipitated PKC-e constructs 
revealed that the presence of a particular proteolytic product (of 
approximately 50kDa) was specifically associated with the PKC-e3A 
protein; this species was also observed in subsequent experiments.
6.2.3 TPA Induced Down regulation
An intimate relationship exists between PKC phosphorylation and 
degradation. Since S234, S316 and S368 are phosphorylated upon TPA 
stimulation, we hypothesised that they may play a role in TPA-induced 
PKC-e down-regulation.
As shown in Figure 6.6, TPA induces degradation of PKC-e in a manner 
that is inhibited by BIM1 in RCC cells; a parallel blot for actin indicates 
that TPA and BIM1 have some effects on total protein levels, but that 
these are less pronounced and occur at later timepoints than the specific 
depletion of PKC-e. S234A, S316A and S368A mutants are down- 
regulated with the same profile as wild type PKC-e under these 
conditions.
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Figure 6.6 TPA-induced degradation of wild type, S234A, S316A & 
S368A PKC-e. RCC cells were seeded on 24-well plates and transfected 
with wild type (WT) PKC-e and a panel of autophosphorylation site 
alanine mutants (S234A, S316A, S368A). 24hrs post-transfection cells 
were pre-treated +/- 1pM BIM1 for 15 mins and incubated +/- 400nM TPA 
over a timecourse of a further 48hrs. Samples were harvested 
simultaneously in sample buffer, resolved by SDS-PAGE and analysed 
by western blotting with anti-GFP 3E1 and anti-actin antibodies.
The combined effects of phosphorylation at S234, S316 and S368 were 
also investigated by comparing the degradation of wild type PKC-e and 
PKC-e3A, again, no significant difference was detected between wild type 
and mutant degradation profiles (Figure 6.7).
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Figure 6.7 TPA-induced degradation of wild type PKC-e and PKC-e3A.
Wild type (WT) PKC-e and a triple alanine mutant (S234A/S316A/S368A; 
PKC-e3A) were overexpressed in NIH 3T3 cells. 24hrs post-transfection 
cells were treated +/- 400nM TPA over a timecourse of a further 24hrs. 
Samples were harvested simultaneously in sample buffer, resolved by 
SDS-PAGE and analysed by western blotting with anti-GFP 3E. Data is 
representative of 2 separate experiments.
PKC-e and PKC-e3A polyclonal, stable cell lines were generated by Dr. 
Angus Cameron, in order to investigate the differences between wild type 
and mutant proteins more readily. PKC-e knock out MEFs were stably 
transfected with either GFP-e or GFP-e3A, and subpopulations expressing 
similar levels of GFP were isolated, through 3 successive rounds of 
Fluorescence Activated Cell Sorting (FACS), to facilitate comparative 
analyses.
As shown in Figure 6.8, a relatively long timecourse of TPA treatment 
was required in order to detect a depletion of GFP-e proteins under these 
conditions. The profiles of wild type and mutant degradation were again 
broadly similar, however basal levels of GFP-e3A were consistently high in 
relation to GFP-e in these cells, despite multiple rounds of FACS sorting 
to normalise GFP-PKC content, and in some experiments appeared to be 
slightly more persistent (perhaps as a result of its relative overexpression; 
see Figure 6.8b).
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Figure 6.8 TPA-induced degradation of wild type PKC-e and PKC-e3A 
in MEFs. PKC"67'6 MEF cells stably re-expressing either GFP-PKC-e or 
GFP-PKC-e3A were seeded on 24-well plates and incubated overnight. 
Cells were treated +/- 400nM TPA over a 72hr timecourse and harvested 
simultaneously in sample buffer. Samples were resolved by SDS-PAGE 
and analysed by western blotting with anti-GFP 3E. Data is 
representative of at least 3 similarly configured experiments.
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6.2.4 Localisation
Protein localisation can be regulated through phosphorylation, and PKC- 
a autophosphorylation has been shown to influence its translocation 
between cytoplasm and membrane (Stensman et al., 2004). As such, we 
sought to explore the effects of S234, S316 and S368 phosphorylation on 
PKC-e localisation under basal, and TPA stimulated, conditions.
Pilot studies were undertaken using GFP and RFP tagged wild type PKC- 
e (Figure 6.9). Under basal conditions, both proteins were shown to 
exhibit a cytoplasmic distribution, with some perinuclear accumulation, in 
accordance with previous reports (Lehel et al., 1995). Following TPA 
treatment, both proteins underwent characteristic translocation to the 
plasma membrane (Lehel et al., 1996). A subpopulation of PKC-e also 
appeared to be localised to certain filamentous structures; PKC-e has 
been reported to associate with actin following TPA treatment in NIH 3T3 
cells (Prekeris et al., 1998). Similar results were also observed when the 
proteins were expressed independently. Since the GFP-PKCe and RFP- 
PKCe demonstrated equivalent patterns of localisation, which were 
consistent with previous reports, we concluded that both fusion constructs 
were suitable for further studies.
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Figure 6.9 GFP-PKCe and RFP-PKCe Colocalise Under Basal 
Conditions & Following TPA Stimulation in HeLa Cells. HeLa cells 
were seeded on coverslips and co-tranfected with GFP-PKCs and RFP- 
PKCs. 24hrs post-transfection cells were treated +/- 400nM TPA for 
45mins. Cells were fixed and coverslips were mounted and analysed by 
confocal microscopy (LSM 510, Carl Zeiss Jena). All images comprise 
representative single 1.0|am 'Z' optical sections. The scale bar is 
equivalent to 10^m.
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Preliminary work was undertaken to try to characterise the filamentous 
structures to which some of the PKC-e protein was localising following 
TPA treatment. We hypothesised that the actin cytoskeleton was a likely 
candidate, since PKC-e bears a functional actin binding motif (Prekeris et 
al., 1996). As shown in Figure 6.10, at least a partial colocalisation was 
demonstrated between PKC-e and actin following TPA treatment. 
Interestingly, this colocalisation occurs in a cytoplasmic compartment, 
rather than at the membrane; there is clear cortical actin staining which is 
not positive for PKC-e.
Since residue 234 lies in close proximity to the actin binding motif 
(LKKQET, 223-228), we predicted that its phosphorylation in particular 
might influence PKC-e localisation. Aspartate mutants were investigated 
in this context, to try to mimic constitutive phosphorylation. Under basal 
conditions, all 3 mutants were localised as the wild type protein, and 
following TPA treatment, all translocated in the same fashion too (Figure 
6.11); thus the addition of a negative charge at any of these sites has no 
discernable effect on localisation under these conditions.
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GFP-PKC-e Phalloidin merge
Figure 6.10 GFP-PKCe and Actin Partially Colocalise Following TPA 
Stimulation in HeLa cells. HeLa cells were seeded on coverslips and 
tranfected with GFP-PKCe. 24hrs post-transfection cells were treated +/- 
400nM TPA for 45mins. Cells were fixed, permeablised, blocked and 
stained with Alexa Fluor 546 Phalloidin. Coverslips were mounted and 
analysed by confocal microscopy (LSM 510, Carl Zeiss Jena). All images 
comprise representative single 1.0pm 'Z' optical sections. The scale bar 
is equivalent to 10pm.
GFP-PKC-e S234D GFP-PKC-e S316D GFP-PKC-e S368D
Figure 6.11 GFP-PKCe S234D, S316D and S368D Mutants are 
Similarly Localised Following TPA Stimulation in HeLa cells. HeLa 
cells were seeded on coverslips and tranfected with GFP-PKCe mutant 
constructs. 24hrs post-transfection cells were treated with 400nM TPA 
for 45mins. Cells were fixed and coverslips were mounted and analysed 
by confocal microscopy (LSM 510, Carl Zeiss Jena). All images comprise 
representative single 1.0pm 'Z' optical sections. The scale bar is 
equivalent to 10pm. The scale bar is equivalent to 10pm.
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In order to explore whether the combined charge effects of pS234, pS316 
and pS368 may influence localisation, the PKC-e3A mutant was 
investigated. RFP-PKCe3A was co-expressed in HeLa cells with GFP- 
tagged wild type protein, in the presence or absence of TPA, and 
confocal images were collected. Colocalisation was observed under all 
conditions (Figure 6.12); similar patterns of behaviour were also detected 
when the constructs were expressed independently. Two fields of view 
are shown to represent the different compartments to which PKC-e can 
localise post-TPA treatment; the central panel demonstrates predominate 
translocation to the membrane, while the lower panel exemplifies putative 
actin colocalisation.
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Figure 6.12 GFP-PKCe and RFP-PKCe3A Colocalise Under Basal 
Conditions & Following TPA Stimulation. HeLa cells were seeded on 
coverslips and co-tranfected with GFP-PKCe and RFP-PKCe3A. 24hrs 
post-transfection cells were treated +/- 400nM TPA for 45mins. Cells 
were fixed and coverslips were mounted and analysed by confocal 
microscopy (LSM 510, Carl Zeiss Jena). All images comprise 
representative single 1.0pM 'Z' optical sections. The scale bar is 
equivalent to 10pM.
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6.2.5 Protein-Protein Interactions
Reversible phosphorylation can influence protein-protein interactions, 
either stimulating association or dissociation. We therefore sought to 
investigate the impact of phosphorylation at S234, S316 and S368 on the 
interactions between PKC-e and some of the binding partners identified 
by yeast 2-hybrid screening in Chapter 3, VBP1, Fbw7 and 14-3-3|3 
(isolated in a parallel screen by Dr. Adrian Saurin).
6.2.5.1 VBP1 & Fbw7
The interactions between PKC-e and VBP1/Fbw7 were not found to be 
responsive to TPA, as such our prediction was that they would not be 
influenced by mutation at S234, S316 or S368. As shown in Figure 6.13, 
this hypothesis proved to be correct, with the wild type protein and triple 
alanine mutant interacting with equal efficiency with both partners.
Lysate, IB: GST
105 — 105 —
75 — 75 —
Lysate, IB: GFPLysate, IB: GFP
50 — 50 —
35 — 35 —
IP: GFP, IB: FLAGIP: GFP, IB: GST
GFP e 3AGFP e 3A
GST-VBP
Figure 6.13 Interactions between wild type PKC-e/PKC-e3A & 
VBP1/Fbw7 Detected by Coimmunoprecipitation. COS7 cells were 
seeded on 6-well plates and transfected with either GFP, GFP tagged 
PKC-e (e) or PKC-e3A (3A) and a) GST-VBP1 or b) FLAG-Fbw7. 24hrs 
post-transfection, cells were treated +/- 400nM TPA for 1 hr. Cell lysates 
were prepared and coimmunoprecipitation was performed using anti-GFP 
4E12/8. Samples were resolved by SDS-PAGE and analysed by Western 
blotting with anti-GFP 3E1 and a) anti-GST or b) anti-FLAG antibodies. 
Data is representative of 2 separate experiments.
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6.2.5.2 14-3-3(5
14-3-3p was isolated from a yeast 2-hybrid screen, using a PKC-e 
regulatory domain bait and a human cardiac cDNA library, by Dr. Adrian 
Saurin in our laboratory. Dr. Saurin's subsequent work has demonstrated 
the existence of a well conserved Mode I 14-3-3 binding site in the PKC-e 
V3 domain, centred at residue S346. As summarised in Figure 6.14, it 
has been shown that upon UV induced stress, p38 MAPK phosphorylates 
PKC-e residue S350, creating a consensus sequence which permits 
GSK3 catalysed phosphorylation of S346; phospho-S346 and adjacent 
residues comprise the 14-3-3 binding site (unpublished data).
Since 14-3-3 proteins typically exist as dimers, and frequently bind to two 
phospho-residues within the same protein (Bridges and Moorhead, 2005), 
it was of particular interest to investigate the effects of S234, S316 and 
S368 phosphorylation on the interaction between 14-3-3p and PKC-e. Of 
particular note in this regard is the fact that sequence alignments reveal 
phospho-S368 and surrounding residues to constitute a loosely 
conserved Mode II 14-3-3 binding site (see Figure 6.14c).
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Figure 6.14 14-3-3 Consensus Binding Sites and PKC-e V3 Domain 
Phosphorylation Sites, a) Structural analyses, and studies employing 
an orientated peptide library, have defined two major consensus motifs 
for 14-3-3 binding: Mode I and Mode II (Yaffe et al., 1997). b) Upon 
treatment with UV, PKC-e is subject to phosphorylation by p38 at residue 
S350. This creates a consensus sequence permitting GSK3 catalysed 
phosphorylation of residue S346. Phospho-S346 and adjacent residues 
comprise a well conserved Mode I binding site for 14-3-3 (Dr. Adrain 
Saurin, unpublished data), c) Autophosphorylated PKC-e S368 and 
adjacent residues comprise a loosely conserved Mode II 14-3-3 binding 
site.
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PKC-e/14-3-3p interactions were explored by GST-pull down. COS7 cells 
were transfected with GFP-tagged PKC-e wild type and mutant constructs 
and incubated in the presence or absence of TPA, with or without a BIM1 
pre-treatment. Bacterially expressed GST-14-3-3p, immobilised on 
Glutathione Sepharose 4B, was used to pull down from these cell lysates, 
in the presence or absence of competing phosphopeptide; one 
phosphopeptide comprised a Mode I site, the other represented a 9-mer 
based around the phospho-S368 site.
As shown in Figure 6.15a, upon TPA treatment, PKC-e is recovered using 
14-3-3(3 bearing beads to levels significantly above background (GST 
alone), in a manner that is inhibited by BIM1. This inducible 14-3-3(3 pull 
down is fully competed by a Mode I consensus sequence peptide, 
indicating that the 14-3-3 phospho-binding pocket represents the site of 
interaction. It is also partially competed by a phospho-S368 based 
peptide, indicating that this site may play a role in binding. That 
phosphorylation of S368 is necessary for 14-3-3P binding under these 
conditions is confirmed through the use of the alanine mutants. While 
S234A and S316A mutants, like wild type PKC-e, exhibit basal interaction 
with 14-3-3P, which is enhanced following TPA treatment, the interaction 
between 14-3-3p and PKC-e is completely abrogated in the S368A 
mutant, in the absence and presence of TPA (Figure 6.15b). It is 
important to note that Dr. Saurin's work has demonstrated that residue 
S346 is not phosphorylated under these conditions, and also that 
mutation of the S368 site does not affect the stress induced 
phosphorylation of S346. As such, we conclude that the requirement for 
S368 phosphorylation relates to a direct role for this residue in the in vitro 
binding of 14-3-3(3.
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Figure 6.15 Wild type PKC-e and S234A, S316A and S368A 14-3-30 
Binding. COS7 cells were seeded on 6-well plates and transfected with 
a) GFP-e or b) GFP-e S234A, S316A or S368A mutants. 24hr post­
transfection, cells were pre-treated +/-1 nM BIM1 for 15mins and 
stimulated +/- 400nM TPA for a further 45mins. Cell lysates were 
prepared and incubated with Glutathione Sepharose 4B beads, bearing 
bacterially expressed GST or GST-14-3-30, overnight at 4°C with 
tumbling, +/- V g /m l competing phosphopeptide (Mode I: 
EDRSKpSAPTSP; p368: RKALpSFDN). Samples were washed, 
harvested in lysis buffer, resolved by SDS-PAGE and analysed by 
Western blotting using anti-GFP 3E1. Blots were subsequently stained 
with Coomassie and scanned. Data is representative of 2 separate 
experiments.
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We predict that S346 and S368 comprise a pair of binding sites, which 
facilitate the recruitment of a 14-3-3p dimer to a single PKC-e molecule. 
This working model is summarised in Figure 6.16.
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Figure 6.16 Working Model of the Interaction between PKC-e and 14-3-30. Phosphorylation of PKC-e at S350 is catalysed by 
p38 MAPK. This creates a consensus sequence which permits GSK3 to mediate phosphorylation of S346. Phospho-S346 forms 
the basis of a Mode I 14-3-3 binding site. S368 phosphorylation is catalysed by PKC itself; phospho-S368 and surrounding 
residues comprise a loosely conserved Mode II 14-3-3 binding site. Simultaneously phosphorylated S346 and S368 constitute a 
pair of 14-3-3 binding sites, which facilitate the stable recruitment of a 14-3-3 dimer to a single PKC-e molecule.
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6.3 Discussion
The reversible phosphorylation of a protein can mediate significant 
regulatory effects, influencing a range of properties including activity, 
protein degradation, localisation and binding partner interactions. We 
therefore sought to investigate the functional consequences of the novel 
PKC-e phosphorylation sites S234, S316 and S368.
The phosphorylation of one residue within a protein can influence the 
subsequent phosphorylation of other sites, and/or its susceptibility to 
dephosphorylation; for instance, phosphorylation events at the PKC 
priming sites are inter-related (Bornancin and Parker, 1996; Bornancin 
and Parker, 1997). Therefore, PKC-e phosphorylation sites S234, S316 
and S368 were investigated with respect to their effects on each other, 
and on the priming T-loop, 'TP' and 'FSY' sites. In each case, mutation of 
a particular phospho-acceptor residue, either to alanine to abolish the 
site, or to aspartate to mimic its phosphorylation, was shown only to affect 
its own phosphorylation. Additionally, the removal of all three 
phosphorylation sites in combination, which would be expected to have 
more profound effects on the protein post-TPA treatment, yielded no 
detectable change in priming site occupation. As such, we concluded 
that the phosphorylation of PKC-e at S234, S316 and S368 does not 
significantly alter its phosphorylation status at other established sites. It 
is noteworthy that phosphorylation of residue S234 is predicted to create 
a consensus sequence for the phosphorylation of S238 by CK1 (analysis 
performed using Phosphobase database); this possibility remains to be 
investigated.
It is well established that an enzyme's phosphorylation status can affect 
its catalytic competence, for instance, the T-loop, 'TP' and 'FSY' priming 
sites serve to 'fine tune' PKC activity (Parekh et al., 2000). A panel of 
different 8234, S316 and S368 mutants were tested with respect to their 
activities towards different classes of PKC substrate in vitro, in the 
presence and absence of lipid cofactors. Despite some subtle variability,
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no significant effect of phosphorylation at any of these sites was detected. 
It would have been worthwhile to also investigate potential effects of 
these phospho-residues on the process of PKC autophosphorylation, 
although assays performed in mammalian cells, using phospho-specific 
antibodies, would suggest that autophosphorylation is neither enhanced 
nor impaired in any of the mutants (see above).
The kinase assays described are adequate for the investigation of the 
inherent catalytic competence of these different PKC-e mutants, however, 
they are of limited physiological relevance given that the PKC is 
immobilised, the lipids are represented by artificially prepared micelles 
rather than membranes, and no additional cellular proteins, which might 
participate in the regulation of catalysis, are present. It would perhaps 
have been more informative to investigate PKC-e wild type/mutant activity 
in a cell based system, using either a cellular substrate (e.g. PKD 
(Waldron and Rozengurt, 2003)), or a reporter gene engineered to be 
regulated downstream of PKC activity. Such a system may have 
permitted the investigation of more subtle features of the different PKC-e 
species, such as the duration, rather than the gross level, of downstream 
signalling.
A secondary observation made during these in vitro kinase assay studies 
was that the PKC-e3A mutant appeared to be uniquely susceptible to a 
proteolytic event, resulting in the detection of a fragment of approximately 
50kDa. Since this product was detected from an immunoprecipitation, we 
must assume either that it represents an N-terminal fragment, with an 
intact GFP-tag for recovery, or that it interacts and coimmunoprecipitates 
with, full length PKC-e. Since it is also detected by western blotting with 
the GFP antibody, the former possibility seems most likely. Its altered 
susceptibility to cleavage suggests that the 3A mutant may be 
conformationally different to the wild type protein, and also to the single 
mutants; this would appear to represent an effect of the combined charge 
properties of S234, S316 and S368. It would be of interest to explore this
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possibility further by investigating PKC-e3A thermal stability and 
susceptibility to oxidation, tryptic digestion and/or phosphatase treatment, 
which are other markers of conformational alteration (Bornancin and 
Parker, 1997).
A primary aim of this work was to investigate the process of PKC down- 
regulation. Previous work has distinguished an association between PKC 
phosphorylation and degradation, but this relationship appears to be cell 
type/context dependent. Dephosphorylation has been shown to precede 
the degradation of PKC-a in LLC-MK2 renal epithelial cells (Lee et al., 
1996), PKC-a and PKC-e in non-immortalised human fibroblasts (Lee et 
al., 1997), PKC-a in COS7 cells (Hansra et al., 1999) and of PKC-a in 
MCF7 cells, via a pathway requiring the caveolar trafficking of the protein 
(Prevostel et al., 2000). Conversely, Srivastava et al determined that 
phosphorylation of PKC-6 was required for its TPA-induced down- 
regulation in NIH 3T3 cells (Srivastava et al., 2002). Recently, two 
pathways of PKC-a have been demonstrated to co-exist in IEC-18 rat 
intestinal epithelial cells, one dependent on phosphorylation, the other on 
dephosphorylation (Leontieva and Black, 2004). Significantly, PKC 
activity has also been shown to be necessary for its degradation in 
numerous studies (Goode et al., 1995; Hansra et al., 1999; Junoy et al., 
2002; Kang et al., 2000; Lu et al., 1998; Ohno et al., 1990; Prevostel et 
al., 2000), with some indications that this input can operate in trans. 
Against this background, it was of particular interest to investigate the 
effects of S234, S316 and S368 phosphorylation with respect to PKC-e 
degradation.
Experiments performed in RCC cells revealed that PKC-e could be 
detectably depleted over a timecourse of TPA treatment, in a manner 
inhibited by BIM1. Since this mirrors the pattern of S234, S316 and S368 
phosphorylation, alanine mutants were assayed in the same way, to 
examine whether any of the phospho-sites are involved in PKC-e 
degradation. The profiles of wild type and mutant down-regulation were
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comparable, suggesting that no single site either triggers or impedes 
PKC-e this process. To reinforce this finding, it would have been 
worthwhile to perform a complementary analysis of phospho-site 
occupation in the wild type protein, over a corresponding timecourse. It 
would also have informative to test the triple alanine mutant in this system 
too, to investigate whether the combined removal of the phospho-sites 
may mediate a more pronounced effect. This possibility, however, was 
explored in NIH 3T3 cells, and once more, wild type and mutant PKC-e 
were shown to be down-regulated in a similar manner.
PKC-e degradation was further tested using polyclonal, stable cell lines, 
derived from PKC-e knock out MEFs, which had been manipulated to 
express either GFP-PKC-e or GFP-PKC-e3A at comparable levels. Again 
the profiles of wild type and mutant TPA-induced degradation were 
broadly similar. However, it was noteworthy that basal levels of GFP- 
PKC-e^  were consistently high in comparison to GFP-PKC-e, despite the 
fact that these cell lines were subjected to multiple rounds of sorting by 
FACS to normalise the GFP-PKC content. It remains to be determined 
whether this represents an artefact of the protocol used to derive these 
cell lines, or a meaningful influence of S234/S316/S368 on PKC-e 
turnover in this cell line.
Subcellular localisation comprises another protein property that can be 
modulated by phosphorylation. GFP- and RFP-tagged PKC-e constructs 
were employed in order to determine whether S234, S316 or S368 
phosphorylation influences localisation, as visualised by scanning 
confocal microscopy. Pilot studies confirmed that both proteins localised 
in accordance with previous reports, demonstrating cytoplasmic and 
perinuclear distribution under basal conditions (Lehel et al., 1995), and 
translocation to the membrane following TPA treatment (Lehel et al.,
1996). PKC-e also appeared to colocalise with some filamentous 
structures; we hypothesised that this might relate to the fact that PKC-e 
contains an actin binding motif (Prekeris et al., 1996), and has been
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shown to associate with the actin cytoskeleton following TPA treatment in 
NIH3T3 cells (Prekeris et al., 1998). We were able to discern that the 
TPA induced pattern of PKC-e distribution at least partially colocalised 
with actin using a phalloidin stain. Interestingly, this colocalisation was 
detected along filamentous structures, rather than at the cell periphery, 
where membrane bound PKC-e may be juxtaposed with cortical actin. 
Staining with further markers will enable a more definitive characterisation 
of this compartment, and further studies will be required in order to 
determine whether PKC-e has any morphological influence on actin under 
these conditions.
Neither phosphomimetic S234, S316 or S368 aspartate mutants, nor an 
alanine mutant lacking all three phospho-acceptor residues, displayed 
differential localisation/translocation properties in the experiments 
performed here; however, a number of other conditions remain to be 
explored. Firstly, it would be worthwhile to explore localisation patterns in 
response to other stimuli. Notably, one pathway of PKC-a down- 
regulation involves caveolar-dependent trafficking to an endosomal 
compartment; an investigation of PKC-e in this context would be of 
interest in terms of both its down-regulation and localisation. Also, PKC-e 
inhibition can result in its accumulation in tetraspanin (CD81)-positive, (31 
integrin containing, vesicular structures (Ivaska et al., 2002); we could 
speculate that PKC-e autophosphorylation may influence this pattern of 
localisation and explore the distribution of mutant proteins accordingly. 
Secondly, it would be of interest to directly visualise the S234/S316/S368 
phosphorylation sites within the wild type protein, alongside examining 
the behaviours of mutants lacking them. This would allow us to analyse 
whether the phosphorylation of a particular site is associated with 
residency in a particular compartment, and also to mark a subpopulation 
of active PKC-e within the cell. Currently, the phospho-specific antibodies 
produced are not of sufficient purity for use in immunofluorescence 
studies; however, affinity purification may facilitate their application. 
Alternatively, a Fluorescent Resonance Energy Transfer (FRET) based
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approach could be employed to attain the required specificity, if 
appropriately conjugated combinations of anti-PKCe and anti-phospho 
site antibodies were prepared. Finally, all of these studies would benefit 
from the application of live imaging, as well as standard confocal 
microscopy on fixed cells. This would permit the investigation of more 
subtle PKC-e changes, for instance, in duration of translocation.
It is well established that reversible phosphorylation can affect protein- 
protein interactions. In some cases, phosphorylation is required to 
facilitate binding partner recruitment, in other cases it causes 
dissociation. Phosphorylation of residues S234, S316 and S368 were 
therefore investigated with respect to their effects on PKC-e protein- 
protein interactions; the binding partners which were identified by yeast 2- 
hybrid analysis in Chapter 3 were tested for interaction with wild type and 
phospho-mutant proteins. The interactions between PKC-e and 
VBP1/Fbw7 were not responsive to TPA, consequently, it would not be 
expected that their interactions would be affected by PKC-e 
autophosphorylation. Consistent with this, wild type PKC-e and the PKC- 
e3A mutant were shown to bind both proteins with equal efficiency. 
Contrastingly, 14-3-3p, which was identified by Dr Adrian Saurin as a 
PKC-e regulatory domain binding partner in a parallel yeast 2-hybrid 
screen, was found to bind to PKC-e, in vitro, in a TPA responsive manner, 
which was inhibited by BIM1; this pattern of behaviour reflects that of the 
autophosphorylation process defined in Chapter 5. The use of a 
competing peptides revealed firstly that the 14-3-3 phospho-binding 
pocket was the interface required for this interaction, and secondly, that 
P-S368 may comprise a point of contact within PKC-e; notably 
phosphorylated S368 conforms loosely to the Mode I114-3-3 binding 
consensus sequence. The role of S368 in binding 14-3-3(3 was confirmed 
using the corresponding alanine mutant; interaction with 14-3-3P was 
completely abolished in this protein. Recent work in the laboratory has 
revealed that phosphorylation of residue S368 has no influence on the 
phosphorylation of S346 (Dr Adrian Saurin, unpublished data);
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consequently, we suggest that phospho-S368 plays a direct role in 14-3- 
3p binding.
Dr Saurin has demonstrated the existence of a well conserved Mode 114- 
3-3 binding site centred at PKC-e residue S346; phosphorylation at this 
site is mediated by the sequential activities of p38 MAPK and GSK3. It is 
well established that 14-3-3 dimers often bind to two sites within the same 
protein (Bridges and Moorhead, 2005), as such, we could hypothesise 
that both S346 and S368 represent functional 14-3-3 binding sites. 
Commonly, one binding motif within the target protein conforms to a high 
affinity Mode I site and interacts with the first 14-3-3 subunit; this is 
referred to as the 'gatekeeper'. The second site is often less well 
conserved, but will interact with the remaining 14-3-3 monomer by virtue 
of its close proximity, thereby stabilising the complex; its lower affinity 
may be physiologically relevant, permitting a degree of dissocation (Yaffe, 
2002).
Our current working model proposes that the Mode I 14-3-3 binding motif 
at residue S346 constitutes the gatekeeper site under physiological 
conditions. Secondary interaction with autophosphorylated S368 is likely 
to stabilise the PKC-e/14-3-30 complex. Since both of these sites are 
unique to PKC-e among the PKC superfamily, this interaction may 
contribute to isoform specificity.
14-3-3 dimers can generally elicit three distinct effects on binding 
partners: conformational change, steric hindrance and dimerisation 
(Bridges and Moorhead, 2005). Preliminary work from Dr Saurin 
suggests that 14-3-3 binding confers lipid independent activity upon PKC- 
e, this would be consistent with a conformational change in which 14-3-3 
binding within the V3 hinge region holds PKC-e in an open conformation, 
such that the kinase domain is inaccessible to the inhibitory 
pseudosubstrate motif. It will be of interest to explore the cellular 
changes associated with this complex formation and change in PKC
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activity. It may also be of value to test whether 14-3-3P is able to mediate 
any other effects on PKC-e. For example, perhaps under certain 
conditions each 14-3-3 dimer may bind to just one site per PKC-e 
molecule; in this way it could facilitate dimerisation between two PKC-e 
molecules, or trans-dimerisation, between PKC-e and other 14-3-3 
targets.
Previous studies have reported on physical and functional interactions 
between different 14-3-3 and PKC isoforms. There have been conflicting 
findings with respect to the functional consequences of the PKC and 14- 
3-3 interaction. Some studies have determined that 14-3-3 is inhibitory 
towards PKC (Matto-Yelin et al., 1997; Meller et al., 1996; Toker et al., 
1992), while others have demonstrated PKC activation associated with 
14-3-3 binding (Acs et al., 1995; Tanji et al., 1994). This disparity is likely 
to result in part from the use of different PKC isoforms, cell types and 
assay systems.
None of the published investigations regarding the interactions between 
14-3-3 and PKC have described a phosphorylation dependent 
mechanism. In fact, Dai and colleagues identified PKC-e S346 as a 
candidate Mode I site, and excluded its involvement in binding under their 
conditions through the use of a corresponding competing phosphopeptide 
(Dai and Murakami, 2003). A phosphorylation independent 14-3-3 
binding site has been mapped to the PKC C1 domain (Matto-Yelin et al.,
1997). It is of note, however, that in those studies which detected a 
degree of PKC isoform specificity, it was always the PKC-e isotype which 
was implicated; we could speculate that in these studies, the 
phosphorylation dependent interaction between PKC-e and 14-3-3 was in 
operation in parallel to less specific, C1 domain mediated binding. For 
instance, Acs et a l demonstrated that recombinant 14-3-3£ was able to 
activate various PKC isoforms by approximately two-fold, but had a 5-fold 
effect on PKC-e; significantly, these assays were performed in the 
absence of lipid, and therefore agree with Dr Saurin's observations that
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14-3-3 can confer lipid independent activity upon PKC-e (Acs et al.,
1995). Another study revealed that PKC-a and PKC-e become 
associated with 14-3-3^ in PC12 cells, following neuronal differentiation 
triggered by NGF. Intriguingly, while both isoforms were recovered by 
immunoprecipitation, only PKC-e was shown to be constitutively activated 
as a result (Gannon-Murakami and Murakami, 2002). It would be of 
interest to determine whether S346 and/or S368 residues are 
phosphorylated in these cells following NGF treatment, as a means of 
exploring the nature of the 14-3-3^/PKC-e interaction under these 
conditions.
In conclusion, the consequences of phosphorylation at residues S234, 
S316 and S368 were explored with respect to a broad panel of PKC-e 
properties. Autophosphorylation was judged to have no significant effect 
on the phosphorylation of other PKC-e sites, on enzyme activity targeted 
towards a number of different substrates, or on localisation under the 
conditions tested. Phosphorylation at these sites also appeared not to be 
involved in the pathway of TPA-induced degradation; this elusive process 
remains to be characterised. However, phosphorylation of PKC-e at 
residue S368 was shown to influence the binding of 14-3-3P; thereby 
linking a phosphorylation site identified in Chapter 5, to one of the binding 
partners identified through work described in Chapter 3. It is likely that 
pS368 operates in combination with a second phospho-site at residue 
S346, to facilitate the recruitment of a 14-3-3P dimer. This complex 
would appear to bear constitutive PKC-e activity, and it will be of 
considerable interest to determine the cellular responses which it 
mediates.
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CHAPTER 7 
Discussion
7.1 Overview
The work presented in this thesis was motivated by the theme of PKC 
down-regulation. It is well established that the chronic activation of the 
cPKCs/nPKCs frequently leads to their inactivation (Ballester and Rosen, 
1985; Stabel et al., 1987), through an increase in rate of degradation 
(Young et al., 1987). It has been suggested that the ability to induce a 
particular profile of PKC isoform degradation is inherent to the tumour 
promoting effects of the phorbol esters (Young et al., 1987). Significantly, 
the ability of Bryostatin 1, an alternative PKC activator, to inhibit TPA- 
induced tumour promotion, correlates with the differential down-regulation 
of various PKC isoforms (Szallasi et al., 1994).
The ubiquitin/proteasome system has been clearly implicated in the 
agonist-induced down-regulation of PKC (Lee et al., 1996), but to date, 
only one E3 ubiquitin ligase, VHL/Elongin C/Elongin B/Cullin 2 (VCB- 
Cul2), has been demonstrated to target PKC (Okuda et al., 2001).
Studies were therefore undertaken to try to identify PKC specific E3 
ubiquitin ligases by yeast 2-hybrid analysis.
PKC activity is required for its agonist induced degradation (Goode et al., 
1995; Kang et al., 2000; Srivastava et al., 2002). Additionally, its 
phosphorylation status is influential with respect to this process; 2 
pathways have been identified, one involving the ubiquitination and 
subsequent proteasomal degradation of the mature, fully phosphorylated 
enzyme, the second, a proteasome-independent mechanism, requires 
caveolar trafficking and dephosphorylation (Leontieva and Black, 2004). 
Together, these observations led us to predict that PKC
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autophosphorylation may serve to target the enzyme for ubiquitin- 
mediated degradation at the proteasome, and so we sought to map sites 
which may behave as phospho-degrons.
Although yeast 2-hybrid analysis successfully identified PKC-e binding 
partners with associations to the ubiquitin/proteasome system, including 
VBP1 and Fbw7, no evidence was obtained to implicate these proteins in 
PKC down-regulation; the potential role of Fbxl15 remains to be tested. 
Similarly, while novel phosphorylation sites for both PKC-e and PKC-6 
were mapped, and validated in mammalian cells, there was no evidence 
that they played critical roles as phospho-degrons. Thus, the 
mechanism(s) of agonist induced PKC down-regulation remain to be 
elucidated.
Nevertheless, these studies catalysed the exploration of some 
fundamental properties of PKC-e, and have proved informative with 
respect to further defining aspects of PKC regulation and function. The 
analysis of Fbw7 as a candidate PKC E3 ligase was followed by its 
investigation as a potential substrate. This led to the identification of a 
novel phosphorylation site, specific to the Fbw7a isoform, with a potential 
role in the post-translational regulation of this key tumour suppressor. 
Additionally, the newly identified phosphorylation sites within PKC-e and 
PKC-6 constitute useful markers of PKC activation status, and may have 
important functional consequences. Most significantly, a relationship has 
been established between regulation of PKC-e at the level of 
phosphorylation and protein-protein interaction, linking the two branches 
of this project, with the finding that phosphorylation at residue S368 is 
required for the recruitment of 14-3-30.
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7.2 PKC Degradation
The work undertaken in this project was not successful in identifying 
either a PKC specific E3 ligase, or a phospho-degron implicated in its 
targeting for degradation. As such, the intriguing mechanism(s) of 
agonist induced PKC down-regulation remain to be determined. Since 
the rather broad methodologies employed here provided such limited 
insight into the process, it seems reasonable to suggest that future 
investigations may benefit from a more focussed approach. By building a 
functional criterion into a screen for E3 ligases, it might be possible to 
target proteins involved in PKC down-regulation more directly. For 
instance, the propensity of mammalian PKCs to be down-regulated in 
S.pombe following chronic phorbol ester treatment could be exploited as 
the basis for a genetic screen (Goode et al., 1994); mutants lacking the 
capacity to degrade PKC would be immediately implicated in the process 
of agonist-induced degradation. Alternatively, the pathway(s) operating in 
mammalian cells in response to TPA could be partially dissected through 
the use of dominant negative ubiquitin/proteasome associated constructs; 
for example, the Cull mutant (Cul1DN) lacks an Rbx1 binding site, and 
therefore sequesters Skp1/F-box protein complexes, and stabilises SCF 
targets (Ye et al., 2004). If C u llDN were to protect PKC from TPA 
induced degradation, the SCF complex would be implicated, and more 
directed studies could be exploited to define the specific F-box protein 
involved; for instance, RNAi could be used to knock-down the F-box 
protein complement.
The further characterisation of the mechanism of PKC down-regulation 
through such studies will be of considerable interest, providing insight into 
both the regulation of PKC, and the tumour promotion process.
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7.3 PKC Binding Partners
The yeast 2-hybrid system established as part of this project proved to be 
effective for identifying PKC-e binding partners. This is evidenced both by 
the fact that a known interacting protein, NELL2, was isolated by the 
screen, and also by the validation of Fbw7 and VBP1 interactions with 
PKC-e, by coimmunoprecipitation in mammalian cells. A number of other 
proteins were classified as candidate PKC-e binding partners using this 
approach, and it may be informative to explore these further. For 
instance, the receptor-type protein tyrosine phosphatase-a (PTPa, clone 
104) represents an intriguing example. It has been shown previously that 
PKC-6 can regulate the activity of PTPa (Brandt et al., 2003), and PKN 2 
has been associated with PTP-BL (Gross et al., 2001); as such, it would 
be interesting to establish whether PKC-e may also participate in the 
control this class of proteins, which play a significant role in modulating 
signal transduction pathways.
Although positive results were obtained using this 2-hybrid system, it is 
important to acknowledge that there were a number of limitations to the 
approach. Some of these problems were specifically associated with this 
particular screen, and could be improved upon in future studies of PKC 
protein-protein interactions. Others are inherent to the yeast 2-hybrid 
system itself.
It could be argued that one disadvantage of the screen employed in this 
work is the nature of the PKC-e bait itself. The full length protein is likely 
to exist in an inactive state under basal conditions in yeast, and may 
therefore be limited in its capacity to interact with partners that require an 
open conformation. One way to address this issue would be to employ a 
constitutively active bait, mutated at the inhibitory pseudosubstrate site. 
Alternatively, isolated regulatory and catalytic domains, which are 
conformationally more exposed than the full length protein, may be used. 
This latter strategy was exploited by Dr Adrian Saurin in our laboratory.
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Using the PKC-e regulatory domain bait described in Chapter 3 Dr. Saurin 
identified 14-3-30 as a binding partner. Interestingly, the interaction 
between PKC-e and 14-3-30 which was subsequently characterised in 
mammalian cells required the phosphorylation of two isoform-specific 
sites within the PKC-e hinge region, S346 and S368. We have not 
retrospectively tested whether these sites are occupied in yeast. Since 
14-3-3 proteins are also known to interact, less selectively, with the PKC 
C1 domain (Dai and Murakami, 2003; Matto-Yelin et al., 1997), it is 
possible that this binding partner was identified by virtue of one mode of 
interaction, which fortuitously led to elucidation of another.
A further issue relating to the study of PKC by yeast 2-hybrid analysis is 
the localisation of the system to the yeast nucleus. Since PKC is 
activated at the membrane, it follows that many functionally significant 
interaction partners may occur in this compartment, and in fact depend 
upon this localisation for binding. One way to circumvent this issue in 
future work would be to exploit a modified 2-hybrid protocol; for instance, 
the split-ubiquitin system is specifically designed to enable the detection 
of binding partners at the membrane (Iyer et al., 2005).
Another profound problem associated with the yeast 2-hybrid screen 
undertaken was the poor reproducibility achieved. It is well documented 
that results obtained using this approach can be variable, only 141 
interactions have been detected in common between two large scale 2- 
hybrid screens performed in yeast (Ito et al., 2001). However, it would 
appear that this inherent variability is exacerbated by the negative 
influence of PKC on yeast proliferation rates (Goode et al., 1994).
In addition, the yeast 2-hybrid system also tends to generate numerous 
false positive and false negative results (Zhu et al., 2003).
Given the limitations discussed above, as well as the significant advances 
which have been made in the field of proteomics in recent years, it would 
be worthwhile to investigate PKC protein-protein interactions using a
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more sophisticated approach. An effective high-throughput system has 
recently been described by Barrios-Rodiles and colleagues, which has 
facilitated the dynamic analysis of the TGFp signalling network (Barrios- 
Rodiles et al., 2005). It would be of interest to explore PKC signalling in a 
similar way. As noted with respect to studies of degradation, it would also 
be preferable to build a layer of functional relevance into the primary 
screen, for example, by exploring differential interactions before and after 
a physiologically relevant stimulus.
7.4 Fbw7 Phosphorylation
The Fbw7 protein was identified as a PKC interacting protein by yeast 2- 
hybrid analysis and subsequently shown to represent an efficient 
substrate in vitro. A novel phosphorylation site was identified in the 
isoform specific N-terminus of Fbw7a at S18, and this site was shown to 
be phosphorylated in cells treated with Calyculin A. It will be critical next 
to establish whether Fbw7a S10 is also phosphorylated; the 
simultaneous occupation of both of sites could have even more profound 
functional consequences. This will be readily testable in vitro using the 
peptides which we have synthesised, corresponding to this region.
It will also be significant to explore whether PKC can catalyse the 
phosphorylation of S18 in cells. Inhibitor studies have excluded a role for 
cPKC/nPKCs in response to Calyculin A, but aPKC and PKN selective 
inhibitors remain to be tested; notably aPKC-5 was recovered with 
particularly high efficiency from an Fbw7 immunoprecipitation. Other 
stimuli should also be screened for their ability to induce Fbw7a S18 
phosphorylation. It would be worthwhile to focus pilot studies towards 
conditions which are known to induce PKC nuclear translocation, since 
Fbw7a is localised to this compartment. For instance, apoptotic stimuli 
(DeVries et al., 2002), hypoxia (Mizukami et al., 2000) and treatment with 
NGF (Wooten et al., 1997) have all been shown to induce the nuclear 
localisation of various isoforms. Given the inhibitor profile described
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above, it is intriguing that the aPKCs have been shown to shuttle between 
cytoplasm and nucleus (Perander et al., 2001). Also, bearing in mind the 
association between Fbw7 and cell cycle control, it is noteworthy that 
PKC-6 translocation to the nucleus occurs specifically in S-phase in BL6T 
melanoma cells (Perego et al., 2002).
It will be of considerable interest to explore the functional consequences 
of Fbw7a phosphorylation. The phospho-acceptor residue S18 lies within 
a particularly significant part of the Fbw7a protein; this unique N-terminal 
region is responsible for isoform specific properties. Importantly, it 
contains one of two nuclear localisation signals (NLS 11-14), which can 
mediate Fbw7a nuclear localisation (Welcker et al., 2004). It is tempting 
to speculate that phosphorylation of Fbw7a at nearby S18 (and perhaps 
S10 too) may disrupt its nuclear localisation, under conditions where NLS 
11-14 predominates. This would be consistent with the effects of PKC 
phosphorylation close to NLSs in numerous other proteins, including 
LIMK2 (Goyal et al., 2005) and the aryl hydrocarbon receptor (Ikuta et al., 
2004). This hypothesis may be tested using a mutant construct which 
lacks the second NLS, and is therefore dependent upon NLS 11-14 for 
nuclear localisation. This mutant could be treated in the presence or 
absence of Calyculin A and studied by immunofluorescence, and/or 
modified further with the incorporation of a mutagenic alanine or 
phosphomimetic aspartate at S18 (and/or S10).
The regulation of E3 ligase activity through localisation is an emerging 
theme. For instance, SV40 large T antigen binding causes the 
mislocalisation of Fbw7y, and interferes with the down-regulation of the 
client protein cyclin E (Welcker and Clurman, 2005). Similarly, the 
nucleolar architecture has been shown to detain MDM2 and VHL in 
response to regulatory cues, permitting the accumulation of their 
substrates elsewhere (Mekhail et al., 2005). If phosphorylation of Fbw7a 
proves to modulate localisation, it will be significant to determine the 
downstream effect on Fbw7a mediated substrate degradation.
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7.5 PKC Autophosphorylation
In addition to identifying a novel PKC substrate, the work presented also 
defined previously unrecognised sites of autophosphorylation within PKC- 
e (S234, S316, S368) and PKC-6 (S299, S302, S304). The PKC-e sites 
were most thoroughly studied; PKC-6 awaits similar investigation.
The PKC-e phosphorylation sites were identified from purified PKC-e, 
phosphorylated in vitro, and were subsequently detected upon TPA 
stimulation in mammalian cells, using phospho-specific antibodies. We 
did not prove exhaustively that S234, S316 and S368 were the only sites 
of autophosphorylation under these conditions. For completion, it would 
be valuable to determine whether radiolabelled phosphate incorporation 
can be detected in the PKC-e S234A/S316A/S368A triple alanine mutant, 
as a means of checking for additional sites; the mutant exhibits a similar 
level of activity as the wild type, such that this is achievable. If evidence 
is obtained for the phosphorylation of additional sites under these 
conditions, it may be necessary to devise an alternative phosphopeptide 
mapping strategy with which to map them. A different protease, such as 
AspN, could be employed to generate a modified selection of peptides, 
and/or an alternative mass spectrometry system could be tested.
The studies undertaken to date have focussed on overexpressed PKC-e 
in response to phorbol ester treatment. As the PKC-e knock-out 
phenotype includes defects in innate immunity, it is potentially significant 
that Dr. Amir Faisal in our laboratory has also observed elevated 
phosphorylation of S368 in response to lipopolysaccharide stimulation of 
RAW264.7 cells. However, again, this observation was made using cells 
overexpressing PKC-e. Ideally, we would hope to investigate the 
phosphorylation of endogenous PKC-e in response to physiological 
stimuli. In order to achieve this, it will be necessary to optimise an
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immunoprecipitation protocol to allow the enrichment of sufficient PKC-e 
for detection, and/or to affinity purify the antisera.
The catalytic mechanism responsible for the phosphorylation of PKC-e at 
PKC-e S234, S316 and S368 remains to be fully characterised. Several 
lines of evidence support the notion that these sites can be 
autophosphorylated, but it is not yet clear whether this involves an intra- 
or inter- molecular process. This may relate to another interesting 
question regarding the nature of PKC activity, namely whether PKC 
undergoes dimerisation, and if so, whether this is of functional 
significance. It would be productive to exploit the GFP/RFP-tagged PKC- 
e constructs generated during this project, to explore these possibilities 
through Fluorescent Resonance Energy Transfer (FRET) studies.
Work was carried out to establish the functional consequences of 
phosphorylation at these sites. No significant effect was detected with 
respect to activity, down-regulation or localisation, but a requirement was 
established for S368 phosphorylation in 14-3-3(3 recruitment. We could 
speculate that autophosphorylation may participate in feedback control of 
PKC activity, mediating 'fine-tuning' rather than gross effects, on signal 
duration or localisation. As such, it will be important to follow these 
relatively crude analyses with more subtle studies, for example using live 
imaging to analyse the timecourse of mutant versus wild type PKC 
translocation.
A consideration of the placement of the phosphorylation sites leads to 
further hypotheses regarding the properties that they may influence. For 
example, S234 lies between the C1a and C1b domains, and so it is 
reasonable to suggest that it may therefore influence actin binding or 
membrane association. It is also juxtaposed to a sequence critical for the 
induction of neurite outgrowth by PKC-e, and it will be interesting to 
explore, for example, whether an aspartate mutant at S234 is altered in 
its capacity to induce this process (Ling et al., 2005).
339
Chapter 7: Discussion
Regardless of the functional significance of these sites, they have 
important implications as markers of PKC activation. They can be 
detected using the phospho-specific antibodies raised, and exploited both 
experimentally, allowing the detection of a specific subpopulation of the 
enzyme, and clinically, facilitating the analysis of disease tissues for 
aberrant PKC activation (Ng et al., 1999). Since PKC comprises an 
enzyme activity subject to acute allosteric regulation, it may well be more 
informative to analyse its activation state than its protein concentration in 
addressing its the potential involvement in disease (Parker, 1999). This 
strategy was pioneered by Ng and colleagues, who employed a 
autophosphorylation site marker of PKC-a activation, pT250, to screen 
breast tumour samples. To obtain the necessary specificity, FRET 
between appropriately conjugated anti phospho-T250 and anti total PKC- 
a was measured by Fluorescence Lifetime Imaging Microscopy (FLIM). 
Activated PKC-a was identified in 11 out of 23 specimens, and notably, 
activation was not shown to correlate with overexpression in all cases (Ng 
et al., 1999). It will be of interest to employ a similar approach in order to 
analyse the roles of PKC-e and PKC-6 isoforms in disease.
7.6 PKC & 14-3-3
14-3-3|3 was identified as a PKC-e regulatory domain binding partner by 
yeast 2-hybrid analysis performed by Dr. Adrian Saurin. Dr Saurin 
subsequently defined a phosphorylated, Mode 1 14-3-3 binding site at 
PKC-e S346, which is implicated in this interaction. We have also 
determined that autophosphorylation of PKC-e at residue S368 is 
required for the recruitment of a 14-3-3P dimer. Consistent with an 
important functional role, both S346 and S368 are conserved among 
mammalian PKC-e species; they are also both unique to PKC-e. As such, 
the further characterisation of this regulatory mechanism may provide 
important insights into PKC-e isoform specific functions.
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Preliminary work from Dr Saurin demonstrates that 14-3-3(3 binding 
confers lipid independent activity to PKC-e. It will be of great interest to 
explore the downstream consequences of this signalling complex. In 
order to address this question, either wild type or S346A/S368A PKC-e 
could be re-expressed against a PKC-e'7' background, and the effects on 
phenotypes associated with PKC-e activity, such as cell spreading (Chun 
et al., 1996) or HGF-induced migration (Kermorgant et al., 2004), 
screened.
To a certain extent, such studies would be best directed by a 
consideration of the stimuli which permit S346/S368 phosphorylation, and 
thereby herald the recruitment of 14-3-3. For instance, since UV stress 
has been shown to initiate S346 phosphorylation, it may be pertinent to 
analyse mutant versus wild type PKC-e function in the context of UV- 
induced apoptosis. Conversely, it would also be worthwhile to determine 
whether, under conditions where 14-3-3 is known to regulate PKC-e, 
these phosphorylation sites have been induced; for instance, perhaps the 
association between 14-3-3^ and PKC-e which is stimulated in PC12 cells 
following NGF treatment involves S346/S368 phosphorylation (Gannon- 
Murakami and Murakami, 2002).
It will also be significant to determine whether 14-3-3 association 
mediates any other effects on PKC-e. The fact that 14-3-3 binding 
confers constitutive activation strongly suggests that it brings about a 
conformational change. By virtue of its more open conformation, the 
population of PKC-e complexed to 14-3-3 may be more sensitive to 
proteolytic cleavage, for example by caspases (Leverrier et al., 2002). 
Caspase cleavage of PKC-6 results in the nuclear import of the catalytic 
fragment, with important functional implications in apoptosis (DeVries et 
al., 2002). The PKC-6 NLS that is exposed to facilitate nuclear 
translocation is shared with PKC-e, thus we could speculate that, either
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directly or indirectly, conformational change mediated by 14-3-3 may 
influence PKC-e/PKC-e catalytic fragment nuclear localisation.
Our current working model, which incorporates the newly defined 
phosphorylation sites, the interaction between 14-3-3 and PKC-e and the 
downstream effects on candidate substrates is summarised in Figure 7.1. 
Further elucidation of this pathway will provide valuable insights into the 
regulation and function of PKC-e.
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PKC-e P38, GSK3
Auto-P
-> PKC-e
?
Cytosolic substrates  
e.g. PKD
I
PKC-e
14 -3 -3
9
PKC-e
Nuclear substrates  
e.g. Fbw 7a
Figure 7.1 Working Model of the PKC-e/14-3-3|3 Signalling Complex.
PKC-e is phosphorylated at Ser-346 through the sequential activities of 
p38 MAPK and GSK3; Ser-368 is autophosphorylated. p346/p368 
represent binding sites for the recruitment of a 14-3-3(3 dimer.
Association with 14-3-3 confers constitutive activity to PKC-e, which is 
likely to result in the phosphorylation of cytosolic substrates. In addition, 
14-3-3 mediates a conformational change, which may render PKC-e more 
susceptible to caspase cleavage and/or expose an NLS, ultimately 
leading to P K C -e /P K C -e  catalytic fragment nuclear translocation. 
Phosphorylation of nuclear substrates, such as Fbw7a, may thereby be 
effected.
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APPENDICES
A1 Yeast 2-Hybrid Analysis
The yeast 2-hybrid screen described in Chapter 3 was performed using a 
full length PKC-e bait and a mouse brain MATCHMAKER cDNA library 
(Clontech). The features of the library vector, pACT2, and the 
sequencing data obtained from the putative positive clones following the 
screen are compiled below.
A1.1 pACT2
The Mouse Brain MATCHMAKER cDNA Library (Clontech) utilized in the 
yeast 2-hybrid screen was constructed in pACT2; the vector map is 
shown in Figure A1 and the multiple cloning site in Figure A2.
A1.2 Mouse Brain MATCHMAKER cDNA Library Adaptor Sequence
The library was cloned into pACT2 between the EcoR I and Xho I 
restriction sites using the following adaptor sequence (overhang, 
compatible with EcoR I sticky end): 5’-AATTCGCGGCCGCGTCGAC-3’, 
and Xho l-(dT)is priming. An illustration of the pACT2 multiple cloning 
site, which shows the incorporation of a library insert, is given in Figure 
A3. The library insert ORF begins directly after the adaptor sequence 
and is in frame with the GAL4 Activation Domain and the HA tag.
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Figure A1.1 pACT2 Vector Map. The pACT2 vector map is 
represented, with unique restriction sites shown in bold.
tfXS
HA e p i t o p e
-jCtl
/VCD
T G A A A  A A C  
stopstop
Figure A1.2 pACT2 Multiple Cloning Site (MCS). The pACT2 MCS is 
shown. Codons are in frame with respect to the GAL4 activation domain 
and HA epitope. Unique restriction sites and stop codons are shown in 
blue.
A AA A A A GAG A TC TG T A TG GCT TAC CCA TAC GAT G TT CCA GAT TAC GCT
AGC TT G GGT C AT A T G GCC A TG GAG GCC CCG GGG A TC CGA A T T CGC GGC
CGC GTC GAC X X X X C T CGA GAG A TC TA T GAA TCG TAG A T A CTG AAA AAC
Figure A1.3 pACT2 Multiple Cloning Site with Library Insert. The
multiple cloning site of pACT2, which corresponds to the sequence 
shown in Figure A 1.2, is indicated in black. The EcoR I and Xho I sites 
are underlined. The adaptor sequence used for library construction is 
shown in red, the library insert is represented in blue. XXXX represents 
the library insert.
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A1.3 Yeast 2-Hybrid Clone Sequences: Forward Sequence
The sequences obtained from the 129 positive yeast 2-hybrid clones 
using the forward sequencing primer are archived on the accompanying 
CD (Appendixi _3.doc). Sequences are shown in FASTA format and 
labelled by clone number. The adaptor sequence is underlined to 
facilitate orientation.
A1.4 Yeast 2-Hybrid Clone Sequences: Reverse Sequence
The sequences obtained from the 129 positive yeast 2-hybrid clones 
using the reverse sequencing primer are archived on the accompanying 
CD (Appendix 1.4.doc). Sequences are shown in FASTA format and 
labelled by clone number. The Xho site is underlined to facilitate 
orientation.
A2 Phosphopeptide Mapping
Phosphopeptide mapping was carried out as described in Chapter 5.
Mass spectrometric data was interpreted by comparing the detected 
peptide masses against an 'in siiico' tryptic digest of the whole protein.
A2.1 PKC-e In S iiico  Tryptic Digest
In Siiico digestion was performed on the human PKC-e sequence using 
the MS-Digest tool from the ProteinProspector database 
(http://prospector.ucsf.edu/); 3 missed cleavages were permitted. See file 
A2.1 on the accompanying CD, which can be viewed using an internet 
browser.
A2.2 PKC-6 In S iiico  Tryptic Digest
In Siiico digestion was performed on the human PKC-6 sequence using 
the MS-Digest tool from the ProteinProspector database 
(http://prospector.ucsf.edu/); 3 missed cleavages were permitted. See file 
A2.2 on the accompanying CD, which can be viewed using an internet 
browser.
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